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ABSTRACT 
 
Total Synthesis of Bioactive Marine Natural Products 
& 
Developments of New Haloalkylations via Soft Enolizations 
 
by 
 
Aaron Thomas Herrmann 
 
 
Marine natural products have long served as promising compounds and scaffolds 
for new therapeutic agents; however, their utilization is often extremely limited due 
to poor availability from natural sources and their molecular complexity. Hence, 
synthetic investigation of utilizing innovative techniques offers shortcuts in the 
production of such agents and modification. Studies directed toward the synthesis of 
marine natural products and their scaffolds inspire the development of new, efficient, 
and economical methods that are useful for medicinal research and for the synthesis 
of new pharmaceuticals and organic compounds. 
The first part of this dissertation focuses on the synthetic studies directed toward 
the synthesis of nuphar thiaspirane alkaloids. The main drive of this effort is to allow 
access to each of the four classes of nuphar thiaspirane alkaloids. During these 
studies, a new procedure for the generation of tetrasubstituted tetrahydrothiophenes 
  xi 
was developed. This method has been further applied for a late-stage Stevens 
rearrangement to generate each class of nuphar thiaspirane alkaloids from common 
intermediates. 
The second part describes the total synthesis of the marine natural product (+)-
brevisamide. The art and science of natural product total synthesis has become 
increasingly more associated with the various principles of the “economies” of 
synthesis. Evaluation of protecting group use serves as one metric of synthetic 
efficiency and can provide a framework for developing a synthesis plan. A new 
protecting-group-free synthesis of, the marine cyclic ether alkaloid, brevisamide was 
completed. 
The third part describes the development of new and exciting chemical 
transformations revolving around haloalkylations of N-acyl oxazolidinones via 
Group IVa metal enolates by both radical and electrophilic methods. These studies 
include: mechanistic eludication of trichloromethylations, perfluoroalkylation and 
trifluoromethylation methodology development, and a generic -fluorination 
method. 
The final part describes a new procedure for the generation of syn-1,3-diols, 
which addresses both stereo- and regiocontrol in the rhenium catalyzed transposition 
of allylic alcohols. 
  xii 
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Chapter 1 
 
Studies Towards the Total Synthesis of Nuphar Thiaspirane Alkaloids 
 
1.1 Nuphar Thiaspirane Alkaloids Background 
Nupharis Rhizoma was used as a tonic, diuretic, and treatment of blood stasis syndrome 
in Chinese and Japanese traditional medicine. Various alkaloids have been isolated from 
rhizome of Nuphar japonicum and Nuphar pumilum (TIMM.) DC, including three types of 
dimeric sesquiterpene alkaloids in the thiobinupharidine, thionuphlutine, and 
neothiobinupharidine series (Figure 1.1.1). In 1965, Birnbaum corrected the structure of 
thiohemiaminal-type dimeric sesquiterpene neothiobinupharidine 1.3b,
1
 which had first been 
isolated by Achmatowicz a year earlier,
2
 via X-ray crystallographic diffraction. In the 1970s, 
LaLonde extensively studied the structural elucidation of these dimeric sesquiterpene 
alkaloids, especially thiohemiaminal-type alkaloids, and also insightfully proposed their 
biogenesis from monomeric sesquiterpene congeners.
3
 
Figure 1.1.1 Nuphar Thiaspirane Alkaloids 
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1.2 Biological Activities of Nuphar Thiaspirane Alkaloids 
In general, alkaloids of botanical origin display a wide variety of unique and potent 
activities against disease targets; furthermore, they possess special promise as anticancer 
agents.
4
 A recent study found that 57% of the 155 antineoplastic agents marketed in Western 
countries since the 1940s have been either unmodified natural products (25 compounds, 
16%) or semi-synthetic derivatives of natural products (48 compounds, 41%).
5 
Despite the long history of these nuphar thiaspirane alkaloids, the remarkable biological 
activities of these dimeric nuphar thiaspirane alkaloids were not detected until the 2000s. 
These include antibacterial, antifungal, immunosuppressive, and potent in vitro cytotoxicity 
against U937 human leukemia, B16F10 mouse melanoma, and HT1080 human fibroblast 
cell lines.
6
 Distinctive nuphar dimers 6-hydroxythiobinupharidine (1.1a), 6,6-
dihydroxythiobiunpharidine (1.1b), and 6-hydroxythionuphlutine B (1.2a) have been shown 
to inhibit invasion of B16 murine melanoma cells across collagen-coated filters in vitro with 
IC50 values of 29 nM, 87 nM, and 360 nM, respectively.
7
 Recently, Gopas and co-workers 
reported that methanolic extracts from Nuphar lutea inhibit nuclear factor κB (NFκB) and 
exhibit synergistic effects with conventional chemotherapy.
8
 NFκB signaling has been 
implicated in oncogenesis and tumor progression, inhibition of which has enabled the search 
for its specific target and applications against cancer and inflammation. 
1.3 Previous Syntheses of Nuphar Thiaspirane Alkaloids 
To date, only one synthesis of one member from this family of natural products has been 
reported. In 2013, Shenvi and co-workers reported an eight-step synthesis of (-)-
neothiobinupharidine (1.4d), an isomer that has never been isolated from natural sources 
(Scheme 1.3.1).
9
 Quinolizidine monomer 1.10 was elegantly prepared from 3-
  3 
methylcyclopentenone 1.5 through a conjugate reduction-allylation sequence to form 
cyclopentane 1.7. Formation of the quinolizidine core 1.9 was completed by ring closing 
metathesis (RCM) followed by protodesilylation. Dimerization of the quinolizidine 
monomers 1.10 in the presence of sodium tetrasulfide produced 1.4d in 62% yield 
stereoselectively. Unfortunately, the authors did not report any biological activity of their 
synthetic isomer.  
Scheme 1.3.1 Shenvi’s Total Synthesis of (-)-Neothiobinupharidine 
 
There have been various syntheses of monomeric sesquiterpene alkaloids by various 
groups shown in Figure 1.3.1 (vide infra).
10
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Figure 1.3.1 Monomeric Sesquiterpene Alkaloid Syntheses 
 
A new strategy is necessary to access other members of the family to provide the 
significant quantities of the natural isomers, which would be necessary for studies towards 
the elucidation of their biological targets and mechanism of action, both of which are absent 
from current literature. 
1.4 Initial Synthetic Plan 
In devising an overall approach to synthesize the four classes of nuphar thiaspirane 
alkaloids, we became interested in developing a general strategy of coupling a piperidine to 
one of four tetrahyrdothiophene isomers, shown in Scheme 1.4.1. Initial coupling of our 
tetrahydrothiophene 1.15 with piperidine 1.14 through reductive amination would deliver 
1.16, followed by RCM to form the first quinolizidine core 1.17. To gain access to 1.18, 
amide bond formation between 1.17 and piperidine 1.14 would be implemented. To form the 
second quinolizidine core, a RCM followed by hydrogenation would yield 1.19. Finally, 
reduction of 1.19 would deliver our desired nuphar thiaspirane alkaloid, 6-
hydroxythionuphlutine 1.2a. 
 
 
 
  5 
Scheme 1.4.1 Synthetic Plan of Nuphar Thiaspirane Alkaloids 
 
1.5 1
st
 Generation Synthesis of Piperidine 1.14  
In order to implement the final stages of our synthetic strategy, we conceived a strategy 
to synthesize piperidine 1.14. We planned to use an asymmetric alkylation methodology, 
devised in the Zakarian group, coupling allene iodide 1.22 with 3-furylacetic acid 1.23 
forming carboxylic acid 1.24.
11
 Curtius rearrangement would deliver carbamate 1.25. A key 
gold cyclization followed by protecting group removal would deliver 1.14. 
Scheme 1.5.1 Synthetic Plan of Piperidine 1.14 
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Scheme 1.5.2 Synthesis of Allene Iodide 1.22 
 
The synthesis of the allene iodide 1.22, shown in Scheme 1.5.2, began from 
commercially available 1,4-butanediol 1.20, which was mono-PMB protected to afford the 
corresponding primary alcohol 1.27, in 85% yield.
12
 After protection, the resultant alcohol 
was oxidized by means of a Jones oxidation yielding carboxylic acid 1.28, and then coupled 
with oxazolidinones 1.29, in 85% yield over two steps.
13
 Methylation of N-acyl oxazolidione 
1.30 formed 1.31 in high yield and diastereoselectivity. Reduction of 1.31 with NaBH4 
delivered primary alcohol 1.32 in 95% and the oxazolidinone 1.29 was quantitatively 
recovered. Swern oxidation followed by a Corey-Fuchs reaction provided alkyne 1.33 in 
91% yield over two steps.
14
 Allene 1.34 was formed using paraformaldehyde in a one carbon 
homologation reaction.
15
 Deprotection of PMB followed by an Appel reaction produced 
allene iodide 1.22.
13,16
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Scheme 1.5.3 Synthesis of 3-Furylacetic Acid 1.23 
 
Formation of 3-furylacetic acid 1.23 was initiated via reduction of commercially 
available 3-furanoic acid 1.21 with LiAlH4, which delivered primary alcohol 1.36 (Scheme 
1.5.3). Alcohol 1.36 was first mesylated, followed by cyanide addition to form nitrile 1.37. 
Treatment of nitrile 1.37 with potassium hydroxide under refluxing conditions produced 3-
furylacetic acid 1.23, in 47% yield over three steps.
17
 
Scheme 1.5.4 Asymmetric Alkylation & Curtius Rearrangement 
 
Utilizing chemistry developed in the Zakarian group, 3-furylacetic acid 1.23 was coupled 
with allene iodide 1.22 through an asymmetric alkylation with (R,R)-tetraamine, delivering 
carboxylic acid 1.24 in good yield and excellent selectivity.
11
 Curtius rearrangement formed 
carbamate 1.25 in 81% yield.
18
 
An initial screen of metals was performed to assess the ability to cyclize carbamate 1.25 
to piperidine 1.26 (Table 1.5.1). Cyclization was not observed when using rhodium, iridium, 
iron, silver, platinum, or palladium
19
 (entries 1-9) as our metal catalyst. When carbamate 
1.25 was subjected to PPh3AuCl, with silver triflate as an additive, cyclization was observed 
in good yield but with no stereoselectivity (entries 12-13).
20
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Table 1.5.1 Metal Screen: Piperidine 1.26 Cyclization  
 
Entry Metal (mol %) Additive (mol %) Solvent Yield 
1 [Rh(COD)Cl]2 (1.0) DPEphos (3.0) EtOH:DCE 0%
a 
2 [Ir(COD)Cl]2 (1.0) DPEphos (3.0) THF 0% 
3 FeCl3∙6H2O (10.0)  CH2Cl2 0% 
4 AgOTf (50.0)  toluene 0% 
5 AgBF4 (50.0)  toluene 0% 
6 AgClO4 (50.0)  toluene 0% 
7 PtCl2 (10.0)  CH2Cl2 0% 
8 [Pdallyl)Cl]2 (10.0) dppf (20.0) THF 0%
a 
9 PdCl2(dppf) (10.0)  THF 0% 
10 AuCl3 (5.0) AgClO4 (10.0) xylenes 0% 
11 AuCl3 (5.0) AgClO4 (10.0) CH2Cl2 0% 
12 PPh3AuCl (20.0) AgOTf (40.0) toluene 68%, dr 1:1 
13 PPh3AuCl (30.0) AgOTf (60.0) CH2Cl2 50%, dr 1:1 
(a) 1.1 was consumed, formation of an unknown product. 
We sought to improve our conversion and diastereoselectivity by using ligands to assist 
in our gold cyclization reaction. Phosphine ligands JohnPhos (L1), XPhos (L2), and (R)-
SegPhos (L5) were tested but no conversion to the cyclized piperidine was observed (Table 
1.5.2, entries 1-2, 5). Chiral ligand MeOBIPHEP (L3) was used and led to full conversion 
but only formed the non-cyclized methyl ketone 1.39 (entry 3). Among the phosphine 
ligands, usage of (R)-BINAP led to full conversion, forming piperidine 1.26 and 1.38 as the 
major products, along with a minor amount of methyl ketone 1.39 (entry 4). Unfortunately 
there was no improvement of diastereoselectivity with the conditions used. 
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Table 1.5.2 Au-Ligand Screen
a 
 
Entry Au source (mol %) Additive (mol %) Solvent Conversion 1.14:1.38:1.39 
1 AuNTf2∙L1 (10.0)
b 
AgOTf (10.0) dioxane 0%  
2 AuNTf2∙L2 (10.0)
c
 AgOTf (10.0) dioxane 0%  
3 AuCl∙L3 (5.0)
d
 AgOTf (10.0) toluene 100% 0:0:1 
4 AuCl∙L4 (25.0)
e
 AgOTf (50.0) CH2Cl2 100%
 
2:2:1
 
5 AuCl∙L5 (25.0)
f
 AgOTf (50.0) toluene 0%  
(a) Standard conditions: solvent (0.5 M) at room temp. (b) L1: Cyclohexyl JohnPhos (c) L2: XPhos (d) L3: (R)-
3,5-Xyl-MeOBIPHEP (e) L4: (R)-BINAP (f) L5: (R)-SegPhos 
Further reaction optimization of the gold cyclization was completed in order to improve 
the diastereoselectivity and minimize the methyl ketone 1.39 by-product. Under optimized 
conditions, 20 mol % of AuCl[(R)-BINAP], 80 mol % of silver tetrafluoroborate (AgBF4) 
and 4Å molecular sieves, in a solvent mixture of toluene and dichloromethane are required 
for affording the piperidine 1.26 albeit in modest yield and selectivity (Table 1.5.3, entry 9). 
Variation of solvents, toluene:acetonitrile and dioxane, led to no product formation (entries 
1, 4). Reduction of gold and silver loading led to reduced yields (entries 2-3). Using 
dichloromethane as the only solvent led to good yield, but poor diastereoselectivity and large 
amount of methyl ketone 1.39 formation (entry 5). In attempts to ensure dry reaction 
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conditions, 4Å MS were added, which led to a reduction in the amount of methyl ketone 
1.39? but low diastereoselectivity remained a problem (entries 6-7).  
Table 1.5.3 Reaction Optimization 
 
Entry AuCl[(R)-BINAP] AgBF4 Additive Solvent Yield 1.14:1.38:1.39 
1
a 
20 mol % 40 mol %  toluene:CH3CN 0%  
2 15 mol % 30 mol %  CH2Cl2 35% 1.7:1:1 
3 15 mol % 30 mol %  toluene:CH2Cl2 49% 2.8:1:1 
4 15 mol % 30 mol %  dioxane 0%  
5 20 mol % 40 mol %  CH2Cl2 85%
 
1:1:0.7
 
6 20 mol % 40 mol % 4Å MS CH2Cl2 64% 1:1:0.4 
7 20 mol % 40 mol % 4Å MS toluene:CH2Cl2 89% 1:1:0.6 
8 20 mol % 40 mol % 4Å MS, LiCl toluene:CH2Cl2 0%  
9 20 mol % 80 mol % 4Å MS toluene:CH2Cl2 71% 2.1:1:1.3 
(a) Standard conditions: 1.25 is added to a mixture of AuCl[(R)-BINAP] and AgBF4 in solvent at room 
temperature. (b) reaction was heated to 45 °C. 
Scheme 1.5.5 Formation of Piperidine 1.14 
 
Deprotection of carbamate 1.26 with zinc in acetic acid and diethyl ether provided 
piperidine 1.14 in high yield (Scheme 1.5.5). Due to the high number of steps and lack of 
selectivity in the key gold cyclization, this plan to synthesize piperidine 1.14 was revised. 
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1.6 Revised Synthetic Plan 
In revising our overall approach to synthesize the four classes of nuphar thiaspirane 
alkaloids, we planned to use an iridium-catalyzed allylic cyclization as our key step to form 
the quinolizidine cores, shown in Scheme 1.6.1. Initial coupling of our tetrahydrothiophene 
1.15 with amine 1.40 through reductive amination would deliver 1.41. A key iridium-
catalyzed allylic cyclization followed by ring closing metathesis would form the first 
quinolizidine core 1.17. To gain access to 1.18, amide bond formation between 1.17 and 
piperidine 1.14 would be implemented. To form the second quinolizidine core, a RCM 
followed by hydrogenation would yield 1.19. Finally, reduction of 1.19 would deliver the 
desired thiaspirane, 6-hydroxythionuphlutine 1.1b.  
Scheme 1.6.1 Synthetic Plan of Nuphar Thiaspirane Alkaloids 
 
1.7 2
nd
 Generation Synthesis of Piperidine 1.14  
Due to the high step count and low overall yield for our initial synthesis of piperidine 
1.14, a revision was proposed. In devising a new approach, we planned to form piperidine 
1.14 in a similar manner to the first generation synthesis. We varied our plan by using an 
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iridium-catalyzed allylic cyclization of amine 1.40 to produce piperidine 1.14 (Scheme 
1.7.1).
21
 
Scheme 1.7.1 Revised Synthetic Plan of Piperidine 1.14 
 
Scheme 1.7.2 Synthesis of Alkyl Iodide 1.43 
 
Acylation of oxazolidione 1.46 with crotonyl chloride delivered N-acyl oxazolidione 
1.47 in high yield. A 1,4-addition of vinyl cuprate produced terminal alkene 1.48 in 87% 
yield and high diastereoselectivity.
22
 Reduction with NaBH4 followed by an Appel reaction 
produced the alkene iodide 1.43. Thus, the synthesis of the iodide was completed in 5 steps, 
an overall 81% yield in 90% enantiomeric excess. 
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Scheme 1.7.3 Asymmetric Alkylation 
 
An asymmetric alkylation of iodide 1.43 with 3-furylacetic acid 1.23 using (R,R)-
tetraamine produced our desired addition producing 1.44 in high yield with great 
stereoselectivity in addition with the remaining three inseparable isomers. The reaction 
increased the enantiomeric excess of our desired product 1.44 over its enantiomer ent-1.44. 
Scheme 1.7.4 Synthesis of Primary Amine 1.40 
 
The sterically bulky Hünig’s base proved to be the key in the Curtius rearrangement of 
acid 1.44 by completely eliminating epimerization during the formation of carbamate 1.45. 
The sterically smaller triethylamine leads to a partion epimerization, reducing dr from 10:1 
to 3:1. Cross-metathesis proved uneventful, providing carbonate 1.52 in good yield, with the 
  14 
starting material making up the remaining mass balance.
23
 Removal of the Troc protecting 
group with zinc powder led to key primary amine 1.40. 
Scheme 1.7.5 Iridium-Catalyzed Allylic Cyclization 
 
Cyclization of primary amine 1.40 via iridium catalysis under Helmchen conditions with 
phosphoramidite ligand
24
 1.53 provided piperidine 1.14 in good yield and excellent 
selectivity.
25
 
1.8 Synthesis of Tetrahydrothiophene 1.15 
Our synthetic strategy was guided by the decision to pursue all four types of dimeric 
sesquiterpene alkaloids, assembled from one of four tetrasubstituted tetrahydrothiophene 
isomers. Preparation of tetrahydrothiophene 1.15 will commence with a Stevens 
rearrangement between thietane 1.54 and diazo 1.53 forming the initial tetrahydrothiophene 
core 1.55.
26
 To access all four isomers, we plan to use enzymatic resolution followed by 
multiple steps to achieve the desired coupling partner 1.15.  
Scheme 1.8.1 Synthetic Plan of Tetrahydrothiophene 1.15 
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Scheme 1.8.2 Synthesis of Tetrahydrothiophene 1.55 
 
Thietane 1.54 was prepared from diol 1.57 by diol protection followed by thio-
substitution with sodium sulfide, depicted in Scheme 1.8.2a.
27
 Commercially available tert-
butyl acetoacetate 1.58 was subjected to diazo formation with p-ABSA, followed by 
reduction with NaBH4, and elimination to deliver diazo 1.53 in three steps (Scheme 
1.8.2b).
28
 Diol 1.55 was prepared in two steps via Stevens rearrangement of 1.54 with 1.53 
and subsequent removal of acetonide (Scheme 1.8.2c) 
Scheme 1.8.3 Enzymatic Resolution of Tetrahydrothiophene 1.55 
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Desymmetrization is a powerful tool for the preparation of enatiomerically pure 
substrates. Desymmetrization of one prochiral carbon center in a racemic substrate would 
give two diastereomers with de facto enantiomeric purity. Although the copper-catalyzed 
desymmetrization reaction gave no better than 40% ee,
29
 enzyme-mediated reaction afforded 
the desired diastereomers 1.59 and 1.60 after optimization. In presence of Novozym 435, 
diastereomers 1.59 and 1.60 could be isolated in 91% combined yield with a nearly 1:1 
diastereomeric ratio and 76% ee (Scheme 1.8.3). In addition, 1.61 and 1.56 could also be 
efficiently prepared using enzyme lipase AK. Thus, four isomers of tetrahydrothiophenes 
could be feasibly accessed by choice of enzyme (Scheme 1.8.3). 
Scheme 1.8.4 Synthesis of Tetrahydrothiophenes – 4 Isomers 
 
To prepare the final four tetrahydrothiophene isomers, the enzymatically resolved 
tetrahydrothiophenes 1.56 and 1.59-1.61 were subjected to Swern oxidation followed by 
Wittig olefination (Scheme 1.8.4b). The tetrahydrothiophenes were subjected to 
deprotection and at this point isomers were separated by column chromatography. Dess-
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Martin oxidation produced the desired tetrahydrothiophene isomers: 1.62, 1.63, 1.64, and 
1.15 in a total of four steps, in good yield and enantiomeric excess. 
1.9 Synthesis of Nuphar Thiaspirane Alkaloids 
Obtaining key fragments, amine 1.5 and all tetrahydrothiophene isomers (1.15, 1.62-
1.64), permitted the total synthesis of nuphar thiaspirane alkaloids to proceed via coupling of 
fragments. 
Scheme 1.9.1 Formation of Quinolizidone Core 
 
Reductive amination of primary amine 1.40 with aldehyde 1.15 provided the coupled 
fragment 1.41 in high yield and good diastereoselectivity (Scheme 1.9.1). Our first key 
iridium allylic cyclization proved to be uneventful, delivering piperidine 1.16 in good yield 
and complete stereoselectivity. At this point diastereomers could be separated and isomer 
1.16 was subjected to RCM conditions.  
A fast screen of metal catalysts revealed that Grubbs 2
nd
 generation catalyst led to full 
conversion (Table 1.9.1, entry 1). Hoveyda-Grubbs 2
nd
 generation (HGII) and Schrock 
catalysts were also screened but led to incomplete conversion (entries 2-3). Extended 
reaction times led to a greater amount of Diels-Alder by-product 1.66 (entry 4). Lowering 
reaction time to 6 hours led to full conversion with a 52% of desired quinolizidine 1.17 
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(entry 5). Due to the high catalyst loading, it was proposed that the GII catalyst was forming 
a tightly bound intermediate with the substrate after one turnover of the catalyst. In an 
attempt to achieve full conversion to the desired quinolizidine 1.17 and lower the catalyst 
loading, ethylene was used to replace argon as the reaction atmosphere but this proved to be 
unfruitful (entry 7). 
Table 1.9.1 Ring-Closing Metathesis
a 
 
Entry Catalyst (mol %) Solvent Time (h) Conversion Yield 1.17:1.66 
1
 
GII
b
 (37.5) benzene 24 100% - 1:1 
2 HGII
c
 (37.5) benzene 24  84% - 1.3:1 
3 Schrock (37.5) benzene 12 50% - 0:1 
4 GII (30.0) benzene 14 100% 74% 1.6:1 
5 GII (50.0) benzene 6 100% 58% 10:1 
6 GII (50.0) benzene 3 100% 56% 10:1 
7
d
 GII (25.0) benzene 8 55% 30% 5:1 
(a) Standard conditions: 1.16 in degassed benzene (0.01 M) in a sealed flask at 80 °C. (b) GII: Grubbs 2
nd
 
generation catalyst. (c) HGII: Hoveyda Grubbs 2
nd
 generation catalyst. (d) reaction run under ethylene 
atmosphere. 
Scheme 1.9.2 Amide Bond Formation 
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Advancing the synthesis, quinolizidine 1.17 was subjected to saponification in 
quantitative yield (Scheme 1.9.2). A screen of peptide bond forming reactions was 
conducted, including EDC/HOBt, DCC, EDC/DMAP, HATU, and HBTU, but no product 
formation was observed. Treatment of the acid with oxalyl chloride proved successful in 
preparing the acid chloride. Amide bond formation was examined with treatment of the acid 
chloride, piperidine 1.17, and triethylamine inhigh concentration. The reaction was screened 
at various temperatures and times, but led exclusively to the undesired Diels-Alder 
byproduct 1.67 due to the Thorpe-Ingold effect. Unable to circumvent this unwanted side-
product, the synthetic route was abandoned. 
1.10 Revised Synthetic Plan of Nuphar Thiaspirane Alkaloids 
Revising our synthetic plan, formation of thietane 1.70 and diazo 1.69 could be formed 
from a common quinolizondine 1.68 intermediate (Scheme 1.10.1b). These two 
quinolizidines 1.69 and 1.70 could then be subjected to a Stevens rearrangement to deliver 
the bis-amide thioalkaloid 1.711 (Scheme 1.10.1a). Simple reduction could afford the bis-
hemiaminal 1.2b or the fully reduced 1.2d. 
To test the key Stevens rearrangement, a model reaction of thietane 1.72 and diazo 
lactam 1.73 was attempted. In the presence of catalytic Rh2(OAc)4, the reaction of thietane 
1.72 with diazo 1.73 smoothly afforded the desired thiaspirane 1.74 in full conversion 
(Scheme 1.10.2) as a single isomer. 
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Scheme 1.10.1 Revised Synthetic Plan 
 
Scheme 1.10.2 Stevens Rearrangement Model Reaction 
 
Scheme 1.10.3 Synthesis of Quinolizidine Core 1.68 
 
Synthesis of quinolizidine 1.68 was completed in two steps from piperidine 1.14 
(Scheme 1.10.3). Amide bond formation took place upon treatment of piperidine 1.14 with 
vinyl acetic acid, EDC, and DMAP in good yield. A small amount of isomerization to the 
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,-unsaturated amide 1.75 was observed, but was easily transformed back to the desired 
unconjugated product 1.76 upon treatment with KHMDS and quenching with dimethyl 
malonate in 75% yield.
30
 RCM followed by hydrogenation proved uneventful, forming the 
quinolizidine core 1.68 in 95% yield. 
Scheme 1.10.4 Synthesis of Thietane 1.70 
 
The initial aldol reaction began with the treatment of quinolizidine 1.68 with LDA and 
diethyl zinc, forming the zinc enolate. A solution of formaldehyde in THF was added, 
providing alcohol 1.77 in high yield (Scheme 1.10.4). An additional aldol was performed, 
but led to incomplete conversion, forming diol 1.78 in modest yield while retaining the 
remaining mixture as starting material 1.77. Thietane formation proved to be successful with 
treatment of diol 1.78 by iodination followed by thio-substitution supplying thietane 1.70 in 
good yield over two steps. 
Scheme 1.10.5 Synthesis of Diazo 1.69 
 
Next the -diazo amide 1.69 was prepared via diazo transfer with use of 
paraacetamidobenzenesulfonyl azide (p-ABSA) from quinolizidine 1.68 (Scheme 
1.10.5).
31
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Table 1.10.1 Stevens Rearrangement
a
  
 
Entry Rh(OAc)2 Solvent Temp Yield 34:1.8:1.7 
1
b 
25 mol % CH2Cl2 45 °C 0% 1.5:0:1 
2
c
 25 mol % CH2Cl2 45 °C 0% 1.5:0:0 
3
d
 25 mol% DCE 90 °C 0%2 1.5:0:0 
(a) Standard conditions: 1.70 (1.5 equiv), 1.69 (1.0 equiv), in DCM (0.05 M). (b) addition of diazo 1.69 over 
1.5 h. (c) addition of diazo 1.69 over 3.5 h. (d) addition of diazo 1.69 over 16 h. 
The key Stevens rearrangement was tested next with thietane 1.70 and diazo 1.69. No 
product formation was observed when diazo 1.69 was added over 1.5 h to a solution of 
thietane 1.70 and Rh2(OAc)4 in dichloromethane at reflux (Table 1.10.1, entry 1). Formation 
of ,-conjugated lactam 1.79 was exclusively observed along with unreacted thietane 1.70. 
Extending addition time from 1.5 h to 3.5 h of diazo 1.69 reduced -hydride elimination but 
no product formation was observed (entry 2). Increasing temperature to 90 °C and addition 
time to 16 h did not produce product 1.71 (entry 3). 
Due to lack of product formation from the Stevens rearrangement, a new late-stage 
model was performed (Scheme 1.10.6). The model systems were to test reactivity of both 
thietane 1.70 and diazo 1.69. Thietane 1.70 was reacted with model diazo 1.73 with 
Rh2(OAc)4 in refluxing benzene (Scheme 1.10.6a). Formation of product 1.80 was observed 
in 50% yield with 1 diastereomer observed. Next diazo 1.69 was reacted with model thietane 
1.81 with Rh2(OAc)4 in refluxing benzene (Scheme 1.10.6b). Again, formation of product 
1.82 was observed in high yield with a dr 2:1. 
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Scheme 1.10.6 Stevens Rearrangement: Late Stage Model 
 
With these results (vide supra), we hypothesized that both the thietane 1.70 and diazo 
1.69 are reactive and can undergo the Stevens rearrangement; however, the steric bulk in 
both compounds may lead to slow reactivity when coupling both together. We have 
observed that different metal/ligand combinations during Stevens rearrangement lead to 
different results be it higher and some times lower yields in the formation of thietanes. With 
the absence of desired thietane formation currently with Rh2(OAc)4, new studies will need to 
be performed. 
1-11 Future Studies 
Future studies will concentrate on screening metal/ligand combinations to deliver the 
desired Stevens rearrangement (Scheme 1.11.1). Metals such as rhodium, ruthenium, copper, 
and iridium have been used in Stevens rearrangements successfully. 
Scheme 1.11.1 Future Stevens Rearrangement Studies 
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Additional studies will include selective reduction to obtain multiple nuphar alkaloids 
(Scheme 1.11.2). 
Scheme 1.11.2 Future Stevens Rearrangement Studies 
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Chapter 2 
 
A Concise Asymmetric Total Synthesis of (+)-Brevisamide 
 
2-1 Introduction 
The art and science of natural product total synthesis has become increasingly more 
associated with the various principles of the “economies” of synthesis.32,33 Evaluation of 
protecting group use serves as one metric of synthetic efficiency and can provide a 
framework for developing a synthesis plan. Among various classes of natural products 
prepared by total synthesis without the use of protecting groups, examples featuring 
polyketides or cyclic ethers are scarce.
5,34
 Herein, we report a concise, enantioselective, 
protecting-group-free total synthesis of the diversely functionalized cyclic ether natural 
product brevisamide. 
2-2 Brevisamide Background 
The “Red Tide” off of the Florida coast and in the Gulf of Mexico has led to the death of 
a wide range of marine life and human food poisoning.
35
 Dinoflagellates blooms have been 
the root cause of this due to the secretion of brevetoxins by Ptychodiscu brevis.
36
 Another 
species of dinoflagellates, Karenia brevis produces the metabolite, brevenal (2.1) (Figure 
2.2.1), which has been shown to have antagonistic activity against the brevetoxins.
37
 In 
2008, Wright and co-workers isolated another metabolite, brevisamide (2.2), from K. brevis. 
This monocyclic ether contains very similar structural features to the ring and dienal 
fragment of brevenal.
38
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Figure 2.2.1. Brevenal 2.1 and Brevisamide 2.2 
 
Brevisamide appears to be an important biosynthetic precursor to brevenal and possibly 
other polycyclic ethers. Brevisamide is comprised of a complex functionalized 
tetrahydropyran core containing a conjugated 3,4-dimethylhepta2,4-dienal and acetylated 
terminal amine subunits. The tetrahydropyran ring also contains methyl and hydroxyl 
substituents. Since brevisamide has been reported as a biosynthetic precursor to brevenal, a 
great deal of interest has been generated towards its total synthesis. Multiple groups have 
synthesized brevisamide since its isolation in 2008, with the first four total syntheses being 
reported in 2009. 
2-3 Previous Syntheses 
2-3-1 Satake’s Synthesis of Brevisamide 
The Satake group completed the first total synthesis, outlined in Scheme 2.3.1.
39
 The 
tetrahydropyran-core (Scheme 2.3.1, part a) was synthesized by three key reactions: Brown 
crotylation to generate 2.5, which led to lactone formation yielding 2.6, and finally 
hydroboration was utilized to install the secondary alcohol 2.8.
40,41,42
 Curtius rearrangement 
generated primary amine 2.10, a precursor to amide 2.11.
43
 Suzuki-Miyaura cross coupling 
(part c) of 2.12 and 2.16 installed the diene fragment, which was then followed by MnO2 
oxidation, which completed the first total synthesis of brevisamide (2.2) in 21 steps and a 
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2.0% overall yield. This synthesis also confirmed the absolute stereochemical structure of 
brevisamide (2.2). 
Scheme 2.3.1. Satake’s Synthesis of Brevisamide 2.2 
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2-3-2 Lindsley’s Synthesis of Brevisamide 
Shortly after the achievement of the first total synthesis, Lindsley and Fadeyi completed 
another total synthesis.
44
 While their approach was similar to Satake’s synthesis in the 
stepwise construction of the tetrahydropyran-core, they differed in the dienal construction. 
The tetrahydropyran-core (Scheme 2.3.2, part a) was synthesized by two key reactions: 
Brown crotylation to generate 2.18 and a samarium(II) iodide reductive cyclization reaction 
to create the key core 2.21.
45
 Curtius rearrangement was used to generate the primary amine 
2.23 that led to amide 2.24.
46
 A Horner-Wadsworth-Emmons reaction (part c) of aldehyde 
2.24 and phosphonate 2.27 installed the diene fragment, which was then followed by MnO2 
oxidation, which completed the shortest total synthesis of brevisamide (2.2) in 18 steps and 
6.3% overall yield. 
2-3-3 Ghosh’s Synthesis of Brevisamide 
Ghosh and Li completed the third total synthesis.
47
 Their synthesis had an alternative 
synthetic plan in construction of the tetrahydropyran-core from previous groups. They used 
Jacobsen’s asymmetric Hetero-Diels-Alder reaction of diene 2.31 and aldehyde 2.32 using 
Jacobsen’s chromium catalyst 2.33 to produce 2.34 (Scheme 2.3.3, part a) in high diastereo- 
and enantioselectivity.
48
 A Rubottom oxidation was used to install the secondary alcohol 
2.35.
 49
 Amide 2.38 was produced from a Mitsunobu reaction followed by azide reduction 
and amine acylation.
50
 A Suzuki-Miyaura cross coupling (part c) of 2.39 and 2.44 installed 
the diene fragment, which was then followed by TEMPO oxidation that delivered 
brevisamide (2.2) in 19 steps and 1.5% overall yield.
51
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Scheme 2.3.2 Lindsley’s Synthesis of Brevisamide 2.2 
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Scheme 2.3.3 Ghosh’s Synthesis of Brevisamide 2.2 
 
2-3-4 Panek’s Synthesis of Brevisamide 
Panek and Lee completed the fourth total synthesis of brevisamide (2.2).
52
 Their 
synthesis centered on Panek’s silicon directed [4+2]-annulation utilizing a Z-crotylsilane to 
construct the tetrahydropyran-core 2.48 (Scheme 2.3.4, part a).
53
 Hydroboration was used to 
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synthesize the equatorial secondary alcohol 2.50. A Negishi cross-coupling (part c) of 2.53 
and 2.56 installed the diene fragment.
54
 The amide 2.58 was produced from a Mitsunobu 
reaction followed by azide reduction and amine acylation, which was then followed by 
MnO2 oxidation, which constructed brevisamide (2.2) in 27 steps and 0.8% overall yield.
55,56 
Scheme 2.3.4 Panek’s Synthesis of Brevisamide 2.2 
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2-3-5 Formal syntheses 
Since this latest completed total synthesis, two formal syntheses have been accomplished 
by the groups of Smith and Sabitha.
57
 
2-4 Synthetic Plan of Brevisamide 
In devising our own approach, we became intrigued by the challenge of developing a 
concise, enantioselective, and protecting-group-free construction of the diversely 
functionalized tetrahydropyran ring in brevisamide. A synthesis plan based on the 
combination of a catalytic asymmetric Henry reaction and an Achmatowicz 
rearrangement,
58
 outlined in Scheme 1, proved to be successful in meeting this challenge. 
The final operation in the synthesis was envisioned to employ a Stille-cross-coupling 
reaction to install the conjugated (E,E)-dieneal. 
Scheme 2.4.1 Synthetic Plan of Brevisamide 2.2 
 
2-5 Total Synthesis of Brevisamide 
The synthesis of the aldehyde 2.62, shown in Scheme 2.5.1, began from commercially 
available ethyl 3-(furan-2-yl)propionate 2.63, which was treated with LiAlH4 to afford the 
corresponding primary alcohol. After oxidation, the resultant aldehyde was immediately 
submitted to the Corey–Fuchs reaction yielding dibromoalkene 2.64,59 which was treated 
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with n-butyllithium and iodomethane to form the desired alkyne 2.65, along with a furan 
methylation byproduct. Addition of DMPU prior to the addition of iodomethane resulted in 
the isolation of only the desired methylated alkyne 2.65 in high yield. Aldehyde 2.62 was 
prepared directly from 2.65 by a Vilsmeier–Haack reaction in 90% yield.60 
Scheme 2.5.1 Synthesis of Aldehyde 2.62 
 
With aldehyde 2.62 in hand, the key enantioselective Henry reaction was investigated. 
Although a variety of methods are available for this transformation, we focused on a 
procedure developed by Wan and co-workers.
61
 This method has been reported to provide 
products in high enantioselectivity, under practical reaction conditions at room temperature 
and within reasonable reaction times. The method employs a catalytic system derived from 
readily available Cu(OAc)2·H2O and ligand 2.66 in ethanol as the solvent. Much to our 
delight, when 2.62 was exposed to these conditions, the product 2.67 was isolated with a 
99% ee. Extended reaction times resulted in accumulation of the nitroalkene 2.67a as a 
byproduct resulting from dehydration of the initially formed nitro-alcohol 2.67 (Scheme 
2.5.2). To minimize this problem, the reaction was terminated after 40 h at room temperature 
and the products were separated to provide the requisite Henry addition product 2.67 (57% 
yield, 99% ee), the starting material (33% yield), and the nitroalkene 2.67a (10% yield). The 
starting material was then resubmitted to the reaction conditions to afford 2.67 in a 69% 
combined yield and 99% ee after one recycle. 
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Scheme 2.5.2 Asymmetric Henry Reaction 
 
After the development of the enantioselective Henry reaction, the synthesis was 
advanced as illustrated in Scheme 2.5.3. The nitro group in 2.67 was reduced to the 
corresponding amine with LiAlH4 under carefully controlled reaction conditions. Lithium 
aluminum hydride was preferred to other commonly used reagents for reduction of nitro 
compounds such as H2 and Pd/C, Raney-Nickel, and SmI2, due to incompatibility of these 
reagents with the alkyne group present in the substrate.
33,62
 After assessment of a variety of 
reaction conditions, it was determined that a dropwise addition of a solution of the nitro 
compound 4 into a precooled solution of LiAlH4 in THF (−15 °C) limited the retro-Henry 
process leading to the formation of an undesired primary alcohol. The reaction was then 
heated to reflux, which delivered the primary amine in optimized yields. The primary amine 
was then chemoselectively acetylated with acetic anhydride in ethyl acetate–methanol (4:1), 
giving amide 2.61 in 67% yield over the two steps. 
Scheme 2.5.3 Synthesis of the Tetrahydropyran Core 
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According to our synthesis plan, acetamide 2.61 was now properly functionalized for the 
ensuing key Achmatowicz rearrangement. Furan 2.61 underwent oxidative ring expansion in 
the presence of NBS to form the cyclic hemiketal, which was then treated with BF3·OEt2 and 
Et3SiH to produce intermediate 2.68 in a satisfactory 54% yield.
63
 Installation of the methyl 
group was achieved by conjugate addition of lithium dimethylcuprate directly to enone 2.68 
(81% yield, 8:1 dr).
64
 
Our next goal was reduction of 2.69 under thermodynamic conditions to generate the 
more stable diastereomer 2.70 that has the desired configuration at the newly generated 
stereocenter. Our initial attempts centered on various versions of the Meerwein–Pondorf–
Verley (MPV) reaction using Al(OPr-i)3 and Sm(OPr-i)3 reagents. With the aluminum-based 
reagent, the desired diastereomer 2.70 was formed exclusively at high temperatures (100 
°C), however, at low yields. An unidentified byproduct was formed in significant quantities 
apparently resulting from reactivity of the acetamide. At lower temperatures (75 °C), an 
equimolar mixture of diastereomeric alcohols was produced. A ligand-based reduction was 
used in our next approach, employing (R)-CBS catalyst. This method led to a mixture of 
diastereomeric alcohols, with poor selection. Similar outcomes were observed with the 
samarium-based reagent. Reduction with sodium borohydride under standard conditions in 
methanol produced the undesired axial alcohol exclusively. On the other hand, reduction 
with NaBH4 in aqueous THF substantially increased the fraction of the desired equatorial 
alcohol, giving a 1:1 mixture of separable products in 85% isolated yield.
65
 The undersired 
isomer could be separated and recycled through an additional oxidation–reduction sequence. 
Installation of vinyl iodide proceeded in high regioselectivity and yield employing the 
silylcupration-iododesylilation protocol.
66,67
 Silylcupration took place with complete 
stereoselectivity and high regioselectivity (∼13:1). Subsequent iododesilyation with N-
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iodosuccinimide (NIS) in hexafluoroisopropanol (HFIP) successfully delivered the (E)-
iodoalkene 2.60 in high yield and with complete retention of the double bond geometry.
38,68
 
Known vinyltin reagent 2.59 (prepared by hydrostannylation of 2-butyn-1-ol)
69
 was used 
in a Stille cross-coupling reaction with 2.60 to forge the conjugated diene (Scheme 2.5.4). 
Sasaki and co-workers previously reported a similar Stille coupling in the total synthesis of 
brevenal.
39
 In our work, copper(I) thiophene-2-carboxylate was replaced with the copper(I) 
bromide dimethylsulfide complex (CuBr•DMS) without any detrimental effect on the 
Pd2(dba)3/Ph3As-catalyzed cross-coupling process, furnishing 2.71 in 78% yield. 
Completion of the synthesis was achieved with a chemoselective oxidation of the allylic 
alcohol using TEMPO in the presence of PhI(OAc)2 in CH2Cl2 at room temperature, yielding 
(+)-brevisamide (2.2) in 90% yield.
19
 
Scheme 2.5.4 Completetion of Brevisamide (2.2) Synthesis 
 
2-6 Conclusion 
In summary, the total synthesis of (+)-brevisamide (2.2) has been completed in 16 steps 
(longest linear sequence) and an overall yield of 2.5% starting from the commercially 
available ethyl 3-(furan-2-yl)propionate 2.63. The strategy was developed based on a notion 
of concise enantioselective assembly of the properly functionalized tetrahydropyran ring 
without the use of protecting groups. A catalytic asymmetric Henry reaction and then an 
Achmatowicz rearrangement were enlisted to successfully achieve this goal. 
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2-7: Brevisamide Supporting Information 
 
3-(Furan-2-yl)propan-1-ol (2.72). Lithium aluminum hydride (4.29 g, 113 mmol, 3.0 
equiv.) in diethyl ether (160 mL) was cooled to -78 °C. Ethyl 3-(furan-2-yl)propionate (2.63) 
(6.00 mL, 37.6 mmol) in diethyl ether (28 mL total with rinses) was added to the reaction 
vessel. After 10 min of stirring at -78 °C, the reaction vessel was allowed to warm to 0 °C 
and was stirred for 1 h. The reaction vessel was then warmed to rt and stirred for an 
additional 1 h before cooling back to 0 °C and slowly quenching with diH2O (4.29 mL). The 
reaction mixture was stirred for 5 min at 0 °C at which time a 15 wt% NaOH (4.29 mL) 
solution and diH2O (12.9 mL) were added sequentially and stirred for 5 min. The reaction 
vessel was then warmed to rt and stirred until a white precipitate and a clear organic solution 
were formed. The precipitate was filtered off and washed with diethyl ether, and the organic 
solution was collected and concentrated in vacuo. The residue was purified by column 
chromatography (silica, 30% ethyl acetate – hexanes) delivering product 2.72 (4.21 g, 33.4 
mmol, 89%). 
1
H NMR (400 MHz, CDCl3); δ(ppm): 7.31-7.30 (m, 1H); 6.28 (dd, J1=3.2 Hz, 
J2=2.0 Hz, 1H); 6.01 (dd, J1=3.2 Hz, J2=1.2 Hz, 1H); 3.69 (dd, J1=J2=6.0 Hz, 2H); 2.74 
(dd, J1=J2=7.2 Hz, 2H); 1.95-1.86 (m, 2H); 1.42 (br s, 1H).
70
 
 
 
2-(4,4-Dibromobut-3-en-1-yl)furan (2.64). Dimethylsulfoxide (1.70 mL, 24.1 mmol, 3.0 
equiv.) was added to oxalyl chloride (1.05 mL, 12.0 mmol, 1.5 equiv.) in dichloromethane 
(30 mL) at -78 ˚C and was stirred for 15 min. Substrate 2.72 (1.00 g, 7.93 mmol) in 
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dichloromethane (22.8 mL total with rinses) was transferred to the reaction vessel and stirred 
at -78 °C for 25 min. Triethylamine (5.00 mL, 35.9 mmol, 4.5 equiv.) was added to the 
reaction vessel and stirred for 10 min at -78 °C. The solution was then warmed to rt and 
stirred for an additional 10 min before 1.0 M HCl (30 mL); diH2O (30 mL); diethyl ether (75 
mL) were added. The phases were separated, and the aqueous phase was extracted with 
diethyl ether (3x50 mL). The combined organic phases were washed with a 1:1 v/v mixture 
of brine and saturated aqueous sodium bicarbonate and dried over sodium sulfate. The 
volatile crude aldehyde was concentrated by simple distillation at 60 °C to a volume of 5-10 
mL remained at which point pentane (20 mL) was added and the distillation was continued 
until 5-10 mL remained. The crude organic mixture was then purified rapidly by column 
chromatography (silica, 30% diethyl ether – pentane) to avoid the decomposition of the 
aldehyde. Fractions containing the aldehyde were collected and concentrated by simple 
distillation at 60 °C until 5-10 mL remained, which was submitted to the Corey-Fuchs 
reaction. 
Triphenylphosphine (8.32 g, 31.7 mmol, 4.0 equiv.) was added to a solution of carbon 
tetrabromide (5.27 g, 15.9 mmol, 2.0 equiv.) in dichloromethane (15.4 mL) at 0 °C and 
stirred for 30 min. Then the diluted pure aldehyde (ca. 7.93 mmol) in dichloromethane (10.0 
mL total with rinses) was added to the reaction vessel and stirred for 15 min at 0 °C. The 
reaction mixture was quenched with the addition of diH2O (20 mL) and diethyl ether (40 
mL). The phases were separated, and the aqueous layer was extracted with diethyl ether 
(3x20 mL). The combined organic phases were washed with brine, dried over sodium 
sulfate, and concentrated in vacuo. Removal of the triphenylphospine oxide was 
accomplished by addition of a small amount of diethyl ether (5 mL) to the crude product 
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followed by addition of pentane (60 mL) with agitation, which caused formation of a white 
solid (triphenylphosphine oxide). Solids were filtered through a plug column and washed 
with pentane. The collected organic phase was concentrated in vacuo. The residue was 
purified by column chromatography (silica, 100% pentane) delivering product 2.64 (1.93 g, 
6.90 mmol, 87% over 2 steps). 
1
H NMR (400 MHz, CDCl3); δ(ppm): 7.33-7.31 (m, 1H); 
6.42 (dd, J1=3.2, J2=2.0 Hz, 1H); 6.29 (dd, J1=3.2 Hz, J2=2.0 Hz, 1H); 6.03 (dd, J1=3.2 
Hz, J2=0.8 Hz, 1H); 2.76 (dd, J1=J2=7.2 Hz, 2H); 2.44 (ddd, J1=J2=J3=7.2 Hz, 2H). 
13
C 
NMR (125 MHz, CDCl3); (ppm): 154.3, 141.5, 137.4, 110.4, 105.8, 90.0, 31.8, 26.4. 
LRMS (ESI) calcd for C8H9Br2O [M+H] 278.90, found 279.89. 
 
 
2-(Pent-3-yn-1-yl)furan (2.65). Substrate 2.64 (0.240 g, 0.857 mmol) in THF (1.10 mL) 
was cooled to -78 °C. n-Butyllithium (2.47 M, 1.05 mL, 2.59 mmol, 3.0 equiv.) was added 
to the reaction mixture and stirred for 1.25 h at -78 °C. DMPU (0.310 mL, 2.56 mmol, 3.0 
equiv.) was added to the mixture at -78 °C and stirred for 5 min; followed by addition of 
methyl iodide (1.00 mL, 16.1 mmol, 18.8 equiv.). The reaction mixture was stirred for 1 h at 
-78°C and was then warmed to rt and stirred for an additional 1 h before adding saturated 
aqueous ammonium chloride. The resulting phases were separated, and the aqueous phase 
was extracted with diethyl ether (3x5 mL). The combined organic phases were washed with 
diH2O (3x10 mL); brine (2x10 mL); dried over sodium sulfate, and concentrated in vacuo. 
The residue was purified by column chromatography (silica, 100% pentane) delivering 
product 2.65 (0.1094 g, 0.815 mmol, 95%). 
1
H NMR (500 MHz, CDCl3); δ(ppm): 7.31-7.30 
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(m, 1H); 6.29-6.28 (m, 1H); 6.07-6.05 (m, 1H); 2.82 (dd, J1=J2=7.0 Hz, 2H); 2.48–2.43 (m, 
2H); 1.77 (dd, J1=J2=2.5 Hz, 3H). 
13
C NMR (125 MHz, CDCl3); (ppm): 154.8, 141.2, 
110.3, 105.5, 78.2, 76.4, 28.2, 18.2, 3.8. LRMS (ESI) calcd for C9H10O [M] 134.07, found 
134.07. 
 
 
5-(Pent-3-yn-1-yl)furan-2-carbaldehyde (2.62). Dimethylformamide (1.35 mL, 17.4 
mmol, 1.3 equiv.) was added to pre-cooled (0 °C) phosphonyl trichloride (1.35 mL, 14.7 
mmol, 1.1 equiv.). The reaction vessel was capped and heated to 85 °C for 1.5 h. The 
reaction vessel was then cooled to 0 °C and substrate 8 (1.77 g, 13.2 mmol) in 
dimethylformamide (6.60 mL total with rinses) was added and stirred for 5 min. The 
reaction vessel was then capped, warmed to rt, and stirred for 24 h. The reaction mixture was 
added slowly to saturated aqueous sodium bicarbonate (50 mL) to quench the reaction. 
Additional saturated aqueous sodium bicarbonate was added until the reaction mixture had a 
pH 8-9. The phases were separated and the aqueous phase was extracted with 
dichloromethane (3x20 mL). The combined organic phases were then washed with a 1:1 
mixture of brine and saturated aqueous sodium bicarbonate, dried over sodium sulfate, and 
concentrated in vacuo. The residue was purified by column chromatography (silica, 20% 
ethyl acetate - hexane) delivering product 2.62 (1.93 g, 11.9 mmol, 90%). 
1
H NMR (500 
MHz, CDCl3); δ(ppm): 9.54 (s, 1H); 7.18 (d, J=4.0 Hz, 1H); 6.34 (d, J=4.0 Hz, 1H); 2.91 
(dd, J1=J2=7.5 Hz, 2H); 2.55–2.50 (m, 2H); 1.75 (dd, J1=J2=2.5 Hz, 3H). 13C NMR (125 
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MHz, C6D6); (ppm): 176.8, 161.4, 153.0, 121.8, 109.3, 77.8, 77.3, 28.6, 18.0, 3.7. LRMS 
(ESI) calcd for C10H10O2 [M] 162.07, found 162.07. 
 
 
(S)-2-Nitro-1-(5-(pent-3-yn-1-yl)furan-2-yl)ethanol (2.67). Copper(II) acetate 
monohydrate (30.9 mg, 0.155 mmol, 0.025 equiv.) and ligand 2.66
71
 (0.235 g, 0.310 mmol, 
0.050 equiv.) were dissolved in freshly distilled ethanol (6.20 mL) and stirred at rt for 1 h. 
Substrate 2.62 (1.00 g, 6.17 mmol) in freshly distilled ethanol (6.20 mL total with rinses) 
was added to the reaction vessel, followed by addition of freshly distilled nitromethane (6.60 
mL, 123 mmol, 20 equiv.) and stirred at rt for 40 h. The reaction mixture was concentrated 
in vacuo and the residue was purified rapidly by column chromatography (silica, 10% diethyl 
ether – pentane, 30 % diethyl ether – pentane). The recovered starting material was then 
resubmitted to similar reaction conditions. Copper(II) acetate monohydrate (9.4 mg, 47 
mol, 0.025 equiv.) and ligand 2.66 (71.3 mg, 94 mol, 0.050 equiv.) were dissolved in 
freshly distilled ethanol (1.90 mL) and stirred at rt for 1 h. Recovered substrate 2.62 (0.304 
g, 1.87 mmol) in freshly distilled ethanol (1.90 mL total with rinses) was added to the 
reaction vessel, followed by addition of freshly distilled nitromethane (2.00 mL, 37.4 mmol, 
20 equiv.) and stirred at rt for 72 h. The reaction mixture was concentrated in vacuo and the 
residue was purified rapidly by column chromatography (silica, 10% diethyl ether – pentane, 
30 % diethyl ether – pentane) delivering the combined product 2.67 (0.955 g, 4.28 mmol, 
69%); ee >99% by chiral HPLC analysis (Daicel Chiralcel OJ-H, 10% i-PrOH/hexanes, 
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=215 nm, r=1.0 ml/min, Rt=30.6 min). []D
23 -38.6 (c 10.0, CHCl3). 
1
H NMR (500 MHz, 
CDCl3); δ(ppm): 6.29 (d, J1=4.0 Hz, 1H); 6.06 (d, J1=4.0 Hz, 1H); 5.45-5.40 (m, 1H); 4.78 
(dd, J1=14.0 Hz, J2=9.5 Hz, 1H); 4.66 (dd, J1=14.0 Hz, J2=3.5 Hz, 1H); 2.79 (dd, 
J1=J2=7.0 Hz, 2H); 2.66 (d, J1=5.5 Hz, 2H); 2.47–2.41 (m, 2H); 1.77 (dd, J1=J2=2.5 Hz, 
3H). 
13
C NMR (125 MHz, CD3OD); (ppm): 156.6, 152.3, 109.3, 107.5, 80.2, 78.7, 77.1, 
65.9, 29.1, 18.7, 3.2. LRMS (ESI) calcd for C11H13NO4Na [M+Na] 246.07, found 246.09. 
 
 
(S)-N-(2-Hydroxy-2-(5-(pent-3-yn-1-yl)furan-2-yl)ethyl)acetamide (2.61). Lithium 
aluminum hydride (0.681 g, 17.9 mmol, 3.0 equiv.) in THF (18.0 mL) was cooled to -15 °C. 
Substrate 2.67 (0.802 g, 3.59 mmol) in THF (54 mL total with rinses) was slowly added to 
the reaction vessel and stirred for 30 min at -15 °C. The reaction mixture was warmed to rt 
and stirred for 30 min; then heated to reflux for 1.5 h before cooling back to 0 °C and slowly 
quenching with diH2O (0.68 mL). The reaction mixture was stirred for 5 min at the same 
temperature at which time 15 wt% NaOH (0.68 mL) and diH2O (2.05 mL) were added 
sequentially and stirred for 5 min. The reaction mixture was warmed to rt and stirred for 4 
hours (until an off-white precipitate formed). The precipitate was filtered off and washed 
with diethyl ether. The collected organic phase was concentrated in vacuo and submitted to 
the next reaction without further purification. 
The crude substrate was suspended in ethyl acetate (11.5 mL) and methanol (2.90 mL). 
Acetic anhydride (0.370 mL, 3.91 mmol, 1.1 equiv.) was added to the reaction vessel and 
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stirred at rt for 12 h. An aqueous solution of 10 wt% K2CO3 (15 mL) was added to the 
reaction vessel and stirred at rt for 10 min. The resulting phases were separated and the 
aqueous phase was extracted with ethyl acetate (3x10 mL). The combined organic phases 
were washed with brine, dried over sodium sulfate, and concentrated in vacuo. The residue 
was purified by column chromatography (silica, 80% ethyl acetate – hexanes, 90% ethyl 
acetate – hexanes, 100% ethyl acetate – hexanes, 95% ethyl acetate – methanol) delivering 
product 2.61 (0.567 g, 2.41 mmol, 67% over 2 steps). []D
23 -35.4 (c 10.0, CHCl3). 
1
H NMR 
(500 MHz, CDCl3); δ(ppm): 6.19 (d, J1=3.0 Hz, 1H); 6.01 (d, J1=3.0 Hz, 1H); 5.96 (br s, 
1H); 4.79-4.75 (m, 1H); 3.75 (ddd, J1=14.0 Hz, J2=6.5 Hz, J3=3.5Hz, 1H); 3.51 (ddd, 
J1=13.5 Hz, J2=7.5 Hz, J3=5.5 Hz, 1H); 3.12-3.10 (m, 1H); 2.78 (dd, J1=J2=7.0 Hz, 2H); 
2.46–2.41 (m, 2H); 2.01 (s, 3H); 1.77 (dd, J1=J2=2.0 Hz, 3H). 13C NMR (125 MHz, 
CDCl3); (ppm): 171.6, 154.8, 152.8, 107.7, 106.4, 78.1, 76.6, 67.7, 44.6, 28.1, 23.4, 18.1, 
3.7. LRMS (ESI) calcd for C13H17NO3Na [M+Na] 258.11, found 258.12. 
 
 
N-(((2R,6S)-3-Oxo-6-(pent-3-yn-1-yl)-3,6-dihydro-2H-pyran-2-yl)methyl)acetamide 
(2.68). N-bromo-succinimide (0.223 g, 1.25 mmol, 1.0 equiv.) was added to a mixture of 
substrate 2.61 (0.293 g, 1.25 mmol), sodium bicarbonate (0.210 g, 2.50 mmol, 2.0 equiv.), 
and sodium acetate (0.103 g, 1.25 mmol, 1.0 equiv.) in THF (7.90 mL) and diH2O (2.6 mL) 
at 0 °C (the reaction vessel was open to air). The reaction vessel was stirred at 0 °C for 1.5 h 
before addition of saturated aqueous ammonium chloride (10 mL). The phases were 
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separated and the aqueous phase was extracted with ethyl acetate (3x10 mL). The combined 
organic phases were washed with brine, dried over sodium sulfate, and concentrated in 
vacuo. The crude product was submitted to the next reaction without further purification. 
The crude substrate in dichloromethane (12.5 mL) was cooled to 0 °C. Triethylsilane (1.00 
mL, 6.26 mmol, 5.0 equiv.) was added to the reaction vessel followed by addition of 
BF3•Et2O (0.310 mL, 2.51 mmol, 2.0 equiv.) at 0 °C and stirring for 30 min. The reaction 
was quenched by addition of saturated aqueous sodium bicarbonate (15 mL). The phases 
were separated and the aqueous phase was extracted with ethyl acetate (3x10 mL). The 
combined organic phases were washed with brine, dried over sodium sulfate, and 
concentrated in vacuo. The residue was purified by column chromatography (silica, 80% 
ethyl acetate – hexanes) delivering product 2.68 (0.159 g, 0.676 mmol, 54% over 2 steps). 
[]D
23 22.5 (c 10.0, CHCl3). 
1
H NMR (400 MHz, CDCl3); δ(ppm): 6.95 (dd, J1=10.4 Hz, 
J2=1.6 Hz, 1H); 6.09 (dd, J1=10.4 Hz, J2=2.4 Hz, 1H); 6.02 (br s, 1H); 4.55-4.49 (m, 1H); 
4.04 (ddd, J1=J2=5.60 Hz, J3=1.6 Hz, 1H); 3.70–3.55 (m, 2H); 2.38–2.22 (m, 2H); 1.97 (s, 
3H); 1.86–1.79 (m, 2H); 1.76 (dd, J1=J2=2.4 Hz, 3H). 13C NMR (100 MHz, CDCl3); 
(ppm): 195.9, 170.2, 151.8, 127.0, 78.1, 77.8, 77.0, 73.1, 39.4, 34.0, 23.5, 14.7, 3.7. LRMS 
(ESI) calcd for C13H17NO3Na [M+Na] 258.11, found 258.11. 
 
 
N-(((2R,5S,6S)-5-Methyl-3-oxo-6-(pent-3-yn-1-yl)tetrahydro-2H-pyran-2-
yl)methyl)acetamide (2.69). Methyl-lithium (1.64 M in diethyl ether, 1.19 mL, 1.95 mmol, 
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3.3 equiv.) was added to a solution of copper(I) bromide-dimethyl sulfide complex (0.200 g, 
0.973 mmol, 1.65 equiv.) in diethyl ether (1.35 mL) at -60 °C. The reaction vessel was 
warmed to -30 °C and stirred for 20 min then cooled to -78 °C and substrate 2.68 (0.138 g, 
0.587 mmol) in diethyl ether (4.50 mL total with rinses) was added dropwise. The reaction 
vessel was stirred at -78 °C for 1 h and then warmed to 0 °C over 30 min before being 
quenched with a 9:1 v/v solution of saturated aqueous ammonium chloride and ammonium 
hydroxide (15 mL). The biphasic mixture was stirred for 3 h at rt (until a dark blue solution 
formed). The phases were separated and the aqueous phase was extracted with diethyl ether 
(3x10 mL). The combined organic phases were washed with brine, dried over sodium 
sulfate, and concentrated in vacuo. The residue was purified by column chromatography 
(silica, 80% ethyl acetate – hexanes) delivering product 2.69 (0.120 g, 0.477 mmol, 81%, 8:1 
dr). A sample of the diastereomers was separated using preparative HPLC. The separation 
was conducted on a YMC-Pack Sil HPLC column (250x30mmID, S-10 m, 12 nm) with 2.0 
mL injection (10% i-PrOH/hexanes as eluent at a rate of 20 mL/min, =210 nm, Rt=48.0 
min) afforded pure product 12 (80.4 mg, 0.320 mmol). []D
23 52.3 (c 10.0, CHCl3). 
1
H NMR 
(500 MHz, CDCl3); δ(ppm): 5.86 (br s, 1H); 4.01 (ddd, J1=9.0 Hz, J2=4.5 Hz, J3=2.0 Hz, 
1H); 3.92 (dd, J1=J2=6.0 Hz, 1H); 3.58 (ddd, J1=14.0 Hz, J2=J3=6.0 Hz, 1H); 3.49 (ddd, 
J1=14.0 Hz, J2=J3=6.0 Hz, 1H); 2.71 (dd, J1=15.0 Hz, J2=6.0 Hz, 1H); 2.34 (dd, J1=15.0 
Hz, J2=2.0 Hz, 1H); 2.32–2.25 (m, 3H); 1.97 (s, 3H); 1.80–1.73 (m, 3H); 1.79 (dd, 
J1=J2=2.5 Hz, 3H); 1.60–1.54 (m, 1H); 0.94 (d, J1=6.5 Hz, 3H). 13C NMR (125 MHz, 
CDCl3); (ppm): 208.1, 170.1, 80.5, 78.4, 78.0, 76.4, 47.4, 39.1, 36.0, 31.9, 23.6, 15.9, 13.5, 
3.8. LRMS (ESI) calcd for C14H21NO3Na [M+Na] 274.14, found 274.15. 
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N-(((2R,3S,5S,6S)-3-Hydroxy-5-methyl-6-(pent-3-yn-1-yl)tetrahydro-2H-pyran-2-
yl)methyl)acetamide (2.70). Sodium borohydride (21.8 mg, 0.576 mmol, 4.0 equiv.) in 
diH2O (0.26 mL) was added dropwise to substrate 2.69 (36.3 mg, 0.144 mmol) in THF (2.60 
mL) at rt and stirred for 5 min before it was quenched with saturated aqueous ammonium 
chloride (5 mL). The phases were separated and the aqueous phase was extracted with ethyl 
acetate (3x5 mL). The combined organic phases were washed with brine, dried over sodium 
sulfate, concentrated in vacuo. The residue was purified by column chromatography (silica, 
70% ethyl acetate – hexanes to 100% ethyl acetate - hexanes) delivering product 2.70 (15.5 
mg, 61.2 µmol, 42.5%) as a single diastereomer. []D
23 124.5 (c 10.0, CHCl3). 
1
H NMR (500 
MHz, CDCl3); δ(ppm): 5.96 (br s, 1H); 3.99–3.93 (m, 2H); 3.54–3.50 (m, 1H); 3.46-3.40 
(m, 1H); 3.14–3.07 (m, 2H); 2.27–2.12 (m, 2H); 2.05 (s, 3H); 1.94 (ddd, J1=12.5 Hz, 
J2=4.5 Hz, J3=2.5 Hz, 1H); 1.90–1.83 (m, 1H); 1.78 (dd, J1=J2=2.5 Hz, 3H); 1.70–1.59 
(m, 2H); 1.50–1.44 (m, 1H); 0.91 (d, J1=7.5 Hz, 3H). 13C NMR (125 MHz, CDCl3); 
(ppm): 172.3, 82.6, 79.1, 78.8, 76.0, 62.3, 41.2, 38.6, 32.8, 32.4, 23.2, 15.9, 13.1, 3.8. 
LRMS (ESI) calcd for C14H23NO3Na [M+Na] 276.33, found 276.19. 
 
 
N-(((2R,5S,6S)-6-((E)-4-(Dimethyl(phenyl)silyl)pent-3-en-1-yl)-5-methyl-3-
oxotetrahydro-2H-pyran-2-yl)methyl)acetamide (2.73). PhMe2SiLi (0.9 M solution in 
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THF, 4.20 mL, 3.78 mmol, 20 equiv.) was added to a solution of copper cyanide (0.170 g, 
1.90 mmol, 10 equiv.) in THF (4.80 mL) at 0 °C and stirred for 20 minutes. The reaction 
vessel was cooled to -78 °C followed by addition of substrate 2.70 (47.9 mg, 0.189 mmol) in 
ether (6.30 mL total with rinses) and then THF (0.30 mL). The reaction vessel was stirred at 
-78 °C for 1 h and was warmed to 0 °C and stirred for 1 h before being quenched with a 9:1 
v/v solution of saturated aqueous ammonium chloride and ammonium hydroxide (15 mL). 
The biphasic mixture was stirred for 3 h at rt (until a dark blue aqueous solution formed). 
The phases were separated and the aqueous layer was extracted with ethyl acetate (3x10 
mL). The combined organic phases were washed with saturated aqueous sodium 
bicarbonate, brine, dried over sodium sulfate, and concentrated in vacuo. The residue was 
purified by column chromatography (silica, 60% ethyl acetate – hexanes to 80% ethyl acetate 
- hexanes) delivering product 2.73 (68.2 mg, 0.175 mmol, 93%,) as a 13:1 inseparable 
mixture of regioisomers. []D
23 62.1 (c 5.0, CHCl3). 
1
H NMR (500 MHz, CDCl3); δ(ppm): 
7.52-7.46 (m, 2H); 7.36-7.32 (m, 3H); 5.97 (br s, 1H); 5.78 (ddd, J1=J2=7.0 Hz, J3=1.5 Hz, 
1H); 4.03–3.89 (m, 2H); 3.47–3.34 (m, 2H); 3.12–3.02 (m, 2H); 2.22-2.10 (m, 2H); 2.04 (s, 
3H); 1.94 (ddd, J1=13.0 Hz, J2=4.5 Hz, J3=2.5 Hz, 1H); 1.90–1.82 (m, 1H); 1.66 (s, 3H); 
1.65–1.51 (m, 2H); 1.41–1.32 (m, 1H); 0.92 (d, J1=6.5 Hz, 3H); 0.32 (s, 6H). 13C NMR 
(125 MHz, CDCl3); (ppm): 172.3, 141.0, 138.9, 135.0, 134.1, 129.0, 127.9, 82.7, 80.0, 
62.2, 41.2, 38.7, 32.8, 32.3, 25.3, 23.2, 14.9, 12.9, -3.2. LRMS (ESI) calcd for 
C32H35NO2SiNa [M+Na] 412.23, found 412.23. 
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N-(((2R,5S,6S)-6-((E)-4-Iodopent-3-en-1-yl)-5-methyl-3-oxotetrahydro-2H-pyran-2-
yl)methyl)acetamide (2.60). N-Iodosuccinimide (74.7 mg, 0.332 mmol, 2.0 equiv.) was 
added to a solution of substrate 2.73 (64.8 mg, 0.166 mmol) and 2,6-lutidine (15.5 µL, 0.133 
mmol, 0.8 equiv.) in hexafluoroisopropanol (1.70 mL) at 0 °C and stirred for 5 min. Ethyl 
acetate (3 mL) and diH2O (3 mL) were added to the reaction mixture. The phases were 
separated and the aqueous phase was extracted with ethyl acetate (3x5 mL). The combined 
organic phases were washed with saturated aqueous sodium thiosulfate (10 mL); 1 M HCl 
(10 mL); diH2O (10 mL); brine, dried over sodium sulfate, and concentrated in vacuo. The 
residue was purified by column chromatography (silica, 60% ethyl acetate – hexanes to 80% 
ethyl acetate - hexanes) delivering product 2.60 (53.0 mg, 0.139 mmol, 84%) as a 13:1 
inseparable mixture of regioisomers. []D
23 104.1 (c 5.0, CHCl3).
 1
H NMR (500 MHz, 
CDCl3); δ(ppm): 6.15 (ddd, J1=J2=7.5 Hz, J3=1.5 Hz, 1H); 5.98 (br s, 1H); 4.05–3.96 (m, 
2H); 3.46–3.35 (m, 2H); 3.11–3.04 (m, 2H); 2.37 (s, 3H); 2.12–2.04 (m, 2H); 2.06 (s, 3H); 
1.94 (ddd, J1=12.5 Hz, J2=4.5 Hz, J3=2.5 Hz, 1H); 1.88–1.80 (m, 1H); 1.70–1.61 (m, 1H); 
1.59-1.49 (m, 1H) 1.38–1.30 (m, 1H); 0.91 (d, J1=7.0 Hz, 3H). 13C NMR (125 MHz, 
CDCl3); (ppm): 172.4, 140.9, 94.1, 82.7, 79.6, 62.1, 41.1, 38.6, 33.0, 32.0, 27.64, 27.60, 
23.2, 13.0. LRMS (ESI) calcd for C14H24NO2INa [M+Na] 404.07, found 404.09. 
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N-(((2R,3S,5S,6S)-3-Hydroxy-6-((3E,5E)-7-hydroxy-4,5-dimethylhept3,5-dien-1-
yl)-5-methyltetrahydro-2H-pyran-2-yl)methyl)acetamide (2.71). Vinyl stannane 2.59
72
 
(56.0 mg, 0.155 mmol, 5.0 equiv.) in a 1:1 v/v solution of THF and dimethylsulfoxide (3.40 
mL) was added to a solution of substrate 14 (14.1 mg, 37.0 µmol) in a 1:1 v/v solution of 
THF and dimethylsulfoxide (1:1, 0.60 mL) at rt. Copper(I) bromide-dimethylsulfide 
complex (81.0 mg, 0.394 mmol, 12.7 equiv.); triphenylarsenic (7.7 mg, 25.1 µmol, 0.8 
equiv.); and Pd2(dba)3 (2.8 mg, 3.1 µmol, 0.8 equiv.) were added sequentially to the reaction 
vessel at rt and stirred for 1 h. diH2O (4 mL) was added to the reaction vessel at rt and stirred 
for 20 min. The reaction vessel was filtered through Celite and washed with ethyl acetate (30 
mL total with rinses). The collected organic phases were washed with diH2O (20 mL); brine 
(20 mL); dried over sodium sulfate, and concentrated in vacuo. The residue was purified by 
column chromatography (silica, 60% ethyl acetate – hexanes to 80% ethyl acetate – hexanes 
to 100% ethyl acetate to 5% methanol - ethyl acetate) and fractions containing product 2.71 
were collected and concentrated in vacuo. The residue was purified again to remove traces of 
the vinyl stannane 2 by column chromatography (silica, 60% ethyl acetate – hexanes to 80% 
ethyl acetate – hexanes to 100% ethyl acetate to 5% methanol - ethyl acetate) delivering 
product 14 (9.4 mg, 28.9 µmol, 78%).[]D
23 92.4 (c 2.0, CHCl3). 
1
H NMR (500 MHz, 
CD3OD); δ(ppm): 8.01 (br s, 1H); 5.65 (dd, J1=J2=6.5 Hz, 1H); 5.60 (dd, J1=J2=6.5 Hz, 
1H); 4.22 (d, J1=6.5 Hz, 2H); 3.58–3.53 (m, 1H); 3.45–3.38 (m, 2H); 3.36–3.32 (m, 1H); 
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3.08 (ddd, J1=9.50 Hz, J2=6.50 Hz, J3=2.5 Hz, 1H); 2.34–2.16 (m, 2H); 1.97 (s, 3H); 1.92 
(ddd, J1=12.5 Hz, J2=4.5 Hz, J3=2.5 Hz, 1H); 1.87–1.82 (m, 1H); 1.81 (s, 3H); 1.80 (s, 
3H); 1.66–1.57 (m, 2H); 1.43–1.33 (m, 1H); 0.97 (d, J1=7 Hz, 3H). 13C NMR (125 MHz, 
CD3OD); (ppm): 173.9, 139.5, 137.7, 128.0, 125.8, 83.2, 80.5, 65.1, 60.2, 42.7, 41.0, 34.3, 
33.9, 26.2, 22.6, 14.4, 14.3, 13.2. LRMS (ESI) calcd for C18H31NO4Na [M+Na] 348.22, 
found 348.30. 
 
 
(+)-Brevisamide (2.2). (Diacetoxyiodo)benzene (7.4 mg, 23.0 µmol, 1.5 equiv.) in 
dichloromethane (0.600 mL) was added dropwise to a solution of substrate 2.71 (4.8 mg, 
14.7 µmol) and TEMPO (1.2 mg, 7.7 µmol, 0.5 equiv.) in CH2Cl2 (0.600 mL) at rt and was 
stirred for 2 h. The reaction mixture was concentrated in vacuo. The residue was purified by 
column chromatography (silica, 2.5% methanol - chloroform) delivering (+)-brevisamide 2.2 
(4.3 mg, 13.3 µmol, 90%). []D
23 15.5 (c 1.0, MeOH) 
1
H NMR (500 MHz, CD3OD); δ(ppm): 
10.10 (d, J1=8.5 Hz, 1H); 6.24 (dd, J1=J2=7.5 Hz, 1H); 6.05 (d, J1=8.5 Hz, 1H); 3.55 (dd, 
J1=14.5 Hz, J2=3.0 Hz, 1H); 3.46–3.38 (m, 2H); 3.37-3.33 (m, 1H); 3.09 (ddd, J1=9.5 Hz, 
J2=7.0 Hz, J3=3.0 Hz, 1H); 2.40 – 2.32 (m, 1H); 2.34 (s, 3H); 1.97 (s, 3H); 1.92 (ddd, 
J1=12.5 Hz, J2=5.0 Hz, J3=2.5 Hz, 1H); 1.88 (s, 3H); 1.87–1.82 (m, 1H); 1.71–1.58 (m, 
2H); 1.50–1.42 (m, 1H); 0.98 (d, J1=7.0 Hz, 3H). 13C NMR (125 MHz, CD3OD); (ppm): 
194.5, 173.9, 161.1, 137.4, 137.0, 126.4, 83.2, 80.5, 65.1, 42.7, 41.0, 34.4, 33.3, 27.0, 22.6, 
14.7, 14.1, 13.2. LRMS (ESI) calcd for C18H29NO4Na [M+Na] 346.20, found 346.23. 
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Table 1. Synthetic Brevisamide Spectral Data Compared to Natural Brevisamide Data 
 
 
 
 
Position 
1
H NMR (mult, J in Hz) 
13
C NMR 
Synthetic Natural Synthetic Natural 
1 10.10 (d, 8.5) 10.10 (d, 7.9) 194.5 194.4 
2 6.05 (d, 8.5) 6.04 (d, 7.9) 126.4 126.3 
3   161.1 160.9 
4   137.4 137.2 
5 6.24 (dd, 7.5) 6.23 (t, 7.1) 137.0 136.8 
6 2.36 m 2.34 m 27.0 26.9 
7a 1.65 m 1.65 m 33.3 33.2 
7b 1.46 m 1.44 m   
8ax 3.42 m 3.39 m 80.5 80.3 
9eq 1.85 m 1.85 m 34.4 34.3 
10eq 
1.92 (ddd, 2.5, 5.0, 
12.5) 
1.90 m 41.0 40.9 
10ax 1.65 m 1.65 m   
11ax 3.42 m 3.42 m 65.1 65.0 
12a 3.09 (ddd, 3.0, 7.0, 9.5) 
3.08 (ddd, 2.6, 7.0, 
9.3) 
83.2 83.1 
13a 3.55 (dd, 3.0, 14.5) 3.53 (dd, 2.6, 14.0) 42.7 42.5 
13b 3.35 m 3.32 (dd, 7.1, 14.0)   
14   173.9 173.7 
15 1.97 s 1.95 s 22.6 22.5 
16 2.34 s 2.33 s 14.7 14.6 
17 1.88 s 1.86 s 14.1 14.0 
18 0.98 (d, 7.0) 0.95 (d, 6.9 Hz) 13.2 13.1 
 
1H NMR: Synthetic at 500 MHz; Natural at 500 MHz in CD3OD 
13C NMR: Synthetic at 125 MHz; Natural at 125 MHz in CD3OD 
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Chapter 3 
 
Haloalkylations of N-Acyl Oxazolidinones via Group IVa Metal Enolates 
 
3-1 Halogenated Natural Products 
Recently there has been a mounting realization of the advantage in both the unique 
physical and chemical properties of a wide variety of halogenated organic compounds. An 
increasingly broad application of these compounds can in turn be used in many areas of 
research: natural product synthesis, medicinal, materials sciences, and agrochemicals are a 
few among the many. Due to this reason, new synthetic methods have been and must be 
developed in order to introduce halogens into a variety of organic compounds. Our group 
focused on the development of synthetic methods for stereoselective haloalkylations in order 
to provide an overall practical, efficient, and operationally simple technique. 
3-2 Trichloroalkylations via TiCl4 Enolates 
Titanium enolates have found widespread use in organic synthesis as a result of their 
unique reactivity and ease of preparation from inexpensive and nontoxic titanium reagents 
under mild conditions that are compatible with a range of functional groups.
73
 The most 
prevalent application of titanium enolates is in stereoselective aldol reactions.
74
 Several 
examples of the alkylation of titanium enolates with strongly electrophilic reagents have also 
been reported.
75
  Valence tautomerism in titanium enolates provided the initial conceptual 
foundation for the development of direct radical chloroalkylation. Using studies completed 
by Moreira and co-workers allowed for the postulation that the unconventional biradical 
character of titanium enolates could allow them to act as efficient radical acceptors.
76
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Titanium enolates can be formed from inexpensive and nontoxic titanium reagents, under 
mild conditions that are compatible with a range of functional groups. This strategy of soft-
enolate formation was coupled with the Kharasch-type reaction involving Ru(II)-catalyzed 
redox of trichloromethyl bromide. Upon initial studies this proved true, when N-acyl 
oxazolidinone 3.1 was treated with TiCl4 and Hünig’s base (i-Pr2NEt); Ti enolate 3.1A was 
formed as evidenced by 
1
H NMR (Scheme 3.2.1). Upon addition of BrCCl3 in the presence 
of [(Ph3P)3RuCl2], product 3.2 was obtained in nearly quantitative yield and excellent 
stereocontrol.
77
 
Scheme 3.2.1 Trichloromethylation of N-Acyl Oxazolidinones 
 
The scope of direct chloroalkylation using the new titanium enolate derived synthetic 
method was carried out in which Table 3.2.1 demonstrates different Evans-type chiral 
auxillaries and a wide variety of substituents on the N-acyl oxazolidinones. Aromatic, 
heterocyclic, along with alkyl substituents proved to be very compatible with the reaction 
conditions proceeding in high yields and high stereocontrol. 
Application of trichloromethylation via titanium enolates was demonstrated by the 
Zakarian group in multiple total syntheses: neodysidenin, barbamide, dysidenin, dysidin, and 
sintokamides A, B, & E (Scheme 3.2.2).
77,78
 The high yield and excellent stereocontrol 
allowed for efficient use in each total synthesis. 
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Table 3.2.1 Radical Trichloromethylation: N-Acyl Oxazolidinone Scope 
 
(a) All yields are of isolated products; dr determined by 500 MHz 
1
H NMR of the crude mixture of products. 
Scheme 3.2.2 Total Syntheses Applying Trichloromethylation Methodology 
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3-3 Dual Ti-Ru Catalysis in the Direct Radical Haloalkylation of N-Acyl 
Oxazolidinones 
We described a different mode of alkylation of titanium enolates in which they serve as 
efficient radical acceptors for haloalkyl radicals generated by a ruthenium-catalyzed redox 
process (vide supra). It has been postulated that the enolate serves as an electroactive ligand 
for the titanium center,
79
 whereby it facilitates the radical addition process and participates in 
the ruthenium catalytic cycle. The utility of this method in the synthesis of a range of 
chloroleucine-derived natural products has been illustrated.
77,80 
 One intriguing aspect of the 
reaction that emerged during our investigations is the possibility of the catalytic generation 
and alkylation of the titanium enolate species. Herein, we describe the development of a 
haloalkylation process that is catalytic in both ruthenium and titanium and thus constitutes 
the first example of a catalytic enolate alkylation involving titanium enolates. 
During an examination of the putative mechanism of the trichloromethylation process 
outlined in Scheme 3.3.1,
77,79
 we directed our attention toward the function of titanium 
tetrachloride. This mechanism suggests that TiCl4 should be regenerated at the completion of 
the reaction, which creates potential for the development of a catalytic process. According to 
the seminal studies by Evans et. al., initial complexation of the substrate and titanium 
tetrachloride is prerequisite to the addition of the amine base and the ensuing enolization.
81
 
If the order of the reagent addition is reversed, enolization is precluded by the apparently 
irreversible formation of an unreactive TiCl4–amine adduct. Thus, the potential interception 
of the regenerated TiCl4 by the amine base would be a major challenge in the catalytic 
recovery of the reagent. 
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Scheme 3.3.1 Radical Trichloromethylation Mechanism 
 
Radical Trichloromethylation Based on Valence Tautomerism in Titanium Enolates: a) an initial overview of 
the mechanism; b) potential sequestering of TiCl4 by the amine. 
Preliminary experimentation revealed that indeed the haloalkylation reaction could reach 
completion withsubstoichiometric titanium tetrachloride under the original reaction 
conditions with diisopropylethylamine (Hünig’s base). On the other hand, the conversion 
decreased precipitously when less than 0.3 equivalents of TiCl4 were used (Table 3.3.1, 
entries 1–4). We hypothesized that the decline in conversion at around 0.3–0.4 equivalents 
of TiCl4 could be attributed to one of the following factors: 1) the possible formation of 
higher-order titanium enolates with a 2:1 or 3:1 ligand-to-metal ratio, in which case no 
catalytic turnover of TiCl4 would occur, or 2) inefficient catalytic recovery of the titanium 
reagent and, possibly, a strong inhibitory effect by the amine. 
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Table 3.3.1 Amine Influence on the Course of the Catalytic Trichloromethylation Reaction 
 
Entry TiCl4 (mol %) Amine (equiv) Conversion (%) 
1 40 iPr2Net (1.1) > 95 
2 30 iPr2Net (1.1) 75 
3 20 iPr2Net (1.1) 50 
4 10 iPr2Net (1.1) 14 
5 30 iPr2Net (3.0) 47 
6 30 iPr2Net (4.5) 28 
7 30 Et3N (1.1) 76 
8 30 Et3N (3.0) 100 
9 10 Et3N (3.0) 75 
10 10 Et3N (3.0) 74 
11 10 Et3N (4.5) 76 
12 30 PMP (1.1) 100 
13 10 PMP (1:1) 100 
(a) Conversion was determined by 
1
H NMR spectroscopy of the crude mixture of products. (b) The reaction 
time was 48 h. PMP = 1,2,2,6,6-pentamethylpiperidine. 
Although it is well-known that titanium forms hexa or octa-coordinated complexes,82 
higher-order titanium enolates such as those depicted in Scheme 3.3.2 have not been 
documented. We monitored the enolization reaction with the Hünig’s base (1.1 equiv) and 
varying amounts of titanium tetrachloride by NMR spectroscopy and found no conclusive 
support for the existence of higher-order titanium enolates; however, it was evident that the 
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degree of enolization diminished proportionally with decreasing substoichiometric amounts 
of TiCl4. Thus, whereas complete enolization was observed with 1.0 equivalent of TiCl4, the 
conversion was approximately 10% with 0.1 equivalents of TiCl4 and about 30% with 0.3 
equivalents of TiCl4. Notably, it could be clearly observed that more than one distinct 
enolate species was generated, and the relative ratios changed substantially as the amount of 
the titanium reagent was varied. Although the nature of the additional species is presently 
unclear,
83
 we concluded that full conversion in the trichloromethylation reaction with a 
substoichiometric amount of TiCl4 could not be rationalized through the implication of 
higher-order titanium enolates. 
Scheme 3.3.2 Hypothetical Formation of Higher-Order TiCl4 Enolates 
 
Higher-order enolates during the enolization of 3.1 with substoichiometric TiCl4. Bn=benzyl. 
The next series of experiments was designed to probe the catalytic recovery of titanium 
tetrachloride. Specifically, we aimed to establish whether titanium tetrachloride could be 
efficiently transferred between different N-acyloxazolidinone species once enolization was 
completed. The cross-over experiment in Scheme 3.3.33  was particularly illuminating and 
revealed a number of notable factors. When the enolization of 3.1 was complete (TiCl4 (0.5 
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equiv), Hünig’s base (1.1 equiv), 0 °C, 45 min), the N-acyloxazolidinone 3.6 (1.0 equiv) was 
added along with additional Hünig’s base (1.1 equiv), and, after 40 min at 0 °C, the 
ruthenium-catalyzed radical trichloromethylation was initiated under the standard conditions. 
With the ultimate loading of titanium tetrachloride at 0.25 equivalents, products 3.2 and 3.7 
resulting from the trichloromethylation of both substrates were produced in nearly equimolar 
amounts, which provided conclusive support for a rapid transfer of TiCl4 between different 
N-acyloxazolidinone species in the presence of diisopropylethylamine. This experiment 
corroborates the feasibility of the catalytic turnover of TiCl4 and suggests inhibition by the 
amine as a reason for its poor efficiency. It can be hypothesized that a fast equilibrium is 
established between titanium enolates 3.3 and 3.8 (Scheme 3.3.3b). This process is 
accompanied by a slow radical addition, and the distribution of products 3.2 and 3.7 is 
determined by the Curtin–Hammett principle. 
Scheme 3.3.3 Cross-over Experiment 
 
a) Cross-over experiment; b) product distribution is in accord with the Curtin–Hammett principle. 
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To ascertain the influence of the amine on the efficiency of the catalytic turnover of 
titanium tetrachloride and to probe further the equilibrium in Scheme 3.3.1b, we carried out 
the trichloromethylation reaction with various amounts of the Hünig’s base as well as less-
hindered triethylamine and more-hindered 1,2,2,6,6-pentamethylpiperidine (PMP; Table 
3.3.1). An increase in the concentration of the Hünig’s base consistently resulted in lower 
conversion (Table 3.3.1, entries 5 and 6), which supports the proposed inhibitory effect of 
the amine. 
Remarkably, both less-hindered triethylamine and more-hindered PMP proved to be 
superior to the Hünig base for the catalytic turnover of TiCl4. Complete conversion was 
observed with 30 mol % of TiCl4 with 3 equivalents of Et3N, whereas conversion was 76 % 
with 1.1 equivalents of the amine (Table 3.3.1, entries 7 and 8). The same conversion (ca. 
75 %) was observed with 10 mol % of TiCl4 and Et3N (3 equiv). Interestingly, no inhibitory 
effect was observed for triethylamine. With PMP (1.1 equiv), full conversion was observed 
with either 10 or 30 mol % of TiCl4 (Table3.3.1, entries 12 and 13). As with Et3N, no 
inhibition of the trichloromethylation reaction was observed in the presence of excess PMP. 
Thus, the inhibitory effect appears to be confined to the Hünig’s base. 
We compared the original catalyst, [RuCl2(PPh3)3], with a more active catalyst, 
[Cp*RuCl(PPh3)2],
84
 to ascertain whether the rate of trichloromethylation was limited by 
low catalytic turnover frequency of TiCl4 or other factors associated with the radical process 
(Scheme 3.3.4). When the reaction was carried out at room temperature in the presence of 
TiCl4 (20 mol %) and PMP (1.1 equiv), a substantial acceleration of the process was 
observed with [Cp*RuCl(PPh3)2] as the redox catalyst. This observation indicates that 
radical generation is the rate-limiting step, and both the turnover frequency of TiCl4 and the 
addition of ⋅CCl3 to the titanium enolate are relatively fast (Scheme 3.3.3b). 
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Scheme 3.3.4 Catalysis Comparison 
 
Catalyst t (h) Conversion (%) 
[RuCl2(PPh3)3 48 76 
[Cp*RuCl(PPh3)2] 3 93 
Comparison between [RuCl2(PPh3)3] and [Cp*RuCl(PPh3)2] as the redox catalyst for radical generation. 
Cp*=1,2,3,4,5-pentamethylcyclopentadienyl anion. 
In the next series of experiments, the order of reagent addition during the formation of 
the titanium enolate was changed to examine the irreversibility of the formation of TiCl4–
amine complexes under the trichloromethylation reaction conditions. The seminal studies by 
Evans et al. emphasized the importance of the initial TiCl4–substrate complexation; no 
enolate formation was observed if diisopropylethylamine or triethylamine were allowed to 
react with uncomplexed titanium tetrachloride first.
45
 Therefore, we were surprised to 
discover substantial conversion in experiments in which TiCl4 and the amine were mixed 
prior to the addition of the substrate (Table 3.3.2). Although the conversion was lower than 
that observed under the original enolization conditions, these results indicate notable, albeit 
rather inefficient, reversibility in the formation of TiCl4–amine adducts. 
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Table 3.3.2 Influence of the Inverse Addition of the Amines on Conversion. 
 
Entry Amine (equiv) T (° C) t (h) Conversion (%) 
1 iPr2NEt 20 12 41 
2 iPr2NEt 45 12 45 
3 iPr2NEt 50 24 57 
4 PMP 20 12 57 
5 PMP 45 12 63 
6 Et3N 45 12 35 
(a) Conversion was determined by 
1
H NMR spectroscopy of the crude mixture of products. (b) The reaction 
time was 48 h. PMP = 1,2,2,6,6-pentamethylpiperidine. 
On the basis of the experimental results of this study, we propose the catalytic cycle 
depicted in Scheme 3.3.5 for the dual Ru–Ti catalysis in the direct trichloroalkylation of N-
acyl oxazolidinones. An initial complexation of TiCl4 and substrate 1, followed by addition 
of the amine, produces enolate 3.3 along with its biradical valence tautomer 3.3A.
79,85
 An 
electron transfer from the Ru
II
 catalyst to BrCCl3 generates ⋅CCl3, which adds to the 
electron-rich titanium enolate to directly afford 3.9, rather than the carbon-centered radical 
3.9A, along with the Ru
III
counterpart.
86
 Intermediate 3.9, which is essentially the final 
product 3.2 complexed to a Ti
III
 center, regenerates the Ru
II
 catalyst, by a slow, rate-limiting 
single-electron-transfer event, to give the Ti
IV
 chelate 3.10. At this stage, TiCl4 is transferred 
directly and at a relatively high rate to another molecule of the substrate, potentially via an 
octacoordinated species, such as 3.11. Alternatively, TiCl4 can be intercepted by excess 
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amine, which accounts for the inhibitory effect of the amine. It is highly unlikely that 
uncoordinated TiCl4 is present at any time during the course of the reaction.
87
 
Scheme 3.3.5 Proposed Mechanism for Ti-Ru Catalysis in the Radical Haloalkylation of 
Titanium Enolates. 
 
In summary, a direct radical trichloromethylation reaction that is catalytic in both the 
titanium and ruthenium reagents has been developed as a result of a deeper mechanistic 
investigation of the process. This reaction constitutes the first alkylation of titanium enolates 
that is catalytic in titanium and provides a foundation for expanding the scope of catalytic 
radical alkylation reactions of titanium enolates. Important findings include: 1) the discovery 
that the complexation of trialkyl amines to TiCl4 appears to be reversible, especially at 
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elevated temperatures, although the decomplexation is of limited efficiency; and 2) the 
observation that the turnover frequency for the catalytic transfer of TiCl4 is relatively high in 
comparison with the rate of radical generation, even with the more reactive ruthenium 
catalyst [Cp*RuCl(PPh3)2]. 
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3-4 Asymmetric Trifluoromethylation of N-Acyl Oxazolidinones via Ru-Catalyzed 
Radical Addition to Zirconium Enolates 
 
3-4-1 Initial Trifluoroalkylation Studies 
The growing appreciation of unique physical and chemical properties of fluorinated 
organic compounds has resulted in their increasingly broad application in medicine, 
materials sciences, agrochemicals, and many other areas of research.
88
 In order to enable 
future advances in the discovery and application of fluorinated materials, practical methods 
for efficient and selective fluorination are needed. Within this general context,
88a,89
 
stereoselective introduction of the trifluoromethyl and other perfluoroalkyl groups at the α-
position of carbonyl compounds has remained an ongoing challenge, with several notable 
developments reported in the past few years. Following early studies in diastereoselective 
radical trifluoromethylation of lithium enolates employing the iodotrifluoromethane–
Et3B/O2 system for CF3 radical generation,
90
 a number of elegant alternatives based on 
electrophilic,
91
 radical,
92
 or photoredox organocatalytic strategies
93
 have been developed.
94
 
These methods collectively constitute important advances toward highly selective α-
fluoroalkylation of a diverse range of carbonyl compounds and highlight novel patterns of 
reactivity. On the other hand, issues of practicality related to experimental simplicity, cost of 
reagents, and energy efficiency (use of cryogenic conditions or high temperatures) remain 
persistent, stimulating continued progress in this area. 
After, we demonstrated that an experimentally simple, high-yielding diastereoselective 
α-trichloromethylation of titanium enolates can be achieved.95 The process is based on a Ru-
catalyzed redox formation of the trichloromethyl radical from BrCCl3 followed by its 
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addition to catalytically generated titanium enolates derived from chiral N-acyl 
oxazolidinones. This type of radical addition may be facilitated by the putative biradical 
character of titanium enolates.
96
 Overall, the process allows for a direct, one-step 
chloroalkylation of N-acyl oxazolidinones, and its utility in the synthesis of natural products 
with CCl3-substituted stereogenic centers has been highlighted.
95c,97
 Although direct 
extension of this type of reactivity to fluoroalkylation reactions has proven to be highly 
challenging, we have succeeded in reaching this goal by enlisting in situ generated zirconium 
enolates (eq 1). The development of this protocol highlighting operational simplicity in the 
direct α-fluoroalkylation of N-acyl oxazolidinones is described herein.98 
 
Early attempts to extend the chloroalkylation reaction of titanium enolates to 
fluoroalkylations concentrated on screening a range of transition metal catalysts, including 
those that have been previously used in Kharasch-type additions of iodoperfluoroalkanes to 
olefins. Typical examples include [Ph3P]3RuCl2,
99
 Ru3(CO)12,
100
 Fe3(CO)12,
13
 and 
Co2(CO)8;
13
 however, in no instance any amount of fluoroalkylation product was detected. 
After exhausting our options with titanium enolates, we explored other metal halides 
potentially capable of effecting soft enolizations (SmBr3, BiCl3, InCl3, Yb(OTf)3, VOCl3, 
VCl3, VCl4, ZrCl4, HfCl4).
101
 In contrast to our expectations, it was the group IVa metal 
halides, ZrCl4 and HfCl4,
102
 that proved to be uniquely competent in the fluoroalkylation 
reactions. 
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Table 3.4.1 Identification of Transition Metal Catalysts Suitable for Fluoroalkylation of 
Zirconium and Hafnium Enolates
a
. 
 
Entry MCl4 metal catalyst (5-7 mol %) Conversion
b
 (%) 3.13 (%)
b
 
1 ZrCl4 Fe3(CO)12 17 0 
2  Co2(CO)8 26 0 
3  Ru3(CO)12 37 0 
4  FeBr2 31 0 
5  Cu(OEP)
f
 33 0 
6  [Rh(cod)Cl]2 30 0 
7  [(p-cymene)RuCl2]2 46 22 
8  [(C6H6)RuCl2]2 61 28 
9  IndRu[PPh3]2Cl∙CH2Cl2 49 19 
10  Cp*Ru[PPh3]2Cl 87 59
c 
11
e 
 Ru[PPh3]3Cl2
g 
97 74
d 
12
e 
HfCl4 Ru[PPh3]3Cl2
g 
>98 57 
(a) Standard conditions: 1 (0.50 mmol), ZrCl4 (1.05 equiv), Et3N (2.0 equiv), n-C4F9I (5.0 equiv), CH2Cl2 
(∼0.1 M), mixed and stirred at 45 °C for 24 h. (b) Determined by the 500 MHz NMR analysis of the crude 
mixture of products. (c) In addition, 18% of α,β-unsaturated byproduct resulting from HF elimination has also 
been observed. (d) In addition, 12% of α,β-unsaturated byproduct resulting from HF elimination has also been 
observed. (e) n-C3F7I (5.0 equiv) was used. (f) OEP = 2,3,7,8,12,13,17,18-octaethyl-21H,23H-porphirine. (g) 7 
mol % of the metal catalyst was used. 
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Once these metal halides had been identified, a number of transition metal redox 
catalysts for the generation of perfluoroalkyl radicals were examined (Table 3.4.1). Among 
these, ruthenium catalysts emerged as the most promising (entries 7–11), with Ru[Ph3P]3Cl2, 
the catalyst used in the original chloroalkylation of titanium enolates, being the most 
effective. The ruthenium-catalyzed perfluoropropylation of N-acyl oxazolidinones 3.12, 
which served as a benchmark reaction, was characterized by a clean transformation to 3.13 
using only a moderate excess (5 equiv) of n-C3F7I (entry 11). The side products were 
comprised of only the α,β-unsaturated imide as a result of HF elimination from 3.13 (12%) 
and the cleaved oxazolidinone auxiliary (11%),
103
 which together accounted for the majority 
of the remaining mass balance. Similar outcomes were observed with hafnium enolates 
derived in situ from hafnium tetrachloride and Et3N (entry 12). 
The scope of perfluoroalkylating agent was investigated next (Table 3.4.2).
104
 No 
byproduct resulting from α,β-elimination of hydrogen fluoride was observed in any 
trifluoromethylation reactions (entry 1; also see Table 3.4.3). We did observe partial (9–
17%) formation of an α,β-unsaturated byproduct (A) with primary perfluoroalkyl- and 
perfluorobenzyl-substituted products (entries 2, 3, 5, and 6). As in the trifluoromethylation 
reaction, no HF elimination was detected when the 2-perfluoropropyl group was introduced 
(entry 4). 
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Table 3.4.2 Scope of Perfluoroalkylating Agent
a
 
 
(a) Yields of isolated products are reported. The numbers in parentheses are yields of the corresponding α,β-
unsaturated byproduct A, when observed. Diastereomer ratios were determined by 500 MHz 
1
H NMR analysis. 
(b) observed for primary perfluoroalkyl groups only. (c) 15 mol % of [Ph3P]3RuCl2 were used. (d) brsm = 
based on recovered starting material. 
A variety of N-acyl oxazolidinones can be successfully trifluoromethylated using the 
simple protocol developed in the course of this investigation (Table 3.4.3). We found that 
reagents can be mixed all at once in any order at room temperature with no influence on the 
isolated yield of the desired product. Therefore, the reaction setup can be guided solely by 
experimental convenience rather than by other factors intrinsic to the reaction. N-Acyl 
oxazolidinones obtained from unfunctionalized alkanoic acids undergo efficient and 
diastereoselective trifluoromethylations, with yields increasing for β-branched substrates 
(entries 1–4). These are clean transformations, where unreacted starting material is the major 
byproduct as indicated by yields based on recovered starting materials (entries 2–4), while 
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auxiliary cleavage (25%) was observed for the reaction in entry 1. The presence of aryl and 
benzyl ethers is well-tolerated (entries 5, 6), as is the presence of functionalized β-aryl 
substitution, although the extent of chiral auxiliary detachment was higher (31–34% for 
entries 7, 8). Substitution with a phenyl group at the α-position resulted in a clean reaction 
(82% yield brsm, entry 9), albeit at a reduced conversion under the standard conditions 
(59%). Diastereoselective alkylations controlled by the oxazolidinone stereochemistry can be 
performed with substrates that have a stereogenic center at the β-position in the N-acyl 
substituent (entries 10, 11). More functionalized heterocyclic substituents such as 
benzofurans and benzoxazoles are also compatible with the reaction conditions (entries 12, 
13). 
The proposed mechanism of the reaction based on the related Ru-catalyzed 
trichloromethylation is depicted in Scheme 3.4.1.
95a,97 
NMR spectroscopic studies of the 
enolate formation using N-propionyl oxazolidinones 3.12, zirconium tetrachloride, 
triethylamine, and CDCl3revealed that a rapid, clean, and essentially complete enolization 
producing enolate 3.15 occurs at room temperature. We succeeded in obtaining a single-
crystal X-ray structure of a complex between the substrate and ZrCl4 revealing a nearly 
perfectly planar arrangement of atoms in the six-membered cyclic chelate 3.17 which is in 
all respects similar to the corresponding titanium complex (not shown). Therefore, we 
surmise that the geometric structures of the zirconium (3.15) and titanium enolates are 
similar, and it is the dissimilarities in their electronic structure that are responsible for 
differences in their reactivity in the ruthenium-catalyzed fluoroalkylation reaction. Once 3.15 
is formed, it undergoes an addition reaction with the trifluoromethyl radical generated by a  
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Table 3.4.3 Scope of N-Acyl Oxazolidinones in the Trifluoromethylation Reaction
a
 
 
(a) Yields of isolated products are reported. At least two experiments were carried out to confirm 
reproducibility. The numbers in parentheses are yields based on recovered starting material (brsm). 
Diastereomer ratios were determined by 500 MHz 
1
H NMR analysis of the crude mixture of products. 
redox process from iodotrifluoromethane and the ruthenium(II) catalyst. The addition 
product is probably better represented by resonance form 3.16b rather than carbon-centered 
form 3.16a, and a potential biradical character of 3.15 may facilitate the addition of the CF3 
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radical. The ruthenium catalyst is recovered by a single electron transfer from intermediate 
3.16b to Ru(III) species. 
Scheme 3.4.1 Proposed Mechanism of the Ru-Catalyzed Trifluoromethylation Reaction 
 
Additional insight into the course of the perfluoroalkylation was acquired from the 
following experiments. First, when the catalyst loading in the perfluoropropylation of 3.12 
was increased from 7 to 30 mol %, the rate of the process was notably enhanced. The 
reaction was complete in 4 rather than 16 h, showing a substantially reduced level of side 
reactions and giving the expected product in 86% isolated yield. Similar, albeit somewhat 
lower efficiency was observed when the amount of n-C3F7I was increased from 5 to 15 
equiv. Taken together, these observations suggest that the generation of the perfluoroalkyl 
radical is the rate-limiting step of the process. Second, monitoring the course of the reaction 
performed in CD2Cl2 by 
1
H and 
19
F NMR spectroscopy revealed that another major pathway 
of reactivity for n-C3F7–I is reduction to n-C3F7–H, which presumably occurs by oxidation of 
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triethylamine. Overall, these key observations are expected to aid in developing more 
efficient perfluoroalkylation processes based on radical additions to transition metal 
enolates. 
Scheme 3.4.2 Preparation of Versatile Enantioenriched Fluorinated Building Blocks by 
Hydrolytic and Reductive Removal of the Chiral Auxiliary
a 
 
(a) The chiral auxiliary is recovered in nearly quantitative yield in all reactions. 
Conversion of the reaction products to broadly useful fluorinated building blocks for 
organic synthesis is illustrated by examples in Scheme 3.4.2 that include hydrolytic and 
reductive removal of the chiral auxiliary. Trifluoromethyl-substituted derivative 3.18 and 
perfluoropropyl derivative 3.19
105
  could be readily hydrolyzed with a LiOH–H2O2 reagent 
system to the corresponding carboxylic acids with a high level of retention of stereochemical 
integrity. While reductions of these compounds with sodium borohydride in aqueous THF 
were sluggish, removal of the oxazolidinone could be readily achieved by treatment with 
lithium aluminum hydride. For substrate 3.19, virtually complete preservation of 
stereochemistry was observed, while only a minor erosion of stereochemistry was noted for 
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the perfluoropropyl-substituted substrate. Notably, these transformations are characterized 
by very good yields and nearly quantitative recovery of the chiral auxiliary. 
In closing, we report an experimentally simple asymmetric fluoroalkylation reaction of 
N-acyl oxazolidinones based on the unique radical reactivity of group IVa metal enolates. 
For titanium enolates, the biradical character has been supported by computational and 
spectroscopic studies that provide an intriguing conceptual basis for reaction development. 
From a practical perspective, the reaction requires inexpensive reagents, which can be mixed 
in any order, and mild heating over the course of a few hours delivers fluoroalkylation 
products directly in good yields and high diastereoselectivities. Ongoing studies are directed 
at the development of a more active catalytic system, catalytic generation of the metal 
enolate, and defining a more detailed picture for the mechanism of the reaction. 
3-4-2: Continuing Trifluoroalkylation Studies 
After the preliminary trifluoroalkylation studies, further investigates were conducted to 
increase either yield or diastereoselectivity. An initial screen of oxazolidinones was 
conducted to see the effect on diastereoselectivity as seen in Table 3.4.3. We found that if 
there was a lack of quaternary substitution at the 5-position on the auxiliary; it led to low 
yield and decomposition of the starting material (entries 1-3). Further screening indicated 
that an isopropyl auxilixary led to improvement for yield and diastereoselectivity (entry 4). 
After selecting 4-isopropyl-5,5-dimethyloxazolidin-2-one as the auxiliary, a small screen 
of N-acyl oxazolidinones was conducted as shown in Table 3.4.4. For all substrates both 
catalyst loading and reaction time was decreased by 50% or more. Drastic improvement in 
both yield +19% and diastereoselectivity >98:2 was observed for the N-Acyl oxazolidinones 
obtained from hexanoic acid (Table 3.4.4, entry 1). An astonishing increase in yield (+30%) 
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and slight improvement in diastereoselectivity was observed for phenyl acetic acid derivative 
(entry 2). 
Table 3.4.3 Scope of N-Acyl Oxazolidinones in the Trifluoromethylation Reaction
a
 
 
(a) Yields of isolated products are reported. Diastereomer ratios were determined by 500 MHz 
1
H NMR 
analysis. 
Table 3.4.4 Scope of Trifluoromethylation of Isopropyl N-Acyl Oxazolidinone
a
 
 
(a) Yields of isolated products are reported. Diastereomer ratios were determined by 500 MHz 
1
H NMR 
analysis. 
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3.5 Stereoselective -Fluorination of N-Acyl Oxazolidinones at Room Temperature 
The importance of organofluorine compounds has been amply validated by broad 
application in medicinal sciences, materials, and agrochemicals.
106
 Fluorine incorporation is 
typically performed to acquire the unique physical and chemical properties that fluorine 
substitution imparts on organic compounds. Although many methods for fluorination have 
already been reported in the literature,
106a,106b,106m,107
 future advancements in the discovery 
and application of fluorinated materials require the availability of new methods for 
economical and selective fluorination. Despite the broad utility of fluorine-containing 
organic compounds, stereoselective incorporation of the fluorine atom at the α-position of 
the carbonyl group has remained an ongoing challenge; several notable recent developments 
exploit reagent, catalyst, or substrate control in α-fluorination reactions.108 Following early 
work on diastereoselective electrophilic α-fluorination of lithium enolates with N-fluoro-o-
benzenedisulfonimide (NFOBS) as the fluorinating reagent,
109
 a number of elegant 
alternatives describing the use of N-fluoropyridinium 2,8-diazobicyclo[2,2,2]octane and 
sulfonamide reagents as the electrophilic source of fluorine were developed.
110
 In all, these 
methods expanded the repertoire of selective α-monofluorination for a diverse range of 
carbonyl compounds, at the same time highlighting their unique patterns of reactivity. On the 
other hand, issues of practicality, limitations in substrate scope, high cost of reagents, 
extended reaction time, and energy efficiency (use of cryogenic conditions or high 
temperatures) remain persistent, stimulating continued progress in this area. 
Demonstration of the efficacy of group IVa metal enolates generated by soft 
enolization
111
  in ruthenium-catalyzed radical trichloromethylation, trifluoromethylation, and 
perfluoroalkylation reactions.
112
 We applied this experimentally simple protocol, good to 
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high yields of various α-haloalkylation products can be achieved with high 
diastereoselectivity. Herein, we describe the utility of group IVa metal enolates derived from 
N-acyl oxazolidinones in rapid economical and operationally simple electrophilic α-
fluorination reactions that take place at room temperature and display high 
diastereoselectivity. 
Table 3.5.1 Identification of Optimal Fluorinating Reagent
a
 
 
Entry Reagent Conversion
b
 (%) $/mmol 
1 NFSI 99 $0.35
c 
2 Selectfluor 70
d 
$0.82
e 
3 1-fluoro-2,4,6-trimethylpyridinium triflate <1 $3.67
f
 
4 1-fluoro-2,4,6-trimethylpyridinium tetrafluoroborate <1 $4.09
f 
 
(a) Standard conditions: 3.20 (0.50 mmol), TiCl4 (1.5 equiv), Et3N (2.0 equiv), CH2Cl2 (0.5 M), reagent (2.0 
equiv), mixed and stirred at room temperature for 1 h. (b) Determined by the 600 MHz NMR analysis of the 
crude mixture of products. (c) Oakwood Products. (d) Reaction solvent was a 1:1 mixture of 
acetonitrile/CH2Cl2, dr 5:1. (e) Apollo Scientific. (f) TCI America. 
The aim of initial experiments was to identify the optimal electrophilic source of 
fluorine, with the chemical efficiency of the α-fluorination reaction and reagent cost being 
the most important factors (Table 3.5.1). Examination of the most common commercial 
sources of electrophilic fluorine, summarized in Table 3.5.1, revealed that N-
fluorobenzenesulfonimide (NFSI), the most inexpensive reagent tested, displayed superior 
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performance by a substantial margin. Under standard conditions, complete conversion in the 
α-fluorination of 3.20 was achieved with NFSI within 1 h at room temperature. The reaction 
occurred with a diastereoselectivty of 98:2. Selectfluor, the second best reagent, provided 
70% conversion with a decrease of diastereoselectivity to 5:1, whereas both 1-fluoro-2,4,6-
trimethylpyridinium triflate and 1-fluoro-2,4,6-trimethylpyridinium tetrafluoroborate were 
not efficient sources of electrophilic fluorine due to lack of solubility in dichloromethane. 
Early experimentation also revealed a rather high reactivity of titanium enolates in the α-
fluorination reaction. In contrast to other reported stereoselective α-fluorinations of carbonyl 
compounds, the reaction reaches 90% conversion within 30 min at room temperature while 
maintaining high diastereoselectivity (Table 3.5.2, entry 1). Full conversion requires 60 min 
at 23 °C (Table 3.5.2, entry 2). Under optimized conditions, 1.5 equiv of TiCl4 and 2 equiv 
each of Et3N and NFSI are required for full conversion (Table 3.5.2, entry 5), and reduction 
in the stoichiometry of any of these reagents erodes conversion (Table 3.5.2, entries 4 and 6–
9) with the strongest effect observed for NFSI (Table 3.5.2, entry 4).
113
 Similar results, 
including high diastereoselectivity of 98:2, were noted when ZrCl4 and HfCl4 (Table 3.5.2, 
entries 10 and 11) were used for enolate generation under identical conditions, although 
conversions were lower by about 10%.
114
 All three common oxazolidinones surveyed 3-
propionyl-5,5-dimethyl-4-benzyl- (Table 3.5.2, entry 12), 3-propionyl-5,5-dimethyl-4-
isopropyl-, and 3-propionyl-4-benzyloxazolidin-2-ones (Table 3.5.2, entry 13) showed high 
diastereoselectivity (>10:1), with the 5,5-dimethyl-4-isopropyl derivative related to 3.20 
giving the highest stereoselectivity (dr 98:2). Therefore, further studies were carried out with 
NFSI as the fluorinating reagent and the 5,5-dimethyl-4-isopropyl-substituted oxazolidinone 
as the stereodirecting group. 
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Table 3.5.2 Optimization of –Fluorination Reactiona 
 
Entry TiCl4 (equiv) Et3N (equiv) NFSI (equiv) Time (h) Conversion
b
 (%) 
1 2.0 3.0 2.0 0.5 90 
2 2.0 3.0
 
2.0 1 99 
3 2.0 2.0 2.0 1 99 
4 2.0 3.0 1.25 1 50 
5 1.5 2.0
 
2.0 1 99 
6 1.25 2.0 2.0 1 93 
7 1.5 1.5 1.5 1 77 
8 0.5 3.0 2.0 12 40
c 
9 1.0 3.0
 
2.0 12 80
c 
10 1.5 (ZrCl4)
d 
2.0 2.0 1 87 
11 1.5 (HfCl4)
e 
2.0 2.0 1 78 
12 1.5 2.0 2.0 1 99
f 
(a) Standard conditions: 3.20 (0.50 mmol), CH2Cl2 (0.5 M), mixed and stirred at room temperature. (b) 
Determined by the 600 MHz 
1
H NMR analysis of the crude mixture of products. (c) Reactions were performed 
at 45 °C. (d) ZrCl4 was used in place of TiCl4. (e) HfCl4 was used in place of TiCl4. (f) 3-propionyl-5,5-
dimethyl-4-benzyloxazolidin-2-one was used (dr 96:4). 
Substrates derived from simple unfunctionalized alkanoic acids generally afford high 
yields of α-fluorination products with high diastereoselectivity under standard conditions at 
room temperature within 1 h (Table 3.5.3, entries 1-4). The derivative of isovaleric acid 
(Table 3.5.3, entry 3) afforded a somewhat depressed yield of 77% due to competitive 
formation of α-chlorination product (10% yield, >99:1 dr). 3-Phenylacetyl-5,5-dimethyl-4-
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isopropyloxazolidinone afforded the α-fluorination product in high yield and 
diastereoselectivity (Table 3.5.3, entry 5). A unique derivative of α-chloro-α-fluoroacetic 
acid has been prepared by this procedure with high stereoselectivity (Table 3.5.3, entry 6). 
An example, entry 4, illustrates that analogues in which the stereodirecting 4-isopropyl 
substituent is replaced with a benzyl group provide comparable yields and diastereomeric 
ratios of α-fluorination products. Aryl ether groups are well tolerated (Table 3.5.3, entry 7). 
A number of compounds produced from hydrocinnamic acids are also good substrates for 
the α-fluorination reaction (Table 3.5.3, entries 8-10), while benzyl ethers undergo partial 
debenzylation, which can be mitigated by replacing TiCl4 with ZrCl4 (Table 3.5.3, entry 11). 
α-Fluorination via titanium enolates of substrates containing unsaturation can be 
accomplished efficiently in the presence of double bonds (Table 3.5.3, entries 12-13), yet 
terminal alkynes can display notably lower yields (Table 3.5.3, entry 14). Although no 
specific byproducts have presently been isolated, the lower efficiency can hypothetically be 
ascribed to the competitive formation of alkynyltitanium species under the reaction 
conditions. The protected form of α-fluoro-β-alanine can be prepared in 70% yield and 94:6 
diastereomeric ratio (Table 3.5.3, entry 15). In most cases, the product can be isolated as the 
isomerically pure diastereomer either by recrystallization or flash column chromatography. 
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Table 3.5.3 Scope of N-Acyl Oxazolidinones in the –Fluorination Reactiona,b 
 
(a) Standard conditions: substrate (0.50 mmol), TiCl4 (1.5 equiv), Et3N (2.0 equiv), NFSI (2.0 equiv), CH2Cl2 
(0.5 M), mixed and stirred at room temperature for 1 h. (b) Yields of isolated products are reported. 
Diastereomer ratios were determined by 600 MHz 
1
H NMR analysis of the crude mixture of products. (c) 1.5 
equiv of ZrCl4 was used in place of TiCl4. (d) (S)-3-(2-Butenoyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one 
was used as the starting material. 
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Table 3.5.4 Optimization of -Fluorination of 3-(4-Methoxyphenylacetyl)-5,5-dimethyl-4-
isopropyloxazolidin-2-one 3.22
a,b
 
 
Entry Reagent % 3.23 (dr)
b,c
 % 3.24 (dr)
b,c 
1 TiCl4 0 82 (1:1) 
2 Ti(OPr-i)2Cl2 52 (93:7) 41 (1:1) 
3 Ti(OPr-i)2Cl2∙2E3NHCl 77 (93:7) 17 (1:1) 
4 Ti(OPr-i)3Cl2∙3E3NHCl 17 (93:7) 0 
5 Ti(OPr-i) Cl2∙E3NHCl 0 100 (1:1) 
6 ZrCl4 0 100 (1:1) 
(a) Standard conditions: 3.22 (0.50 mmol), Ti reagent (1.75 equiv), Et3N (2.0 equiv), NFSI (2.0 equiv), CH2Cl2 
(0.5 M), mixed and stirred at room temperature for 1 h. (b) Percent composition of the compound in the crude 
mixture of products as determined by 600 
1
H NMR analysis. (c) Diastereomeric ratio (dr) was determined by 
the 600 MHz 
1
H NMR analysis of the crude mixture of products. 
In contrast to the unfunctionalized phenylacetic acid derivative (cf. Table 3.5.4, 3.22), 
substitution in the phenyl ring resulted in substantially different reactivity under the standard 
conditions. In fact, the attempted α-fluorination of 4-methoxyphenyl analogue 3.22 resulted 
in the exclusive formation of α-chlorination product 3.24 as a 1:1 mixture of diastereomers 
(Table 3.5.4, entry 1). The hypothesis that replacing TiCl4 with an alternative titanium(IV) 
Lewis acid would minimize the competitive chlorination was put to the test next. 
Delightfully, a significant improvement in α-fluorination was achieved when Ti(OPr-i)2Cl2, 
prepared by a reaction of equimolar amounts of TiCl4 and Ti(OPr-i)4,
115
 was used for enolate 
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generation (Table 3.5.4, entry 2). When diisopropoxytitanium dichloride was prepared by an 
alternative procedure from TiCl4, 2 equiv of 2-propanol, and 2 equiv of triethylamine, a 
further improvement was achieved (Table 3.5.4, entry 3).
116
 The use of 
triisopropoxytitanium chloride, isopropoxytitanium trichloride, or zirconium tetrachloride 
led to either low reactivity or exclusive formation of the α-chlorination product (Table 3.5.4, 
entries 4–6). 
With the protocol utilizing the Ti(OPr-i)2Cl2·2Et3NHCl reagent, a range of substituted 
phenylacetic acid derivatives can be effectively α-fluorinated with very good 
diastereocontrol (Table 3.5.5). Modification of the phenyl group with electron-donating or 
mildly electron-withdrawing substituents in the ortho-, met, and parpositions is 
tolerated (Table 3.5.5, entries 1-7, 11). Diastereoselectivities are lower than with substrates 
represented in Table 3.5.4 but still in the practically useful range of greater than 10:1, and in 
most cases, the diastereomers are separable by column chromatography. 
In addition, heteroaromatic substituents can effectively afford α-fluorination products 
with high diastereoselectivity, as demonstrated with the derivatives of 3-furanacetic acid 
(Table 3.5.5, entry 8) and 2-(benzo[d]oxazol-5-yl)acetic acid (Table 3.5.5, entry 10). On the 
other hand, fluorination of oxazolidinone derived from 2-(benzo[d]oxazol-2-yl)acetic acid 
(Table 3.5.5, entry 11) afforded a 2:1 mixture of diastereomers. The reduction in 
diastereoselectivity may be attributed to increased C–H acidity of this compound resulting in 
the enolization of products. Isolation of difluorination products observed for these examples 
supports this hypothesis. 
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Table 3.5.5 Scope of -Fluorination of -Aryl Acetic Acid N-Acyl Oxazolidinone 
Derivatives
a,b,c
 
 
(a) Yields are of isolated pure major diastereomers unless indicated otherwise. Diastereomer ratios were 
determined by 600 MHz 
1
H NMR analysis of the crude mixture of products. (b) Standard conditions: substrate 
(0.50 mmol), TiCl2(O
i
Pr)2·2Et3NHCl (1.75 equiv), Et3N (2.0 equiv), NFSI (2.0 equiv), CH2Cl2 (0.5 M), mixed 
and stirred at room temperature for 1 h. (c) Less than 10% of chlorinated products were observed along with 
products entries 2-11. (d) Ti(OPr-i)2Cl2 (1.75 equiv) was used; product isolated as a mixture of diastereomers. 
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Scheme 3.5.1 Mechanistic Hypothesis for the -Fluorination Reaction 
 
A plausible mechanism outlined in Scheme 3.4.1 accounts for the experimental 
observations, including higher than expected reactivity of titanium enolates in the 
electrophilic fluorination as well as the appearance of α-chlorination byproduct 3.24. Soft 
enolization of 4-methoxyphenyl derivative 3.22 with TiCl4 and Et3N affords affords the 
expected Ti enolate. This newly formed Lewis acid could activate NFSI directly to form 
3.26, or NFSI could be activated by excess TiCl4 to form 3.27. The latter mode of activation 
may explain the need for 1.5–1.75 equiv of the reagent required for complete conversion. 
Activation of the NSFI by Lewis acid was documented to be essential for electrophilic 
fluorination of enolates by others.
108e,117
 Subsequent electrophilic fluorination typically 
affords 3.23 as the major product. Concurrently, a group exchange between Cl–TiLn reagent 
(3.26, 3.27, or other) and NFSI may take place giving rise to chlorine(I) fluoride, which is an 
electrophilic source of chloronium. When ClF reacts with the titanium enolate, α-
chlorination product 3.24 is formed.
118
 The kinetics of these processes is likely affected by 
the identity of the Ti reagent among other reaction parameters. 
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Scheme 3.5.2 Preparation of Enantioenriched Fluorinated Building Blocks via Hydrolytic 
and Reductive Removal of the Chiral Auxiliary
 
 
Conversion of the reaction products to broadly useful fluorinated building blocks for 
organic synthesis is illustrated by examples in Scheme 3.4.2. These include hydrolytic and 
reductive removal of the chiral auxiliary. The monofluorinated derivative 3.28 could be 
readily reduced using sodium borohydride in aqueous THF, delivering the corresponding 
fluoroalcohol 3.29 in high yields and with a high level of retention of stereochemical 
integrity. Compound 3.28 could also be hydrolyzed with a LiOH–H2O2 reagent system to 
yield the corresponding acid 3.30 in high yields and virtually complete preservation of 
stereochemistry. Notably, these transformations are characterized by excellent yields and 
nearly quantitative recovery of the chiral auxiliary. 
We have reported an operationally simple asymmetric α-fluorination reaction of N-acyl 
oxazolidinones based on the unique reactivity of group IVa metal enolates. From a practical 
perspective, the reaction requires inexpensive reagents, mild conditions, short reaction times 
at ambient temperatures, and delivers α-fluorination products directly in good yields and 
high diastereoselectivities.
119,120
 Ongoing studies are directed at defining a more detailed 
picture of the mechanism for the fluorination of α-arylacetic acid derivatives and 
determination of the structure and function of the TiCl2(OPr-i)2·2Et3NHCl complex. 
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Chapter 3: Supporting Information 
 
3-6: Dual Ti-Ru Catalysis Supporting Information 
 
Titanium tetrachloride (1.0 M in CH2Cl2, 0.25 ml, 0.25 mmol, 0.50 eq) was added to a 
solution of the substrate 3.1 (0.131 g, 0.50 mmol) in CH2Cl2 (0.75 ml) in a vial at 0 °C and 
the mixture was stirred for 5 min at the same temperature. Diisopropylethylamine (96 l, 
0.55 mmol, 1.1 eq) was added and the resulting deep red mixture was stirred at 0 °C for 40 
min. Bromotrichloromethane (0.60 ml, 6.0 mmol, 12 eq) was added, followed by 
RuCl2(PPh3)3 (34 mg, 0.035 mmol, 7 mol%) and the mixture was sealed and heated at 45 °C 
for 20 h. After cooling to room temperature, the reaction was quenched by adding water and 
extracted with CH2Cl2. The organic layer was washed with brine and dried over Na2SO4. 
After filtration and concentration, the crude product was analyzed by 
1
H NMR spectroscopy 
indicating >97% conversion. 
 
 
Titanium tetrachloride (1.0 M in CH2Cl2, 0.10 ml, 0.10 mmol, 0.1 eq) was added to a 
solution of 4-benzyl-5,5-dimethyl-N-propionyloxazolidin-2-one (0.261 g, 1.0 mmol) in 
CH2Cl2 (1.2 ml) in a vial at 0 °C and the mixture was stirred for 5 min at the same 
temperature. 1,2,2,6,6-Pentamethylpiperidine (0.20 ml, 1.10 mmol, 1.1 eq) was added and 
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the resulting deep red mixture was stirred at 0 °C for 40 min. Bromotrichloromathane (0.30 
ml, 3.0 mmol, 3 eq) was added, followed by RuCl2(PPh3)3 (68 mg, 0.070 mmol, 7 mol%) 
and the mixture was sealed and heated at 45 °C for 12 h. After cooling down, the reaction 
was quenched by adding water and extracted with CH2Cl2. The organic layer was washed 
with brine and dried over Na2SO4. After filtration and concentration, the residue was 
analyzed by 
1
H NMR spectroscopy, which indicated a 100% conversion. Purification by 
column chromatography on silica gel afforded the product (0.368 g, 0.97 mmol, 97%). 1H 
NMR (400 MHz, CDCl3); (ppm): 7.38-7.20 (m, 5H); 5.31 (q, J=6.4 Hz, 1H); 4.53(dd, 
J1=2.8 Hz, J2=10.4 Hz, 1H); 3.27 (dd, J1=2.8 Hz, J2=14.4 Hz, 1H); 2.81(dd, J1=10.4 Hz, 
J2=14.4 Hz, 1H); 1.60 (J=6.4 Hz, 3H); 1.34 (s, 3H); 1.30 (s, 3H). 
 
The crossover experiment: 
 
Titanium tetrachloride (1.0 M in CH2Cl2, 0.25 ml, 0.25 mmol) was added to a solution of the 
substrate 3.1 (0.131 g, 0.50 mmol, 1.0 eq) in CH2Cl2 (0.75 mL) in a vial at 0 °C and the 
mixture was stirred for 5 min at the same temperature. Diisopropylethylamine (96 l, 0.55 
mmol, 1.1 eq) was added and the resulting deep red mixture was stirred at 0 °C for 40 min. 
Oxazolidinone 3.6 (0.117 g, 0.50 mmol, 1.0 eq) in CH2Cl2 (0.4 ml) was added to the above 
reaction mixture and 5 min later i-Pr2NEt (96 l, 0.55 mmol, 1.1 eq) was added. After 
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stirring for additional 40 min at 0 °C, BrCCl3 (0.60 ml, 6.0 mmol, 12 eq) and RuCl2(PPh3)3 
(34 mg, 0.035 mmol, 7 mol%) were added, and the mixture was sealed and heated at 45 °C 
for 20 h. After cooling down, the reaction was quenched by adding water and extracted with 
CH2Cl2. The organic layer was washed with brine and dried over Na2SO4. After filtration 
and concentration, the residue was analyzed by 
1
H NMR, which indicated a clean 
transformation with a 74% conversion of 3.1 and 70% conversion of 3.6. 
 
The effects of the order of addition of reagents: 
 
1,2,2,6,6-Pentamethylpiperidine (0.10 ml, 0.55 mmol) was added to a solution of TiCl4 (1.0 
M in CH2Cl2, 0.50 ml, 0.50 mmol, 1.0 eq) at 0 °C and stirred for 5 min. A solution of 3.1 
(0.131 g, 0.50 mmol, 1.0 eq) in CH2Cl2 (1.2 ml) was added. After stirring at the same 
temperature for 40 min, BrCCl3 (0.15 ml, 1.50 mmol, 3 eq) and RuCl2(PPh3)3 (34 mg, 0.035 
mmol, 7 mol%) were added, and the mixture was allowed to stir at room temperature for 12 
h. After cooling down, the reaction was quenched by adding water and extracted with 
CH2Cl2. The organic layer was washed with brine and dried over Na2SO4. After filtration 
and concentration, the residue was monitored by 
1
H NMR with a conversion of 57%. 
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The effect of Ru-catalyst: 
 
Titanium tetrachloride (1.0 M in CH2Cl2, 0.10 ml, 0.10 mmol, 0.2 eq) was added to a 
solution of the substrate 3.1 (0.131 g, 0.50 mmol, 1.0 eq) in CH2Cl2 (1.2 ml) in a vial at 0 °C 
and the mixture was stirred for 5 min at the same temperature. PMP (0.10 ml, 0.55 mmol, 
1.1 eq) was added and the resulting deep red mixture was stirred at 0 °C for 40 min. 
Bromotrichloromathane (0.15 ml, 1.5 mmol, 3 eq) was added, followed by Cp*RuCl(PPh3)2 
(28 mg, 0.035 mmol, 7 mol%) and the mixture was stirred at room temperature. The reaction 
was monitored by TLC indicating around 90% conversion after 1.5 h, and the reaction was 
quenched at 3 h by adding water. The mixture extracted with CH2Cl2 and the organic layer 
was washed with brine and dried over Na2SO4. The conversion was 93% measured by 
1
H 
NMR of the crude material. 
 
1
H NMR Studies of enolization in CDCl3: 
 
Titanium tetrachloride (1.0 M in CDCl3, 0.15 ml, 0.15 mmol, 0.1 eq) was added to a solution 
of the substrate 3.1 (0.392 g, 1.50 mmol, 1.0 eq) in CDCl3 (5.2 ml) in a vial at 0 °C and the 
mixture was stirred for 5 min at the same temperature. Diisopropylethylamine (0.274 ml, 
1.58 mmol, 1.05 eq) was added and the resulting deep red mixture was stirred at 0 °C for 40 
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min. The reaction mixture was transferred via cannula to a NMR tube which was pre-filled 
with Ar. 
 
Titanium tetrachloride (1.0 M in CDCl3, 0.17 ml, 0.17 mmol, 0.33 eq) was added to a 
solution of the substrate 3.1 (0.136 g, 0.52 mmol, 1.0 eq) in CDCl3 (1.8 ml) in a vial at 0 °C 
and the mixture was stirred for 5 min at the same temperature. Diisopropylethylamine (95 l, 
0.55 mmol, 1.05 eq) was added and the resulting deep red mixture was stirred at 0 °C for 40 
min. The reaction mixture was transferred via cannula to a NMR tube which was pre-filled 
with Ar. 
 
Titanium tetrachloride (1.0 M in CDCl3, 0.58 ml, 0.58 mmol, 1.1 eq) was added to a solution 
of the substrate 3.1 (0.138 g, 0.53 mmol, 1.0 eq) in CDCl3 (1.8 ml) in a vial at 0 °C and the 
mixture was stirred for 5 min at the same temperature. Diisopropylethylamine (0.l0 ml, 0.58 
mmol, 1.1 eq) was added and the resulting deep red mixture was stirred at 0 °C for 40 min. 
The reaction mixture was transferred via cannula to a NMR tube which was pre-filled with 
Ar. 
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3-7: Perfluoroalkylations of N-Acyl Oxazolidinones Supporting Information 
 
(S)-4-Benzyl-5,5-dimethyloxazolidin-2-one. Thionyl chloride (5.50  mL, 74.8 mmol) 
was added dropwise to a solution of L-phenylalanine (6.17 g, 37.4 mmol) in methanol (104 
mL) at 0 °C. The reaction was stirred for 30 min at 0 °C, and then heated to reflux for 4 h. 
The solution was cooled to rt and methanol was removed in vacuo. The crude residue was 
submitted to the next step without purification. 
Di-tert-butyl dicarbonate (8.08 g, 37.0 mmol) was added to a mixture of the crude 
substrate (37.4 mmol), triethylamine (5.70 mL, 41.4 mmol), and dichloromethane (83.0 mL) 
at rt. The reaction was stirred at rt for 2 h and then quenched with HCl (1M). The layers 
were separated. The aqueous layer was extracted with dichloromethane (3x30 mL). The 
combined organic layers were dried with sodium sulfate and concentrated in vacuo to afford 
a white solid. The crude residue was submitted to the next step without further purification. 
Methylmagnesium bromide (3 M in Et2O, 49.9 mL, 150 mmol) was added dropwise to a 
solution of the crude substrate (37.4 mmol) in THF (125 mL) at 0 °C. The reaction was 
stirred at 0 °C for 10 min, then warmed to rt and stirred for 36 h. The solution was cooled to 
0 °C and quenched with methanol. The solvent was removed in vacuo, and the solids were 
re-dissolved in ethyl acetate and water. The layers were separated. The aqueous layer was 
extracted with ethyl acetate (3x75 mL). The combined organic layers were dried with 
sodium sulfate and concentrated in vacuo delivering a light yellow oil. The crude residue 
was submitted to the next step without further purification. 
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Potassium tert-butoxide (4.74 g, 42.2 mmol) was added to a solution of the crude 
substrate (37.4 mmol) in THF (101 mL) at 0 °C. The reaction was warmed to rt and stirred 
for 2.5 h. The reaction was then quenched with saturated aqueous ammonium chloride. The 
layers were separated. The aqueous layer was extracted with ethyl acetate (3x40 mL). The 
combined organic layers were washed with brine, dried with sodium sulfate, and 
concentrated in vacuo. The crude product was purified by column chromatography (silica, 
40% ethyl acetate – hexanes, 60% ethyl acetate - hexanes) to afford the white/yellow solid 
oxazolidinone S1 (6.31 g, 30.7 mmol, 82% over 4 steps)
121
. 
1
H NMR (400 MHz, CDCl3); 
δ(ppm): 7.37-7.32 (m, 1H); 7.30-7.23 (m, 1H); 7.19-7.16 (m, 2H); 4.69 (brs, 1H); 3.68 (dd, 
J1=10.8 Hz, J2=3.6 Hz, 1H); 2.84 (dd, J1=13.6 Hz, 3.6 Hz, 1H); 2.67 (dd, J1=13.6 Hz, 
J2=10.8 Hz, 1H); 1.50 (s, 3H); 1.47 (s, 3H). 
 
 
(S)-4-Benzyl-5,5-dimethyl-3-propionyloxazolidin-2-one (3.12). n-Butyllithium (10.4 
mL, mmol, 2.45 M in hexanes) was added to a solution of the oxazolidinones S1 (5.00 g, 
24.4 mmol) in THF (81.3 mL) at -78
 
°C. After 30 min, propionyl chloride (2.16 mL, 24.9 
mmol) was added and the reaction was stirred for an additional 30 min. The reaction was 
warmed to 0 °C and stirred for 1.5 h. The reaction was quenched with saturated aqueous 
ammonium chloride and the layers were separated. The aqueous layer was extracted with 
ethyl acetate (3x100 mL). The combined organic layers were washed with brine, dried with 
sodium sulfate, concentrated, and purified by column chromatography (silica, 30% ethyl 
acetate - hexanes) to afford the desired product (5.93 g, 24.5 mmol, 93%). D
22 -29.3° (c 1.0, 
  124 
dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.32-7.25 (m, 4H); 7.25-7.20 (m, 
1H); 4.50 (dd, J1=10.2 Hz, J2=4.2 Hz, 1H); 3.15 (dd, J1=15.0 Hz, J2=4.2 Hz, 1H); 2.98-
2.88 (m, 2H); 2.88 (dd, J1=4.2 Hz, J2=15.0 Hz, 1H); 1.37 (s, 3H); 1.36 (s, 3H); 1.14 (dd, 
J1=J2=7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 174.5, 152.9, 137.2, 129.3 (2C), 
128.9 (2C), 127.0, 82.4, 63.7, 35.6, 29.6, 28.8, 22.5, 8.6. LRMS (ESI) calcd for 
C15H19NO3Na [M+Na] 284.1263, found 284.14. 
 
Standard procedure for the synthesis of N-acyl oxazolidinones:  
 
Oxalyl chloride (0.96 mL, 11.0 mmol) was added to a solution of carboxylic acid (1.26 
mL, 10.0 mmol), dimethylformamide (10 μl), and dichloromethane (3.30 mL) at 0 °C. After 
10 min, the solution was warmed to rt and stirred for 1 h (until bubbling stops). The solution 
was concentrated on a rotary evaporator. In a separate flask, n-butyllithium (2.48 M in 
hexanes, 2.82 mL, 7.0 mmol), was added to a solution of oxazolidinone S1 (1.37 g, 6.67 
mmol) in THF (18.2 mL) at -78 °C under argon. The solution was stirred for 30 min at -78 
°C. A solution of the crude acyl chloride in THF (16.7 mL total with rinses) was added 
dropwise at -78 °C. After stirring at -78 °C for 2 h, the reaction mixture was quenched with 
saturated aqueous ammonium chloride. The aqueous layer was extracted with ethyl acetate 
(3x20 mL). The combined organic layers were washed with brine, dried with sodium sulfate, 
and concentrated on a rotary evaporator. The resultant oil or solid was purified by column 
chromatography to give the corresponding N-acyl oxazolidinone. 
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(S)-4-Benzyl-3-hexanoyl-5,5-dimethyloxazolidin-2-one (3.31). The title compound 
was prepared from commercially available hexanoic acid (0.630 mL, 5.00 mmol) following 
the standard procedure for the synthesis of N-acyl oxazolidinones and was obtained as a 
colorless oil (1.17 g, 3.86 mmol, 77%) after purification by column chromatography (silica, 
30% ethyl acetate - hexanes). D
23 -28.8° (c 1.0, dichloromethane). 
1
H NMR (400 MHz, 
CDCl3); δ(ppm): 7.34-7.20 (m, 5H); 4.51 (dd, J1=9.6 Hz, J2=4.0 Hz, 1H); 3.13 (dd, J1=14.4 
Hz, J2=4.0 Hz, 1H); 2.98-2.82 (m, 3H); 1.68-1.60 (m, 2H); 1.37 (s, 3H); 1.35 (s, 3H); 1.40-
1.30 (m, 4H); 0.90 (dd, J=7.2 Hz, 3H); 
13
C NMR (125 MHz, CDCl3); δ(ppm): 173.9, 152.9, 
137.2, 129.3 (2C), 128.9 (2C), 127.0, 82.3, 63.7, 35.9, 35.6, 31.5, 28.8, 24.3, 22.7, 22.5, 
14.2. LRMS (ESI) calcd for C18H25NO3Na [M+Na] 326.1732, found 326.18. 
 
HO
O
O N
O
Bn
O(COCl)2, cat. DMF, CH2Cl2;
then S2 , THF
O NLi
O
Bn
S4
S2
 
(S)-4-Benzyl-5,5-dimethyl-3-(3-methylbutanoyl)oxazolidin-2-one (3.32). The title 
compound was prepared from commercially available isovaleric acid (1.09 mL, 10.0 mmol) 
following the standard procedure for the synthesis of N-acyl oxazolidinones and was 
obtained as a colorless oil (1.29 g, 4.46 mmol, 45%) after purification by column 
chromatography (silica, 10% ethyl acetate - hexanes). D
24 -31.8° (c 1.0, dichloromethane). 
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1
H NMR (600 MHz, CDCl3); δ(ppm): 7.32-7.26 (m, 4H); 7.24-7.20 (m, 1H); 4.52 (dd, 
J1=9.6 Hz, J2=3.6 Hz, 1H); 3.14 (dd, J1=14.4 Hz, J2=3.6 Hz, 1H); 2.88 (dd, J1=14.4 Hz, 
J2=9.6 Hz, 1H); 2.85-2.78 (m, 2H); 2.19-2.12 (m, 1H); 1.36 (s, 3H); 1.35 (s, 3H); 0.97 (d, 
J=7.2 Hz, 3H); 0.96 (d, J=7.2 Hz, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 173.1, 152.8, 
137.2, 129.3 (2C), 128.9 (2C), 127.0, 82.2, 63.7, 44.3, 35.6, 28.7, 25.4, 22.7, 22.6, 22.5. 
LRMS (ESI) calcd for C17H23NO3Na [M+Na] 312.1576, found 312.17. 
 
HO
O O
O N
O
Bn
(COCl)2, cat. DMF, CH2Cl2;
then S2 , THF
O NLi
O
Bn
S5
S2
 
(S)-4-Benzyl-3-(2-cyclohexylacetyl)-5,5-dimethyloxazolidin-2-one (3.33). The title 
compound was prepared from commercially available cyclohexaneacetic acid (0.710 g, 5.00 
mmol) following the standard procedure for the synthesis of N-acyl oxazolidinones and was 
obtained as a white solid (1.00 g, 3.04 mmol, 61%) after purification by column 
chromatography (silica, 10% ethyl acetate - hexanes). D
24 -31.5° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.32-7.25 (m, 4H); 7.24-7.20 (m, 1H); 4.51 (dd, 
J1=9.6 Hz, J2=3.6 Hz, 1H); 3.13 (dd, J1=14.4 Hz, J2=3.6 Hz, 1H); 2.88 (dd, J1=14.4 Hz, 
J2=9.6 Hz, 1H); 2.81 (ddd, J1=22.8 Hz, J2=15.6 Hz, J3=7.2 Hz, 2H); 1.88-1.79 (m, 1H); 
1.73-1.62 (m, 5H); 1.36 (s, 3H); 1.35 (s, 3H); 1.32-1.22 (m, 2H); 1.19-1.10 (m, 1H); 1.05-
0.95 (m, 2H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 173.1, 152.9, 137.2, 129.3 (2C), 128.9 
(2C), 127.0, 105.2, 82.2, 63.7, 42.9, 35.7, 34.7, 33.3, 33.2, 28.8, 26.4, 26.3, 22.5. LRMS 
(ESI) calcd for C20H27NO3Na [M+Na] 352.1889, found 352.20. 
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O
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O NLi
O
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(S)-4-Benzyl-3-(3,3-dimethylbutanoyl)-5,5-dimethyloxazolidin-2-one (3.34). The title 
compound was prepared from commercially available 3,3-dimethylbutyric acid (1.27 mL, 
10.0 mmol) following the standard procedure for the synthesis of N-acyl oxazolidinones and 
was obtained as a colorless oil (1.74 g, 5.74 mmol, 57%) after purification by column 
chromatography (silica, 10% ethyl acetate - hexanes). D
23 -28.8° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.32-7.27 (m, 4H); 7.24-7.21 (m, 1H); 4.55 (dd, 
J1=9.6 Hz, J2=3.6 Hz, 1H); 3.17 (dd, J1=13.8 Hz, J2=3.6 Hz, 1H); 2.96-2.83 (m, 3H); 1.35 
(s, 6H); 1.05 (s, 9H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 172.4, 152.9, 137.3, 129.2 (2C), 
128.9 (2C), 127.0, 81.8, 63.8, 46.5, 35.6, 31.8, 29.9 (3C), 28.8, 22.6. LRMS (ESI) calcd for 
C18H25NO3Na [M+Na] 326.1732, found 326.18. 
 
HO
O
O N
O
Bn
O
OPhOPh
(COCl)2, cat. DMF, CH2Cl2;
then S2 , THF
O NLi
O
Bn
S7
S2
 
(S)-4-Benzyl-5,5-dimethyl-3-(4-phenoxybutanoyl)oxazolidin-2-one (3.35). The title 
compound was prepared from commercially available 4-phenoxybutanoic acid (1.80 g, 10.0 
mmol) following the standard procedure for the synthesis of N-acyl oxazolidinones and was 
obtained as a yellowish oil (1.55 g, 4.22 mmol, 42%) after purification by column 
chromatography (silica, 30% ethyl acetate - hexanes). D
22 -27.0° (c 1.0, dichloromethane). 
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1
H NMR (600 MHz, CDCl3); δ(ppm): 7.30-7.24 (m, 6H); 7.22-7.20 (m, 1H); 6.95-6.92 (m, 
1H); 6.90-6.88 (m, 2H); 4.52 (dd, J1=9.6 Hz, J2=4.8, 1H); 4.04-3.95 (m, 2H); 3.16-3.10 (m, 
3H); 2.88 (dd, J1=13.8 Hz, J2=9.0 Hz, 1H); 2.16-2.07 (m, 2H); 1.38 (s, 3H); 1.36 (s, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 173.1, 159.0, 152.9, 137.1, 129.6 (2C), 129.3 (2C), 
128.9 (2C), 127.0, 120.9, 114.7 (2C), 82.5, 66.7, 63.7, 35.7, 32.6, 28.7, 24.2, 22.5. LRMS 
(ESI) calcd for C22H25NO4Na [M+Na] 390.1681, found 390.17. 
 
 
(S)-4-Benzyl-3-(5-(benzyloxy)pentanoyl)-5,5-dimethyloxazolidin-2-one (3.36). A 
solution of 1,5-pentanediol (1.60 mL, 15.2 mmol) in THF (3.20 mL) was added to a slurry of 
sodium hydride (60wt% in mineral oil, 0.104 g, 2.62 mmol) in THF (6.39 mL) over 30 min 
at 0 ˚C. After stirring for an additional 30 min, a solution of benzyl bromide (0.260 mL, 2.18 
mmol) in THF (3.21 mL) was added to the reaction mixture over 30 min. The reaction 
mixture was then warmed to rt and stirred an additional 20 h. The reaction was quenched 
with water, and THF was removed in vacuo. The aqueous layer was extracted with ethyl 
acetate (3x20 mL). The combined organic layers were washed with water (6x20 mL), dried 
with sodium sulfate, and concentrated in vacuo. The resulting oil was submitted to the next 
reaction without further purification. 
 
The crude mono-protected alcohol (0.517 g, 2.66 mmol) was dissolved in acetone (14.8 
mL) and cooled to 0 ˚C. Jones reagent (3.35 M in water, 1.98 mL, 6.65 mmol) was added 
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dropwise over 20 min. After 1 h at 0 ˚C, isopropanol (3.8 mL) was added to the reaction 
mixture. After 30 min at 0 ˚C, solid sodium bicarbonate was added until the reaction mixture 
was neutral (pH ~ 7). The reaction mixture was filtered through Celite and the solids were 
washed with acetone and diethyl ether. The solution was concentrated in vacuo. Solid 
sodium hydroxide was added to the resulting aqueous solution until basic (pH ~ 12). The 
aqueous layer was extracted with diethyl ether (3x20 mL). Concentrated HCl (12 M) was 
then added to the aqueous layer until acidic (pH ~ 1). The aqueous layer was extracted with 
diethyl ether (3x20 mL). The combined organic layers were dried with sodium sulfate and 
concentrated in vacuo. The resulting white solid was submitted to the next reaction without 
further purification. 
 
Oxalyl chloride (0.660 mL, 0.770 mmol) was added to a solution of the crude carboxylic 
acid (0.146 g, 0.700 mmol), dimethylformamide (about 10 μl), and dichloromethane (0.470 
mL) at 0 °C. After 10 min, the solution was warmed to rt and stirred an additional 15 min 
(until all bubbling had stopped). The solution was concentrated in vacuo. In a separate flask, 
n-butyllithium (2.43 M in hexanes, 0.200 mL, 0.490 mmol), was added to a solution of 
oxazolidinone S1 (94.0 mg, 0.460 mmol) in THF (1.20 mL) at -78 °C under argon. The 
solution was stirred for 30 min at -78 °C then the crude acid chloride in THF (1.30 mL total 
with rinses) was added dropwise at -78 °C. After 2 h, the reaction mixture was warmed to 0 
°C over 30 min and was quenched with saturated aqueous ammonium chloride. The aqueous 
layer was extracted with ethyl acetate (3x10 mL). The combined organic layers were washed 
with brine, dried with sodium sulfate, and concentrated in vacuo. The desired compound S8 
was obtained as a yellowish oil (0.123 g, 0.311 mmol, 44% over 3 steps) after purification 
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by column chromatography (silica, 30% ethyl acetate – hexanes). D
24 -20.8° (c 1.0, 
dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.34-7.22 (m, 10H); 4.52-4.47 (m, 
3H); 3.50 (dd, J1=J2=6.0 Hz, 2H); 3.13 (dd, J1=11.4 Hz, J2=3.6 Hz, 1H); 3.00-2.89 (m, 
2H); 2.85 (dd, J1=13.8 Hz, J2=9.0 Hz, 1H); 1.77-1.71 (m, 2H); 1.70-1.64 (m, 2H); 1.36 (s, 
3H); 1.34 (s, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 173.5, 152.9, 138.8, 137.2, 129.3 
(2C), 128.7 (2C), 128.6 (2C), 127.9 (2C), 127.7, 127.0, 82.4, 73.1, 70.2, 63.7, 35.60, 35.59, 
29.3, 28.8, 22.5, 21.3. LRMS (ESI) calcd for C24H29NO4Na [M+Na] 418.1994, found 
418.21. 
 
HO
O
Ph O N
O
Bn
O
Ph
(COCl)2, cat. DMF, CH2Cl2;
then S2 , THF
O NLi
O
Bn
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(S)-4-Benzyl-5,5-dimethyl-3-(3-phenylpropanoyl)oxazolidin-2-one (3.37). The title 
compound was prepared from commercially available hydrocinnamic acid (1.50 g, 10.0 
mmol) following the standard procedure for the synthesis of N-acyl oxazolidinones and was 
obtained as a white solid (1.74 g, 5.16 mmol, 52%) after purification by column 
chromatography (silica, 20% ethyl acetate - hexanes). D
24 -21.7° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.32-7.18 (m, 10H); 4.50 (dd, J1=9.6 Hz, J2=4.2 Hz, 
1H); 3.31-3.21 (m, 2H); 3.13 (dd, J1=14.4 Hz, J2=4.2 Hz, 1H); 3.01-2.92 (m, 2H); 2.86 (dd, 
J1=14.4 Hz, J2=9.6 Hz, 1H); 1.36 (s, 3H); 1.32 (s, 3H); 
13
C NMR (150 MHz, CDCl3); 
δ(ppm): 172.8, 152.8, 140.6, 137.1, 129.3 (2C), 128.9 (2C), 128.70 (2C), 128.66 (2C), 
127.0, 126.4, 82.4, 63.7, 37.4, 35.5, 30.7, 28.7, 22.5. LRMS (ESI) calcd for C21H23NO3Na 
[M+Na] 360.1576, found 360.16. 
  131 
 
HO
O
O N
O
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(COCl)2, cat. DMF, CH2Cl2;
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O
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(S)-4-Benzyl-3-(3-(3,4-dimethoxyphenyl)propanoyl)-5,5-dimethyloxazolidin-2-one 
(3.38). The title compound was prepared from commercially available 3-(3,4-
dimethoxyphenyl)propanoic acid (2.10 g, 10.0 mol) following the standard procedure for the 
synthesis of N-acyl oxazolidinones and was obtained as a yellowish solid (2.37 g, 5.96 
mmol, 60%) after purification by column chromatography (silica, 40% ethyl acetate - 
hexanes). D
22 -17.3° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.31-
7.20 (m, 5H); 6.80-6.76 (m, 3H); 4.49 (dd, J1=10.2 Hz, J2=4.2 Hz, 1H); 3.87 (s, 3H); 3.85 
(s, 3H); 3.29-3.19 (m, 2H); 3.11 (dd, J1=14.4 Hz, J2=4.2 Hz, 1H); 2.94-2.87 (m, 2H); 2.85 
(dd, J1=14.4 Hz, J2=10.2 Hz, 1H); 1.36 (s, 3H); 1.31 (s, 3H); 
13
C NMR (150 MHz, CDCl3); 
δ(ppm): 172.9, 152.8, 149.1, 147.7, 137.1, 133.2, 129.3 (2C), 128.9 (2C), 127.0, 120.6, 
112.0, 114.5, 82.5, 63.7, 56.2, 56.0, 37.6, 35.5, 30.4, 28.7, 22.5. LRMS (ESI) calcd for 
C23H27NO5Na [M+Na] 420.1787, found 420.18. 
 
HO
O O
O N
O
Bn
(COCl)2, cat. DMF, CH2Cl2;
then S2 , THF
O NLi
O
Bn
S11
S2
 
(S)-4-Benzyl-5,5-dimethyl-3-(2-phenylacetyl)oxazolidin-2-one (3.39). The title 
compound was prepared from commercially available phenylacetic acid (0.681 g, 5.00 
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mmol) following the standard procedure for the synthesis of N-acyl oxazolidinones and was 
obtained as a white solid (0.788 g, 2.44 mmol, 49%) after purification by column 
chromatography (silica, 20% ethyl acetate - hexanes). D
24 -21.5° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.35-7.31 (m, 2H); 7.31-7.19 (m, 8H); 4.50 (dd, 
J1=9.6 Hz, J2=3.6 Hz, 1H); 4.28 (AB, JA=18.6 Hz, JB=15.6 Hz, 2H); 3.14 (dd, J1=13.8 Hz, 
J2=3.6 Hz, 1H); 2.86 (dd, J1=13.8 Hz, J2=9.6 Hz, 1H); 1.36 (s, 3H); 1.32 (s, 3H); 
13
C NMR 
(150 MHz, CDCl3); δ(ppm): 171.7, 152.8, 137.0, 133.9, 129.9 (2C), 129.3 (2C), 128.9 (2C), 
128.8 (2C), 127.4, 127.0, 85.6, 64.0, 42.0, 35.4, 28.8, 22.5. LRMS (ESI) calcd for 
C20H21NO3Na [M+Na] 346.1419, found 346.15. 
 
 
(S)-4-Benzyl-3-((R)-3,7-dimethyloct-6-enoyl)-5,5-dimethyloxazolidin-2-one (3.40). 
The title compound was prepared from (R)-(+)-citronellic acid S14 (5.88 g, 16.5 mmol) 
following the standard procedure for the synthesis of N-acyl oxazolidinones and was 
obtained as a colorless oil (4.82 g, 13.5 mmol, 82%) after purification by column 
chromatography (silica, 20% ethyl acetate - hexanes). D
22 -21.4° (c 10.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.32-7.26 (m, 4H); 7.25-7.20 (m, 1H); 5.11-5.06 (m, 
1H); 4.52 (dd, J1=9.0 Hz, J2=3.6 Hz, 1H); 3.15 (dd, J1=14.4 Hz, J2=3.6 Hz, 1H); 2.93-2.84 
(m, 2H); 2.79 (dd, J1=16.8 Hz, J2=7.8 Hz, 1H); 2.08-1.92 (m, 3H); 1.67 (s, 3H), 1.59 (s, 
3H); 1.42-1.35 (m, 1H); 1.36 (s, 3H); 1.35 (s, 3H); 1.28-1.20 (m, 1H); 0.93 (d, J=6.6 Hz, 
3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 173.2, 152.7, 137.2, 131.7, 129.3 (2C), 128.9 
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(2C), 127.0, 124.6, 82.2, 63.7, 42.7, 37.0, 35.6, 29.7, 28.8, 25.9, 25.7, 22.5, 19.8, 17.9. 
LRMS (ESI) calcd for C22H31NO3Na [M+Na] 380.2202, found 380.24. 
 
 
(S)-4-Benzyl-3-((R)-3,7-dimethyloctanoyl)-5,5-dimethyloxazolidin-2-one (3.41). The 
substrate 3.40 (0.441 g, 1.23 mmol) and palladium on carbon (30.4 mg) were dissolved in 
methanol (6.83 mL). Hydrogen gas was bubbled through the reaction mixture for 2 min at 
room temp. The reaction mixture flask was pressurized with hydrogen and the reaction was 
stirred for 1 h at rt. The reaction mixture was filtered through Celite and the solvent was 
removed in vacuo to afford the desired product (0.476 g, 1.33 mmol, 74%). D
23 -21.5° (c 
1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.32-7.25 (m, 4H); 7.25-7.20 
(m, 1H); 4.52 (dd, J1=9.6 Hz, J2=4.2 Hz, 1H); 3.15 (dd, J1=14.4 Hz, J2=4.2 Hz, 1H); 2.94-
2.84 (m, 2H); 2.75 (dd, J1=15.6 Hz, J2=7.8 Hz, 1H); 2.06-1.98 (m, 1H); 1.57-1.50 (m, 1H); 
1.36 (s, 3H); 1.35 (s, 3H); 1.35-1.12 (m, 6H); 0.92 (d, J=6.6 Hz, 3H); 0.862 (d, J=6.6 Hz, 
3H); 0.859 (d, J=6.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 173.3, 152.9, 137.2, 
129.3 (2C), 128.9 (2C), 127.0, 82.2, 63.7, 42.8, 39.3, 37.2, 35.6, 30.0, 28.8, 28.2, 24.9, 22.9, 
22.8, 22.5, 19.9. LRMS (ESI) calcd for C22H33NO3Na [M+Na] 382.2358, found 382.23. 
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(R)-4-Benzyl-3-((R)-3,7-dimethyloct-6-enoyl)-5,5-dimethyloxazolidin-2-one (3.42). 
Oxalyl chloride (0.200 mL, 2.20 mmol) was added to a solution of (R)-(+)-citronellic acid 
(0.341 g, 2.00 mmol), dimethylformamide (10 μl), and dichloromethane (1.00 mL) at 0 °C. 
After 10 min, the solution was warmed to rt and stirred an additional 15 min (until all 
bubbling had stopped). The solution was concentrated in vacuo. In a separate flask, n-
butyllithium (2.39 M in hexanes, 0.880 mL, 2.10 mmol) was added to a solution of 
oxazolidinone (0.411 g, 2.00 mmol) in THF (4.00 mL) at -78 °C under argon. The solution 
was stirred for 30 min at -78 °C then the crude acyl chloride in THF (4.00 mL total with 
rinses) was added dropwise at -78 °C. After 2 h, the reaction mixture was warmed to 0 °C 
over 30 min and was quenched with saturated aqueous ammonium chloride. The aqueous 
layer was extracted with ethyl acetate (3x20 mL). The combined organic layers were washed 
with brine, dried with sodium sulfate, and concentrated in vacuo. The resultant oil was 
submitted to the next reaction without further purification. 
 
The crude substrate and palladium on carbon (48.0 mg) were dissolved in methanol (10.0 
mL). Hydrogen gas was bubbled through the reaction mixture for 2 min at room temp. The 
reaction mixture flask was pressurized with hydrogen and the reaction was stirred for 3h at 
rt. The reaction mixture was filtered through Celite and the solvent was removed in vacuo. 
The desired compound 3.42 was obtained as an oil (0.406 g, 1.12 mmol, 56%) after 
purification by column chromatography (silica, 20% ethyl acetate - hexanes). D
23 22.1° (c 
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1.0, CHCl3). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.32-7.26 (m, 4H); 7.25-7.20 (m, 1H); 
4.52 (dd, J1=9.6 Hz, J2=3.6 Hz, 1H); 3.15 (dd, J1=14.4 Hz, J2=3.6 Hz, 1H); 2.93-2.84 (m, 
2H); 2.75 (dd, J1=15.6 Hz, J2=7.8 Hz, 1H); 2.07-1.97 (m, 1H); 1.56-1.48 (m, 1H); 1.36 (s, 
3H); 1.35 (s, 3H); 1.35-1.11 (m, 6H); 0.93 (d, J=6.6 Hz, 3H); 0.87 (d, J=6.6 Hz, 3H); 0.86 
(d, J=6.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 173.4, 152.9, 137.2, 129.3 (2C), 
128.9 (2C), 127.0, 82.2, 63.7, 42.9, 39.3, 37.3, 35.6, 30.0, 28.7, 28.2, 24.9, 22.9, 22.8, 22.5, 
19.9. LRMS (ESI) calcd for C22H33NO3Na [M+Na] 382.2358, found 382.22. 
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(S)-3-(3-(Benzo[d]oxazol-2-yl)propanoyl)-4-benzyl-5,5-dimethyloxazolidin-2-one 
(3.44). The title compound was prepared from carboxylic acid 3.43 (0.471 g, 2.46 mmol)
122
 
following the standard procedure for the synthesis of N-acyl oxazolidinones and was 
obtained as white solid (0.391 g, 1.03 mmol, 44%) after purification by column 
chromatography (silica, 25% ethyl acetate – hexanes, 40% ethyl acetate – hexanes). D
23 -
11.9° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.65-7.58 (m, 1H); 
7.48-7.42 (m, 1H); 7.31-7.15 (m, 7H); 4.50 (dd, J1=9.6 Hz, J2=3.6 Hz, 1H); 3.66-3.55 (m, 
1H); 3.54-3.42 (m, 1H); 3.33-3.18 (m, 2H); 3.14 (dd, J1=14.4 Hz, J2=3.6 Hz, 1H); 2.90 (dd, 
J1=14.4 Hz, J2=9.6 Hz, 1H); 1.39 (s, 3H); 1.37 (s, 3H). 
13
C NMR (150 MHz, CDCl3); 
δ(ppm): 171.7, 165.8, 152.8, 151.0, 141.5, 137.0, 129.2 (2C), 128.8 (2C), 127.0, 124.7, 
124.3, 119.8, 110.5, 82.8, 63.7, 35.5, 32.6, 28.7, 23.4, 22.5. LRMS (ESI) calcd for 
C22H22N2O4Na [M+Na] 401.1477, found 401.14. 
  136 
 
Pd/C, H2, MeOH
S19 S20
MeO
O
O
MeO
O
O
 
Methyl 3-(benzofuran-2-yl)propanoate (3.46). Crude ,-unsaturated ester 3.45 (0.753 
g, 3.42 mmol)
123
 and palladium on carbon (75.3 mg) were dissolved in methanol (23.0 mL). 
Hydrogen was bubbled through the reaction mixture for 2 min at rt. The reaction mixture 
flask was pressurized with Hydrogen gas and the reaction was stirred for 1.5 h at rt. The 
reaction mixture was filtered through Celite and the solvent was removed in vacuo. The 
desired compound 3.46 was obtained as an oil (0.379 g, 1.86 mmol, 54%) after purification 
by column chromatography (silica, 5% ethyl acetate – hexanes, 10% ethyl acetate – hexanes, 
15% ethyl acetate – hexanes). 1H NMR (600 MHz, CDCl3); (ppm): 7.50-7.46 (m, 1H); 
7.43-7.39 (m, 1H); 7.24-7.16 (m, 2H); 6.43 (s, 1H); 3.71 (s, 3H); 3.12 (dd, J1=J2=7.8 Hz, 
2H); 2.78 (dd, J1=J2=8.4 Hz, 2H); 
13
C NMR (150 MHz, CDCl3 172.9, 157.4, 
154.9, 128.9, 123.7, 122.8, 120.6, 111.0, 102.7, 52.0, 32.3, 24.1. LRMS (ESI) calcd for 
C12H12O3Na [M+Na] 227.0786, found 227.08. 
 
O
O N
O
Bn
O
O NLi
Bn
O
S2
1. LiOH·H2O, THF
2. (COCl)2, cat. DMF, CH2Cl2;
    then S2, THF
S20 S21
MeO
O
O
 
(S)-3-(3-(Benzofuran-2-yl)propanoyl)-4-benzyl-5,5-dimethyloxazolidin-2-one (3.48). 
LiOHH2O (3.00 mL, 7.2 mmol, 2.42 M in water) was added to methyl ester 3.47 (0.367 g, 
1.80 mmol) in THF (9.00 mL) at 0 C. After 10 min the reaction mixture was warmed to rt 
  137 
and stirred for 12 h. HCl (1 M) was then added until the reaction mixture was acidic (pH ~ 
4), and the layers were separated. The aqueous layer was extracted with ethyl acetate (3x20 
mL). The combined organic layers were dried with sodium sulfate and concentrated. The 
resultant solid was submitted to the next reaction without further purification. 
Oxalyl chloride (0.172 mL, 1.97 mmol) was added to a solution of the crude carboxylic 
acid (0.340 g, 1.79 mmol), dimethylformamide (10 μl), and dichloromethane (1.80 mL) at 0 
°C. After 10 min, the solution was warmed to rt and stirred an additional 15 min (until all 
bubbling had stopped). The solution was concentrated in vacuo. In a separate flask, n-
butyllithium (2.10 M in hexanes, 0.895 mL, 1.88 mmol), was added to a solution of 
oxazolidinone (0.376 g, 1.83 mmol) in THF (3.60 mL) at -78 °C under argon. The solution 
was stirred for 30 min at -78 °C then the crude acid chloride in THF (3.60 mL total with 
rinses) was added dropwise at -78 °C. After 2 h, the reaction mixture was warmed to 0 °C 
over 30 min and was quenched with saturated aqueous ammonium chloride. The layers were 
separated. The aqueous layer was extracted with ethyl acetate (3x20 mL). The combined 
organic layers were washed with brine, dried with sodium sulfate, and concentrated. The 
desired compound 3.48 was obtained as a white solid (0.538 g, 1.43 mmol, 79%) after 
purification by column chromatography (silica, 15% ethyl acetate – hexanes, 30% ethyl 
acetate – hexanes). D
23 -25.7° (c 1.63, CHCl3). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.50-
7.46 (m, 1H); 7.43-7.38 (m, 1H); 7.32-7.24 (m, 4H); 7.24-7.15 (m, 3H); 6.45 (s, 1H); 4.53 
(dd, J1=9.6 Hz, J2=4.2 Hz, 1H); 3.45-3.34 (m, 2H); 3.19-3.09 (m, 3H); 2.88 (dd, J1=14.4 
Hz, J2=9.6 Hz, 1H); 1.38 (s, 3H), 1.36 (s, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 172.0, 
157.5, 154.8, 152.8, 137.0, 129.2 (2C), 129.0, 128.8 (2C), 127.0, 123.5, 122.7, 120.6, 111.0, 
102.8, 82.6, 63.7, 35.5, 34.0, 28.7, 23.3, 22.5. LRMS (ESI) calcd for C23H23NO4Na [M+Na] 
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400.1525, found 400.11. 
 
Standard procedure for perfluoralkylation of N-acyl oxazolidinones: 
O
O N
O
Bn
O
O N
O
Bn
R
ZrCl4, Et3N, DCM
RuCl2(PPh3)3 (0.07 equiv.)
RFI (5.0 equiv.)
O
O N
O
Bn
R'
by-product  
An N-acyl oxazolidinone (63.5 mg, 0.250 mmol), zirconium(IV) chloride (61.3 mg, 
0.263 mmol, 1.05 equiv), and RuCl2(PPh3)3 (16.8 mg, 0.0175 mmol, 0.07 equiv) were 
weighed out and added to a oven-dried vial equipped with a magnetic stir bar. Each reaction 
was capped with a black phenolic open-top screw cap lined with a white Silicone/TFE 
septum. The reaction vial was then backfilled with argon followed by addition of dry 
dichloromethane (2.50 mL) at rt. Triethylamine (0.122 mL, 0.875 mmol, 3.50 equiv) was 
added to the reaction mixture and stirred for 5 min, followed by addition of perfluoroalkyl 
iodide (1.25 mmol, 5.00 equiv). The vial cap was then replaced with a Teflon-lined cap. The 
reaction mixture was stirred for 1 h at rt, then heated to 45 ˚C and stirred for an additional 16 
h. The sealed reaction vial was slowly opened (reaction is under pressure), and then added to 
HCl (1 M, 20 mL) in a separatory funnel. The layers were separated. The aqueous layer was 
extracted with dichloromethane (3x10 mL). The combined organic layers were dried with 
sodium sulfate, and concentrated on a rotary evaporator. The resulting compound was 
purified by column chromatography to give the corresponding -perfluoralkylated 
oxazolidinone. 
Alternative procedure for workup: The final reaction mixture can simply be filtered 
through a 1.5 cm plug of silica gel with ~ 1.0 cm of Celite on top washing with ethyl acetate. 
The filtrate is concentrated under reduced pressure to deliver the crude product. 
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Standard procedure for trifluoromethylation of N-acyl oxazolidinones: 
 
O
O N
O
R
ZrCl4, Et3N, DCM
RuCl2(PPh3)3 (0.15 equiv.)
F3CI (6.0 equiv.)
O
O N
O
R
CF3
Bn Bn  
For solid substrates: The N-acyl oxazolidinone (0.500 mmol), zirconium(IV) chloride 
(0.122 g, 0.525 mmol, 1.05 equiv), and RuCl2(PPh3)3 (71.9 mg, 0.075 mmol, 0.15 equiv) 
were weighed out and added to a oven-dried vial equipped with a magnetic stir bar. Each 
reaction was capped with a black phenolic open-top screw cap lined with a white 
Silicone/TFE septum. The reaction vial was then backfilled with argon followed by addition 
of dry dichloromethane (1.00 mL) at rt. The reaction was cooled to -78 ˚C, then 
triethylamine (0.280 mL, 2.00 mmol, 4.00 equiv) was added and the reaction was stirred for 
5 min. Trifluoroiodomethane (~0.230 mL, ~3.00 mmol, ~6.00 equiv) was then bubbled in 
via needle at -78 ˚C. The vial cap was then replaced with a solid Teflon-lined cap. The 
reaction was warmed to rt and stirred for 1 h, then heated to 45 ˚C and stirred for an 
additional 16 h. The sealed reaction vial was slowly opened (reaction is under pressure) until 
bubbling stopped, and then added to HCl (1 M, 20 mL) in a separatory funnel. The aqueous 
layer was extracted with dichloromethane (3x10 mL). The combined organic layers were 
dried with sodium sulfate, and concentrated on a rotary evaporator. The resulting compound 
was purified by column chromatography to give the corresponding -trifluoromethylated N-
acyl oxazolidinone. 
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Alternative procedure for workup: The final reaction mixture can simply be filtered 
through a 1.5 cm plug of silica gel with ~ 1.0 cm of Celite on top washing with ethyl acetate. 
The filtrate is concentrated under reduced pressure to deliver the crude product. 
For liquid or amorphous substrates: Zirconium(IV) chloride (0.122 g, 0.525 mmol, 
1.05 equiv) and RuCl2(PPh3)3 (71.9 mg, 0.075 mmol, 0.15 equiv) were weighed out and 
added to a oven-dried vial equipped with a magnetic stir bar. Each reaction was capped with 
a black phenolic open-top screw cap lined with a white Silicone/TFE septum. The reaction 
vial was then backfilled with argon followed by addition of a solution of the N-acyl 
oxazolidinone (0.500 mmol) in dichloromethane (3 rinses, total of 1.00 mL) at rt. The 
reaction mixture was cooled to -78 ˚C, then triethylamine (0.280 mL, 2.00 mmol, 4.00 
equiv) was added and the reaction was stirred for 5 min. Trifluoroiodomethane (~0.230 mL, 
~3.00 mmol, ~6.00 eq.) was then bubbled in via needle at -78 ˚C. The vial cap was then 
replaced with a solid Teflon-lined cap. The reaction was warmed to rt and stirred for 1 h, 
then heated to 45 ˚C and stirred for an additional 16 h. The sealed reaction vial was slowly 
opened (reaction is under pressure) until bubbling stopped, and then added to HCl (1 M, 20 
mL) in a separatory funnel. The aqueous layer was extracted with dichloromethane (3x10 
mL). The combined organic layers were dried with sodium sulfate, and concentrated on a 
rotary evaporator. The resulting compound was purified by column chromatography to give 
the corresponding -trifluoromethylated N-acyl oxazolidinone. 
Alternative procedure for workup: The final reaction mixture can simply be filtered 
through a 1.5 cm plug of silica gel with ~ 1.0 cm of Celite on top washing with ethyl acetate. 
The filtrate is concentrated under reduced pressure to deliver the crude product. 
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Table 3.4.2, entry 1. The title compound was prepared from oxazolidinone 3.12 (0.131 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.122 g, 0.370 mmol, 74%, dr 9:1) after purification by column 
chromatography (silica, 45% dichloromethane – hexanes, 15% ethyl acetate – hexanes, 20% 
ethyl acetate – hexanes). D
25 14.5° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); 
δ(ppm): 7.33-7.29 (m, 2H); 7.28-7.22 (m, 3H); 4.83 (app heptet, J=7.8 Hz, 1H); 4.53 (dd, 
J1=9.6 Hz, J2=3.6 Hz, 1H); 3.19 (dd, J1=14.4 Hz, J2=3.0 Hz, 1H); 2.88 (dd, J1=14.4 Hz, 
J2=9.6 Hz, 1H); 1.44 (d, J=7.2 Hz, 3H); 1.40 (s, 3H); 1.34 (s, 3H); 
13
C NMR (150 MHz, 
CDCl3); δ(ppm): 168.6 (q, J=2.9 Hz), 152.3, 136.6, 129.2 (2C), 129.0 (2C), 127.2, 125.2 (q, 
J=278.4 Hz), 82.9, 64.2, 42.5 (q, J=27.3 Hz), 35.1, 28.8, 22.6, 11.4 (q, J=2.9 Hz). 
19
F NMR 
(564.3 MHz, CDCl3); δ(ppm): -69.15 (d, J=7.9 Hz, 3F). LRMS (ESI) calcd for 
C16H18F3NO3Na [M+Na] 352.1136, found 352.13. 
 
O
O N
O
Bn
C3F7
 
Table 3.4.2, entry 2. The title compound was prepared from oxazolidinone 3.12 (65.3 
mg, 0.250 mmol) following the standard perfluoroalkylation procedure and was obtained as 
a colorless oil (79.0 mg, 0.185 mmol, 74%, dr 24:1) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes, 
50% dichloromethane – hexanes). Analytically pure sample (white solid) was obtained using 
HPLC by dissolving the mixture in 0.5% i-ProH/hexanes with the concentration of 10 
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mg/ml. The separation was conducted on a YMC-Pack Sil HPLC column (250x30mmID, S-
10 m, 12 nm) with 4.5 mL injection (0.25% i-PrOH/hexanes as eluent at a rate of 20 
mL/min, =215 nm, Rt=14.55 min) afforded pure product. D
25 -32.7° (c 1.0, 
dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.33-7.26 (m, 4H); 7.26-7.22 (m, 
1H); 5.09 (app octet, J=7.2 Hz, 1H); 4.54 (dd, J1=10.8 Hz, J2=3.0 Hz, 1H); 3.25 (dd, 
J1=14.4 Hz, J2=3.0 Hz, 1H); 2.82 (dd, J1=14.4 Hz, J2=10.8 Hz, 1H); 1.48 (d, J=7.2 Hz, 
3H); 1.38 (s, 3H); 1.32 (s, 3H); 
13
C NMR (125 MHz, CDCl3); δ(ppm): 168.7 (t, J=3.3 Hz), 
152.3, 136.8, 129.1 (2C), 129.0 (2C), 127.2, 121.8-105.0 (m, 3C), 82.8, 64.4, 39.3 (t, J=21.0 
Hz), 34.7, 29.9, 28.9, 22.7, 11.4-11.2 (m, 1C). 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -
80.59 (dd, J1=J2=10.2 Hz, 3F), -115.4 (m, 2F), -124.68 (m, 2F). LRMS (ESI) calcd for 
C18H18F7NO3Na [M+Na] 452.1073, found 452.13. 
 
O
O N
O
Bn
C4F9
 
Table 3.4.2, entry 3. The title compound was prepared from oxazolidinone 3.12 (65.3 
mg, 0.250 mmol) following the standard perfluoroalkylation procedure and was obtained as 
a colorless oil (85.4 mg, 0.178 mmol, 71%, dr 24:1) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes, 
50% dichloromethane – hexanes). Analytically pure sample (white solid) was obtained using 
HPLC by dissolving the mixture in 0.5% i-ProH/hexanes with the concentration of 10 
mg/ml. The separation was conducted on a YMC-Pack Sil HPLC column (250x30mmID, S-
10 m, 12 nm) with 4.5 mL injection (0.25% i-PrOH/hexanes as eluent at a rate of 20 
mL/min, =215 nm, Rt=12.49 min) afforded pure productD
25 -24.3° (c 1.0, 
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dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.34-7.26 (m, 4H), 7.26-7.22 (m, 
1H), 5.11 (app octet, J=7.2 Hz, 1H), 4.54 (dd, J1=10.2 Hz, J2=3.0 Hz, 1H), 3.24 (dd, 
J1=15.0 Hz, J2=3.0 Hz, 1H); 2.83 (dd, J1=15.0 Hz, J2=10.2 Hz, 1H); 1.48 (d, J=7.2 Hz, 
3H); 1.38 (s, 3H); 1.33 (s, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 168.8-168.6 (m, 1C), 
152.3, 136.8, 129.2 (2C), 129.0 (2C), 127.2, 121.0-106.4 (m, 4C), 82.6, 64.4, 39.4 (t, J=21.5 
Hz), 34.7, 28.8, 22.6, 11.5-11.3 (m, 1C). 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -80.91 
(dd, J=9.6 Hz, 3F), -114.77 (m, 2F), -121.4 (m, 2F), -126.06 (m, 2F). LRMS (ESI) calcd for 
C19H18F9NO3Na [M+Na] 502.1041, found 502.13. 
 
O
O N
O
Bn
CF3F
CF3  
Table 3.4.2, entry 4. The title compound was prepared from oxazolidinone 3.12 (0.131 
mg, 0.500 mmol) following the standard perfluoroalkylation procedure and was obtained as 
a colorless oil (0.161 g, 0.374 mmol, 75%, dr >98:2) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes, 
50% dichloromethane – hexanes). D
23 -17.2° (c 1.0, dichloromethane). 
1
H NMR (500 MHz, 
CDCl3); δ(ppm): 7.34-7.27 (m, 4H); 7.26-7.20 (m, 1H); 5.18 (dq, Jd=14.5 Hz, Jq=7.5 Hz, 
1H); 4.53 (dd, J1=11.0 Hz, J2=2.5 Hz, 1H); 3.29 (dd, J1=14.5 Hz, J2=2.5 Hz, 1H); 2.76 (dd, 
J1=14.5 Hz, J2=11.0 Hz, 1H); 1.50 (d, J=7.0 Hz, 3H); 1.36 (s, 3H); 1.30 (s, 3H); 
13
C NMR 
(150 MHz, CDCl3); δ(ppm): 169.2 (d, J=3.3 Hz), 152.3, 136.8, 129.1 (2C), 129.0 (2C), 
127.1, 120.98 (dq, J=28.1 Hz, J=286.4 Hz), 120.96 (dq, J=28.1 Hz, 286.4 Hz), 92.4 (dh, 
J=31.4 Hz, J=210.0 Hz), 82.6, 64.5, 37.5 (d, J=19.4 Hz), 34.1, 28.7, 22.3, 12.4. 
19
F NMR 
(564.3 MHz, CDCl3); δ(ppm): -72.94 (dddd, J=9.6 Hz, 3F), -73.38 (dddd, J=9.6 Hz, 3F), -
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182.04 (m, 1F). LRMS (ESI) calcd for C18H18F7NO3Na [M+Na] 452.1073, found 452.09. 
 
O
O N
O
Bn
C6F13
 
Table 3.4.2, entry 5. The title compound was prepared from oxazolidinone 3.12 (65.3 
mg, 0.250 mmol) following the standard perfluoroalkylation procedure and was obtained as 
a white solid (93.0 mg, 0.159 mmol, 64%, dr >98:2) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes, 
50% dichloromethane – hexanes). Analytically pure sample (white solid) was obtained using 
HPLC by dissolving the mixture in 0.5% i-ProH/hexanes with the concentration of 10 
mg/ml. The separation was conducted on a YMC-Pack Sil HPLC column (250x30mmID, S-
10 m, 12 nm) with 4.5 mL injection (0.25% i-PrOH/hexanes as eluent at a rate of 20 
mL/min, =215 nm, Rt=14.65 min) afforded pure product. D
25 -19.1° (c 1.0, 
dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.33-7.27 (m, 4H); 7.26-722 (m, 
1H); 5.11 (app octet, J=7.2 Hz, 1H); 4.54 (dd, J1=10.2 Hz, J2=3.0 Hz, 1H); 3.25 (dd, 
J1=14.4 Hz, J2=3.0 Hz, 1H); 2.82 (dd, J1=14.4 Hz, J2=10.2 Hz, 1H); 1.48 (d, J=7.2 Hz, 
3H); 1.38 (s, 3H); 1.33 (s, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 168.8-168.6 (m, 1C), 
152.3, 136.8, 129.2 (2C), 129.0 (2C), 127.2, 120.5-106.4 (m, 6C), 82.7, 64.4, 39.4 (t, J=21.5 
Hz), 34.7, 28.8, 22.6, 11.4. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -80.78 (dd, J1=J2=9.6 
Hz, 3F), -114.52 (m, 2F), -120.36 (m, 2F), -121.91 (m, 2F), -122.72 (m, 2F), -126.09 (m, 
2F). LRMS (ESI) calcd for C21H18F13NO3Na [M+Na] 602.0977, found 602.08. 
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Table 3.4.2, entry 6. The title compound was prepared from oxazolidinone 3.12 (65.3 
mg, 0.250 mmol) following the standard perfluoroalkylation procedure and was obtained as 
a white solid (87.4 mg, 0.183 mmol, 73%, dr >98:2) after purification by column 
chromatography (silica, 12.5% ethyl acetate – hexanes, 15% ethyl acetate – hexanes, 20% 
ethyl acetate – hexanes). Analytically pure sample (white solid) was obtained using HPLC 
by dissolving the mixture in 0.5% i-ProH/hexanes with the concentration of 10 mg/ml. The 
separation was conducted on a YMC-Pack Sil HPLC column (250x30mmID, S-10 m, 12 
nm) with 4.5 mL injection (0.25% i-PrOH/hexanes as eluent at a rate of 20 mL/min, =215 
nm, Rt=13.44 min) afforded pure product. D
23 -28.7° (c 1.0, dichloromethane). 
1
H NMR 
(600 MHz, CDCl3); δ(ppm): 7.30-7.26 (m, 2H); 7.25-7.20 (m, 3H); 5.00 (app octet, J=6.6 
Hz, 1H); 4.49 (dd, J1=10.2 Hz, J2=3.6 Hz, 1H); 3.14 (dd, J1=14.4 Hz, J2=3.6 Hz, 1H); 2.81 
(dd, J1=14.4 Hz, J2=10.2 Hz, 1H); 1.45 (d, J=6.6 Hz, 3H); 1.37 (s, 3H); 1.33 (s, 3H); 
13
C 
NMR (150 MHz, CDCl3); δ(ppm): 169.9 (dd, J1=1.8 Hz, J2=6.2 Hz), 152.3, 146.0-144.0 
(m, 2C), 143.6-141.6 (m, 1C), 139.0-137.0 (m, 2C), 136.7, 129.2 (2C), 128.9 (2C), 127.1, 
119.5 (t, J=251.7 Hz), 110.3 (m, 1C), 82.9, 64.2, 45.8 (t, J=25.2 Hz), 34.8, 28.8, 22.5, 11.5 
(t, J=4.5 Hz). 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -77.97 (dtd, Jd1=10.6 Hz, Jt=22.1 Hz, 
Jd2=232 Hz, 1F), -80.68 (dtd, Jd1=12.1 Hz, Jt=25.8 Hz, Jd2=232 Hz, 1F), -117.90 (m, 2F), -
127.67 (t, J=17.5 Hz, 1F), 136.77 (m, 2F). LRMS (ESI) calcd for C22H18F7NO3Na [M+Na] 
500.1073, found 500.09. 
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Table 3.4.3, entry 1. The title compound was prepared from oxazolidinone 3.31 (0.152 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.131 g, 0.353 mmol, 71%, dr ~9.4:1) after purification by column 
chromatography (silica, 40% dichloromethane – hexanes, 15% ethyl acetate – hexanes). D
23 
6.8° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.33-7.25 (m, 4H); 
7.25-7.21 (m, 1H); 4.99-4.89 (m, 1H); 4.56 (dd, J1=9.6 Hz, J2=3.6 Hz, 1H); 3.15 (dd, 
J1=14.4 Hz, J2=3.6 Hz, 1H); 2.90 (dd, J1=14.4 Hz, J2=9.6 Hz, 1H); 2.04-1.95 (m, 1H); 
1.87-1.79 (m, 1H); 1.39 (s, 3H); 1.42-1.25 (m, 4H); 1.35 (s, 3H); 0.90 (dd, J1=J2=6.6 Hz, 
3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 168.1 (q, J=3.5 Hz), 152.3, 136.7, 129.2 (2C), 
128.9 (2C), 127.1, 125.0 (q, J=279 Hz), 82.7, 64.3, 47.0 (q, J=26.3 Hz), 35.2, 29.0, 28.7, 
26.4 (q, J=1.7 Hz), 22.6, 22.4, 13.9. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -67.11 (d, 
J=7.9 Hz, 3F). LRMS (ESI) calcd for C19H24F3NO3Na [M+Na] 394.1606, found 394.17. 
 
O
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Table 3.4.3, entry 2. The title compound was prepared from oxazolidinone 3.32 (0.145 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.141 g, 0.395 mmol, 79%, dr >24:1) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes, 
20% ethyl acetate – hexanes). D
24 5.4° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, 
CDCl3); δ(ppm): 7.33-7.27 (m, 4H); 7.25-7.21 (m, 1H), 4.82 (dq, Jd=Jq=8.4 Hz, 1H), 4.56 
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(dd, J1=10.2 Hz, J2=3.6 Hz, 1H), 3.16 (dd, J1=14.4 Hz, J2=3.6 Hz, 1H), 2.90 (dd, J1=14.4 
Hz, J2=10.2 Hz, 1H), 2.47-2.37 (m, 1H), 1.37 (s, 3H), 1.36 (s, 3H), 1.14 (d, J=6.6 Hz, 3H), 
1.03 (d, J=6.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 168.1 (q, J=3.9 Hz), 152.4, 
136.8, 129.2 (2C), 128.9 (2C), 127.1, 125.1 (q, J=280.1 Hz), 82.5, 64.3, 52.9 (q, J=25.7 Hz), 
35.1, 28.8, 28.1, 22.4, 20.8, 20.4. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -63.03 (d, J=9.0 
Hz, 3F). LRMS (ESI) calcd for C18H22F3NO3Na [M+Na] 380.1449, found 380.15. 
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Table 3.4.3, entry 3. The title compound was prepared from oxazolidinone 3.33 (0.165 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.150 g, 0.378 mmol, 76%, dr >24:1) after purification by column 
chromatography (silica, 25% dichloromethane – hexanes, 35% dichloromethane – hexanes, 
20% ethyl acetate – hexanes). D
23 19.3° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, 
CDCl3); δ(ppm): 7.34-7.27 (m, 4H); 7.25-7.21 (m, 1H); 4.88 (dq, Jd=Jq=9.0 Hz, 1H); 4.55 
(dd, J1=10.2 Hz, J2=3.6 Hz, 1H); 3.16 (dd, J1=14.4 Hz, J2=3.6 Hz, 1H); 2.90 (dd, J1=14.4 
Hz, J2=10.2 Hz, 1H); 2.18-2.09 (m, 1H); 2.01-1.95 (m, 1H); 1.81-1.69 (m, 2H); 1.69-1.60 
(m, 2H); 1.37 (s, 3H); 1.36 (s, 3H); 1.33-1.24 (m, 2H); 1.22-1.15 (m, 3H); 
13
C NMR (150 
MHz, CDCl3); δ(ppm): 168.2 (q, J=3.9 Hz), 152.4, 136.9, 129.2 (2C), 128.9 (2C), 127.1, 
125.1 (q, J=280.7 Hz), 82.5, 64.3, 52.3 (q, J=25.2 Hz), 37.2, 35.2, 30.7, 30.4, 28.8, 26.1, 
25.9 (2C), 22.4. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -62.32 (d, J=7.9 Hz, 3F). LRMS 
(ESI) calcd for C21H26F3NO3Na [M+Na] 420.1762, found 420.18. 
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Table 3.4.3, entry 4. The title compound was prepared from oxazolidinone 3.34 (0.153 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.129 g, 0.348 mmol, 70%, dr >98:2) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes). 
D
25 90.9° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.33-7.29 (m, 
4H); 7.26-7.21 (m, 1H); 5.10 (q, J=9.0 Hz, 1H); 4.57 (dd, J1=10.2 Hz, J2=3.0 Hz, 1H); 3.15 
(dd, J1=14.4 Hz, J2=3.0 Hz, 1H); 2.90 (dd, J1=14.4 Hz, J2=10.2 Hz, 1H); 1.36 (s, 3H); 1.36 
(s, 3H); 1.18 (s, 9H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 167.3 (q, J=3.3 Hz), 152.6, 
136.9, 129.2 (2C), 128.9 (2C), 127.1, 125.4 (q, J=281.3 Hz), 82.3, 64.3, 53.8 (q, J=24.6 Hz), 
35.2, 34.2, 28.9, 28.7 (3C), 22.4. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -59.86 (d, J=9.0 
Hz, 3F). LRMS (ESI) calcd for C19H24F3NO3Na [M+Na] 394.1606, found 394.17. 
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Table 3.4.3, entry 5. The title compound was prepared from oxazolidinone 3.35 (0.184 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.146 g, 0.336 mmol, 75%, dr 9:1) after purification by column 
chromatography (silica, 10% ethyl acetate – hexanes, 15% ethyl acetate – hexanes). D
23 
42.8° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.34-7.29 (m, 2H); 
7.29-7.21 (m, 5H); 6.94 (t, J=7.2 Hz, 1H); 6.86 (m, J=8.4 Hz, 2H); 5.41-5.31 (m, 1H); 4.51 
(dd, J1=9.6 Hz, J2=3.6 Hz, 1H); 4.19-4.13 (m, 1H); 3.98-3.81 (m, 1H); 3.16 (dd, J1=14.4 
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Hz, J2=3.6 Hz, 1H); 2.88 (dd, J1=14.4 Hz, J2=9.6 Hz, 1H); 2.56-2.48 (m, 1H); 2.35-2.28 
(m, 1H); 1.33 (s, 3H); 1.05 (s, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 167.2 (q, J=3.3 
Hz), 158.5, 152.2, 136.8, 129.7 (2C), 129.2 (2C), 128.9 (2C), 127.1, 125.1 (q, J=279.0 Hz), 
121.6, 115.0 (2C), 82.6, 65.0, 64.3, 44.4 (q, J=27.3 Hz) 35.2, 28.3, 26.5-26.3 (m, 1C), 22.5. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -67.44 (d, J=7.9 Hz, 3F). LRMS (ESI) calcd for 
C23H24F3NO4Na [M+Na] 458.1555, found 458.18. 
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Table 3.4.3, entry 6. The title compound was prepared from oxazolidinone 3.36 (0.198 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.119 g, 0.256 mmol, 51%, dr 9:1) after purification by column 
chromatography (silica, 15% ethyl acetate – hexanes, 20% ethyl acetate – hexanes, 30% 
ethyl acetate – hexanes). D
23 10.3° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); 
δ(ppm): 7.38-7.22 (m, 10H); 5.08-4.98 (m, 1H); 4.58-4.53 (m, 1H); 4.53-4.46 (m, 2H); 3.54-
3.43 (m, 2H); 3.17 (dd, J1=14.4 Hz, J2=3.6 Hz, 1H); 2.90 (dd, J1=14.4 Hz, J2=10.2 Hz, 
1H); 2.17-2.08 (m, 1H); 2.01-1.92 (m, 1H); 1.72-1.62 (m, 2H); 1.39 (s, 3H); 1.33 (s, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 167.8 (q, J=2.9 Hz), 152.2, 138.4, 136.7, 129.2 (2C), 
128.9 (2C), 128.6 (2C), 127.9 (2C), 127.8, 127.1, 125.0 (q, J=280.7 Hz), 82.7, 73.2, 69.4, 
64.2, 46.8, (q, J=26.9 Hz), 35.1, 28.6, 26.9, 23.7, 22.4. 
19
F NMR (564.3 MHz, CDCl3); 
δ(ppm): -66.99 (d, J=7.9 Hz, 3F). LRMS (ESI) calcd for C25H28F3NO4Na [M+Na] 486.1868, 
found 486.17. 
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Table 3.4.3, entry 7. The title compound was prepared from oxazolidinone 3.37 (0.175 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.128 g, 0.315 mmol, 63%, dr 9.2:1) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes, 
20% ethyl acetate – hexanes). D
25 96.0° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, 
CDCl3); δ(ppm): 7.31-7.25 (m, 4H); 7.25-7.18 (m, 6H); 5.45-5.36 (m, 1H); 4.25 (dd, J1=9.6  
Hz, J2=4.8 Hz, 1H); 3.26-3.15 (m, 2H); 3.01 (dd, J1=15.0 Hz, J2=4.8 Hz, 1H); 2.85 (dd, 
J1=15.0 Hz, J2=9.6 Hz, 1H); 1.26 (s, 3H); 0.74 (s, 3H); 
13
C NMR (150 MHz, CDCl3); 
δ(ppm): 166.8 (q, J=3.1 Hz), 152.1, 136.6, 136.0, 129.4 (2C), 129.2 (2C), 129.0 (2C), 128.9 
(2C), 127.5, 127.1, 124.6 (q, J=279.6 Hz), 82.7, 64.0, 48.1 (q, J=26.3 Hz), 35.5, 32.9 (q, 
J=2.2 Hz), 27.6, 22.2. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -67.38 (d, J=7.9 Hz, 3F). 
LRMS (ESI) calcd for C22H22F3NO3Na [M+Na] 428.1449, found 428.16. 
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Table 3.4.3, entry 8. The title compound was prepared from oxazolidinone 3.38 (0.199 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.140 g, 0.300 mmol, 60%, dr 9:1) after purification by column 
chromatography (silica, 15% ethyl acetate – hexanes, 25% ethyl acetate – hexanes). D
25 
90.9° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.31-7.26 (m, 2H); 
7.26-7.21 (m, 3H); 6.78-6.73 (m, 3H); 5.44 (app sextet, J=7.2 Hz, 1H); 4.26 (dd, J1=9.0 Hz, 
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J2=4.2 Hz, 1H); 3.87 (s, 3H); 3.81 (s, 3H); 3.15 (d, J=7.8 Hz, 2H); 3.02 (dd, J1=14.4 Hz, 
J2=4.2 Hz, 1H); 2.87 (dd, J1=14.4 Hz, J2=9.0 Hz, 1H); 1.29 (s, 3H); 0.80 (s, 3H); 
13
C NMR 
(150 MHz, CDCl3); δ(ppm): 166.8 (q, J=2.9 Hz), 152.2, 149.3, 148.4, 136.5, 129.2 (2C), 
128.9 (2C), 128.2, 127.1, 124.6 (q, J=279.0 Hz), 121.4, 112.2, 111.6, 82.6, 64.0, 56.1 (2C), 
47.9 (q, J=26.3 Hz), 35.5, 32.5 (q, J=2.3 Hz), 27.4, 22.1. 
19
F NMR (564.3 MHz, CDCl3); 
δ(ppm): -67.31 (d, J=7.9 Hz, 3F). LRMS (ESI) calcd for C24H26F3NO5Na [M+Na] 488.1661, 
found 488.19. 
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Table 3.4.3, entry 9. The title compound was prepared from oxazolidinone 3.39 (0.162 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (93.1 mg, 0.238 mmol, 48%, dr 8.4:1) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes, 
20% ethyl acetate – hexanes). D
24 24.3° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, 
CDCl3); δ(ppm): 7.50-7.46 (m, 2H); 7.40-7.36 (m, 3H); 7.34-7.27 (m, 4H); 7.27-7.23 (m, 
1H); 5.90 (q, J=7.8 Hz, 1H); 4.44 (dd, J1=9.6 Hz, J2=3.6 Hz, 1H); 3.22 (dd, J1=14.4 Hz, 
J2=3.6 Hz, 1H); 2.96 (dd, J1=14.4 Hz, J2=9.6 Hz, 1H); 1.34 (s, 3H); 1.04 (s, 3H); 
13
C NMR 
(150 MHz, CDCl3); δ(ppm): 166.0 (q, J=2.3 Hz), 152.0, 136.6 (2C), 130.4 (2C), 129.6, 
129.3 (2C), 129.1 (2C), 129.0 (2C), 127.2, 124.0 (q, J=278.4 Hz), 83.1, 64.3, 53.1 (q, J=28.5 
Hz), 35.5, 28.4, 22.2. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -66.71 (d, J=7.9 Hz, 3F). 
LRMS (ESI) calcd for C21H20F3NO3Na [M+Na] 414.1293, found 414.15. 
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Table 3.4.3, entry 10. The title compound was prepared from oxazolidinone 3.41 (0.133 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.105 g, 0.245 mmol, 49%, dr 6.4:1) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes, 
20% ethyl acetate – hexanes). D
22 11.7° (c 0.46, dichloromethane). 
1
H NMR (600 MHz, 
CDCl3); δ(ppm): 7.33-7.27 (m, 4H); 7.25-7.21 (m, 1H); 4.86 (dq, Jd=Jq=8.4 Hz, 1H); 4.56 
(dd, J1=9.6 Hz, J2=3.0 Hz, 1H); 3.16 (dd, J1=15.0 Hz, J2=3.0 Hz, 1H); 2.90 (dd, J1=15.0 
Hz, J2=10.2 Hz, 1H); 2.33-2.23 (m, 1H); 1.55-1.46 (m, 1H); 1.37 (s, 3H); 1.36 (s, 3H); 1.43-
1.20 (m, 6H); 1.11 (d, J=6.0 Hz, 3H); 0.86 (d, J=2.4 Hz, 3H); 0.85 (d, J=2.4 Hz, 3H); 
13
C 
NMR (150 MHz, CDCl3); δ(ppm): 168.30-168.25 (m, 1C), 152.4, 136.8, 129.2 (2C), 129.0 
(2C), 127.1, 125.1 (q, J=280.8 Hz), 82.6, 64.3, 52.3 (q, J=26.3 Hz), 39.1, 35.2, 34.8, 32.8, 
28.8, 28.1, 24.5, 22.9, 22.7, 22.4, 16.6. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -62.35 (d, 
J=7.9 Hz, 3F). LRMS (ESI) calcd for C23H32F3NO3Na [M+Na] 450.2232, found 450.20. 
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Table 3.4.3, entry 11. The title compound was prepared from oxazolidinone 3.42 (0.183 
g, 0.500 mmol) following the standard trifluoromethylation procedure and was obtained as a 
colorless oil (0.113 g, 0.265 mmol, 53%, dr 10:1) after purification by column 
chromatography (silica, 35% dichloromethane – hexanes, 45% dichloromethane – hexanes, 
20% ethyl acetate – hexanes). D
22 -7.2° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, 
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CDCl3); δ(ppm): 7.33-7.27 (m, 4H); 7.26-7.21 (m, 1H); 4.95 (dq, Jd=Jq=8.4 Hz, 1H); 4.55 
(dd, J1=9.6 Hz, J2=3.0 Hz, 1H); 3.16 (dd, J1=15.0 Hz, J2=3.0 Hz, 1H); 2.91 (dd, J1=15.0 
Hz, J2=9.6 Hz, 1H); 2.32-2.24 (m, 1H); 1.62-1.48 (m, 2H); 1.38 (s, 3H); 1.36 (s, 3H); 1.34-
1.20 (m, 3H); 1.20-1.12 (m, 2H); 1.02 (d, J=6.6 Hz, 3H); 0.87 (d, J=3.0 Hz, 3H); 0.86 (d, 
J=3.0 Hz, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 168.0 (q, J=3.5 Hz), 152.4, 136.8, 
129.2 (2C), 129.0 (2C), 127.1, 125.1 (q, J=280.5 Hz), 82.3, 64.1, 51.4 (q, J=25.5 Hz), 39.1, 
35.2, 33.8, 32.7, 28.8, 28.1, 24.2, 22.9, 22.7, 22.4, 17.1. 
19
F NMR (564.3 MHz, CDCl3); 
δ(ppm): -62.73 (d, J=8.5 Hz, 3F). LRMS (ESI) calcd for C23H32F3NO3Na [M+Na] 450.2232, 
found 450.24. 
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Table 3.4.3, entry 12. The title compound was prepared from oxazolidinone 3.44 (97.5 
mg, 0.250 mmol) following the standard trifluoromethylation procedure (shorter reaction 
time: 4 h at 45 ˚C) with 0.20 equiv of RuCl2(PPh3)3 (47.9 mg, 0.05 mmol) and was obtained 
as a colorless oil (37.5 mg, 0.084 mmol, 34%, dr 8.3:1) after purification by column 
chromatography (silica, 20% ethyl acetate – hexanes, 30% ethyl acetate – hexanes). 
Isomerically pure sample was obtained using HPLC by dissolving the mixture in 0.5% i-
PrOH/hexanes with the concentration of 10 mg/ml. The separation was conducted on a 
YMC-Pack Sil HPLC column (250x30mmID, S-10 m, 12 nm) with 4.5 mL injection 
(0.25% i-PrOH/hexanes as eluent at a rate of 20 mL/min, =215 nm, Rt=13.37 min) 
affording pure product. D
23 36.1° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); 
δ(ppm): 7.50-7.45 (m, 2H); 7.32-7.20 (m, 7H); 5.74-5.66 (m, 1H); 4.57 (dd, J1=9.0 Hz, 
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J2=5.4 Hz, 1H); 3.76 (dd, J1=17.4 Hz, J2=12.0 Hz, 1H); 3.31 (dd, J1=17.4 Hz, J2=3.0 Hz, 
1H); 3.07 (dd, J1=14.4 Hz, J2=5.4 Hz, 1H); 2.99 (dd, J1=14.4 Hz, J2=9.0 Hz, 1H); 1.56 (s, 
3H); 1.44 (s, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 166.3 (m, 1C), 162.9, 152.6, 
151.3, 141.0, 136.6, 129.3 (2C), 128.9 (2C), 127.1, 125.3, 124.6, 124.2 (q, J=279.8 Hz), 
119.7, 110.8, 83.3, 64.2, 43.8 (q, J=28.1 Hz), 36.0, 28.6, 25.6 (q, J=2.9 Hz), 22.3. 
19
F NMR 
(564.3 MHz, CDCl3); δ(ppm): -67.58 (d, J=7.9 Hz, 3F). LRMS (ESI) calcd for 
C23H21F3N2O4Na [M+Na] 469.1351, found 469.14. 
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Table 3.4.3, entry 13. The title compound was prepared from oxazolidinone 3.45 (83.0 
mg, 0.220 mmol), zirconium(IV) chloride (61.3 mg, 0.263 mmol), and RuCl2(PPh3)3 (47.9 
mg, 0.05 mmol) following the standard trifluoromethylation procedure  (shorter reaction 
time: 4 h at 45 ˚C). The product was obtained as a colorless oil (48.0 mg, 0.108 mmol, 49%, 
dr 9.1:1) after purification by column chromatography (silica, 15% ethyl acetate – hexanes, 
20% ethyl acetate – hexanes). D
23 104.9° (c 1.0, CHCl3). 
1
H NMR (600 MHz, CDCl3); 
δ(ppm): 7.48-7.44 (m, 1H); 7.40-7.35 (m, 1H); 7.32-7.27 (m, 2H); 7.26-7.14 (m, 5H), 6.51 
(s, 1H); 5.60-5.50 (m, 1H); 4.43 (dd, J1=9.6 Hz, J2=4.2 Hz, 1H); 3.55 (dd, J1=15.0 Hz, 
J2=11.4 Hz, 1H); 3.28 (dd, J1=15.0 Hz, J2=3.6 Hz, 1H); 3.09 (dd, J1=14.4 Hz, J2=4.2 Hz, 
1H); 2.89 (dd, J1=14.4 Hz, J2=9.6 Hz, 1H), 1.31 (s, 3H); 0.97 (s, 3H); 
13
C NMR (150 MHz, 
CDCl3); δ(ppm): 166.4 (q, J=2.7 Hz), 155.0, 153.2, 152.1, 136.5, 129.2 (2C), 128.9 (2C), 
128.4, 127.1, 124.4 (q, J=279.6 Hz), 124.3, 123.1, 120.9, 111.2, 104.7, 82.9, 64.2, 45.7 (q, 
J=26.9 Hz), 35.4, 27.9, 25.9-25.8 (m, 1C), 22.3. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -
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67.57 (d, J=8.5 Hz, 3F). LRMS (ESI) calcd for C24H22F3NO4Na [M+Na] 468.1399, found 
468.10. 
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(S)-2-Cyclohexyl-3,3,3-trifluoropropanoic acid. Lithium hydroxide monohydrate (32 
mg, 0.763 mmol) was added to a solution of the substrate (99.4 mg, 0.25 mmol), hydrogen 
peroxide (30%, 0.24 mL), and water (0.24 mL) in THF (1.00 mL) at 0 °C. The reaction was 
warmed to rt and stirred for 3 h, after which time H2O (0.15 mL), H2O2 (0.15 mL), and 
LiOH·H2O (30.0 mg) were added at rt and stirred for 3 h. The reaction was quenched with 
aqueous sodium sulfite (1.5 M) and HCl (1 M) and allowed to stir until two transparent 
layers were visible (pH ~4). The layers were separated and the aqueous layer was extracted 
with ethyl acetate (3x10 mL). The organic layer was then washed with brine, dried with 
sodium sulfate, and concentrated in vacuo. The crude material was then dissolved in ethyl 
acetate (5 mL) and extracted with aqueous sodium hydroxide (3 M, 3x5 mL) and water (2x5 
mL). The aqueous extractions were combined and set aside. The organic layer was washed 
with HCl (1 M), brine, dried with sodium sulfate, and concentrated in vacuo to afford the 
oxazolidinone auxiliary (50.3 mg, 0.245 mmol, 98%). The previously saved aqueous layers 
were acidified with HCl (1 M). The aqueous layer was extracted with ethyl acetate (3x30 
mL). The combined organic layers were washed with brine, dried with sodium sulfate, and 
concentrated to afford the desired pure carboxylic acid (51.9 mg, 0.247 mmol, 99%). D
21 
5.3° (c 1.0, dichloromethane). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 10.22-8.63 (bs, 1H); 
2.98 (apparent pentet, J=8.5 Hz, 1H); 2.06-1.97 (m, 1H); 1.93-1.86 (m, 1H); 1.82-1.73 (m, 
  156 
3H); 1.71-1.65 (m, 1H); 1.35-1.10 (m, 5H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 173.5 
(m, 1C), 124.7 (q, J=279.8 Hz), 56.4 (q, J=25.8 Hz), 36.3, 31.0, 30.5, 26.1, 26.0, 25.9. 
19
F 
NMR (564.3 MHz, CDCl3); δ(ppm): -64.28 (d, J=8.5 Hz, 3F). LRMS (-ESI) calcd for 
C9H12F3O2 [M-H] 209.09, found 209.08. 
 
Determination of er for the acid: A solution of the (S)-2-cyclohexyl-3,3,3-
trifluoropropanoic acid in diethyl ether (0.2 M) was added to a solution of lithium aluminum 
hydride (4.0 equiv.) in diethyl ether (0.5 M) at -78 °C and stirred for 15 min. The reaction 
mixture was warmed to rt over 1 h and then quenched using Feiser workup and allowed to 
stir for 2 h. The reaction mixture was filtered and concentrated in vacuo. No further 
purification was done. 
2-Naphthoyl chloride (2.0 equiv.) was added to a solution of the crude alcohol, 
triethylamine (2.0 equiv.), and 4-dimethylaminopyridine (0.1 equiv.) in dichloromethane 
(0.2 M) at 0 °C. After 10 min, the reaction was warmed to rt and stirred for 30 min. The 
mixture was quenched with aqueous ammonium chloride and the layers were separated. The 
aqueous layer was extracted with ethyl acetate (3x10 mL). The combined organic layers 
were washed with brine, dried with sodium sulfate, concentrated in vacuo, and purified by 
column chromatography (silica, 100% hexanes, 5% ethyl acetate – hexanes) to afford the 
desired naphthoyl ester derivative. HPLC analysis of the 2-naphthoyl ester derivative (OD-
H, 2% Pr
i
OH - hexanes, 1.0 mL/min, 254 nm) indicated er 97.2:2.8: RT (major) = 6.8 
minutes, RT (minor) = 9.1 minutes. 
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(S)-2-Cyclohexyl-3,3,3-trifluoropropan-1-ol. A solution of the substrate (0.128 g, 
0.322 mmol) in THF (1.10 mL total with rinses) was added to a solution of lithium 
aluminum hydride (22.1 mg, 0.582 mmol) in THF (0.58 mL) at -78 °C. After stirring 30 min, 
the reaction mixture was warmed to -50 °C and stirred an additional 30 min. The reaction 
mixture was quenched with water (23 μL) at -78 °C and stirred for 5 min. Then aqueous 
sodium hydroxide (3 M, 23 μL) was added at -78 °C and stirred for 5 min and warmed to rt. 
Then additional water (69 μL) was added and the reaction was stirred 2 h. The reaction 
mixture was filtered, concentrated in vacuo, and purified by column chromatography (silica, 
15% EtOAc – Hexanes, 20% EtOAc – Hexanes, 40% EtOAc – Hexanes) to afford the 
desired alcohol (50.9 mg, 0.260 mmol, 81%) and the purified oxazolidinone (65.7 mg, 0.320 
mmol, 99%). D
21 -4.0° (c 1.0, CHCl3). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 3.89 (dd, 
J1=11.4 Hz, J2=5.4 Hz, 1H); 3.82 (dd, J1=11.4 Hz, J2=4.2 Hz, 1H); 2.17-2.09 (m, 1H); 
1.82-1.71 (m, 5H); 1.69-1.65 (m, 1H); 1.59 (bs, 1H); 1.30-1.20 (m, 3H); 1.19-1.10 (m, 2H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 128.5 (q, J=280.8 Hz), 59.0 (q, J=3.9 Hz), 51.2 (q, 
J=21.6 Hz), 35.7, 31.2, 29.9, 26.9, 26.8, 26.3. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -
65.04 (d, J=10.2 Hz, 3F). FI calcd for C9H15F3O [M] 196.11, found 196.11.  
 
Determination of er for the alcohol: 2-Naphthoyl chloride (2.0 equiv.) was added to a 
solution of the crude alcohol substrate, triethylamine (2.0 equiv.), and 4-
dimethylaminopyridine (0.1 equiv.) in dichloromethane (0.2 M) at 0 °C. After 10 min, the 
reaction was warmed to rt and stirred for 30 min. The reaction was quenched with aqueous 
  158 
ammonium chloride and the layers were separated. The aqueous layer was extracted with 
ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried with 
sodium sulfate, concentrated in vacuo, and purified by column chromatography 
chromatography (silica, 100% hexanes, 5% ethyl acetate – hexanes) to afford the desired 
naphthoyl ester derivative. HPLC analysis of the 2-naphthoyl ester derivative (OD-H, 2% 
Pr
i
OH - hexanes, 1.0 mL/min, 254 nm) indicated er 99.2:0.8: RT (major) = 6.5 minutes, RT 
(minor) = 8.7 minutes. 
 
NO
O O
Ph
CF2CF2CF3
NO
O O
Ph
CF3CF2CF2I, (Ph3P)3RuCl
ZrCl4, Et3N, CH2Cl2, 
45 oC, 5 h
 
Perfluoropropylation product 3.19: The title compound was prepared from 
oxazolidinone 3.31 (0.740 g, 2.44 mmol), zirconium(IV) chloride (0.597 g, 2.56 mmol), and 
RuCl2(PPh3)3 (0.468 g, 0.488 mmol) following the standard perfluoroalkylation procedure  
(shorter reaction time: 5 h at 45 ˚C). The product was obtained as a an oil (0.750 g, 1.59 
mmol, 65%, dr >98:2) along with recovered starting material (0.154 g, 0.510 mmol, 21%) 
after purification by column chromatography (silica, 15% ethyl acetate – hexanes, 20% ethyl 
acetate – hexanes). D
23 9.2° (c 1.0, CH2Cl2). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 7.33-
7.29 (m, 4H); 7.25-7.21 (m, 1H), 5.24-5.15 (m, 1H); 4.58 (dd, J1=10.8 Hz, J2=3.0 Hz, 1H); 
3.22 (dd, J1=14.4 Hz, J2=3.0 Hz, 1H); 2.84 (dd, J1=14.4 Hz, J2=10.8 Hz, 1H), 2.12-2.05 
(m, 1H); 1.93-1.84 (m, 1H); 1.42-1.24 (m, 4H); 1.36 (s, 3H); 1.34 (s, 3H); 0.91 (dd, J=7.2 
Hz, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 168.2 (d, J=5.7 Hz), 152.3, 136.9, 129.1 
(2C), 129.0 (2C), 127.1, 119.1-107.3 (m, 3C), 82.5, 64.5, 43.9 (m, 1C), 34.8, 28.9, 28.8, 
26.0 (m, 1C), 22.6, 22.5, 13.9. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -80.55 (d, J=10.2 
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Hz, 3F); -113.99 (m, 2F); -127.70 (m, 2F). LRMS (ESI) calcd for C24H22F3NO4Na [M+Na] 
494.06, found 494.06. 
 
LiOH, aq. H2O2, THF
NHO
O
Ph
+NO
O O
Ph
CF2CF2CF3
O
CF2CF2CF3
HO
 
(S)-2-(Perfluoropropyl)hexanoic acid. Lithium hydroxide monohydrate (33.9 mg, 
0.804 mmol) was added to a solution of the substrate (0.127 g, 0.269 mmol), hydrogen 
peroxide (30% in water, 0.40 mL), and water (0.40 mL) in THF (1.60 mL) at 0 °C and 
stirred for 10 min. The reaction was then warmed to rt and stirred for 3 h, after which 
additional H2O (0.20 mL), H2O2 (0.20 mL), and LiOH·H2O (30.0 mg) were added at rt and 
stirred for 2 h. The reaction was quenched with aqueous sodium sulfite (1.5 M) and HCl (1 
M) and allowed to stir until two transparent layers were visible (pH ~4). The layers were 
separated and the aqueous layer was extracted with ethyl acetate (3x10 mL). The organic 
layer was then washed with brine, dried with sodium sulfate, and concentrated in vacuo. The 
crude material was then dissolved in ethyl acetate (5 mL) and extracted with aqueous sodium 
hydroxide (3 M, 3x5 mL) and water (2x5 mL). The aqueous extractions were combined and 
set aside. The organic layer was washed with HCl (1 M), brine, dried with sodium sulfate, 
and concentrated in vacuo to afford the oxazolidinone auxiliary (54.1 mg, 0.263 mmol, 
98%). The previously saved aqueous layers were acidified with HCl (1 M). The aqueous 
layer was extracted with ethyl acetate (3x30 mL). The combined organic layers were washed 
with brine, dried with sodium sulfate, and concentrated in vacuo to afford the desired 
carboxylic acid (65.4 mg, 0.230 mmol, 86%). D
21 9.5° (c 1.0, CHCl3). 
1
H NMR (600 MHz, 
CDCl3); δ(ppm): 10.48 (bs, 1H); 3.22-2.13 (m, 1H); 2.01-1.93 (m, 1H); 1.92-1.84 (m, 1H); 
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1.45-1.32 (m, 4H); 0.93 (dd, J1=J2=6.6 Hz, 3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 
174.0 (d, J=8.0 Hz), 121.0-107.2 (m, 3C), 48.1 (t, J=20.7 Hz), 29.1, 25.0, 22.4, 13.8. 
19
F 
NMR (564.3 MHz, CDCl3); δ(ppm): -80.59 (dd, J=11.3 Hz, 3F), -115.52 (m, 2F), -125.45 
(m, 2F). FI calcd for C9H11F7O2 [M] 284.06, found 284.06. 
 
Determination of er for the acid: A solution of the substrate in diethyl ether (0.2 M) 
was added to a solution of lithium aluminum hydride (4.0 equiv.) in diethyl ether (0.5 M) at -
78 °C and stirred for 15 min. The reaction was warmed to rt over 1 h then the reaction was 
quenched using Feiser workup and allowed to stir for 2 h. The reaction mixture was filtered 
and concentrated in vacuo. No further purification was done. 
 
2-Naphthoyl chloride (2.0 equiv.) was added to a solution of the crude alcohol substrate, 
triethylamine (2.0 equiv.), and 4-dimethylaminopyridine (0.1 equiv.) in dichloromethane 
(0.2 M) at 0 °C. After 10 min, the reaction was warmed to rt and stirred for 30 min. The 
reaction was quenched with aqueous ammonium chloride and the layers were separated. The 
aqueous layer was extracted with ethyl acetate (3x10 mL). The combined organic layers 
were washed with brine, dried with sodium sulfate, concentrated in vacuo, and purified by 
column chromatography (silica, 100% hexanes, 5% ethyl acetate – hexanes) to afford the 
desired naphthoyl ester derivative. HPLC analysis of the 2-naphthoyl ester derivative (OD-
H, 0.5% Pr
i
OH - hexanes, 1.0 mL/min, 254 nm) indicated er 98.1:1.9: RT (major) = 7.6 
minutes, RT (minor) = 11.2 minutes. 
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LiAlH4, Et2O
NHO
O
Ph
+
CF2CF2CF3
HO
NO
O O
Ph
CF2CF2CF3
 
(S)-2-(Perfluoropropyl)hexan-1-ol.  A solution of the substrate (0.150 g, 0.318 mmol) 
in diethyl ether (1.60 mL total with rinses) was added to a solution of lithium aluminum 
hydride (24.3 mg, 0.640 mmol) in Et2O (1.28 mL) at -78 °C and stirred for 30 min. Feiser 
workup: The reaction was quenched with water (24 μL) at -78 °C and stirred for 5 min. Then 
aqueous sodium hydroxide (3 M, 24 μL) was added at -78 °C and stirred for 5 min and 
warmed to rt. Then additional water (72 μL) was added and the reaction was stirred 2h. The 
reaction mixture was filtered, concentrated in vacuo, and purified by column 
chromatography (silica, 15% Et2O – Pentane, 25% Et2O – Pentane, 50% Et2O – Pentane) to 
afford a mixture of the alcohol and allylic alcohol (76.9 mg, 0.286 mmol, 90%, containing 
6% allylic alcohol) and the purified auxiliary (65.0 mg, 0.317 mmol, 99%). D
21 3.8° (c 1.0, 
CHCl3). 
1
H NMR (600 MHz, CDCl3); δ(ppm): 3.93-3.84 (m, 2H); 2.34-2.24 (m, 1H); 1.74-
1.67 (m, 1H); 1.67-1.57 (m, 2H); 1.52-1.45 (m, 1H); 1.40-1.31 (m, 3H); 0.93 (dd, J=7.2 Hz, 
3H); 
13
C NMR (150 MHz, CDCl3); δ(ppm): 121.2-107.7 (m, 3C), 59.2 (dd, J=5.9 Hz), 43.9 
(dd, J=18.5 Hz), 29.4, 23.8-23.7 (m), 22.8, 14.0. 
19
F NMR (564.3 MHz, CDCl3); δ(ppm): -
80.76 (m, 3F), -114.74 (m, 2F), -125.36 (m, 2F). FI calcd for C9H14F7O [M+H] 271.09, 
found 271.10.  
 
Determination of er for the alcohol: 2-Naphthoyl chloride (2.0 equiv.) was added to a 
solution of the crude alcohol substrate, triethylamine (2.0 equiv.), and 4-
dimethylaminopyridine 0.1 equiv.) in dichloromethane (0.2 M) at 0 °C. After 10 min, the 
reaction was warmed to rt and stirred for 30 min. The reaction was quenched with aqueous 
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ammonium chloride and the layers were separated. The aqueous layer was extracted with 
ethyl acetate (3x10 mL). The combined organic layers were washed with brine, dried with 
sodium sulfate, concentrated in vacuo, and purified by column chromatography 
chromatography (silica, 100% hexanes, 5% ethyl acetate – hexanes) to afford the desired 
naphthoyl ester derivative. HPLC analysis of the 2-naphthoyl ester derivative (OD-H, 0.5% 
Pr
i
OH - hexanes, 1.0 mL/min, 254 nm) indicated er 96.6:3.4: RT (major) = 7.5 minutes, RT 
(minor) = 11.0 minutes. 
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3-8: -Fluorination of N-Acyl Oxazolidinones Supporting Information 
HO
O
1. SOCl2, MeOH
2. NaHCO3, Boc2O,   
    THF:MeOH
3. MeMgBr, THF
4. KtBuO, THF
O NH
O
NH2
S1  
(S)-4-Isopropyl-5,5-dimethyloxazolidin-2-one (S2).  Thionyl chloride (31.1 mL, 427 
mmol) was added dropwise to a solution of L-valine (25.0 g, 213 mmol) in methanol (430 
mL) at 0 °C. The reaction was stirred for 10 min at 0 °C, and then heated to reflux for 4 h. 
The solution was cooled to rt and methanol was removed in vacuo. The crude residue was 
submitted to the next step without purification. 
Sodium hydrogen carbonate (53.7 g, 640 mmol) was added to a solution of crude 
substrate (213 mmol) in a 4:1 mixture of THF:MeOH (560 mL) at 0 °C and stirred for 5 
min. Di-tert-butyl dicarbonate (47.0 g, 215 mmol) was added to the mixture at 0 °C. The 
reaction was warmed to rt and stirred for 2 h and then quenched with water. The layers were 
separated. The aqueous layer was extracted with diethyl ether (3 x 100 mL). The combined 
organic layers were washed with saturated sodium bicarbonate, brine, and dried with sodium 
sulfate and concentrated in vacuo to afford a yellow oil. The crude residue was submitted to 
the next step without further purification.  
Methylmagnesium bromide (3.0 M in Et2O, 250 mL, 750 mmol) was added dropwise to 
a solution of the crude substrate (213 mmol) in THF (500 mL) at 0 °C. The reaction mixture 
was stirred at 0 °C for 10 min, then warmed to rt and stirred for 48 h. The solution was 
cooled to 0 °C and quenched with saturated ammonium chloride. The layers were separated. 
The aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic 
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layers were washed with brine and dried with sodium sulfate and concentrated in vacuo 
delivering a light yellow oil. The crude residue was submitted to the next step without 
further purification. 
Potassium tert-butoxide (26.8 g, 239 mmol) was added to a solution of the crude 
substrate (213 mmol) in THF (575 mL) at 0 °C. The reaction was warmed to rt and stirred 
for 2.5 h. The reaction was then quenched with saturated aqueous ammonium chloride. The 
layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 100 mL). The 
combined organic layers were washed with brine, dried with sodium sulfate, and 
concentrated in vacuo. The crude product was purified by column chromatography (silica, 
40% ethyl acetate in hexanes, 75% ethyl acetate in hexanes) to afford the white/yellow solid 
oxazolidinone S2 (28.1 g, 179 mmol, 84%). 
 
Standard procedure 1: Synthesis of N-acyl oxazolidinones via acyl chloride 
n-BuLi, 
acyl chloride, 
THF
O N
O O
R
O NH
O
S1  
n-Butyllithium (2.48 M in hexanes, 2.88 ml, 7.14 mmol, 1.1 equiv) was added to a 
solution of S2 (1.02 g, 6.49 mmol, 1.0 equiv) in tetrahydrofuran (22.0 ml, 0.30 M) at –78 ̊C 
and stirred at room temperature for 30 minutes. The solution was cooled to –78 ̊C and the 
corresponding acyl chloride (7.78 mmol, 1.2 equiv) was added to the reaction mixture and 
stirred for 15 min at -78 °C. The reaction solution was warmed to rt and stirred for 2 h. The 
reaction was quenced with saturated ammonium chloride and the layers were seperated. The 
aqeuous layer was extracted with ethyl acetate (3 x 20 ml). The combined organic layers 
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were washed with brine, dried over sodium sulfate, concentrated in vacuo, and purified by 
column chromatography to give the corresponding N-acyl oxazolidinone. 
 
n-BuLi,
 hexanoyl chloride, 
THF
O NH
O
S1
O N
O O
S2  
(S)-3-Hexanoyl-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.49). The title compound 
was prepared from commercially available hexanoyl chloride (1.08 ml, 7.78 mmol) 
following standard procedure 1 for the synthesis of N-acyl oxazolidinones via acyl chloride 
and was obtained as a yellow oil (1.36 g, 5.32 mmol, 82%) after purification by column 
chromatography (silica, 6% ethyl acetate in hexanes – 12% ethyl acetate in hexanes). D
27 + 
31.21 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3); (ppm): 4.11 (d, J = 3.3 Hz, 1H), 3.01 – 
2.92 (m, 1H), 2.87 – 2.79 (m, 1H), 2.15 – 2.06 (m, 1H), 1.69 – 1.59 (m, 2H), 1.47 (s, 3H), 
1.34 (s, 3H), 1.33 – 1.29 (m, 4H), 0.99 (dd, J = 7.0, 3.5 Hz, 3H), 0.91 (dd, J = 6.8, 3.5 Hz, 
3H), 0.88 – 0.84 (m, 3H); 13C NMR (126 MHz, CDCl3); (ppm): 173.84 (s), 153.46 (s), 
82.56 (s), 66.12 (s), 35.34 (s), 31.23 (s), 29.46 (s), 28.72 (s), 24.34 (s), 22.31 (s), 21.41 (s), 
21.30 (s), 16.97 (s), 13.83 (s); HRMS-ESI (m/z): [M+Na]
+
 calcd for C14H25NO3Na, 
278.1732; found, 278.1728. 
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n-BuLi, 
propionoyl chloride,
 THF
O NH
O
S1
O N
O O
S3  
(S)-4-Isopropyl-5,5-dimethyl-3-propionyloxazolidin-2-one (3.50). The title compound 
was prepared from commercially available propionoyl chloride (0.68 mL, 7.78 mmol) 
following standard procedure 1 for the synthesis of N-acyl oxazolidinones via acyl chloride 
and was obtained as a white solid (1.22 g, 5.72 mmol, 88%) after purification by column 
chromatography (silica, 10 ethyl acetate in hexanes - 15% ethyl acetate in hexanes).
 D
25 + 
38.28 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3); (ppm): 4.13 (d, J = 3.3 Hz, 1H), 2.99 
(dddd, J = 17.4, 7.4 Hz, 1H), 2.89 (dddd, J = 17.4, 7.3 Hz, 1H), 2.13 (ddd, J = 13.8, 6.9, 3.4 
Hz, 1H), 1.49 (s, 3H), 1.36 (s, 3H), 1.17 (dd, J = 9.6, 5.2 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H), 
0.93 (d, J = 6.8 Hz, 3H).; 
13
C NMR (126 MHz, CDCl3); (ppm): 174.59 (s), 153.56 (s), 
82.71 (s), 66.24 (s), 29.51 (s), 29.07 (s), 28.80 (s), 21.43 (s), 21.37 (s), 17.02 (s), 8.72 (s); 
HRMS-ESI (m/z): [M+Na]
+
 calcd for C11H19NO3Na, 236.1263; found, 236.1268. 
 
n-BuLi, 
chloroacetyl chloride, 
Et2O
O NH
O
S1
O N
O O
Cl
S4  
(S)-3-(2-Chloroacetyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.51). The title 
compound was prepared from commercially available chloroacetyl chloride (0.62 ml, 7.78 
mmol) following standard procedure 1 for the synthesis of N-acyl oxazolidinones via acyl 
chloride using diethyl ether (22.0 mL, 0.30 M) and was obtained as a yellow oil (1.25 g, 5.38 
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mmol, 83%) after purification by column chromatography (silica, 10 ethyl acetate in hexanes 
- 15% ethyl acetate in hexanes). D
27 + 39.55 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); 
J = 15.3 Hz, 2H), 4.16 (d, J = 3.2 Hz, 1H), 2.22 – 2.14 (m, 1H), 1.54 (s, 
3H), 1.42 (s, 3H), 1.06 (d, J = 7.0 Hz, 3H), 0.97 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, 
CDCl3 44 (s), 152.97 (s), 83.96 (s), 66.77 (s), 43.38 (s), 29.37 (s), 28.63 (s), 
21.29 (s), 21.18 (s), 16.67 (s); HRMS-ESI (m/z): [M+Na]
+
 calcd for C10H16ClNO3Na, 
256.0716; found, 256.0700. 
 
O N
O O
n-BuLi, 
hydrocinnamoyl chloride, 
THF
O NH
O
S1 S5  
(S)-4-Isopropyl-5,5-dimethyl-3-(3-phenylpropanoyl)oxazolidin-2-one (3.52). The 
title compound was prepared from commercially available hydrocinnamoyl chloride (1.16 
mL, 7.78 mmol) following standard procedure 1 for the synthesis of N-acyl oxazolidinones 
via acyl chloride and was obtained as a yellow oil (1.41 g, 4.87 mmol, 74%) after 
purification by column chromatography (silica, 10 ethyl acetate in hexanes - 18% ethyl 
acetate in hexanes). D
27 + 36.16 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.30 
– 7.26 (m, 3H), 7.25 (s, 1H), 7.21 – 7.17 (m, 1H), 4.13 (d, J = 3.3 Hz, 1H), 3.34 (ddd, J = 
16.5, 9.0, 6.3 Hz, 1H), 3.29 – 3.22 (m, 1H), 3.08 – 2.93 (m, 2H), 2.12 (dddd, J = 13.8, 6.9, 
3.5 Hz, 1H), 1.50 (s, 3H), 1.32 (s, 3H), 0.99 (d, J = 7.0 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H);
 13
C 
NMR (126 MHz, CDCl3); ppm): 172.89 (s), 153.48 (s), 140.41 (s), 128.46 (s), 128.39 (s), 
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126.15 (s), 82.77 (s), 66.27 (s), 36.82 (s), 30.68 (s), 29.47 (s), 28.70 (s), 21.35 (s), 16.99 (s); 
HRMS-ESI (m/z): [M+Na]
+
 calcd for C17H23NO3Na, 312.1576; found, 312.1559. 
 
n-BuLi, 
4-methoxyphenylacetyl chloride, 
THF
O NH
O
S1
O N
O O
O
S6  
(S)-4-Isopropyl-3-(2-(4-methoxyphenyl)acetyl)-5,5-dimethyloxazolidin-2-one (3.53). 
The title compound was prepared from commercially available 4-methoxyphenylacetyl 
chloride (1.19 mL, 7.78 mmol) following standard procedure 1 for the synthesis of N-acyl 
oxazolidinones via acyl chloride and was obtained as a yellow oil (1.02 g, 3.34 mmol, 52%) 
after purification by column chromatography (silica, 15 - 22% ethyl acetate in hexanes. D
26 
70.63 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.27 (s, 1H), 7.26 – 7.25 (m, 
1H), 6.85 (d, J = 8.6 Hz, 2H), 4.30 (d, J = 15.0 Hz, 1H), 4.19 (d, J = 15.0 Hz, 1H), 4.12 (d, J 
= 3.1 Hz, 1H), 3.79 (s, 3H), 2.10 (ddd, J = 10.5, 6.8, 3.4 Hz, 1H), 1.49 (s, 3H), 1.31 (s, 3H), 
0.95 (d, J = 7.0 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H); 
13
C NMR (126 MHz, CDCl3); ppm): 
172.05 (s), 158.62 (s), 153.48 (s), 130.60 (s), 125.97 (s), 113.86 (s), 82.77 (s), 66.39 (s), 
55.14 (s), 40.58 (s), 29.53 (s), 28.69 (s), 21.38 (s), 21.29 (s), 16.79 (s); HRMS-EI (m/z): 
[M]
+ 
calcd for C17H23NO4, 305.1627, found, 305.1637. 
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n-BuLi, 
4-fluorophenylacetyl chloride,
 THF
O NH
O
S1
O N
O O
F
S7  
(S)-3-(2-(4-Fluorophenyl)acetyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.54). 
The title compound was prepared from commercially available 4-fluorophenylacetyl 
chloride, (1.07 mL, 7.78 mmol) following standard procedure 1 for the synthesis of N-acyl 
oxazolidinones via acyl chloride and was obtained as a colorless oil (1.06 g, 3.61 mmol, 
56%) after purification by column chromatography (silica, 9 ethyl acetate in hexanes - 13% 
ethyl acetate in hexanes).
 D
27 + 45.86 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 
7.32 (dd, J = 8.1, 5.7 Hz, 2H), 7.01 (dd, J = 8.7 Hz, 2H), 4.35 (d, J = 15.1 Hz, 1H), 4.20 (d, J 
= 15.1 Hz, 1H), 4.13 (d, J = 3.1 Hz, 1H), 2.14 – 2.06 (m, 1H), 1.50 (s, 3H), 1.32 (s, 3H), 
0.95 (d, J = 7.0 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 
171.52 (s), 162.90 (s), 160.95 (s), 153.41 (s), 131.15 (d, J = 8.0 Hz), 129.63 (d, J = 3.2 Hz), 
115.25 (d, J = 21.4 Hz), 82.87 (s), 66.39 (s), 40.61 (s), 29.50 (s), 28.65 (s), 21.36 (s), 21.23 
(s), 16.74 (s); HRMS-ESI (m/z): [M]
+
 calcd for C16H20NO3, 293.1427; found, 293.1435. 
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Standard procedure 2: Synthesis of N-acyl oxazolidinones via carboxylic acid 
 
HO
O
R
PivCl, Et3N, THF; 
then S8, THF
O N
O O
R
O NLi
O
S8  
Solution A: Trimethylacetic acid chloroanhydride (1.45 equiv) was added to a solution 
of carboxylic acid (1.20 equiv) and triethylamine (4.80 equiv) in tetrahydrofuran (0.15 M) at 
–20 ̊C. The solution was allowed to stir at -20 °C for 2 h. 
 
Solution B: In a separate flame-dried flask, n-butyllithium (1.10 equiv) was added to a 
solution of oxazolidione S2 (1.00 equiv) in tetrahydrofuran (0.30 M) at -78 °C and the 
mixture was allowed to warm to room temperature and stir for 30 min. 
 
Both flasks were then chilled to –78 ̊C. The flask containg the lithianted oxazolidione S3 
(solution B), was cannulated to the flask containing the mixed anhydride (solution A). After 
the addition was complete, the reaction mixture was warmed to room temperature and stirred 
for 3 h. The reaction was quenced with saturated ammonium chloride and the layers were 
seperated. The aqeuous layer was extracted with ethyl acetate (3 x 25 ml). The combined 
organic layers were washed with brine, dried over sodium sulfate, concentrated in vacuo, and 
purified by column chromatography to give the corresponding N-acyl oxazolidinone.  
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HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
S9  
(S)-4-Isopropyl-5,5-dimethyl-3-(3-methylbutanoyl)oxazolidin-2-one (3.55). The title 
compound was prepared from commercially available 3-methylbutanoic acid (0.84 mL, 7.63 
mmol) following standard procedure 2 for the synthesis of N-acyl oxazolidinones via 
carboxylic acid and was obtained as a colorless oil (1.34 g, 3.64 mmol, 88%) after 
purification by column chromatography (silica, 10 ethyl acetate in hexanes - 15% ethyl 
acetate in hexanes). D
25 + 30.87 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 4.16 
(d, J = 3.2 Hz, 1H), 2.91 (dd, J = 15.6, 6.7 Hz, 1H), 2.76 (dd, J = 15.6, 7.1 Hz, 1H), 2.25 – 
2.16 (m, 1H), 2.14 (ddd, J = 16.9, 8.5, 5.2 Hz, 1H), 1.50 (s, 3H), 1.37 (s, 3H), 1.06 – 0.96 
(m, 9H), 0.95 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 173.10 (s), 153.51 
(s), 82.53 (s), 66.16 (s), 43.87 (s), 29.50 (s), 28.76 (s), 25.30 (s), 22.50 (s), 22.34 (s), 21.46 
(s), 21.34 (s); HRMS-ESI (m/z): [M+Na]
+
 calcd for C13H23NO3Na, 264.1576; found, 
264.1561. 
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
S10  
(S)-3-(Hept-6-enoyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.56). The title 
compound was prepared from commercially available 6-heptenoic acid (0.63 mL, 7.63 
mmol) following standard procedure 2 for the synthesis of N-acyl oxazolidinones via 
carboxylic acid and was obtained as a colorless oil (1.53 g, 3.38 mmol, 90%) after 
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purification by column chromatography (silica, 9% ethyl acetate in hexanes). D
26 + 32.15 (c 
1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3); ppm): 5.78 (dddd, J = 16.9, 10.2, 6.7 Hz, 1H), 
5.02 – 4.91 (m, 2H), 4.13 (d, J = 3.3 Hz, 1H), 2.99 (ddd, J = 16.1, 8.5, 6.4 Hz, 1H), 2.90 – 
2.82 (m, 1H), 2.16 – 2.04 (m, 3H), 1.75 – 1.60 (m, 2H), 1.49 (s, 3H), 1.48 – 1.42 (m, 2H), 
1.36 (s, 3H), 1.00 (d, J = 7.0 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H.);
 13
C NMR (126 MHz, 
CDCl3); ppm): 173.69 (s), 153.50 (s), 138.39 (s), 114.59 (s), 82.65 (s), 66.19 (s), 35.25 (s), 
33.40 (s), 29.49 (s), 28.77 (s), 28.31 (s), 24.12 (s), 21.44 (s), 21.35 (s), 17.02 (s); HRMS-ESI 
(m/z): [M+Na]
+ 
calcd for C15H25NO3Na, 290.1732; found, 290.1720. 
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
OBnOBn
S11  
(S)-3-(5-(Benzyloxy)pentanoyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.57). 
The title compound was prepared from 6-heptenoic acid
124
 (2.08 g, 10.0 mmol) following 
the standard procedure for the synthesis of N-acyl oxazolidinones via carboxylic acid and 
was obtained as a white solid (2.71 g, 7.81 mmol, 78%) after purification by column 
chromatography (silica, 15% ethyl acetate – hexanes). D
26 + 24.09 (c 1.0, CHCl3); 
1
H NMR 
(500 MHz, CDCl3); ppm): 7.33 (d, J = 4.4 Hz, 4H), 7.28 (dd, J = 8.3, 4.1 Hz, 1H), 7.25 (s, 
1H), 4.50 (s, 2H), 4.14 (d, J = 3.3 Hz, 1H), 3.51 (t, J = 6.2 Hz, 2H), 3.03 (ddd, J = 16.8, 8.1, 
6.5 Hz, 1H), 2.91 (ddd, J = 16.8, 8.2, 6.3 Hz, 1H), 2.13 (dddd, J = 13.8, 6.9, 3.4 Hz, 1H), 
1.82 – 1.74 (m, 2H), 1.73 – 1.66 (m, 2H), 1.50 (s, 3H), 1.37 (s, 3H), 1.02 (d, J = 7.0 Hz, 3H), 
0.93 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 173.58 (s), 153.54 (s), 
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138.55 (s), 128.31 (s), 127.60 (s), 127.45 (s), 82.71 (s), 72.86 (s), 69.91 (s), 66.23 (s), 35.19 
(s), 29.52 (s), 29.13 (s), 28.81 (s), 21.48 (s), 21.42 (s), 21.39 (s), 17.07 (s); HRMS-ESI (m/z): 
[M+Na]
+
 calcd for C20H29NO4Na, 370.1994; found, 370.2002. 
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
S12  
(S)-3-(Hept-6-ynoyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.58). The title 
compound was prepared from commercially available 6-heptynoic acid (0.69 g, 5.42 mmol) 
following standard procedure 2 for the synthesis of N-acyl oxazolidinones via carboxylic 
acid and was obtained as a clear oil (1.41 g, 2.15 mmol, 75%) after purification by column 
chromatography (silica, 10 ethyl acetate in hexanes – 18% ethyl acetate in hexanes). D
26 + 
33.58 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 4.15 (d, J = 3.3 Hz, 1H), 3.03 
(ddd, J = 16.6, 8.4, 6.5 Hz, 1H), 2.91 (ddd, J = 16.7, 8.3, 6.6 Hz, 1H), 2.24 (ddd, J = 7.1, 2.6 
Hz, 2H), 2.14 (dtd, J = 13.8, 6.9, 3.4 Hz, 1H), 1.95 (dd, J = 2.6 Hz, 1H), 1.86 – 1.74 (m, 
2H), 1.66 – 1.59 (m, 2H), 1.51 (s, 3H), 1.38 (s, 3H), 1.02 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 6.8 
Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 173.37 (s), 153.51 (s), 83.96 (s), 82.73 (s), 
68.51 (s), 66.22 (s), 34.92 (s), 29.49 (s), 28.80 (s), 27.86 (s), 23.69 (s), 21.45 (s), 21.36 (s), 
18.21 (s), 17.04 (s); HRMS-ESI (m/z): [M+Na]
+
 calcd for C15H23NO3Na, 288.1576; found, 
288.1571 
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HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
N
O
O
N
O
O
S13  
(S)-2-(3-(4-Isopropyl-5,5-dimethyl-2-oxooxazolidin-3-yl)-3-oxopropyl)isoindoline-
1,3-dione (3.59). The title compound was prepared from commercially available 3-(1,3-
Dioxo-1,3-dihydro-2H-isoindol-2-yl)-propanoic acid (8.69 g, 39.7 mmol) following standard 
procedure 2 for the synthesis of N-acyl oxazolidinones via carboxylic acid and was obtained 
as a white solid (6.78 g, 18.9 mmol, 48%) after purification by column chromatography 
(silica, 20 ethyl acetate in hexanes - 25% ethyl acetate in hexanes); D
26 + 18.79 (c 1.0, 
CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.86 – 7.83 (m, 2H), 7.73 – 7.69 (m, 2H), 
4.13 (d, J = 3.2 Hz, 1H), 4.09 – 4.05 (m, 2H), 3.43 – 3.35 (m, 1H), 3.29 (ddd, J = 17.1, 7.5 
Hz, 1H), 2.14 (ddd, J = 13.9, 6.9, 3.2 Hz, 1H), 1.51 (s, 3H), 1.44 (s, 3H), 1.02 (d, J = 7.0 Hz, 
3H), 0.96 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 170.79 (s), 167.96 (s), 
153.43 (s), 133.91 (s), 132.00 (s), 123.21 (s), 83.15 (s), 66.30 (s), 34.24 (s), 33.44 (s), 29.48 
(s), 28.78 (s), 21.41 (s), 21.21 (s), 16.95 (s); HRMS-ESI (m/z): [M+Na]
+
 calcd for 
C19H22N2O5Na, 381.1426; found, 381.1427. 
 
HO
O
1. PivCl, Et3N, THF; 
then S8, THF
2. Pd/C, H2, MeOH
O N
O O
CF3CF3
S14  
(S)-4-Isopropyl-5,5-dimethyl-3-(3-(3-(trifluoromethyl)phenyl)propanoyl)oxazolidin-
2-one (3.60). The title compound was prepared starting from commercially available 3-
trifluoromethylcinnamic acid (1.65 g, 7.63 mmol) following standard procedure 2 for the 
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synthesis of N-acyl oxazolidinones via carboxylic acid without purification. The resultant oil 
was then submitted to the next reaction. 
 
The crude substrate and palladium on carbon (0.20 g) were mixed in ethanol (28.0 mL, 
0.2 M). Hydrogen gas was then bubbled through the reaction mixture for 15 min at rt. The 
reaction mixture flask was pressurized with hydrogen gas and the reaction was stirred for 3h 
at rt. The reaction mixture was filtered through Celite and the solvent was removed in vacuo. 
The title compound was obtained as a clear oil (1.98 g, 5.54 mmol, 88%) after purification 
by column chromatography (silica, 15% ethyl acetate in hexanes).
 D
26 + 25.37 (c 1.0, 
CHCl3); 
1
H NMR (500 MHz, CDCl3); ppm): 7.50 (s, 1H), 7.45 (d, J = 7.7 Hz, 2H), 7.41 – 
7.37 (m, 1H), 4.13 (d, J = 3.4 Hz, 1H), 3.37 (ddd, J = 16.9, 8.6, 6.6 Hz, 1H), 3.24 (ddd, J = 
16.9, 8.2, 6.7 Hz, 1H), 3.14 – 2.99 (m, 2H), 2.11 (dddd, J = 13.8, 6.9, 3.4 Hz, 1H), 1.49 (s, 
3H), 1.32 (s, 3H), 0.96 (d, J = 7.0 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, 
CDCl3); ppm): 172.39 (s), 153.50 (s), 141.40 (s), 131.99 (d, J = 1.3 Hz), 130.69 (q, J = 
32.0 Hz), 128.84 (s), 125.22 (q, J = 3.8 Hz), 123.23 – 122.77 (m), 82.94 (s), 66.34 (s), 36.58 
(s), 30.34 (s), 29.46 (s), 28.70 (s), 21.35 (s), 21.33 (s), 16.96 (s); HRMS-ESI (m/z): [M+Na]
+
 
calcd for C18H22F3NO3Na, 380.1449; found, 380.1450. 
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
S15  
(S,E)-3-(But-2-enoyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.61). The title 
compound was prepared from commercially available crotonoic acid (0.517 g, 6.00 mmol) 
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following standard procedure 2 for the synthesis of N-acyl oxazolidinones via carboxylic 
acid and was obtained as a white soild (0.770 g, 3.42 mmol, 68%) after purification by 
column chromatography (silica, 10 ethyl acetate in hexanes - 30% ethyl acetate in hexanes).
 
D
26 + 52.90 (c 1.0, CHCl3). 
1
H NMR (500 MHz, CDCl3); ppm): 7.29 (ddd, J = 15.2, 3.2, 
1.5 Hz, 1H), 7.12 (dddd, J = 15.1, 6.9 Hz, 1H), 4.19 (d, J = 3.4 Hz, 1H), 2.13 (dddd, J = 
13.8, 6.9, 3.5 Hz, 1H), 1.93 (dd, J = 6.9, 1.6 Hz, 3H), 1.49 (s, 3H), 1.36 (s, 3H), 1.01 (d, J = 
7.0 Hz, 3H), 0.93 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 165.54 (s), 
153.48 (s), 146.44 (s), 121.88 (s), 82.63 (s), 66.23 (s), 29.60 (s), 28.73 (s), 21.37 (s), 21.33 
(s), 18.40 (s), 17.03 (s); HRMS-ESI (m/z): [M+Na]
+
 calcd for C12H19NO3Na, 248.1263; 
found, 248.1255. 
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
S16  
(S)-4-Isopropyl-5,5-dimethyl-3-(2-phenylacetyl)oxazolidin-2-one (3.62). The title 
compound was prepared from commercially available phenyl acetic acid (1.51 g, 11.1 mmol) 
following standard procedure 2 for the synthesis of N-acyl oxazolidinones via carboxylic 
acid and was obtained as yellow oil (2.24 g, 8.1 mmol, 81%) after purification by column 
chromatography (silica, 15% ethyl acetate – hexanes. D
26 + 36.65 (c 0.7, CHCl3); 
1
H NMR 
(500 MHz, CDCl3); ppm): 7.36 – 7.30 (m, 4H), 7.27 (dd, J = 1.9 Hz, 1H), 7.26 – 7.24 (m, 
1H), 4.37 (d, J = 15.0 Hz, 1H), 4.26 (d, J = 15.0 Hz, 1H), 4.13 (d, J = 3.3 Hz, 1H), 2.11 
(dddd, J = 13.8, 6.9, 3.3 Hz, 1H), 1.49 (s, 3H), 1.31 (s, 3H), 0.96 (d, J = 7.0 Hz, 3H), 0.87 
(d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3
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(s), 129.64 (s), 128.50 (s), 127.12 (s), 82.86 (s), 66.51 (s), 41.56 (s), 29.60 (s), 28.76 (s), 
21.43 (s), 21.37 (s), 16.86 (s); HRMS-ESI (m/z): [M+Na]
+
 calcd for C16H21NO3Na 
298.1419; found, 298.1414. 
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
Cl Cl
S17  
(S)-3-(2-(4-Chlorophenyl)acetyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.63). 
The title compound was prepared from commercially available 2-(4-chlorophenyl)acetic acid 
(1.30 g, 7.63 mmol) following standard procedure 2 for the synthesis of N-acyl 
oxazolidinones via carboxylic acid and was obtained as green solid (0.54 g, 1.7 mmol, 28%) 
after purification by column chromatography (silica, 20 - 25% ethyl acetate in hexanes). D
27 
+ 37.17 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.29 (d, J = 2.0 Hz, 4H), 4.35 
(d, J = 15.1 Hz, 1H), 4.20 (d, J = 15.1 Hz, 1H), 4.13 (d, J = 3.2 Hz, 1H), 2.14 – 2.06 (m, 
1H), 1.50 (s, 3H), 1.33 (s, 3H), 0.96 (d, J = 7.0 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H);
 13
C NMR 
(126 MHz, CDCl3); ppm): 171.05 (s), 153.28 (s), 132.83 (s), 132.34 (s), 130.87 (s), 128.44 
(s), 82.81 (s), 66.30 (s), 40.70 (s), 29.41 (s), 28.57 (s), 21.31 (s), 21.14 (s), 16.69 (s); HRMS-
EI (m/z): [M]
+
 calcd for C16H20ClNO3, 309.1132; found, 309.1132. 
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O OO
O O
O
S18  
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(S)-3-(2-(Benzo[d][1,3]dioxol-5-yl)acetyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one 
(3.64). The title compound was prepared from commercially available 2-(benzo[1,3]dioxol-
5-yl)acetic acid (1.65 g, 7.63 mmol) following standard procedure 2 for the synthesis of N-
acyl oxazolidinones via carboxylic acid and was obtained as white solid (1.43 g, 4.45 mmol, 
71%) after purification by column chromatography (silica, 11% ethyl acetate in hexanes).
 
D
23 + 39.58 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 6.84 (d, J = 1.3 Hz, 1H), 
6.81 – 6.78 (m, 1H), 6.75 (d, J = 7.9 Hz, 1H), 5.93 (s, 2H), 4.27 (d, J = 15.1 Hz, 1H), 4.17 
(s, 1H), 4.13 (d, J = 3.2 Hz, 1H), 2.15 – 2.07 (m, 1H), 1.50 (s, 3H), 1.33 (s, 3H), 0.97 (d, J = 
7.0 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 171.81 (s), 
153.47 (s), 147.62 (s), 146.64 (s), 127.50 (s), 122.75 (s), 110.09 (s), 108.20 (s), 100.91 (s), 
82.85 (s), 66.45 (s), 41.06 (s), 29.55 (s), 28.75 (s), 21.42 (s), 21.32 (s), 16.85 (s); HRMS-ESI 
(m/z): [M+Na]
+
 calcd for C17H21NO5Na, 342.1317; found, 342.1306.  
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
OPh OPh
S19  
(S)-4-Isopropyl-5,5-dimethyl-3-(2-(3-phenoxyphenyl)acetyl)oxazolidin-2-one (3.65). 
The title compound was prepared from commercially available 2-(3-phenoxyphenyl)acetic 
acid (0.326 g, 1.43 mmol) following standard procedure 2 for the synthesis of N-acyl 
oxazolidinones via carboxylic acid and was obtained as yellow oil (0.36 g, 0.98 mmol, 76%) 
after purification by column chromatography (silica, 12% ethyl acetate in hexanes). D
22 + 
52.08 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.34 – 7.26 (m, 3H), 7.09 (dd, J 
= 7.4 Hz, 2H), 7.02 – 6.97 (m, 3H), 6.91 (dd, J = 8.1, 1.9 Hz, 1H), 4.36 (d, J = 15.1 Hz, 1H), 
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4.22 (d, J = 15.1 Hz, 1H), 4.14 (d, J = 3.2 Hz, 1H), 2.11 (dddd, J = 13.8, 6.9, 3.3 Hz, 1H), 
1.49 (s, 3H), 1.33 (s, 3H), 0.97 (d, J = 7.0 Hz, 3H), 0.88 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 
MHz, CDCl3); ppm): 171.28 (s), 157.21 (s), 157.08 (s), 153.40 (s), 129.67 (s), 129.64 (s), 
124.55 (s), 123.14 (s), 120.14 (s), 118.79 (s), 117.55 (s), 82.85 (s), 66.42 (s), 41.37 (s), 29.55 
(s), 28.74 (s), 21.40 (s), 21.31 (s), 16.85 (s); HRMS-ESI  (m/z): [M+Na]
+
 calcd for 
C22H25NO4Na, 390.1681; found, 390.1698. 
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O O
FF
S20  
(S)-3-(2-(3-Fluorophenyl)acetyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.66) 
The title compound was prepared from commercially available 2-(3-fluorophenyl)acetic acid 
(1.17 g, 7.60 mmol) following standard procedure 2 for the synthesis of N-acyl 
oxazolidinones via carboxylic acid and was obtained as yellow oil (1.46 g, 4.97 mmol, 79%) 
after purification by column chromatography (silica, 12% ethyl acetate in hexanes). D
23 + 
48.61 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3); ppm): 7.30 – 7.26 (m, 1H), 7.25 (s, 
1H), 7.11 (dd, J = 7.7, 0.4 Hz, 1H), 7.08 – 7.04 (m, 1H), 6.98 – 6.93 (m, 1H), 4.37 (d, J = 
15.1 Hz, 1H), 4.23 (d, J = 15.1 Hz, 1H), 4.13 (d, J = 3.3 Hz, 1H), 2.11 (dddd, J = 13.8, 6.9, 
3.3 Hz, 1H), 1.49 (s, 3H), 1.33 (s, 3H), 0.96 (d, J = 7.0 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H); 
13
C NMR (126 MHz, CDCl3); ppm): 171.07 (s), 162.71 (d, J = 245.8 Hz), 153.44 (s), 
136.24 (d, J = 7.9 Hz), 129.86 (d, J = 8.4 Hz), 125.33 (d, J = 3.1 Hz), 116.62 (d, J = 21.8 
Hz), 114.08 (d, J = 21.0 Hz), 82.97 (s), 66.49 (s), 41.20 (d, J = 2.0 Hz), 29.55 (s), 28.74 (s), 
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21.41 (s), 21.31 (s), 16.83 (s); HRMS-ESI (m/z): [M+Na]
+
 calcd for C16H20FNO3Na, 
316.1325; found, 316.1324. 
 
HO
O
PivCl, Et3N, THF; 
then S8, THF
O N
O OO O
S21  
(S)-3-(2-(Furan-3-yl)acetyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.67) The 
title compound was prepared from commercially available 3-furylacetic acid (0.191 g, 1.51 
mmol) following standard procedure 2 for the synthesis of N-acyl oxazolidinones via 
carboxylic acid and was obtained after purification by column chromatography (silica, 20% 
ethyl acetate in hexanes) as a clear oil (0.266 g, 1.00 mmol, 66%).
 D
21 + 39.04 (c 1.0, 
CHCl3); 
1
H NMR (500 MHz, CDCl3); ppm): 7.41 (d, J = 0.5 Hz, 1H), 7.34 (t, J = 1.6 Hz, 
1H), 6.37 (d, J = 1.1 Hz, 1H), 4.13 (d, J = 16.0 Hz, 1H), 4.10 (d, J = 3.2 Hz, 1H), 4.04 (d, J 
= 16.0 Hz, 1H), 2.09 (dtd, J = 13.8, 6.9, 3.3 Hz, 1H), 1.46 (s, 3H), 1.30 (s, 3H), 0.95 (d, J = 
7.0 Hz, 3H), 0.86 (d, J = 6.8 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) ppm): 171.04 (s), 
153.34 (s), 142.69 (s), 140.89 (s), 117.09 (s), 111.33 (s), 82.82 (s), 66.28 (s), 31.63 (s), 29.45 
(s), 28.59 (s), 21.31 (s), 21.19 (s), 16.71 (s). LRMS (m/z): [M+Na]
+
 calcd for C15H23NO3Na, 
288.12; found, 288.15.  
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Standard procedure 3: Synthesis of N-acyl oxazolidinones via acyl chloride from 
carboxylic acid 
HO
O
R
(COCl)2, cat DMF, CH2Cl2;
 then S8, THF
O N
O O
R
 
Oxalyl chloride (1.65 equiv) was added to a solution of carboxylic acid (1.50 equiv), 
dimethylformamide (10 μl), and dichloromethane (2.0 M) at 0 °C. After 10 min, the solution 
was warmed to rt and stirred for 45 min (or until bubbling stops). The solution was 
concentrated on a rotary evaporator. 
In a separate flask, n-butyllithium (1.05 equiv), was added to a solution of oxazolidinone 
S2 (1.00 equiv) in THF (0.35 M) at -78 °C under argon. The solution was stirred for 30 min 
at -78 °C. A solution of the crude acyl chloride in THF (0.6 M total, 3 rinses) was added 
dropwise at -78 °C. After stirring at -78 °C for 2 h, the reaction mixture was warmed to rt 
and stirred for 2 h. The reaction mixture was quenched with saturated aqueous ammonium 
chloride. The layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 
20 mL). The combined organic layers were washed with brine, dried with sodium sulfate, 
and concentrated in vacuo. The resultant oil or solid was purified by column chromatography 
to give the corresponding N-acyl oxazolidinone. 
 
HO
O
(COCl)2, cat DMF, CH2Cl2;
 then S8, THF
O N
O O ClCl
S22  
(S)-3-(3-(2-Chlorophenyl)propanoyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one 
(3.68). The title compound was prepared from commercially available  3-(2-
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Chlorophenyl)propanoic acid (1.29 g, 7.00 mmol) following the standard procedure for the 
synthesis of N-acyl oxazolidinones via acyl chloride from carboxylic acid and was obtained 
as a yellow oil (1.77 g, 5.46 mmol, 74%) after purification by column chromatography 
(silica, 15% ethyl acetate in hexanes). D
26 + 30.14 (c 1.0, CHCl3); 
1
H NMR (500 MHz, 
CDCl3) ppm): 7.36 – 7.27 (m, 2H), 7.16 (ddd, J = 13.5, 10.5, 6.2 Hz, 2H), 4.15 (d, J = 3.1 
Hz, 1H), 3.38 – 3.20 (m, 2H), 3.12 (dt, J = 9.0, 6.0 Hz, 2H), 2.14 (ddd, J = 10.3, 8.3, 5.1 Hz, 
1H), 1.50 (s, 3H), 1.36 (s, 3H), 1.02 (d, J = 7.0 Hz, 3H), 0.94 (s, 3H); 
13
C NMR (126 MHz, 
CDCl3) ppm): 172.66 (s), 153.47 (s), 138.05 (s), 134.00 (s), 130.50 (s), 129.48 (s), 127.71 
(s), 126.80 (s), 82.85 (s), 66.36 (s), 35.15 (s), 29.49 (s), 28.83 (s), 28.34 (s), 21.40 (s), 17.07 
(s). HRMS-ESI (m/z): [M+Na]
+
 calcd for C17H22ClNO3Na, 346.1186; found, 346.1189. 
 
HO
O (COCl)2, cat DMF, CH2Cl2;
 then S8, THFOPh
O N
O O
OPh
S23  
(S)-4-Isopropyl-5,5-dimethyl-3-(4-phenoxybutanoyl)oxazolidin-2-one (3.69).
 
The 
title compound was prepared from commercially available 4-phenoxybutanoic acid (2.70 g, 
15.0 mmol) following the standard procedure for the synthesis of N-acyl oxazolidinones via 
acyl chloride from carboxylic acid and was obtained as a white solid (2.95 g, 0.92 mmol, 
92%) after purification by column chromatography (silica, 5 -25% ethyl acetate in hexanes). 
D
26 + 29.90 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3); ppm): 7.29 – 7.27 (m, 1H), 
7.25 (dd, J = 4.7, 2.6 Hz, 1H), 6.95 – 6.88 (m, 3H), 4.15 (d, J = 3.4 Hz, 1H), 4.04 (dd, J = 
6.2 Hz, 2H), 3.16 (ddddd, J = 17.5, 7.8, 6.8 Hz, 2H), 2.22 – 2.11 (m, 3H), 1.50 (s, 3H), 1.37 
(s, 3H), 1.02 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); 
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ppm): 173.16 (s), 158.80 (s), 153.51 (s), 129.35 (s), 120.61 (s), 114.50 (s), 82.82 (s), 66.58 
(s), 66.31 (s), 32.11 (s), 29.51 (s), 28.81 (s), 28.81 (s), 24.22 (s), 21.44 (s), 21.37 (s), 17.05 
(s); HRMS-ESI (m/z): [M+Na]
+
 calcd for C18H25NO4Na, 342.1681; found, 342.1679.  
 
HO
O
(COCl)2, cat DMF, CH2Cl2;
 then S8, THF
O N
O O
O O
S24  
(S)-4-Isopropyl-3-(2-(2-methoxyphenyl)acetyl)-5,5-dimethyloxazolidin-2-one (3.70). 
The title compound was prepared from commercially available 2-(2-methoxyphenyl)acetic 
acid (0.73 g, 4.00 mmol) following standard procedure 3 for the synthesis of N-acyl 
oxazolidinones via acyl chloride from carboxylic acid and was obtained as white solid (0.51 
g g, 1.67 mmol, 42%) after purification by column chromatography (silica, 15% ethyl acetate 
in hexanes). D
26 + 25.03 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.28 (d, J = 
1.5 Hz, 1H), 7.25 (d, J = 1.7 Hz, 1H), 7.17 (d, J = 7.3 Hz, 1H), 6.92 (dd, J = 7.1 Hz, 1H), 
6.87 (d, J = 8.2 Hz, 1H), 4.25 (ddd, J = 17.3 Hz, 2H), 4.17 (d, J = 3.2 Hz, 1H), 3.78 (s, 3H), 
2.18 – 2.12 (m, 1H), 1.53 (s, 3H), 1.42 (s, 3H), 1.02 (d, J = 7.0 Hz, 3H), 0.99 (d, J = 6.8 Hz, 
3H);
 13
C NMR (126 MHz, CDCl3); ppm): 171.74 (s), 157.36 (s), 153.77 (s), 131.16 (s), 
128.50 (s), 123.31 (s), 120.46 (s), 110.26 – 109.82 (m), 82.80 (s), 66.50 (s), 55.26 (s), 37.19 
(s), 29.57 (s), 28.69 (s), 21.51 (s), 21.31 (d, J = 6.5 Hz), 16.89 (s); HRMS-ESI (m/z): 
[M+Na]
+
 calcd for C17H23NO4Na, 328.1525; found, 328.1522. 
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HO
O
(COCl)2, cat DMF, CH2Cl2;
 then S8, THF
O N
O O
CF3CF3
S25  
(S)-4-Isopropyl-5,5-dimethyl-3-(2-(3-(trifluoromethyl)phenyl)acetyl)oxazolidin-2-
one (3.71). The title compound was prepared from commercially available 2-(3-
trifluoromethyl)acetic acid (1.71 g, 8.40 mmol) following standard procedure 3 for the 
synthesis of N-acyl oxazolidinones via acyl chloride from carboxylic acid and was obtained 
as yellow oil (1.01 g, 2.94 mmol, 35%) after purification by column chromatography (silica, 
30% ethyl acetate – hexanes). D
23 + 33.10 (c 0.1, CHCl3); 
1
H NMR (600 MHz, CDCl3); 
ppm): 7.59 (s, 1H), 7.53 (d, J = 7.8 Hz, 2H), 7.44 (dd, J = 7.7 Hz, 1H), 4.44 (d, J = 15.4 
Hz, 1H), 4.29 (d, J = 15.4 Hz, 1H), 4.15 (d, J = 3.2 Hz, 1H), 2.15 – 2.09 (m, 1H), 1.50 (s, 
3H), 1.50 (s, 3H), 1.34 (s, 3H), 1.34 (s, 3H), 0.96 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.0 Hz, 
3H), 0.87 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 6.8 Hz, 3H); 
13
C NMR (126 MHz, CDCl3); 
ppm): 170.90 (s), 153.44 (s), 134.90 (s), 133.25 (d, J = 1.2 Hz), 131.31 – 130.18 (m), 
128.88 (d, J = 7.3 Hz), 126.29 (q, J = 3.8 Hz), 124.00 (q, J = 3.8 Hz), 124.00 (d, J =272.2 
Hz), 83.07, (s), 66.52 (s), 41.34 (s), 29.57 (s), 28.75 (s), 21.38 (s), 21.31 (s), 16.81 (s); 
HRMS-ESI (m/z): [M+Na]
+
 calcd for C17H20F3NO3Na, 366.1293; found, 366.1292. 
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O
O
1. Pd/C, H2, EtOH:EtOAc
2. Triethylorthoformate
3. NaOH, H2O
4. PivCl, Et3N, THF; 
    then S8, THF
OH
NO2
O N
O O
O
N
S26 S27  
(S)-3-(2-(benzo[d]oxazol-5-yl)acetyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one 
(3.73) The title compound was prepared starting from known methyl ester 3.72
125
 using the 
following procedure.  
Pd/C (20 mol %) was added to a solution of 3.72 (1.37 g, 6.48 mmol) in a 1:1 mixture of 
EtOH/EtOAc (0.16 M). The reaction mixture was placed under an atmosphere of H2 and   
stirred for 14 h. The reaction mixture was then filtered through a pad of celite and the 
remaining residue was washed using a solvent system of 1:1 EtOH and EtOAc. The filtrate 
was concentrated in vacuo
 
providing a dark brown solid (1.08 g, 99%). The crude product 
was used without further purification  
Triethylorthoformate (13.3 mL, 0.8 M) was added to the crude substrate (10.6 mmol) and 
the mixture was heated at reflux for 18 h. The reaction mixture was then transferred to a 
separatory funnel containing water (90 mL) and extracted with ethyl acetate (3 x 15 ml). The 
organic layer was dried over Na2SO4 and concentrated in vacuo providing a light brown oil 
(1.75 g, 10.5 mmol, 99%). The crude product was used without further purification.  
An aqueous solution of NaOH was added (0.4 M, 11.36 mmol, 1.2 equiv) to a solution 
of crude substrate (1.81 g, 9.47 mmol) in methanol (0.37 M) and the mixture was stirred for 
12 h. The reaction mixture was diluted with H2O to a concentration of 0.035 M. 
Concentrated aqueous HCl was added until a pH of ~4 was achieved. The solution was 
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allowed to stir for 1 h and the solids were collected by filtration and washed with cold water 
providing the product as a crude tan solid (0.673 g, 3.52 mmol, 41%). 
The title compound was prepared from the solid collected (0.375 g, 2.11 mmol) 
following standard procedure 2 for the synthesis of N-acyl oxazolidinones via carboxylic 
acid and was obtained as white solid (0.433 g, 1.37 mmol, 65%) after purification by column 
chromatography (silica, 24% ethyl acetate to 30% ethyl acetate in hexanes). D
21 + 29.80 (c 
1.0, CHCl3). 
1
H NMR (600 MHz, CDCl3) (ppm): 8.05 (s, 1H), 7.73 (s, 1H), 7.49 (d, J = 8.4 
Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 4.47 (d, J = 15.4 Hz, 1H), 4.33 (d, J = 15.4 Hz, 1H), 4.11 
(d, J = 3.1 Hz, 1H), 2.11 – 2.03 (m, 1H), 1.45 (s, 3H), 1.29 (s, 3H), 0.92 (d, J = 7.0 Hz, 3H), 
0.83 (d, J = 6.8 Hz, 3H). 
13
C NMR (126 MHz, CDCl3) ppm): 171.51 (s), 153.38 (s), 
152.77 (s), 149.04 (s), 140.20 (s), 130.55 (s), 127.25 (s), 121.47 (s), 110.62 (s), 82.86 (s), 
66.37 (s), 41.27 (s), 29.44 (s), 28.67 (s), 21.35 (s), 21.21 (s), 16.77 (s). HRMS-ESI (m/z): 
[M+Na]
+
 calcd for C17H20N2O4Na, 339.1321; found, 339.1314. 
 
O N
O O
N
O
O NH
O
1. n-BuLi, ccetyl chloride, 
    THF
2. 2-chlorobenzoxazole,
    NaHMDS, toluene
S1 S28  
(S)-3-(2-(benzo[d]oxazol-2-yl)acetyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one 
(3.74) The title compound was prepared starting from oxazolidone S2 using the following 
procedure. 
To a solution of S2 (1.5 g, 9.54 mmol) in THF (0.3 M) at –78 °C, n-BuLi (4.5 mL, 2.33 
M in hexanes, 10.5 mmol, 1.1 equiv) was added dropwise. After the addition was complete, 
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the reaction mixture was warmed to room temperature and stirred for 30 min. The reaction 
mixture was chilled to -78 °C and acetyl chloride (0.82 mL, 11.45 mmol, 1.2 equiv) was 
added. After the addition was complete, the reaction mixture was warmed to room 
temperature and stirred for 12 h. The reaction was quenced with saturated ammonium 
chloride and the layers were seperated. The aqeuous layer was extracted with ethyl acetate (3 
x 25 ml). The combined organic layers were washed with brine, dried over sodium sulfate, 
concentrated in vacuo. (S)-3-acetyl-4-isopropyl-5,5-dimethyloxazolidin-2-one was obtained 
after purification by column chromatography (silica, 12% ethyl acetate to 14% ethyl acetate 
in hexanes) as a colorless oil (1.4 g, 7.03 mmol, 74%). 
To a solution of (S)-3-acetyl-4-isopropyl-5,5-dimethyloxazolidin-2-one (0.500 g, 2.50 
mmol) and 2-chlorobenzoxazole (0.385 g, 2.50 mmol) in toluene (11 mL) at 0 °C, NaHMDS 
(0.6 M in toluene, 8.3 mL, 5 mmol, 2 equiv) was added dropwise. After the addition was 
complete, the reaction mixture was allowed to stir at 0 °C for 2 h and then warmed to room 
temperature and stirred 12 h. The reaction was quenched with 1N NH4Cl solution (38 mL, 
15.3 equiv). The organic layer was separated and collected. The aqueous layer was extracted 
with EtOAc (3 x 15 mL), the combined organic layers were dried over Na2SO4 and 
concentrated in vacuo. The title compound was obtained after purification by column 
chromatography (silica, 21% ethyl acetate to 25% ethyl acetate in hexanes as a green solid 
(0.510 g, 1.61 mmol, 65%). D
20 + 49.79 (c 1.0, CHCl3). 
1
H NMR (600 MHz, CDCl3) 
(ppm):  7.68 – 7.64 (m, 1H), 7.48 (d, J = 5.0 Hz, 1H), 7.32 – 7.27 (m, 2H), 4.73 (d, J = 17.1 
Hz, 1H), 4.55 (d, J = 17.1 Hz, 1H), 4.20 (d, J = 2.5 Hz, 1H), 2.21 – 2.15 (m, 1H), 1.52 (d, J 
= 6.3 Hz, 3H), 1.47 (s, 3H), 1.06 (d, J = 7.0 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H).
 13
C NMR 
(126 MHz, CDCl3) ppm):  166.63 (s), 159.96 (d, J = 0.9 Hz), 153.40 (s), 151.02 (s), 
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141.07 (s), 124.88 (s), 124.21 (s), 119.85 (s), 110.48 (s), 83.63 (s), 66.76 (s), 36.75 (s), 29.56 
(s), 28.74 (s), 21.42 (s), 21.30 (s), 16.85 (s). HRMS-ESI (m/z): [M+Na]
+
 calcd for 
C17H20N2O4Na, 339.1321; found, 339.1331. 
 
 
(S)- 
 
3-(2-Cyclohexylacetyl)-4-isopropyl-5,5-dimethyloxazolidin-2-one (3.75). The title 
compound was prepared from commerically available 2-cyclohexylacetic acid following 
known literature protocols by Herrmann et al. 
1
H NMR (500 MHz, CDCl3); (ppm): 7.32 – 
7.26 (m, 4H), 7.26 – 7.25 (m, 1H), 7.22 (ddd, J = 8.5, 3.8, 1.8 Hz, 1H), 4.51 (dd, J = 9.6, 3.9 
Hz, 1H), 3.13 (dd, J = 14.4, 3.8 Hz, 1H), 2.91 – 2.75 (m, 3H), 1.88 – 1.78 (m, 1H), 1.74 – 
1.60 (m, 5H), 1.36 (s, 3H), 1.34 (s, 3H), 1.31 – 1.21 (m, 2H), 1.18 – 1.10 (m, 1H), 1.04 – 
0.95 (m, 2H).
 13
C NMR (126 MHz, CDCl3); (ppm): 172.78 (s), 152.58 (s), 136.96 (s), 
129.02 (s), 128.59 (s), 126.71 (s), 81.92 (s), 77.25 (s), 77.00 (s), 76.75 (s), 63.46 (s), 42.68 
(s), 35.39 (s), 34.44 (s), 33.01 (d, J = 10.0 Hz), 28.50 (s), 26.11 (d, J = 10.4 Hz), 22.24 (s). 
 
Standard procedure for a–monofluorination of N-acyl oxazolidinones: 
1.5 eq TiCl4, 2 eq Et3N, 
2 eq NFSI,
CH2Cl2(.5M), r.t.,1 h
O N
O O
R
F
O N
O O
R
 
The substrate (0.50 mmol, 1.00 equiv) was charged to a flame dried 10 ml round bottom 
flask or 1 dram vial. The reaction vessel was then backfilled with argon 3 times. Next, 
O N
O O
Ph
S30
HO
O
(COCl)2, cat DMF, CH2Cl2; 
then S29, THF O NLi
O
Ph
S29
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dichloromethane (0.50 M) was added and the solution was then cooled to 0 °C. A solution of 
TiCl4 (1.00 M in CH2Cl2, 0.75 mL, 0.75 mmol, 1.50 equiv) was added dropwise to the 
reaction mixture at 0 °C and the mixture was stirred for 5 min. Triethylamine (0.14 mL, 1.00 
mmol, 2.00 equiv) was added and the reaction mixture was stirred at 0 °C for 30 min. N-
Fluorobenzenesulfonimide (NFSI, 0.315 g, 2.00 mmol, 2.00 equiv) was then added to the 
reaction mixture in one portion at 0 °C (CAUTION: reaction may bubble vigourously upon 
addition). The reaction was then warmed to rt and stirred for 1 h. The reaction mixture was 
filtered through a 1.5 cm silica gel plug, and the silica plug was washed with 
dichloromethane (5 mL) and ethyl acetate (40 mL). The combined filtrate was concentrated 
in vacuo and the residue purified by flash column chromatography to give the corresponding 
α–monofluorinated N-acyl oxazolidinone. 
 
O N
O O
F
 
Table 3.5.3, entry 1. The title compound was prepared from oxazolidinone 3.49 (0.128 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 98:2) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 15% ethyl acetate in hexanes) to 
afford product as a colorless oil (0.128 g, 0.47 mmol, 94%, single diastereomer). D
24 + 
13.60 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); (ppm): 5.99 (d, J = 51.4 Hz, 1H), 4.10 
(d, J = 3.0 Hz, 1H), 2.20 (dddd, J = 13.8, 6.9, 3.1 Hz, 1H), 1.87 – 1.76 (m, 2H), 1.53 (s, 3H), 
1.52 – 1.45 (m, 1H), 1.41 (dd, J = 13.2, 7.8 Hz, 1H), 1.39 (s, 3H), 1.38 – 1.30 (m, 1H), 1.07 
(d, J = 7.0 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.91 (dd, J = 7.3 Hz, 3H); 
13
C NMR (151 MHz, 
  259 
CDCl3); (ppm): 170.50 (d, J = 22.7 Hz), 153.08 (s), 89.14 (d, J = 178.5 Hz), 84.01 (s), 
66.87 (s), 32.04 (d, J = 22.1 Hz), 29.47 (s), 28.95 (s), 26.90 (d, J = 1.9 Hz), 22.13 (s), 21.40 
(s), 21.31 (s), 16.98 (s), 13.82 (s); 
19
F NMR (564 MHz, CDCl3); ppm): -192.24 – -192.48 
(m, 1F); HRMS-ESI (m/z): [M+Na]
+
 calcd for C14H24FNO3Na, 296.1638; found, 296.1633. 
 
 
 
Table 3.5.3, entry 2. The title compound was prepared form oxazolidinone 3.50 (0.107 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 98:2) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 11% ethyl acetate in hexanes) to 
afford product as a white solid (0.105 g, 0.46 mmol, 91%, single diastereomer. D
26 + 14.78 
(c 0.42, CHCl3); 
1
H NMR (600 MHz, CDCl3); (ppm): 6.08 (dddd, J = 49.2, 6.5 Hz, 1H), 
4.11 (d, J = 3.2 Hz, 1H), 2.19 (dddd, J = 13.9, 7.0, 3.2 Hz, 1H), 1.57 (dd, J = 23.8, 6.5 Hz, 
3H), 1.53 (s, 3H), 1.39 (s, 3H), 1.06 (d, J = 7.0 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H); 
13
C NMR 
(201 MHz, CDCl3); ppm): 172.79 (d, J = 22.4 Hz), 154.80 (s), 87.58 (d, J = 176.6 Hz), 
85.87 (s), 68.62 (s), 31.27 (s), 30.74 (s), 23.16 (s), 23.11 (s), 19.90 (d, J = 23.6 Hz), 18.73 
(s); 
19
F NMR (564 MHz, CDCl3); ppm): -183.56 - -183.80 (m, 1F). HRMS-ESI  (m/z): 
[M+Na]
+
 calcd for C11H18FNO3Na, 254.1168; found, 254.1164. 
 
 
O N
O O
F
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O N
O O
F
 
Table 3.5.3, entry 3. The title compound was prepared form oxazolidinone 3.55 (0.121 
g, 0.50 mmol) following the standard –monofluorination procedure. The 
diastereoselectivity (dr >98:2) was determined by 
1
H NMR of the crude reaction mixture. 
The residue was purified by column chromatography (silica, 6% ethyl acetate in hexanes) to 
afford product as a colorless oil (0.100 g, 0.39 mmol, 77%, single diastereomer). D
26 + 
42.22 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 5.89 (dd, J = 49.6, 3.2 Hz, 1H), 
4.11 (d, J = 3.0 Hz, 1H), 2.23 – 2.11 (m, 2H), 1.53 (s, 3H), 1.38 (s, 3H), 1.11 (d, J = 6.9 Hz, 
3H), 1.08 (d, J = 7.0 Hz, 3H), 0.97 (dd, J = 6.6 Hz, 6H); 
13
C NMR (151 MHz, CDCl3); 
ppm): 169.73 (d, J = 23.0 Hz), 153.12 (s), 92.31 (dd, J = 181.2, 19.7 Hz), 83.86 (s), 67.03 
(d, J = 19.1 Hz), 30.63 (t, J = 20.2 Hz), 29.49 (d, J = 19.9 Hz), 28.86 (d, J = 11.6 Hz), 21.40 
(d, J = 6.6 Hz), 21.24 (s), 18.85 (d, J = 18.9 Hz), 16.98 (d, J = 17.4 Hz), 15.26 (d, J = 16.3 
Hz);
 19
F NMR (564 MHz, CDCl3); ppm): -204.40 (dd, J = 50.2, 28.3 Hz, 1F). HRMS-ESI 
(m/z): [M+Na]
+
 calcd for C13H22FNO3Na, 282.1481; found, 282.1489. 
 
O N
O O
Ph
F
 
Table 3.5.3, entry 4. The title compound was prepared from oxazolidinone 3.75 (0.165 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 96:4) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 20% ethyl acetate in hexanes - 25% 
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ethyl acetate in hexanes) to afford product as a white soild (0.160 g, 0.46 mmol, 92%, single 
diastereomer). D
26 + 19.05 (c 0.42, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.33 – 
7.27 (m, 4H), 7.24 (dd, J = 7.1 Hz, 1H), 5.83 (dd, J = 49.6, 3.6 Hz, 1H), 4.46 (dd, J = 9.9, 
3.0 Hz, 1H), 3.25 (dd, J = 14.5, 2.8 Hz, 1H), 2.93 (dd, J = 14.5, 9.9 Hz, 1H), 1.84 (dddd, J = 
58.1, 34.1, 16.5, 8.1 Hz, 4H), 1.65 (dd, J = 21.0, 12.8 Hz, 2H), 1.44 – 1.35 (m, 7H), 1.35 – 
1.27 (m, 2H), 1.23 – 1.11 (m, 2H); 13C NMR (201 MHz, CDCl3); ppm): 169.54 (d, J = 
23.5 Hz), 152.13 (s), 136.63 (s), 129.04 (s), 128.75 (s), 126.93 (s), 92.10 (d, J = 180.8 Hz), 
83.50 (s), 64.05 (s), 40.34 (d, J = 20.8 Hz), 35.02 (s), 28.63 (d, J = 3.3 Hz), 28.53 (s), 26.07 
(d, J = 4.3 Hz), 26.01 (s), 25.81 (s), 25.76 (s), 22.15 (s); 
19
F NMR (564 MHz, CDCl3); 
ppm): -201.83 (dd, J = 50.1, 26.9 Hz, 1F); HRMS-ESI (m/z): [M+Na]+ calcd for 
C20H26FNO3Na, 370.1794; found, 370.1800. 
 
O N
O O
F
 
Table 3.5.3, entry 5. The title compound was prepared from oxazolidinone 3.62 (0.138 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 96:4) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 3% diethyl ether in toluene - 5% 
diethyl ether in toluene) to afford product as a yellow solid (0.135 g, 0.46 mmol, 92%, single 
diastereomer). D
26 + 132.53 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.52 (d, 
J = 4.9 Hz, 2H), 7.38 (d, J = 5.4 Hz, 3H), 6.98 (d, J = 48.8 Hz, 1H), 3.99 (d, J = 3.1 Hz, 1H), 
2.18 (dddd, J = 13.8, 6.9, 3.2 Hz, 1H), 1.44 (s, 3H), 1.12 (d, J = 7.0 Hz, 3H), 1.00 (d, J = 6.8 
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Hz, 3H), 0.94 (s, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 168.89 (d, J = 26.9 Hz), 
152.96 (s), 133.44 (d, J = 20.2 Hz), 130.10 (d, J = 3.1 Hz), 128.77 (s), 128.76 (s), 128.49 (s), 
128.46 (s), 88.87 (d, J = 180.2 Hz), 84.20 (s), 67.54 (s), 29.47 (s), 28.35 (s), 21.43 (s), 21.25 
(s), 16.98 (s); 
19
F NMR (564 MHz, CDCl3); ppm): -172.63 (d, J = 48.8 Hz, 1F); HRMS-
ESI (m/z): [M+Na]
+
 calcd for C16H20FNO3Na, 316.1325; found, 316.1324. 
 
O N
O O
Cl
F
 
Table 3.5.3, entry 6. The title compound was prepared from oxazolidinone 3.51 (0.117 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 98:2) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 15% ethyl acetate in hexanes - 25% 
ethyl acetate in hexanes) to afford product as a white solid (84 mg, 0.34 mmol, 67%, single 
diastereomer). D
26 + 38.40 (c 0.7, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.45 (d, J 
= 51.6 Hz, 1H), 4.08 (d, J = 3.0 Hz, 1H), 2.24 – 2.18 (m, 1H), 1.56 (s, 3H), 1.45 (s, 3H), 
1.09 (d, J = 7.0 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H); 
13
C NMR (126 MHz, CDCl3); ppm): 
163.97 (d, J = 26.3 Hz), 152.59 (s), 90.25 (d, J = 248.8 Hz), 85.16 (s), 67.67 (s), 29.47 (s), 
28.91 (s), 21.46 (s), 21.31 (s), 16.87 (s); 
19
F NMR (564 MHz, CDCl3); ppm): -149.72 (dd, 
J = 51.6, 3.6 Hz, 1F);. HRMS-ESI (m/z): [M+Na]
+
 calcd for C10H15FClNO3Na, 274.0622; 
found, 274.0610. 
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Table 3.5.3, entry 7. The title compound was prepared from oxazolidinone 3.69 (0.160 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 98:2) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 1.5% diethyl ether in toluene) to 
afford product as a white soild (0.155 g, 0.46 mmol, 92%, single diastereomer). D
26 + 31.81 
(c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.27 (d, J = 7.6 Hz, 1H), 7.25 (s, 1H), 
6.95 (dd, J = 7.3 Hz, 1H), 6.89 (d, J = 8.3 Hz, 2H), 6.21 (ddd, J = 49.0, 5.3 Hz, 1H), 4.22 – 
4.14 (m, 2H), 4.13 (d, J = 3.0 Hz, 1H), 2.41 (ddd, J = 5.9 Hz, 1H), 2.37 (ddd, J = 5.9 Hz, 
1H), 2.21 (ddd, J = 13.8, 8.4, 5.0 Hz, 1H), 1.53 (s, 3H), 1.41 (s, 3H), 1.08 (d, J = 7.0 Hz, 
3H), 0.99 (d, J = 6.8 Hz, 3H); 
13
C NMR (126 MHz, CDCl3); ppm): 169.52 (d, J = 22.6 
Hz), 158.44 (s), 153.03 (s), 129.39 (s), 121.07 (s), 114.81 (d, J = 0.7 Hz), 86.32 (d, J = 178.7 
Hz), 84.16 (s), 66.92 (s), 62.85 (d, J = 3.3 Hz), 32.01 (d, J = 21.8 Hz), 29.44 (s), 28.94 (s), 
21.39 (s), 21.25 (s), 16.95 (s);
 19
F NMR (564 MHz, CDCl3); ppm): -192.47 – -192.69 (m, 
1F); HRMS-ESI (m/z): [M+Na]
+
 calcd for C18H24FNO4Na, 360.1587; found, 360.1594. 
 
O N
O O
F
 
Table 3.5.3, entry 8. The title compound was prepared from oxazolidinone 3.52 (0.145 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 98:2) was determined by 
1
H NMR of the crude reaction mixture. The 
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residue was purified by column chromatography (silica, 12% ethyl acetate in hexanes - 15% 
ethyl acetate in hexanes) to afford product as a colorless oil after purification (0.136 g, 0.44 
mmol, 88%, single diastereomer). D
26 + 37.73 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); 
ppm): 7.34 – 7.29 (m, 4H), 7.25 (dd, J = 8.4, 2.4 Hz, 1H), 6.22 (ddd, J = 49.5, 8.6, 3.3 Hz, 
1H), 4.10 (d, J = 3.0 Hz, 1H), 3.14 (dddd, J = 22.9, 19.4, 14.3, 6.0 Hz, 2H), 2.19 (dddd, J = 
13.7, 6.9, 3.2 Hz, 1H), 1.51 (s, 3H), 1.30 (s, 3H), 1.07 (d, J = 7.0 Hz, 3H), 0.97 (d, J = 6.8 
Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 169.50 (d, J = 22.5 Hz), 152.95 (s), 135.05 
(d, J = 1.9 Hz), 129.43 (s), 128.45 (s), 127.07 (s), 89.17 (d, J = 181.1 Hz), 84.00 (s), 66.73 
(s), 38.47 (d, J = 22.5 Hz), 29.37 (s), 28.72 (s), 21.29 (s), 21.20 (s), 16.87 (s); 
19
F NMR (564 
MHz, CDCl3); ppm): -188.75 (ddd, J = 49.6, 33.6, 19.4 Hz, 1F); HRMS-ESI (m/z): 
[M+Na]
+
 calcd for C17H22FNO3Na, 330.1481; found, 330.1485. 
 
O N
O O
F
Cl
 
Table 3.5.3, entry 9. The title compound was prepared from oxazolidinone 3.68 (0.162 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 96:4) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 12% diethyl ether in toluene - 15% 
diethyl ether in toluene) to afford product as a colorless oil (0.133 g, 0.39 mmol, 78%, single 
diastereomer). D
25 + 26.92 (c 0.1, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.43 (d, J 
= 7.3 Hz, 1H), 7.36 (d, J = 7.6 Hz, 1H), 7.32 (d, J = 5.8 Hz, 1H), 7.25 – 7.18 (m, 2H), 6.32 
(ddd, J = 48.7, 8.2, 4.2 Hz, 1H), 4.13 (d, J = 3.1 Hz, 1H), 3.46 (ddd, J = 18.6, 14.7, 8.1 Hz, 
1H), 3.30 (ddd, J = 30.1, 14.6, 4.1 Hz, 1H), 2.21 (dddd, J = 13.8, 5.1 Hz, 1H), 1.53 (s, 3H), 
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1.35 (s, 3H), 1.07 (d, J = 7.0 Hz, 3H), 0.99 (d, J = 6.8 Hz, 3H); 
13
C NMR (126 MHz, 
CDCl3); ppm): 169.34 (d, J = 22.6 Hz), 152.78 (s), 134.54 (s), 132.75 (d, J = 2.9 Hz), 
131.58 (d, J = 1.3 Hz), 129.55 (s), 128.61 (s), 126.93 (s), 87.69 (d, J = 181.0 Hz), 83.95 (s), 
66.88 (s), 35.20 (d, J = 22.7 Hz), 29.52 (s), 28.90 (s), 21.49 (s), 21.33 (s), 16.96 (s). 
19
F 
NMR (564 MHz, CDCl3); ppm): -187.68, -187.87 (m, 1F); HRMS-ESI (m/z): [M+Na]
+
 
calcd for C17H21FClNO3Na, 364.109; found, 364.1102. 
 
O N
O O
CF3
F
 
Table 3.5.3, entry 10. The title compound was prepared from oxazolidinone 3.60 (0.179 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 98:2) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 1.5% diethyl ether in toluene) to 
afford product as a white solid (0.115 g, 0.31 mmol, 61%, 98:2 dr. D
26 + 25.27 (c 1.0, 
CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.57 (s, 1H), 7.56 – 7.51 (m, 2H), 7.45 (dd, J 
= 7.7 Hz, 1H), 6.18 (ddd, J = 49.4, 8.7, 2.5 Hz, 1H), 4.12 (d, J = 2.9 Hz, 1H), 3.19 (dddd, J 
= 34.6, 23.1, 14.5, 5.7 Hz, 2H), 2.21 (dddd, J = 13.7, 6.9, 3.2 Hz, 1H), 1.54 (s, 3H), 1.35 (s, 
3H), 1.07 (d, J = 7.0 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); 
ppm): 169.15 (d, J = 22.5 Hz), 153.11 (s), 136.24 (d, J = 1.0 Hz), 133.00 (s), 130.88 (q, J 
= 32.2 Hz), 129.03 (s), 126.26 (q, J = 3.7 Hz), 124.12 (q, J = 3.8 Hz), 124.01 (d, J = 273.42 
Hz), 89.08 (d, J = 181.9 Hz), 84.29 (s), 66.87 (s), 38.23 (d, J = 22.5 Hz), 29.48 (s), 28.91 (s), 
21.38 (s), 21.27 (s), 16.95 (s);
 19
F NMR (564 MHz, CDCl3); ppm): -62.65 (s, 3F), -189.13 
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(ddd, J = 49.5, 34.0, 20.1 Hz, 1F); HRMS-ESI (m/z): [M+Na]
+
 calcd for C18H21F4NO3Na, 
398.1355; found, 398.1356. 
 
O N
O O
F
OBn
 
Table 3.5.3, entry 11. The title compound was prepared from oxazolidinone 3.57 (0.174 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 98:2) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 15% ethyl acetate in hexanes 
hexanes – 25% ethyl acetate in hexanes) to afford product as a colorless oil (0.124 g, 0.34 
mmol, 68%, single diastereomer). D
25 + 30.86 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); 
ppm): 7.35 – 7.30 (m, 4H), 7.29 – 7.26 (m, 1H), 6.10 – 5.99 (m, 1H), 4.49 (d, J = 2.8 Hz, 
2H), 4.10 (d, J = 3.0 Hz, 1H), 3.57 – 3.49 (m, 2H), 2.20 (dddd, J = 13.9, 7.0, 3.2 Hz, 1H), 
2.02 – 1.91 (m, 2H), 1.90 – 1.79 (m, 2H), 1.53 (s, 3H), 1.36 (s, 3H), 1.07 (d, J = 7.0 Hz, 3H), 
0.98 (d, J = 6.8 Hz, 3H);
 13
C NMR (201 MHz, CDCl3); ppm): 171.99 (d, J = 22.7 Hz), 
154.85 (s), 140.20 (s), 130.11 (s), 129.43 (s), 129.29 (s), 90.71 (d, J = 178.8 Hz), 85.87 (s), 
74.58 (s), 70.99 (s), 68.68 (s), 31.26 (s), 31.01 (d, J = 22.1 Hz), 30.71 (s), 26.80 (d, J = 2.0 
Hz), 23.18 (s), 23.10 (s), 18.76 (s); 
19
F NMR (564 MHz, CDCl3); ppm): -192.32 (ddd, J = 
50.1, 30.1, 24.4 Hz, 1F). HRMS-ESI (m/z): [M+Na]
+
 calcd for C20H28FNO4Na, 388.1900; 
found, 388.1901. 
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Table 3.5.3, entry 12. The title compound was prepared from oxazolidinone 3.61 (0.113 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr >98:2) was determined by 
1
H NMR of the crude reaction mixture. 
The residue was purified by column chromatography (silica, 15% ethyl acetate in hexanes - 
25% ethyl acetate in hexanes) to afford product as a clear oil (56 mg, 0.23 mmol, 46%, 
single diastereomer). D
25 + 36.44 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); dppm): 6.46 
(dd, J = 48.7, 6.2 Hz, 1H), 6.07 – 5.97 (m, 1H), 5.65 (dd, J = 17.3, 3.2 Hz, 1H), 5.46 (d, J = 
10.7 Hz, 1H), 4.07 (d, J = 2.9 Hz, 1H), 2.19 (dddd, J = 13.7, 6.9, 3.1 Hz, 1H), 2.19 (dddd, J 
= 13.7, 6.9, 3.1 Hz, 1H), 1.52 (s, 3H), 1.34 (s, 3H), 1.08 (d, J = 7.0 Hz, 3H), 0.98 (d, J = 6.8 
Hz, 3H);
 13
C NMR (126 MHz, CDCl3); dppm): 168.36 (d, J = 24.7 Hz), 153.03 (s), 129.94 
(d, J = 19.8 Hz), 121.75 (d, J = 10.9 Hz), 87.69 (d, J = 179.0 Hz), 84.32 (s), 67.19 (s), 29.46 
(s), 28.96 (s), 21.33 (s), 16.94 (s); 
19
F NMR (564 MHz, CDCl3); ppm): -186.01 (ddd, J = 
49.0, 14.3, 3.6 Hz, 1F); HRMS-ESI (m/z): [M+Na]
+
 calcd for C12H18FNO3Na, 266.1168; 
Found, 266.1158. 
 
O N
O O
F
 
Table 3.5.3, entry 13. The title compound was prepared from oxazolidinone 3.56 (0.134 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 98:2) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 9% ethyl acetate in hexanes - 11% 
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ethyl acetate in hexanes) to afford product as a colorless oil (0.114 g, 0.40 mmol, 80%, 
single diastereomer). D
26 + 31.46 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 
6.05 – 5.94 (m, 1H), 5.78 (dddd, J = 16.9, 10.2, 6.6 Hz, 1H), 4.99 (dd, J = 32.4, 13.7 Hz, 
2H), 4.10 (d, J = 2.9 Hz, 1H), 2.19 (dddd, J = 10.3, 7.2, 3.3 Hz, 1H), 2.16 – 2.05 (m, 2H), 
1.88 – 1.77 (m, 2H), 1.70 – 1.60 (m, 2H), 1.53 (s, 3H), 1.38 (s, 3H), 1.07 (d, J = 7.0 Hz, 3H), 
0.97 (d, J = 6.9 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 170.32 (d, J = 22.6 Hz), 
153.05 (s), 137.78 (s), 115.14 (s), 89.00 (d, J = 178.7 Hz), 84.04 (s), 66.86 (s), 32.95 (s), 
31.72 (d, J = 22.1 Hz), 29.45 (s), 28.94 (s), 24.01 (d, J = 1.9 Hz), 21.37 (s), 21.29 (s), 16.95 
(s); 
19
F NMR (564 MHz, CDCl3); ppm): -192.17 – -192.40 (m, 1F); HRMS-ESI (m/z): 
[M+Na]
+
 calcd for C15H24FNO3Na, 308.1638; found, 308.1642. 
O N
O O
F
 
Table 3.5.3, entry 3.58. The title compound was prepared from oxazolidinone S12 
(0.132 g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 5:1) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 12% ethyl acetate in hexanes) to 
afford product as a colorless oil (79 mg, 0.28 mmol, 56%, single diastereomer). D
26 + 30.73 
(c 0.316, CHCl3); 
1
H NMR (600 MHz, CDCl3) ppm): 6.02 (ddd, J = 50.1, 7.4, 3.6 Hz, 
1H), 4.11 (d, J = 2.8 Hz, 1H), 2.28 (dt, J = 16.7, 8.0 Hz, 2H), 2.24 – 2.18 (m, 1H), 2.06 – 
1.89 (m, 3H), 1.78 (ddd, J = 22.5, 14.4, 7.0 Hz, 2H), 1.54 (s, 3H), 1.40 (s, 3H), 1.08 (d, J = 
7.0 Hz, 3H), 0.98 (d, J = 6.8 Hz, 2H);
 13
C NMR (201 MHz, CDCl3) ppm): 170.04 (d, J = 
22.6 Hz), 153.06 (s), 88.76 (d, J = 179.1 Hz), 84.12 (s), 83.36 (s), 69.02 (s), 66.91 (s), 31.27 
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(d, J = 22.1 Hz), 29.48 (s), 29.02 (s), 23.77 (d, J = 2.0 Hz), 21.41 (s), 21.31 (s), 17.99 (s), 
16.98 (s). 
19
F NMR (564 MHz, CDCl3); ppm): -192.21 (ddd, J = 50.0, 31.2, 23.3 Hz). 
HRMS-ESI (m/z): [M+Na]
+
 calcd for C15H22FNO3Na, 306.1481; found, 306.1476. 
 
 
O N
O O
F
N
O
O
 
Table 3.5.3, entry 15. The title compound was prepared from oxazolidinone 3.59 (0.179 
g, 0.50 mmol) following the standard a–monofluorination procedure. The 
diastereoselectivity (dr 94:6) was determined by 
1
H NMR of the crude reaction mixture. The 
residue was purified by column chromatography (silica, 5% diethyl ether in toluene - 10% 
diethyl ether in toluene) to afford product as a white solid (0.132 g, 0.35 mmol, 70%, single 
diastereomer). D
22 + 13.20 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.75 (ddd, 
J = 72.2, 5.3, 3.1 Hz, 4H), 6.22 (ddd, J = 46.7, 4.4, 1.9 Hz, 1H), 4.38 (ddd, J = 15.3, 10.7, 
4.7 Hz, 1H), 4.26 (ddd, J = 31.6, 15.2, 1.6 Hz, 1H), 4.16 (d, J = 2.8 Hz, 1H), 2.19 (dddd, J = 
6.8, 3.9 Hz, 1H), 1.69 (s, 3H), 1.55 (s, 3H), 1.01 (d, J = 7.0 Hz, 3H), 0.95 (d, J = 6.8 Hz, 
3H);
 13
C NMR (126 MHz, CDCl3); ppm): 167.74 (s), 167.51 (d, J = 23.2 Hz), 153.48 (s), 
134.07 (s), 131.73 (s), 123.47 (s), 85.87 (d, J = 183.8 Hz), 84.73 (s), 66.68 (s), 38.08 (d, J = 
21.7 Hz), 29.43 (s), 28.83 (s), 21.84 (s), 21.16 (s), 17.01 (s);
 19
F NMR (564 MHz, CDCl3); 
ppm): -194.15 (ddd, J = 44.1, 32.2, 11.3 Hz, 1F); HRMS-ESI (m/z): [M+Na]+ calcd for 
C19H21FN2O5Na, 399.1332; found, 399.1339. 
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Standard procedure for –monofluorination of N-(arylacetyl)oxazolidinones: 
1.75 eq TiCl2(i-PrO)22 Et3NHCl                                 
 2 equiv Et3N, 
2 equiv  NFSI,
CH2Cl2(0.5M), r.t.,1 h
O N
O O
F
O N
O O
R R
 
Preparation of TiCl2(iPrO)2·2 Et3NHCl: In a flame dried flask, i-PrOH (2 equiv) was 
added to TiCl4 (1 equiv, 1.0 M in CH2Cl2) dropwise over 5 min at rt under an argon. The 
mixture was stirred for an additional 10 min (HCl gas evolution was observed). Et3N (2 
equiv) was then added dropwise over 10 min at rt. The mixture was stirred for an additional 
30 min (most of the initially formed white precipitate eventually redissolves).  
α-Monofluorination reaction: In a separate flame-dried flask, TiCl2(iPrO)22Et3NHCl 
(1.75 equiv) was added dropwise to the solution of N-acyl oxazolidinone (0.50 mmol, 1.00 
equiv) in CH2Cl2 (0.5 M) at 0 C under argon, and the resultant mixture was stirred for 5 
min (solution becomes a deep red upon complete addition). Et3N (2.0 equiv) was added 
dropwise at 0 C and the reaction mixture was stirred for 30 min. NFSI (2.0 equiv) was 
added in one portion to the reaction at 0 C (CAUTION: reaction mixture may bubble 
vigorously upon addition of NFSI). The reaction mixture was warmed to rt and stirred for 1 
h. The reaction was filtered through a 1.5 cm silica gel plug and washed with 
dichloromethane (10 mL) and ethyl acetate (50 mL). The filtrate was then concentrated and 
the residue was purified by flash column chromatography to give the product. 
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Table 3.5.5, entry 1. The title compound was prepared from oxazolidinone 3.53 (0.153 
g, 0.50 mmol) following the standard a–monofluorination of N-(arylacetyl)oxazolidinones. 
The diastereoselectivity (dr 93:7) was determined by 
1
H NMR of the crude reaction mixture. 
The residue was purified by column chromatography (silica, 4% diethyl ether in toluene) to 
afford product as a colorless oil (0.102 g, 0.31 mmol, 63%, single diastereomer). D
26 + 
141.92 (c 0.3, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.45 (d, J = 8.3 Hz, 2H), 6.91 
(d, J = 48 Hz, 1 H), 6.89 (d, J = 8.5 Hz, 2H), 4.01 (d, J = 3.0 Hz, 1H), 3.81 (s, 3H), 2.18 
(dddd, J = 13.8, 6.9, 3.2 Hz, 1H), 1.57 (s, 3H), 1.45 (s, 3H), 1.12 (d, J = 7.1 Hz, 3H), 1.00 
(d, J = 6.8 Hz, 3H), 0.98 (s, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 169.14 (d, J = 27.8 
Hz), 160.89 (d, J = 2.9 Hz), 152.94 (s), 130.25 (s), 130.22 (s), 125.55 (d, J = 21.0 Hz), 
114.15 (s), 114.14 (s), 88.60 (d, J = 179.9 Hz), 84.14 (s), 67.45 (s), 55.29 (s), 29.50 (s), 
28.49 (s), 21.45 (s), 21.28 (s), 17.01 (s);
 19
F NMR (564 MHz, CDCl3); ppm): -169.50 (d, J 
= 49.4 Hz, 1F). HRMS-ESI (m/z): [M+Na]
+
 calcd for C17H22FNO4Na, 346.1431; found, 
346.1439. 
 
O N
O O
F
F
 
Table 3.5.5, entry 2. The title compound was prepared from oxazolidinone 3.54 (0.146 
g, 0.50 mmol) following the standard procedure for a–monofluorination of N-
(arylacetyl)oxazolidinones. The diastereoselectivity (dr 10:1) was determined by 
1
H NMR of 
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the crude reaction mixture. The residue was purified by column chromatography (silica, 1% 
diethyl ether in toluene) to afford product as a white soild  (0.110 g, 0.36 mmol, 71%, single 
diastereomer). D
25 + 141.77 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3); ppm): 7.53 – 
7.49 (m, 1H), 7.06 (dd, J = 8.4 Hz, 1H), 6.94 (d, J = 48.6 Hz, 1H), 3.99 (d, J = 2.9 Hz, 1H), 
2.17 (ddd, J = 10.5, 6.8, 3.3 Hz, 1H), 1.44 (s, 2H), 1.10 (d, J = 7.0 Hz, 2H), 0.98 (d, J = 6.8 
Hz, 1H), 0.97 (s, 1H);
 13
C NMR (126 MHz, CDCl3); ppm): 168.66 (d, J = 27.2 Hz), 
163.58 (dd, J = 250.0, 3.2 Hz), 152.90 (s), 130.65 (d, J = 4.3 Hz), 130.59 (d, J = 4.3 Hz), 
129.45 (dd, J = 20.9, 3.3 Hz), 115.91 (d, J = 1.7 Hz), 115.73 (d, J = 1.7 Hz), 88.00 (d, J = 
180.5 Hz), 84.26 (s), 67.44 (s), 29.43 (s), 28.40 (s), 21.39 (s), 21.16 (s), 16.90 (s); 
19
F NMR 
(564 MHz, CDCl3); ppm): -110.25 – -110.31 (m, 1F), -171.32 (dd, J = 48.6, 5.4 Hz, 1F); 
HRMS-ESI (m/z): [M+Na]
+
 calcd for C16H19F2NO3Na, 334.1234; found, 334.1240. 
 
O N
O O
Cl
F
 
Table 3.5.5, entry 3. The title compound was prepared from oxazolidinone 3.63 (0.155 
g, 0.50 mmol) following the standard procedure for a–monofluorination of N-
(arylacetyl)oxazolidinones. The diastereoselectivity (dr 10:1) was determined by 
1
H NMR of 
the crude reaction mixture. The residue was purified by column chromatography (silica, 3% 
diethyl ether in toluene – 5% diethyl ether in toluene) to afford product as green crystals 
(0.100 g, 0.31 mmol, 61%, 10:1 dr, single diastereomer). D
26 + 125.38 (c 1.0, CHCl3); 
1
H 
NMR (600 MHz, CDCl3); ppm): 7.47 (d, J = 7.6 Hz, 2H), 7.36 (d, J = 8.2 Hz, 2H), 6.95 
(d, J = 48.5 Hz, 1H), 4.00 (d, J = 2.7 Hz, 1H), 2.21 – 2.15 (m, 1H), 1.45 (s, 3H), 1.11 (d, J = 
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7.0 Hz, 3H), 1.00 (s, 4H), 0.99 (s, 1H);
 13
C NMR (151 MHz, CDCl3); ppm): 168.46 (d, J = 
26.9 Hz), 152.91 (s), 136.21 (d, J = 3.5 Hz), 131.95 (d, J = 20.6 Hz), 129.89 (s), 129.86 (s), 
129.05 (s), 129.04 (s), 88.02 (d, J = 180.6 Hz), 84.33 (s), 67.45 (s), 29.46 (s), 28.54 (s), 
21.42 (s), 21.22 (s), 16.94 (s); 
19
F NMR (564 MHz, CDCl3); ppm): -172.51 (d, J = 48.5 
Hz, 1F); HRMS-ESI (m/z): [M+Na]
+
 calcd for C16H19FNO3Na, 350.0935; found, 350.0928. 
 
O N
O O
F
F
 
Table 3.5.5, entry 4. The title compound was prepared from oxazolidinone 3.66 (0.147 
g, 0.50 mmol) following the standard procedure for a–monofluorination of N-
(arylacetyl)oxazolidinones. The diastereoselectivity (dr 93:7) was determined by 
1
H NMR of 
the crude reaction mixture. The residue was purified by column chromatography (silica, 1% 
diethyl ether in toluene) to afford product as a white soild (0.107 g, 0.35 mmol, 69%, single 
diastereomer). D
26 + 126.11 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3); ppm): 7.38 – 
7.29 (m, 2H), 7.26 – 7.22 (m, 1H), 7.08 (ddddd, J = 9.6, 5.6, 1.4 Hz, 1H), 6.98 (d, J = 48.5 
Hz, 1H), 3.99 (d, J = 3.2 Hz, 1H), 2.18 (dddd, J = 13.9, 6.9, 3.2 Hz, 1H), 1.45 (s, 3H), 1.10 
(d, J = 7.0 Hz, 3H), 1.02 – 0.97 (m, 6H); 13C NMR (126 MHz, CDCl3); ppm): 168.34 (d, J 
= 26.6 Hz), 162.64 (dd, J = 247.8, 1.5 Hz), 152.97 (s), 135.72 (dd, J = 20.6, 7.4 Hz), 130.44 
(dd, J = 8.1, 1.4 Hz), 124.13 (dd, J = 4.8, 3.2 Hz), 117.17 (dd, J = 21.1, 2.8 Hz), 115.34 (dd, 
J = 22.7, 4.8 Hz), 87.95 (dd, J = 181.1, 1.8 Hz), 84.37 (s), 67.54 (s), 29.48 (s), 28.46 (s), 
21.43 (s), 21.24 (s), 16.95 (s);
 19
F NMR (564 MHz, CDCl3); ppm): -111.55 (td, J = 9.6, 6.0 
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Hz, 1F), -173.59 (d, J = 48.9 Hz); HRMS-ESI (m/z): [M+Na]
+
 calcd for C16H19F2NO3Na; 
334.1231; found, 334.1241. 
 
O N
O O
CF3
F
 
Table 3.5.5, entry 5. The title compound was prepared from oxazolidinone 3.71 (0.172 
g, 0.50 mmol) following the standard procedure for a–monofluorination of N-
(arylacetyl)oxazolidinones. The diastereoselectivity (dr 10:1) was determined by 
1
H NMR of 
the crude reaction mixture. The residue was purified by column chromatography (silica, 1% 
diethyl ether in toluene) to afford product as a white solid (0.117 g, 0.33 mmol, 65%, 10:1 
dr, single diastereomer). D
26 + 140.82 (c 0.8, CHCl3); 
1
H NMR (500 MHz, CDCl3); 
ppm): 7.79 – 7.72 (m, 2H), 7.67 (d, J = 7.4 Hz, 1H), 7.54 (dd, J = 7.8 Hz, 1H), 7.04 (d, J = 
48.5 Hz, 1H), 4.03 (d, J = 3.2 Hz, 1H), 2.20 (dddd, J = 13.9, 6.9, 3.2 Hz, 1H), 1.46 (s, 3H), 
1.12 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 7.7 Hz, 6H);
 13
C NMR (126 MHz, CDCl3); ppm): 
168.17 (d, J = 26.4 Hz), 152.93 (s), 134.56 (d, J = 20.6 Hz), 132.21 (dd, J = 4.5, 1.1 Hz), 
131.80 – 130.88 (m), 129.40 (d, J = 1.2 Hz), 126.96 – 126.64 (m), 125.02 – 124.76 (m), 
123.60 (d, J = 272.5 Hz), 88.06 (d, J = 181.2 Hz), 84.45 (s), 67.50 (s), 29.50 (s), 28.43 (s), 
21.43 (s), 21.25 (s), 16.97 (s);
 19
F NMR (564 MHz, CDCl3); ppm): -62.85 (s, 3F), -173.31 
(d, J = 48.5 Hz, 1F); HRMS-ESI (m/z): [M+Na]
+
 calcd for C17H19F4NO3Na, 384.1199; 
found, 384.1196. 
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Table 3.5.5, entry 6. The title compound was prepared from oxazolidinone 3.70 (0.153 
g, 0.50 mmol) following the standard procedure for a–monofluorination of N-
(arylacetyl)oxazolidinones. The diastereoselectivity (dr 10:1) was determined by 
1
H NMR of 
the crude reaction mixture. The residue was purified by column chromatography (silica, 
1.5% diethyl ether in toluene – 3% diethyl ether in toluene) to afford product as a colorless 
oil (0.129 g, 0.40 mmol, 80%, single diastereomer. D
26 + 158.73 (c 1.0, CHCl3); 
1
H NMR 
(600 MHz, CDCl3); ppm): 7.35 (dd, J = 7.8 Hz, 1H), 7.28 (d, J = 7.5 Hz, 1H), 7.22 (d, J = 
48.5 Hz, 1H), 6.94 (dd, J = 14.7, 7.7 Hz, 2H), 4.11 (d, J = 3.0 Hz, 1H), 3.86 (s, 3H), 2.20 
(dddd, J = 13.7, 6.9, 2.9 Hz, 1H), 1.46 (s, 3H), 1.21 (s, 3H), 1.11 (d, J = 7.0 Hz, 3H), 0.99 
(d, J = 6.8 Hz, 3H);
 13
C NMR (126 MHz, CDCl3); ppm): 168.90 (d, J = 25.6 Hz), 157.66 
(d, J = 3.7 Hz), 152.55 (s), 131.39 (d, J = 3.4 Hz), 128.11 (d, J = 5.0 Hz), 122.39 (d, J = 19.1 
Hz), 120.54 (d, J = 1.2 Hz), 111.38 (s), 84.82 (d, J = 177.7 Hz), 83.84 (s), 67.14 (s), 55.80 
(s), 29.51 (s), 28.57 (s), 21.40 (s), 21.32 (s), 16.88 (s); 
19
F NMR (564 MHz, CDCl3); 
ppm): -177.76 (d, J = 48.4 Hz, 1F); HRMS-ESI (m/z): [M+Na]+ calcd for C17H22FNO4Na, 
346.1431; found, 346.1436. 
 
O N
O O
O
O
F
 
Table 3.5.5, entry 7. The title compound was prepared from oxazolidinone 3.64 (0.160 
g, 0.50 mmol) following the standard procedure for a–monofluorination of N-
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(arylacetyl)oxazolidinones. The diastereoselectivity (dr 10:1) was determined by 
1
H NMR of 
the crude reaction mixture. The residue was purified by column chromatography (silica, 
1.5% diethyl ether in toluene – 2% diethyl ether in toluene) to afford product as a white solid 
(0.107 g, 0.32 mmol, 64%, single diastereomer). D
26 + 138.76 (c  0.83, CHCl3); 
1
H NMR 
(600 MHz, CDCl3); ppm): 7.01 (d, J = 9.2 Hz, 2H), 6.88 (d, J = 48.7 Hz, 1H), 6.80 (d, J = 
7.8 Hz, 1H), 5.98 (s, 2H), 4.01 (d, J = 3.1 Hz, 1H), 2.21 – 2.15 (m, 1H), 1.47 (s, 3H), 1.12 
(d, J = 7.0 Hz, 3H), 1.05 (s, 3H), 1.00 (d, J = 6.8 Hz, 3H);
 13
C NMR (201 MHz, CDCl3); 
ppm): 206.97 (s), 168.90 (d, J = 27.8 Hz), 152.94 (s), 148.52 (dd, J = 224.9, 2.4 Hz), 
127.10 (d, J = 20.9 Hz), 123.07 (d, J = 5.2 Hz), 108.63 (dd, J = 89.3, 2.9 Hz), 101.46 (s), 
88.54 (d, J = 180.6 Hz), 84.21 (s), 67.47 (s), 30.92 (s), 29.50 (s), 28.59 (s), 21.45 (s), 21.29 
(s), 17.00 (s); 
19
F NMR (564 MHz, CDCl3); ppm): -169.32 – -169.84 (m, 1F). HRMS-ESI 
(m/z): [M+Na]
+
 calcd for C17H20FNO5Na 360.1223; found, 360.1226 
 
O N
O O
OPh
F
 
Table 3.5.5, entry 8. The title compound was prepared from oxazolidinone 3.65 (0.184 
g, 0.50 mmol) following the standard procedure for a–monofluorination of N-
(arylacetyl)oxazolidinones. The diastereoselectivity (dr 95:5) was determined by 
1
H NMR of 
the crude reaction mixture. The residue was purified by column chromatography (silica, 1% 
diethyl ether in toluene) to afford product as a white solid (0.119 g, 0.31 mmol, 62%, single 
diastereomer). D
26 + 148.96 (c 1.0, CHCl3); 
1
H NMR (500 MHz, CDCl3); ppm): 7.31 – 
7.26 (m, 3H), 7.19 (d, J = 7.9 Hz, 1H), 7.13 (s, 1H), 7.05 (dd, J = 7.4 Hz, 1H), 6.97 (d, J = 
  277 
8.1 Hz, 1H), 6.93 (s, 1H), 6.91 (d, J = 7.9 Hz, 2H), 6.83 (s, 1H), 3.94 (d, J = 3.0 Hz, 1H), 
2.13 (dddd, J = 13.8, 6.9, 3.1 Hz, 1H), 1.40 (s, 3H), 1.05 (d, J = 7.0 Hz, 3H), 0.97 (s, 3H), 
0.94 (d, J = 6.8 Hz, 3H); 
13
C NMR (126 MHz, CDCl3); ppm): 168.53 (d, J = 26.7 Hz), 
157.57 (d, J = 1.6 Hz), 156.66 (s), 152.91 (s), 135.24 (d, J = 20.3 Hz), 130.17 (d, J = 1.6 
Hz), 129.83 (s), 123.65 (s), 123.16 (d, J = 4.6 Hz), 120.38 (d, J = 3.0 Hz), 118.96 (s), 118.79 
(d, J = 4.6 Hz), 88.50 (d, J = 180.8 Hz), 84.28 (s), 67.51 (s), 29.50 (s), 28.54 (s), 21.43 (s), 
21.28 (s), 16.99 (s);
 19
F NMR (564 MHz, CDCl3); ppm): -172.83 (d, J = 48.8 Hz, 1F). 
HRMS-ESI (m/z): [M+Na]
+
 calcd for C22H24FNO4Na, 408.1587; found, 408.1600   
 
O N
O O
F
O
N
 
Table 3.5.5, entry 9  
Preparation of TiCl2(iPrO)2·2 Et3NHCl: In a flame dried flask under argon, iPrOH (2 
equiv) was added dropwise to TiCl4 (1 equiv, 1.0 M in CH2Cl2) over 5 min at rt . The 
mixture was stirred for an additional 10 min (HCl gas evolution was observed). Et3N (2 
equiv) was then added dropwise over 10 min at rt. The mixture was stirred for an additional 
30 min (white precipitate initially forms but majority eventually redissolves into solution). 
α-Monofluorination reaction: In a separate flame dried flask under argon 
TiCl2(iPrO)22Et3NHCl (0.33 mL, ca. 1.0 M solution in CH2Cl2, 1.75 equiv) was added 
dropwise to the solution of N-acyl oxazolidinone 3.73 (0.10 g, 0.31 mmol, 1.00 equiv) in 
CH2Cl2 (0.38 mL) at 0 C and stirred for 3 min (solution should become a deep red upon 
complete addition). Et3N (86 L, 0.62 mmol, 2.0 equiv) was added dropwise to the reaction 
  278 
mixture at 0 C and stirred for 3 min. NFSI (0.195 g, 062 mmol, 2.0 equiv) was added in one 
portion to the reaction at 0 C. The reaction mixture was warmed to room temperature and 
stirred for 1 h. The reaction was filtered through a 1.5 cm silica gel plug and washed with 
dichloromethane (10 mL) and ethyl acetate (60 mL). The filtrate was then concentrated in 
vacuo. The diastereoselectivity (dr 92:8) was determined by 
1
H NMR of the crude reaction 
mixture. The residue was purified by column chromatography (silica, 4% diethyl ether in 
toluene) to afford product as a white solid (0.119 g, 0.31 mmol, 87%, mixture of 
diastereomers).
 D
21 + 115.77 (c 1.0, CHCl3);
1
H NMR (600 MHz, CDCl3) ppm): 8.13 (s, 
1H), 7.98 (s, 1H), 7.61 (s, 2H), 7.10 (d, J = 48.6 Hz, 1H), 4.03 (d, J = 2.9 Hz, 1H), 2.25 – 
2.15 (m, 1H), 1.44 (s, 3H), 1.13 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H), 0.95 (s, 3H)
 
13
C NMR (126 MHz, CDCl3) ppm): 168.69 (d, J = 27.1 Hz), 153.42 (s), 152.87 (s), 150.88 
– 150.72 (m), 140.35 (s), 130.35 (d, J = 20.8 Hz), 126.45 (d, J = 4.2 Hz), 121.22 (d, J = 4.6 
Hz), 111.40 (d, J = 1.5 Hz), 88.62 (d, J = 180.9 Hz), 84.25 (s), 67.42 (s), 29.50 (s), 28.59 (s), 
21.44 (s), 21.24 (s), 16.98 (s).
19
F NMR (564 MHz, CDCl3) ppm): -169.22 (s), -169.31 (s). 
HRMS-ESI (m/z): [M+Na]
+
 calcd for C17H19FN2O4Na, 357.1227; found, 357.1224.   
 
O N
O O
O
N
F
 
Table 3.5.5, entry 10. 
Preparation of TiCl2(OPr-i)2: In a flame-dried flask, Ti(OPr-i)4 (1.0 equiv) was added 
dropwise to TiCl4 (1.0 equiv, 1.0 M in CH2Cl2) over 5 min at rt under argon. The mixture 
was stirred for an additional 10 min. 
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α-Monofluorination reaction: In a separate flame-dried flask, TiCl2(OPr-i)2 (0.44 mL, 
ca. 2.0 M solution in CH2Cl2, 1.75 equiv) was added dropwise to the solution of N-acyl 
oxazolidinone 3.74 (0.158 g, 0.50 mmol, 1.00 equiv) in CH2Cl2 (0.38 mL) at 0 C and 
stirred for 2 min under argon. Et3N (0.14 mL, 1.0 mmol, 2.0 equiv) was added dropwise at 0 
C and the reaction mixture was stirred for 2 min. NFSI (0.315 g, 1.0 mmol, 2.0 equiv) was 
added in one portion to the reaction at 0 C. The reaction mixture was warmed to rt and 
stirred for 30 min. The reaction was filtered through a 1.5 cm silica gel plug and washed 
with dichloromethane (10 mL) and ethyl acetate (60 mL). The filtrate was then concentrated 
in vacuo. The diastereoselectivity (dr 2:1) was determined by 
1
H NMR analysis of the crude 
product. The residue was purified by column chromatography (silica, 4% diethyl ether in 
toluene) to afford product as a white solid (0.105 g, 0.32 mmol, 63%, single diastereomer. 
D
21 + 77.97 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3) ppm): 7.68 (d, J = 7.9 Hz, 1H), 
7.60 (d, J = 8.2 Hz, 1H), 7.42 (t, J = 7.8 Hz, 1H), 7.36 (t, J = 7.7 Hz, 1H), 7.06 (d, J = 50.4 
Hz, 1H), 4.30 (d, J = 3.0 Hz, 1H), 2.24 (dq, J = 6.8, 3.8 Hz, 1H), 1.59 (s, 3H), 1.53 (s, 3H), 
1.15 (d, J = 7.0 Hz, 3H), 1.02 (d, J = 6.8 Hz, 3H).
 13
C NMR (126 MHz, CDCl3) ppm): 
164.15 (d, J = 23.3 Hz), 158.11 (d, J = 21.8 Hz), 153.66 (s), 151.09 (s), 126.53 (d, J = 1.2 
Hz), 124.96 (s), 120.82 (d, J = 0.9 Hz), 111.34 (d, J = 0.9 Hz), 85.65 (s), 82.90 (d, J = 183.5 
Hz), 67.34 (s), 29.56 (s), 28.81 (s), 21.59 (s), 21.43 (s), 16.99 (s).
 19
F NMR (564 MHz, 
CDCl3) ppm): -185.48 (s), -185.57 (s). HRMS-ESI (m/z): [M+Na]
+
 calcd for 
C17H19FN2O4Na, 357.1227; found, 357.1216. 
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Table 3.5.5, entry 8. 
Preparation of TiCl2(OPr-i)2·2 Et3NHCl: In a flame dried-flask, i-PrOH (2 equiv) was 
added dropwise to TiCl4 (1 equiv, 1.0 M in CH2Cl2) over 5 min at rt under argon. The 
mixture was stirred for an additional 10 min (HCl gas evolution was observed). Et3N (2 
equiv) was then added dropwise over 10 min at rt. The mixture was stirred for an additional 
30 min (white precipitate initially forms but eventually redissolves). 
α-Monofluorination reaction: In a separate flame-dried flask, TiCl2(OPr-i)22Et3NHCl 
(0.33 mL, ca. 1.0 M solution in CH2Cl2, 1.75 equiv) was added dropwise to the solution of 
N-acyl oxazolidinone 3.67 (50 mg, 0.19 mmol, 1.00 equiv) in CH2Cl2 (0.38 mL) at 0 C 
under argon, and the resulting mixture was stirred for 2 min (solution should become a deep 
red upon complete addition). Et3N (53 L, 0.38 mmol, 2.0 equiv) was added dropwise at 0 
C and the reaction mixture was stirred for 2 min. NFSI (0.12 g, 0.38 mmol, 2.0 equiv) was 
added in one portion to the reaction at 0 C. The reaction mixture was warmed to rt and 
stirred for 30 min. The reaction was filtered through a 1.5 cm silica gel plug and washed 
with dichloromethane (10 mL) and ethyl acetate (60 mL). The filtrate was then concentrated 
in vacuo. The diastereoselectivity (10:1) was determined by 
1
H NMR analysis of the crude 
mixture of products. The residue was purified by column chromatography (silica, 4% diethyl 
ether in toluene) to afford product as a white solid (29 mg, 0.103 mmol, 54%, single 
diastereomer).
 D
20 + 61.94 (c 1.0, CHCl3); 
1
H NMR (600 MHz, CDCl3) ppm): 7.65 (d, J 
= 4.0 Hz, 1H), 7.41 (d, J = 1.1 Hz, 1H), 6.99 (d, J = 48.6 Hz, 1H), 6.52 (s, 1H), 4.02 (d, J = 
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2.5 Hz, 1H), 2.22 – 2.13 (m, 1H), 1.48 (s, 3H), 1.10 (d, J = 5.8 Hz, 6H), 1.00 (d, J = 6.6 Hz, 
3H).
 13
C NMR (126 MHz, CDCl3) ppm): 168.55 (d, J = 27.2 Hz), 153.03 (s), 143.80 (d, J 
= 7.4 Hz), 143.29 (d, J = 8.7 Hz), 118.94 (d, J = 24.2 Hz), 108.79 (s), 84.31 (s), 82.04 (dd, J 
= 177.6, 10.1 Hz), 67.30 (d, J = 12.0 Hz), 29.50 (s), 28.58 (s), 21.44 (s), 21.26 (d, J = 2.7 
Hz), 16.96 (d, J = 4.1 Hz).
19
F NMR (564 MHz, CDCl3) ppm): -176.65 (d, J = 4.8 Hz), -
176.73 (d, J = 4.8 Hz). HRMS-ESI (m/z): [M+Na]
+
 calcd for C14H48FNO4Na, 306.1118; 
found, 306.1122.   
 
O N
O O
F
NaBH4, aq THF, r.t.
1 h
95%
OH
F
O NH
O
 
(S)-2-Fluoro-2-phenylethanol. Sodium borohydride (63.7 mg, 1.68 mmol) was added to 
a solution of the substrate (0.175 g, 0.561 mmol) in a 3:1 mixture of THF:H2O (8.50 mL) at 
0 °C and the reaction mixture was stirred for 10 min. The reaction mixture was warmed to rt 
and stirred an additional 1 h. The reaction mixture was quenched with aqueous 1 M HCl (5 
mL). The layers were separated. The aqueous layer was extracted with diethyl ether (3 x 5 
mL). The organic layers were combined and washed with brine, dried with sodium sulfate, 
concentrated in vacuo, and the residue purified by column chromatography (silica, 50% 
diethyl ether in pentane - 80% diethyl ether in pentane) to afford the desired alcohol (72.2 
mg, 0.52 mmol, 93%) and the purified oxazolidinone (83 mg, 0.53 mmol, 95%). D
23 + 
51.03 (c 1.0, CHCl3). 
1
H NMR (600 MHz, CDCl3) ppm): 7.38 (dt, J = 17.5, 7.3 Hz, 5H), 
5.57 (ddd, J = 48.7, 7.8, 2.8 Hz, 1H), 3.98 – 3.89 (m, 1H), 3.83 (dd, J = 30.1, 12.5 Hz, 1H), 
2.38 (s, 1H
13
C NMR (126 MHz, CDCl3) ppm): 136.34 (d, J = 19.6 Hz), 128.74 (d, J = 1.7 
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Hz), 128.54 (s), 125.68 (d, J = 7.0 Hz), 94.80 (d, J = 171.9 Hz), 66.48 (d, J = 24.7 Hz). 
19
F 
NMR (564 MHz, CDCl3) ppm): -186.89 (ddd, J = 49.5, 30.6, 19.1 Hz). HRMS-EI (m/z): 
[M]
+
 calcd for C8H9FO, 140.0637; found, 140.0634. 
 
Determination of er for the product: 2-Naphthoyl chloride (3.0 equiv.) was added to a 
solution of the purified alcohol, triethylamine (3.0 equiv.), and 4-dimethylaminopyridine 
(0.5 equiv.) in dichloromethane (0.1 M) at 0 °C. After 10 min, the reaction was warmed to rt 
and stirred for 30 min. The reaction was quenched with aqueous ammonium chloride and the 
layers were separated. The aqueous layer was extracted with ethyl acetate (3 x 10 mL). The 
combined organic layers were washed with brine, dried with sodium sulfate, concentrated in 
vacuo, and purified by column chromatography chromatography (silica, 15% ethyl acetate in 
hexanes) to afford the desired naphthoyl ester derivative. HPLC analysis of the 2-naphthoyl 
ester derivative (OJ-H, 2.5% 
i
PrOH - hexanes, 1.0 mL/min, 254 nm) indicated er of 0.8:99.2: 
RT (minor) = 37.5 minutes, RT (major) = 45.5 minutes. 
 
O N
O O
F
LiOH, aq H2O2,
H2O, THF r.t., 1 h
96%
O
F
O NH
O
HO
 
(S)-2-Fluoro-2-phenyacetic acid. Lithium hydroxide monohydrate (32.1 mg, 0.765 
mmol) was added to a solution of the substrate (0.117 g, 0.373 mmol), hydrogen peroxide 
(30%, 0.40 mL), and water (0.40 mL) in THF (1.50 mL) at 0 °C, and the mixture was stirred 
for 5 min. The reaction was warmed to room temperature and stirred for 1 h. The reaction 
was quenched with aqueous sodium sulfite (1.5 M, 3.0 mL) and HCl (1 M, 3.0 mL) and 
allowed to stir for 5 min until two transparent layers were visible. The layers were separated 
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and the aqueous layer was extracted with diethyl ether (3 x 10 mL). The organic layer was 
extracted with aqueous sodium hydroxide (3 M, 3 x 3 mL) and water (3 x 5 mL). The 
aqueous extractions were combined and set aside. The organic layer was washed with HCl (1 
M), brine, dried with sodium sulfate, and concentrated in vacuo to recover the oxazolidinone 
auxiliary (56.6 mg, 0.36 mmol, 97%). The previously saved aqueous layers were acidified 
with aqueous HCl (1 M). The aqueous layer was extracted with diethyl ether (3 x 30 mL). 
The combined organic layers were washed with brine, dried with sodium sulfate, and 
concentrated in vacuo to afford the desired pure carboxylic acid (55.2 mg, 0.358 mmol, 
96%). D
21 + 116.06 (c 0.843, CHCl3); 
1
H NMR (600 MHz, CDCl3) ppm): 9.23 (s, 1H), 
7.46 (d, J = 34.7 Hz, 5H), 5.83 (d, J = 47.4 Hz, 1H). 
13
C NMR (151 MHz, CDCl3) ppm): 
174.06 (d, J = 28.0 Hz), 133.42 (d, J = 20.5 Hz), 129.90 (d, J = 30.1 Hz), 128.87 (d, J = 31.6 
Hz), 126.65 (d, J = 33.8 Hz), 88.78 (dd, J = 186.7, 15.5 Hz). 
19
F NMR (564 MHz, CDCl3) 
ppm): -180.78 (d, J = 47.8 Hz). HRMS-EI (m/z): [M]+ calcd for C8H7FO2, 154.0430; 
found, 154.0434. 
 
Determination of er for the acid: A solution of the (S)-2-fluoro-2-phenyacetic acid (1.0 
equiv) in diethyl ether (0.2 M) was added to a solution of lithium aluminum hydride (4.0 
equiv) in diethyl ether (0.5 M) at 0 °C and the mixture was stirred for 10 min. The reaction 
mixture was warmed to room temperature and stirred for 10 min and quenched using the 
Feiser workup: the reaction was cooled to 0 ˚C; H2O (1:1 volume/weight to LiAlH4) was 
added dropwise to the reaction (CAUTION: highly exothermic) and stirred for 5 min. A 
solution (1:1 by volume/weight to LiAlH4) of aqueous NaOH (15 wt% NaOH in H2O) was 
added dropwise and stirred for 5 min. Finally H2O (3:1 by volume/weight to LiAlH4) was 
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added dropwise. The solution was warmed to room temperature and allowed to stir for 1 h, 
until a white precipitate forms. The reaction mixture was filtered and concentrated in vacuo. 
No further purification was done. 
2-Naphthoyl chloride (5.0 equiv.) was added to a solution of the crude alcohol, 
triethylamine (5.0 equiv.), and 4-dimethylaminopyridine (1.0 equiv.) in dichloromethane 
(0.1 M) at 0 °C. After 10 min, the reaction was warmed to room temperature and stirred for 
30 min. The mixture was quenched with aqueous ammonium chloride and the layers were 
separated. The aqueous layer was extracted with ethyl acetate (3 x 10 mL). The combined 
organic layers were washed with brine, dried with sodium sulfate, concentrated in vacuo, 
and purified by column chromatography (silica, 12.5% ethyl acetate in hexanes) to afford the 
desired naphthoyl ester derivative. HPLC analysis of the 2-naphthoyl ester derivative (OJ-H, 
2.5% 
i
PrOH - hexanes, 1.0 mL/min, 254 nm) indicated er 1.1:98.9: RT (minor) = 35.9 
minutes, RT (major) = 46.4 minutes. 
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Chapter 4 
 
Regio- and Stereocontrol in Rhenium-Catalyzed Transposition of Allylic Alcohols 
 
4-1: Introduction 
Direct catalytic transposition of allylic alcohols is a powerful approach to the synthesis 
of complex hydroxylated organic compounds.
126
 Several transition metal catalysts have been 
developed for this purpose, including vanadium,
127
 molybdenum,
127
 and rhenium 
reagents.
128
 Among these, rhenium(VII) oxide and triphenylsilyl perrhenate have been found 
to be superior in terms of reactivity and chemoselectivity, displaying high activity at low 
temperatures with no competitive oxidation observed with some of the other catalysts. One 
drawback of the reversible process (eq 1) is a general lack of regioselectivity;
129
 
stereoselectivity in the transposition of primary allylic alcohols is also low. 
 
We describe a practical method that allows for control of the regio- and stereoselectivity 
in the rhenium-catalyzed transposition of allylic alcohols, expanding the scope of the 
reaction for the stereoselective synthesis of complex molecules.
130
 
4-2: Initial Screen and Reaction Optimization 
In our initial experiments, rearrangement of substrate 4.1 in the presence of Re2O7 (2.5 
mol %) occurred with low regio- and stereoselectivity as expected, delivering 4.2 with 60% 
conversion as a 3:2 mixture of diastereomers (Scheme 4.2.1). We hypothesized that the 
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reaction medium must be slightly acidic due to formation of a catalytic amount of perrhenic 
acid (pKa= 1.25)
131
 upon interaction of rhenium(VII) oxide with the substrate and/or 
adventitious water.
132
 In the presence of a catalytic acid the rearranged product can in 
principle be trapped as an acetal or ketal, and then the 1,3-syn diastereomer should be 
favored on thermodynamic grounds. Remarkably, upon exposure of 4.1 to benzaldehyde 
dimethyl acetal and Re2O7 (2.5 mol %), essentially a single product was formed in 94% yield 
after 20 h at room temperature. Thus, the rhenium catalyst performs a dual catalytic function 
as a transition metal catalyst for the hydroxyl group transposition and as an acid catalyst for 
acetal formation. 
Scheme 4.2.1 Re-Catalyzed Transposition of 4.1
 
 
Screening of the reaction parameters demonstrated that although a number of solvents 
can be used (toluene, Et2O, THF, CH2Cl2),
133
 dichloromethane provides the best results in 
terms of reaction rate. Typically, reactions are characterized by a rapid formation of a 
diastereomeric mixture of rearranged diol acetals (within ∼20 min at room temperature) 
followed by slow equilibration of the acetals to the 1,3-syn product (4.3). 
The influence of reaction time with alternative rhenium catalysts is summarized in Table 
4.2.1. With all three catalysts studied, methyltrioxorhenium (MTO), Ph3SiOReO3, and 
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Re2O7, the rearrangement/acetalization was complete within 3 h at room temperature. As 
expected, MTO is the least reactive catalyst.
127c,134 
Notably, with all of the three rhenium 
catalysts the initial acetal formation was followed by equilibration to 4.3. The highest rate of 
equilibration was observed with Re2O7, generating 4.3 with >98% selectivity after 20 h. 
With Ph3SiOReO3, a high level of selectivity (96:4) was also reached after 20 h at room 
temperature. 
Table 4.2.1 Influence of the Catalyst and Reaction Time 
 
Entry Catalyst (mol %) Time Conversion
a
 (%) 4.2:4.3
a 
1 MeReO3 (5) 40 min 45 36:64 
2 MeReO3 (5) 3 h 100 40:60 
3 MeReO3 (5) 20 h 100 63:37 
4 Ph3SiOReO3 (5) 40 min 100 65:35 
5 Ph3SiOReO3 (5) 3 h 100 87:13 
6 Ph3SiOReO3 (5) 20 h 100 96:4 
7 Re2O7 (2.5) 40 min 100 80:20 
8 Re2O7 (2.5) 3 h 100 91:9 
9 Re2O7 (2.5) 20 h 100 >98:2 
(a) Measured by 500 MHz NMR spectroscopy using a crude mixture of products. 
As illustrated in Scheme 4.1.2, the highly stereo- and regioselective transposition can be 
achieved with other commonly employed diol masking groups. Acetonide formation 
occurred in an 81% yield (96% ds), and the p-methoxyphenyl (PMP) acetal 4.6 was isolated 
in a 95% yield with greater than 98% diastereoselectivity. 
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Scheme 4.2.2 Formation of the Acetonide and PMP-Acetals
 
 
4-3: Substrate Scope 
The reaction scope with a range of substrates of higher complexity was explored next 
(Table 4.3.1). Migration of the resident benzylidene group accompanying the transposition 
was possible as illustrated in entry 1 (Table 4.3.1). Desilylation can be accomplished 
simultaneously without a need for an additional step (Table 4.3.1, entry 2). A Cbz-protected 
primary amine is compatible with the reaction conditions, and the relative stereochemistry of 
the amino alcohol has no influence on the stereoselectivity of the reaction (Table 4.3.1, 
entries 3, 4). Upon prolonged exposure (20 h), a complete removal of acid sensitive PMB 
and TBDPS groups was observed, which were replaced with the benzylidene acetal (Table 
4.3.1, entries 5, 6). A more oxidized p-methoxybenzoyl (MBz) group and shorter reaction 
times (4 h) resulted in a much improved conservation of the original protecting groups 
(Table 4.3.2, entries 1, 2). Functionalized tetrahydropyran substrates underwent the 
transposition reaction with the generally observed high regiocontrol and high 
stereoselectivity (Table 4.3.2, entries 3, 4). Thermodynamically disfavored 1,1-disubstituted 
alkenes can be readily prepared in high yield (Table 4.3.2, entry 5). 
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Table 4.3.1 Scope of the Re-Catalyzed Transposition/Acetalization with Complex 
Substrates
a 
 
(a) Reactions were performed in CH2Cl2 (∼0.2 M) with 2.5 mol % of Re2O7 and 2.0 equiv of PhCH(OMe)2 or 
4-MeOPhCH(OMe)2; dr is determined by 500 MHz 
1
H NMR.  
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Table 4.3.2 Scope of the Re-Catalyzed Transposition/Acetalization with Complex 
Substrates
a 
 
(a) Reactions were performed in CH2Cl2 (∼0.2 M) with 2.5 mol % of Re2O7 and 2.0 equiv of PhCH(OMe)2 or 
4-MeOPhCH(OMe)2; dr is determined by 500 MHz 
1
H NMR. (b) Overall yield after treatment with TBAF. (c) 
R═H/R═TBS 5.3:1. 
An intriguing aspect of the reaction is that the transposition and acetalization are 
typically complete in an initially nonstereoselective manner within minutes (less than 30 
min), followed by relatively slow isomerization to the preferred stereoisomer. In a control 
experiment, when a 6:3:1 diastereomeric mixture of benzylidene acetals 4.4 was subjected to 
the standard reaction conditions (dry CH2Cl2, argon atmosphere, 2.5 mol % Re2O7, rt, 20 h), 
a single stereoisomer (4.3) was isolated in 90% yield. In contrast, treatment of the same 
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mixture with p-TsOH (5 mol %, dry CH2Cl2, argon atmosphere, rt, 21 h) resulted in no 
change. 
As was also noted by Grubbs and Rychnovsky,
128b,131
 addition of 0.2 equiv of 2,6-di-tert-
butyl-4-methylpyridine (DTMP) completely suppressed the transposition and acetalization 
with either Re2O7 or Ph3SiOReO3. Addition of Bu4NOAc or a proton sponge also suppressed 
the reaction. These results may be explained either by increasing the pH of the medium or by 
a modification of the catalyst through irreversible complexation.
128b,131
 To conclusively 
establish reactivity in the absence of acid or alternative ligands, we prepared the catalyst in 
situ using an excess of strongly basic Me3SiOK (0.35 equiv) and Re2O7 (0.20 equiv) in 
THF.
135
 As shown in Scheme 4.3.1, the system maintained full catalytic activity, indicating a 
possibility where the acetal formation is likely due to the Lewis acidic character of 
trimethylsilyl perrhenate. 
Scheme 4.3.1 Reactivity in the Absence of a Brønsted Acid
 
 
In summary, we developed a method that allows the control of regio- and 
stereoselectivity by a neighboring hydroxyl group in the Re-catalyzed transposition of allylic 
alcohols with accompanying formation of acetals. 
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4-4: Rhenium-Catalyzed Transposition of Allylic Alcohols Supporting Information 
 
OH
OAc
OH
AcO OAc
Grubbs II catalyst (0.7 mol%)
(10 eq)
CH2Cl2
 
Typical procedure for cross metathesis: (E)-5-Cyclohexyl-5-hydroxypent-2-enyl acetate. 
Grubbs II catalyst (0.116 g, 0.136 mmol) was added to a solution of the substrate
136
 (3.00 g, 19.4 
mmol) and cis-1,4-diacetoxy-2-butene (33.5 g, 0.19 mol) in degassed dichloromethane (280 ml).  
The reaction vessel was sealed and heated at 40 °C. After 4 h, the reaction vessel was removed 
from the oil bath and continued to stir at room temperature for 12 h.  The reaction was 
concentrated on a rotary evaporator, and cis-1,4-diacetoxy-2-butene was distilled off.  The 500 
MHZ 
1
H NMR of the crude mixture indicated a 5:1 selectivity favoring the E-isomer. The 
residue was purified by column chromatography (silica, 15% (500 ml) to 20% (500 ml) to 30% 
EtOAc – hexanes) delivering the product (3.51 g, 15.5 mmol, 80%).  1H NMR (500 MHz, 
CDCl3); ppm): 5.81 (ddd, J1=15.0 Hz, J2=J3=6.5 Hz, 1H); 5.67 (ddd, J1=15.0 Hz, J2=J3=6.0 
Hz, 1H); 4.54 (d, J=6.0 Hz, 2H); 3.40 (bs, 1H); 2.34-2.28 (m, 1H); 2.19-2.11 (m, 1H); 2.06 (m, 
3H); 1.84 (d, J=12.0 Hz, 1H); 1.80-1.72 (m, 2H); 1.68-1.61 (m, 2H); 1.51 (bs, 1H); 1.38-1.31 (m, 
1H); 1.28-0.97 (m, 5H). 
13
C NMR (125 MHz, CDCl3); ppm): 171.1, 132.9, 127.3, 75.2, 65.2, 
43.4, 37.4, 29.3, 28.2, 26.7, 26.5, 26.3, 21.2. HRMS (ESI) calcd for C13H22O3Na [M+Na] 
249.1467, found 249.1474. 
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OH
OAc
OH
OH
K2CO3 (1.5 eq)
MeOH
 
Typical procedure for deacetylation: (E)-5-Cyclohexylpent-2-ene-1,5-diol. Potassium 
carbonate (3.22 g, 23.3 mmol) was added to a solution of the substrate (3.51 g, 15.5 mmol) in 
methanol (78 ml) at 0 °C.  After 10 min, the reaction was warmed to rt and continued to stir for 1 
h 20 min.  Dilute with water and ethyl acetate. The mixture was extracted with ethyl acetate 
(4x30 ml), and the organic layers were washed with brine, dried with sodium sulfate, 
concentrated, and the residue was purified by column chromatography (silica, 60% to 80% to 
100% EtOAc – hexanes) delivering the product (2.52 g, 13.7 mmol, 88%). IR (cm-1) 3306.4, 
2925.5, 1668.1, 1095.4; 
1
H NMR (500 MHz, CDCl3); ppm): 5.79-5.70 (m, 2H); 4.16-4.10 (m, 
2H); 3.42-3.37 (m, 1H); 2.34-2.29 (m, 1H); 2.17-2.11 (m, 1H); 1.87-1.82 (m, 1H); 1.79-1.74 (m, 
2H); 1.70-1.64 (m, 2H); 1.53 (bs, 1H); 1.45-1.40 (m, 1H); 1.39-1.32 (m, 1H); 1.29-0.97 (m, 5H). 
13
C NMR (125 MHz, CDCl3); ppm): 132.3, 129.6, 75.4, 63.4, 43.4, 37.2, 29.2, 28.4, 26.7, 
26.4, 26.3. HRMS (ESI) calcd for C11H20O2Na [M+Na] 207.1361, found 207.1356. 
 
OH
OH
OH OH
Re2O7 (2.5 mol%), CH2Cl2, rt, 3 h
 
1-Cyclohexylpent-4-ene-1,3-diol, mixture of diastereomers. Rhenium(VII) oxide (6 mg, 
0.013 mmol) was quickly weighed out into a flame-dried flask.  The flask was evacuated and 
backfilled with argon (x3). Dichloromethane (2 ml) was added to the flask.  The substrate (92 
mg, 0.50 mmol) in dichloromethane (3 ml total with rinses) was added to the reaction vessel. 
After 3 h of stirring at rt, saturated aqueous sodium bicarbonate was added and the biphasic 
mixture was stirred vigorously for 10 min. The aqueous layer was extracted with 
  379 
dichloromethane (3x10 ml).  The combined organic layers were dried with sodium sulfate, 
concentrated, and the residue was purified by column chromatography (silica, 40% EtOAc – 
hexanes) delivering the product (55.3 mg, 0.300 mmol, 60%). The remaining starting material 
was not collected.  
1
H NMR (500 MHz, CDCl3); ppm): 5.94 (ddd, J1=17.0 Hz, J2=10.5 Hz, 
J3=5.5 Hz, 0.4H); 5.89 (ddd, J1=17.5 Hz, J2=10.5 Hz, J3=6.5 Hz, 0.6H); 5.30 (ddd, J=17.0 Hz, 
J2=J3=1.5 Hz, 0.4H); 5.26 (ddd, J1=17.5 Hz, J2=J3=1.5 Hz, 0.6H); 5.14 (ddd, J1=11.0 Hz, 
J2=J3=1.5 Hz, 0.4H); 5.10 (ddd, J1=10.5 Hz, J2=1.5 Hz, 0.6H); 4.47 (bs, 0.4H); 4.36 (bs, 0.6H); 
3.72-3.64 (m, 1H); 2.95 (s, 0.6H); 2.63 (s, 0.6H); 2.50 (d, J=4.5 Hz, 0.4H); 2.11 (d, J=3.5 Hz, 
0.4H); 1.86-1.53 (m, 7H); 1.39-1.31 (m, 1H); 1.28-0.95 (m, 5H). LRMS (ESI) calcd for 
C11H20O2Na [M+Na] 207, found 207. 
 
OH OH
TsOH (5 mol%), PhCH(OMe)2 (3 eq), CH2Cl2, rt, 20 h
O O
Ph
 
4-Cyclohexyl-2-phenyl-6-vinyl-1,3-dioxane, mixture of diastereomers. p-Toluenesulfonic 
acid (3 mg, 0.015 mmol) was added to a solution of the substrate (55 mg, 0.300 mmol), and 
benzaldehyde dimethyl acetal (0.14 ml, 0.90 mmol) in dichloromethane (3.0 ml). After 20 h of 
stirring at rt, saturated aqueous sodium bicarbonate was added and the biphasic mixture stirred 
vigorously for 10 min. The aqueous layer was extracted with dichloromethane (3x20 ml).  The 
combined organic layers were dried with sodium sulfate, concentrated, and the residue was 
purified by column chromatography (silica, 5% EtOAc – hexanes) delivering the product (65.5 
mg, 0.240 mmol, 80%) as a 6:3:1 mixture of three diastereomers as determined by 500 MHz 
1
H 
NMR.  
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O O
Ph
O O
Ph
Re2O7 (2.5 mol%), CH2Cl2, rt, 21 h
 
cis,cis-4-Cyclohexyl-2-phenyl-6-vinyl-1,3-dioxane. Rhenium(VII) oxide (6.7 mg, 13.7 
-dried flask.  The flask was evacuated and backfilled 
with argon (x3). Dichloromethane (2.5 ml) was added to the flask.  The substrate (0.150 g, 0.551 
mmol) in dichloromethane (3 ml total with rinses) was added to the reaction vessel. After 21 h of 
stirring at rt, saturated aqueous sodium bicarbonate was added and the biphasic mixture stirred 
vigorously for 10 min. The aqueous layer was extracted with dichloromethane (3x10 ml).  The 
combined organic layers were dried with sodium sulfate, concentrated, and the residue was 
purified by column chromatography (silica, 5% EtOAc – hexanes) delivering the product (0.136 
mg, 0.498 mmol, 90%). IR (cm
-1
) 3423.0, 3035.4, 2926.5, 1451.17, 1273.6; 
1
H NMR (500 MHz, 
CDCl3); ppm): 7.55-7.53 (m, 2H); 7.38-7.30 (m, 3H); 5.95 (ddd, J1=17.0 Hz, J2=10.5 Hz, 
J3=5.5 Hz, 1H); 5.57 (s, 1H); 5.35 (ddd, J1=17.5 Hz, J2=J3=1.5 Hz, 1H); 5.17 (ddd, J1=11.0 Hz, 
J2=J3=1.5 Hz, 1H); 4.33 (dddd, J1=10.0 Hz, J2=5.5 Hz, J3=3.0 Hz, J4=1.5 Hz, 1H); 3.59 (ddd, 
J1= 11.0 Hz, J2=7.0 Hz, J3=2.5 Hz, 1H); 2.04-2.02 (m, 1H); 1.78-1.75 (m, 3H); 1.70-1.67 (m, 
2H); 1.57-1.50 (m, 2H); 1.30-1.13 (m, 3H); 1.11-1.01 (m, 2H). 
13
C NMR (125 MHz, CDCl3); 
ppm): 139.2, 138.4, 128.7, 128.3, 126.4, 115.5, 100.7, 81.2, 77.7, 42.8, 34.2, 29.1, 28.4, 26.8, 
26.3, 26.2. HRMS (ESI) calcd for C18H24O2Na [M+Na] 295.1674, found 295.1674. 
 
OH
OH
O O
Re2O7 (2.5 mol%), PhCH(OMe)2 (2 eq), CH2Cl2, rt, 20h
Ph
 
Typical procedure for the stereoselective Re-catalyzed transposition/ acetalization: 
cis,cis-4-Cyclohexyl-2-phenyl-6-vinyl-1,3-dioxane. Rheni-um(VII) oxide (12 mg, 0.025 mmol) 
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was quickly weighed out into a flame-dried flask.  The flask was evacuated and backfilled with 
argon (x3), and dichloromethane (5 ml) was added.  The substrate (0.184 g, 1.00 mmol) in 
dichloromethane (5 ml total with rinses) was added to the reaction vessel followed by addition of 
benzaldehyde dimethyl acetal (0.30 ml, 2.00 mmol). After 20 h of stirring at rt, saturated aqueous 
sodium bicarbonate was added and the biphasic mixture stirred vigorously for 10 min. The 
aqueous layer was extracted with dichloromethane (3x20 ml).  The combined organic layers were 
dried with sodium sulfate, concentrated, and the residue was purified by column chromatography 
(silica, 5% EtOAc – hexanes) delivering the product (0.255 g, 0.936 mmol, 94%). IR (cm-1) 
3423.0, 3035.4, 2926.5, 1451.17, 1273.6; 
1
H NMR (500 MHz, CDCl3); ppm): 7.55-7.53 (m, 
2H); 7.38-7.30 (m, 3H); 5.95 (ddd, J1=17.0 Hz, J2=10.5 Hz, J3=5.5 Hz, 1H); 5.57 (s, 1H); 5.35 
(ddd, J1=17.5 Hz, J2=J3=1.5 Hz, 1H); 5.17 (ddd, J1=11.0 Hz, J2=J3=1.5 Hz, 1H); 4.33 (dddd, 
J1=10.0 Hz, J2=5.5 Hz, J3=3.0 Hz, J4=1.5 Hz, 1H); 3.59 (ddd, J1= 11.0 Hz, J2=7.0 Hz, J3=2.5 
Hz, 1H); 2.04-2.02 (m, 1H); 1.78-1.75 (m, 3H); 1.70-1.67 (m, 2H); 1.57-1.50 (m, 2H); 1.30-1.13 
(m, 3H); 1.11-1.01 (m, 2H). 
13
C NMR (125 MHz, CDCl3); ppm): 139.2, 138.4, 128.7, 128.3, 
126.4, 115.5, 100.7, 81.2, 77.7, 42.8, 34.2, 29.1, 28.4, 26.8, 26.3, 26.2. HRMS (ESI) calcd for 
C18H24O2Na [M+Na] 295.1674, found 295.1674.  
 
OH
OH
O O
Re2O7 (2.5 mol%), CH2Cl2, rt, 20 h PMP
MeO
OMe
OMe
(2 eq)
 
cis,cis-4-Cyclohexyl-2-(4-methoxyphenyl)-6-vinyl-1,3-dioxane. Rhenium(VII) oxide (12 
mg, 0.025 mmol) was quickly weighed out into a flame-dried flask.  The flask was evacuated and 
backfilled with argon (x3).  To the flask was added dichloromethane (5 ml).  The substrate 
(0.184 g, 1.00 mmol) in dichloromethane (5 ml total with rinses) was added to the reaction vessel 
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followed by addition of anisaldehyde dimethyl acetal (0.34 ml, 2.00 mmol). After 20 h of stirring 
at rt, saturated aqueous sodium bicarbonate was added and the biphasic mixture stirred 
vigorously for 10 min. The aqueous layer was extracted with dichloromethane (3x20 ml).  The 
combined organic layers were dried with sodium sulfate, concentrated, and the residue was 
purified by column chromatography (silica, 5% EtOAc – hexanes) delivering the product (0.285 
g, 0.942 mmol, 94%). IR (cm
-1
) 2926.5, 1615.1, 1517.7, 1248.7; 
1
H NMR (500 MHz, CDCl3); 
ppm): 7.47-7.43 (m, 2H); 6.89-6.87 (m, 2H); 5.94 (ddd, J1=17.5 Hz, J2=10.5 Hz, J3=5.5 Hz, 
1H); 5.52 (s, 1H); 5.33 (ddd, J1=17.5 Hz, J2=J3=1.5 Hz, 1H) 5.15 (ddd, J1=10.5 Hz, J2=J3=1.5 
Hz, 1H); 4.30 (dddd, J1=9.5 Hz, J2=5.5 Hz, J3=2.5 Hz, J4=1.0 Hz, 1H); 3.80 (s, 3H); 3.57 (ddd, 
J1=11.5 Hz, J2=7.0 Hz, J3=2.5 Hz, 1H); 2.0 (bd, J=13.0 Hz, 1H); 1.77-1.71 (m, 3H); 1.70-1.64 
(m, 2H); 1.55-1.48 (m, 2H); 1.30-1.12 (m, 3H); 1.10-0.98 (m, 2H). 
13
C NMR (125 MHz, 
CDCl3); ppm): 159.9, 138.4, 131.8, 127.6, 115.5, 113.7, 100.6, 81.1, 77.6, 55.5, 42.8, 34.1, 
29.0, 28.4, 26.8, 26.3, 26.2. HRMS (ESI) calcd for C19H26O3Na [M+Na] 325.1780, found 
325.1791. 
 
OH
OH
O ORe2O7 (5 mol%), 2,2-dimethoxypropane (4 eq)
CH2Cl2, 40 
oC, 20 h
 
cis-4-Cyclohexyl-2,2-dimethyl-6-vinyl-1,3-dioxane. Rhenium(VII) oxide (24 mg, 0.050 
mmol) was quickly weighed out into a flame-dried flask.  The flask was evacuated and backfilled 
with argon (x3). Dichloromethane (5 ml) was added to the flask.  The substrate (0.184 g, 1.00 
mmol) in dichloromethane (5 ml total with rinses) was added to the reaction vessel followed by 
addition of 2,2-dimethoxypropane (0.60 ml, 4.00 mmol). The reaction vessel was sealed and 
heated at 40 °C. After 20 h, the reaction vessel was allowed to cool to room temperature, and 
saturated aqueous sodium bicarbonate was added. The biphasic mixture stirred vigorously for 10 
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min. The aqueous layer was extracted with dichloromethane (3x20 ml).  The combined organic 
layers were dried with sodium sulfate, concentrated, and the residue was purified by column 
chromatography (silica, 5% EtOAc – hexanes) delivering the product (0.182 g, 0.811 mmol, 
81%). IR (cm
-1
) 2924.5, 1645.0, 1026.9;
1
H NMR (500 MHz, CDCl3); ppm): 5.83 (ddd, 
J1=16.5 Hz, J2=10.0 Hz, J3=5.5 Hz, 1H); 5.25 (ddd, J1=17.0 Hz, J2=J3=1.0 Hz, 1H); 5.11 (ddd, 
J1=10.5 Hz, J2=J3=1.0 Hz, 1H); 4.31 (dddd, J1=10.0 Hz, J2=6.0 Hz, J3=2.5 Hz, J4=1.5 Hz, 1H); 
3.57 (ddd, J1=11.5 Hz, J2=7.0 Hz, J3=2.5 Hz, 1H); 1.94-1.88 (m, 1H); 1.75-1.64 (m, 4H); 1.53 
(ddd, J1=13.0 Hz, J2=J3=3.0 Hz, 1H); 1.45 (s, 3H); 1.41 (s, 3H); 1.37-1.09 (m, 5H); 0.99-0.88 
(m, 2H). 
13
C NMR (125 MHz, CDCl3); ppm): 139.3, 115.4, 98.7, 73.2, 70.7, 43.0, 34.1, 30.5, 
29.1, 28.2, 26.9, 26.3, 26.2, 20.0. LRMS (CI) calcd for C14H24O2Na [M+H] 225, found 225. 
 
HO
OH O
OEt
PhCH(OMe)2 (2 eq), TsOH (5 mol%), CH2Cl2 O
OEt
O
O
Ph
 
Ethyl 2-(2-phenyl-1,3-dioxolan-4-yl)acetate. p-Toluenesulfonic acid (0.118 g, 12.4 mmol) 
was added to a solution of the substrate
137
 (1.84 g, 12.4 mmol) and benzaldehyde dimethyl acetal 
(5.60 ml, 37.2 mmol) in dichloromethane (41 ml) at rt.  After 30 min, saturated aqueous sodium 
bicarbonate was added. The aqueous layer was extracted with dichloromethane (2x30 ml).  The 
combined organic layers were dried with sodium sulfate, concentrated, and the residue was 
purified by column chromatography (silica, 10%  20% EtOAc – hexanes) delivering the 
product (1.80 g, 7.62 mmol, 61%). IR (cm
-1
) 3064.3, 2935.1, 1717.3, 1654.6, 1602.6, 1273.8; 
1
H 
NMR (500 MHz, CDCl3); ppm): 7.49-7.45 (m, 2H); 7.41-7.35 (m, 3H); 5.95 (s, 0.5H); 5.81 (s, 
0.5H); 4.66-4.60 (m, 1H); 4.37 (dd, J1=8.0 Hz, J2=5.5 Hz, 0.5H); 4.222 (dd, J1=8.5 Hz, J2=6.5 
Hz, 0.5H); 4.20-4.13 (m, 2H); 3.87 (dd, J1=8.0 Hz, J2=5.5 Hz, 0.5H); 3.75 (dd, J1=8.5 Hz, 
J2=6.5 Hz, 0.5H); 2.85 (dd, J1=16.0 Hz, J2=6.0 Hz, 1H); 2.63 (ddd, J1=16.0 Hz, J2=J3=8.0 Hz, 
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1H); 1.28 (dd, J1=J2=6.5 Hz, 1.5H); 1.27 (dd, J1=J2=7.0 Hz, 1.5H). LRMS (ESI) calcd for 
C13H16O4Na [M+Na] 259.1, found 259.1. 
 
O
OEt
O
O
Ph
1.i-Bu2AlH (1.05 eq), CH2Cl2
2. NaH, (EtO)2P(O)CH2CO2Et, THF
O
O
Ph
O
OEt  
(E)-Ethyl 4-(2-phenyl-1,3-dioxolan-4-yl)but-2-enoate. Diisobutylaluminum hydride (1 M 
in toluene, 6.45 ml, 6.44 mmol) was added to a solution of the substrate (1.45 g, 6.13 mmol) in 
dichloromethane (30.6 ml) at -78 °C over 30 min. The reaction was allowed to stir at -78 °C for 
an additional 30 min before being quenched with a solution of Rochelle’s salt at -78 °C. The 
mixture was stirred vigorously at rt for 2 h, the layers were separated, and the aqueous layer was 
extracted with dichloromethane (2x30 ml). The organic layers were dried with sodium sulfate 
and concentrated, and the residue was submitted to the next reaction without further purification.  
 To a suspension of sodium hydride (60% suspension in oil, 0.295 g, 7.36 mmol) and 
dry THF (20.6 ml) was added triethyl phosphonoacetate (1.85 ml, 9.19 mmol) at -10 °C, and the 
mixture was stirred for 30 min. A solution of the residue in THF (10 ml total with rinses) was 
added to the solution at -10 °C. The mixture was allowed to stir for 30 min before being 
quenched with saturated aqueous ammonium chloride. The mixture was extracted with ethyl 
acetate (3x30 ml), and the combined organic layers were washed with water and brine, dried with 
sodium sulfate, concentrated, and the residue was purified by column chromatography (silica, 
20% EtOAc – hexanes) delivering the product (1.28 g, 4.88 mmol, 80% over 2 steps). IR (cm-1) 
3064.3, 2935.1, 1717.3, 1654.6, 1602.6, 1273.8; 
1
H NMR (500 MHz, CDCl3); ppm): 7.50-7.45 
(m, 2H); 7.40-7.36 (m, 3H); 7.01-6.94 (m, 1H); 5.97-5.92 (m, 1H); 5.96 (s, 0.4H); 5.81 (s, 0.6H); 
4.42-4.34 (m, 1H); 4.27 (dd, J1=8.0 Hz, J2=6.0 Hz, 0.4 H); 4.22-4.17 (m, 2H); 4.13 (dd, J1=8.0 
Hz, J2=7.0 Hz, 0.6H); 3.79 (dd, J1=8.0 Hz, J2=6.0 Hz, 0.6H); 3.69 (dd, J1=8.0 Hz, J2=7.0 Hz, 
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0.4H); 2.68-2.61 (m, 1H); 2.58-2.49 (m, 1H); 1.30-1.26 (m, 3H). LRMS (ESI) calcd for 
C15H18O4Na [M+Na] 285.1, found 285.1. 
 
O
O
Ph
O
OEt
i-Bu2AlH (3 eq)
O
O
Ph
OH  
(E)-4-(2-phenyl-1,3-dioxolan-4-yl)but-2-en-1-ol. Diisobutylaluminum hydride (1 M in 
toluene, 14.5 ml, 14.5 mmol) was added to a solution of the substrate (1.27 g, 4.84 mmol) in 
dichloromethane (24.2 ml) at -78 °C. The reaction was allowed to warm from -78 °C to -20 °C 
over 1 h before being quenched with a solution of Rochelle’s salt at 0 °C. The mixture was 
stirred vigorously for 2 h, the layers were separated, and the aqueous layer was extracted with 
dichloromethane (2x30 ml). The combined organic layers were dried with sodium sulfate and 
concentrated, and the residue was purified by column chromatography (silica, 60%  80% ethyl 
acetate – hexanes) to give the desired product (0.571 g, 2.59 mmol, 54%).  1H NMR (500 MHz, 
CDCl3); ppm): 7.52-7.45 (m, 2H); 7.40-7.33 (m, 3H); 5.95 (s, 1H); 5.82-5.71 (m, 2H); 4.30 
(dd, J1=8.0 Hz, J2=6.5 Hz, 1H); 4.25-4.22 (m, 1H); 4.14-4.11 (m, 2H); 3.68 (dd, J1=8.0 Hz, 
J2=7.0 Hz, 1H); 2.52 (ddd, J1=13.5 Hz, J2=J3=6.5 Hz, 1H); 2.38 (ddd, J1=13.5 Hz, J2=J3=7.0 
Hz, 1H); 1.36-1.30 (m, 1H). LRMS (ESI) calcd for C13H16O3Na [M+Na] 243.1, found 243.1. 
 
 
O
O
Ph
OH
Re2O7 (2.5 mol%), PhCH(OMe)2 (0.3 eq), CH2Cl2, rt, 20 h
HO
O O
Ph
 
cis,cis-2-Phenyl-6-vinyl-1,3-dioxan-4-yl)methanol. The typical procedure was followed: 
rhenium(VII) oxide (12 mg, 0.025 mmol) was quickly weighed out into a flame-dried flask.  The 
flask was evacuated and backfilled with argon (x3). Dichloromethane (2.5 ml) was added.  The 
substrate (0.220 g, 1.00 mmol) in dichloromethane (2.5 ml total with rinses) was added to the 
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20 h of stirring at rt, saturated aqueous sodium bicarbonate was added and the biphasic mixture 
stirred vigorously for 10 min. The aqueous layer was extracted with dichloromethane (3x20 ml).  
The combined organic layers were dried with sodium sulfate, concentrated, and the residue was 
purified by column chromatography (silica, 35% EtOAc – hexanes) delivering the product (0.175 
g, 0.795 mmol, 80%). IR (cm
-1
) 3420.1, 3067.2, 2921.6, 1647.9, 1601.59, 1275.7; 
1
H NMR (500 
MHz, CDCl3); ppm): 7.54-7.52 (m, 2H); 7.40-7.34 (m, 3H); 5.95 (ddd, J1=17.5 Hz, J2=11.0 
Hz, J3=5.5 Hz, 1H); 5.63 (s, 1H); 5.36 (ddd, J1=17.0 Hz, J2=J3=1.5 Hz, 1H); 5.20 (ddd, J1=11.0 
Hz, J2=J3=1.5 Hz, 1H); 4.40-4.36 (s, 1H); 4.05-4.00 (m, 1H); 3.74-3.68 (m, 1H); 3.65 (dd, 
J1=11.5 Hz, J2=6.5 Hz, 1H); 2.23 (bs, 1H); 1.69-1.59 (m, 2H). 
13
C NMR (125 MHz, CDCl3); 
ppm): 138.4, 137.7, 129.5, 128.5, 126.5, 116.1, 100.9, 77.3, 77.1, 65.8, 32.4. HRMS (ESI) 
calcd for C13H16O3Na [M+Na] 243.0997, found 243.0993. 
 
O O
PMP
O O
PMP
+
OTBS
OH
Re2O7 (2.5 mol%), CH2Cl2, rt, 20 h
MeO
OMe
OMe
(2 eq)
ds 5:1  
(2S,4R,5S)-2-(4-Methoxyphenyl)-5-methyl-4-vinyl-1,3-dioxane. Following the typical 
procedure, rhenium(VII) oxide (7.9 mg, 0.016 mmol) was quickly weighed out into a flame-dried 
flask.  The flask was evacuated and backfilled with argon (x3).  To the flask was added 
dichloromethane (1.25 ml).  The substrate
138
 (0.150 g, 0.651 mmol) in dichloromethane (2.5 ml 
total with rinses) was added to the reaction vessel followed by addition of anisaldehyde dimethyl 
acetal (0.220 ml, 1.30 mmol). After 20 h of stirring at rt, saturated aqueous sodium bicarbonate 
was added and the biphasic mixture stirred vigorously for 10 min. The aqueous layer was 
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extracted with dichloromethane (3x20 ml).  The combined organic layers were dried with sodium 
sulfate, concentrated, and the residue was purified by column chromatography (silica, 5% EtOAc 
– hexanes) delivering the product (0.128 g, 0.546 mmol, 84%) as a 5:1 inseparable mixture 
diastereomers. IR (cm
-1
) 2958.3, 1615.1, 1518.7, 1249.7; 
1
H NMR (500 MHz, CDCl3); ppm): 
(major diastereomer) 7.46-7.43 (m, 2H); 6.90-6.87 (m, 2H); 5.89 (ddd, J1=17.5 Hz, J2=10.5 Hz, 
J3=7.4 Hz, 1H); 5.50 (s, 1H); 5.35 (ddd, J1=17.5 Hz, J2=J3=2.0 Hz, 1H); 5.25 (ddd, J1=10.5 Hz, 
J2=1.5 Hz, J3=0.5 Hz, 1H); 4.15 (dd, J1=11.5 Hz, J2=5.0 Hz, 1H); 3.87 (dd, J1=10.0 Hz, J2=7.0 
Hz, 1H); 3.80 (s, 3H); 3.54 (dd, J1=J2=11.0 Hz, 1H); 1.94-1.86 (m, 1H); 0.79 (d, J=7.0 Hz, 3H). 
13
C NMR (125 MHz, CDCl3); ppm): 160.1, 136.2, 131.2, 127.7, 118.1, 113.8, 101.1, 84.9, 
73.1, 55.5, 34.0, 12.5. HRMS (ESI) calcd for C14H18O3Na [M+Na] 257.1154, found 257.1147. 
 
NHCBz
OTBS
OH
NHCBz
OH
OH
TBAF (3 eq), THF
 
anti-Benzyl 3,7-dihydroxy-1-phenylhept-5-en-2-ylcarbamate. Tetrn-butyl-ammonium 
fluoride (1M in THF, 0.385 ml, 0.385 mmol) was added to a solution of the substrate
139
 (60 mg, 
0.128 mmol) in THF (0.25 ml) at room temperature.  The solution was stirred at room 
temperature for 2 h and was quenched with a saturated solution of ammonium chloride.  The 
aqueous layer was extracted with ethyl acetate (3x10 ml), dried with sodium sulfate, 
concentrated, and the residue was purified by column chromatography (silica, 5% methanol - 
dichloromethane) to give the desired diol (43.1 mg, 0.121 mmol, 95%). IR (cm
-1
) 3394.1, 3029.6, 
2930.2, 1696.1, 1516.7, 1254.5; 
1
H NMR (500 MHz, CDCl3); ppm): 7.37-7.16 (m, 10H); 5.69 
(ddd, J1=16.0 Hz, J2=J3=5.5 Hz, 1H); 5.60 (ddd, J1=15.0 Hz, J2=J3=6.5 Hz, 1H); 5.17 (bd, 
J=8.5 Hz, 1H); 5.08 (AB, JA=16.0 Hz, JB=12.5 Hz, 2H); 4.07 (d, J=5.0 Hz, 2H); 3.85 (dd, 
J1=15.0 Hz, J2=7.0 Hz, 1H); 3.63 (dd, J1=J2=6.5 Hz, 1H); 2.95-2.82 (m, 2H); 2.23 (dd, 
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J1=J2=7.5 Hz, 2H). 
13
C NMR (125 MHz, CDCl3); ppm): 156.8, 138.3, 136.7, 133.0, 
129.5(2C), 128.7(2C), 128.3, 128.1, 126.7, 70.4, 66.9, 63.4, 56.0, 39.0, 37.9. HRMS (ESI) calcd 
for C21H25NO4Na [M+Na] 378.1681, found 378.1667. 
 
NHCbz
OH
OAc
NHCbz
OH
AcO OAc
Hoveyda-Grubbs II catalyst (1 mol%), CH2Cl2
(10 eq)
 
syn-6-(Benzyloxycarbonylamino)-5-hydroxy-7-phenylhept-2-enyl acetate. The typical 
procedure for cross-metathesis was followed using HoveydGrubbs II catalyst (17 mg, 27.9 
mol), cis-1,4-diacetoxy-2-butene (0.480 g, 2.79 mmol) in degassed dichloromethane (4.2 ml).  
The crude product (E-selectivity 10:1) was purified by column chromatography (silica, 30% (350 
ml) to 45% (250 ml) to 50% EtOAc – hexanes) delivering the product (57.5 mg, 0.145 mmol, 
52%). 
1
H NMR (500 MHz, CDCl3); ppm):7.36-7.18 (m, 10H); 5.86-5.77 (ddd, J1=13.5 Hz, 
J2=J3=6.5 Hz, 1H); 5.73-5.67 (ddd, J1=12.5 Hz, J2=J3=6.0 Hz, 1H); 5.03 (s, 2H); 4.92-4.86 (m, 
1H); 4.55-4.54 (d, J=6.0 Hz, 2H); 3.96-3.86 (m, 1H); 3.81-3.72 (m, 1H); 2.96 (dd, J1=14.0 Hz, 
J2=4.5 Hz, 1H); 2.84-2.78 (m, 1H); 2.64-2.58 (m, 1H); 2.39-2.33 (m, 1H); 2.32-2.24 (m, 1H); 
2.07 (s, 3H). 
13
C NMR (125 MHz, CDCl3); ppm): 171.1, 156.6, 137.9, 136.5, 131.6, 129.5, 
128.8, 128.7, 128.3, 128.1, 127.9, 126.8, 72.8, 67.0, 65.0, 56.7, 37.0, 35.5, 21.2. HRMS (ESI) 
calcd for C23H27NO5Na [M+Na] 378.1681, found 378.1667.  
 
NHCBz
OH
OAc
NHCBz
OH
OH
K2CO3 (0.4 eq), MeOH
 
syn-Benzyl 3,7-dihydroxy-1-phenylhept-5-en-2-ylcarbamate. The typical procedure for 
deacetylation was followed with potassium carbonate (15.1 mg, 0.109 mmol), the substrate (57.5 
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mg, 0.145 mmol) in methanol (2.9 ml) at rt. The crude product was crystallized in a mixture of 
EtOAc and hexanes, delivering the product (43.1 mg, 0.121 mmol, 84%). IR (cm
-1
) 3031.6, 
2940.0, 1694.2, 1603.5, 1548.6; 
1
H NMR (500 MHz, CDCl3); ppm): 7.36-7.17 (m, 10H); 5.79-
5.70 (m, 2H); 5.02 (s, 2H); 4.83 (bd, J=8.0 Hz, 1H); 4.13 (bs, 2H); 3.95-3.86 (m, 1H); 3.78-3.71 
(m, 1H); 2.96 (dd, J1=14.0 Hz, J2=4.5 Hz, 1H); 2.81 (dd, J1=13.5 Hz, J2=9.5 Hz, 1H); 2.48 (bs, 
1H); 2.35 (ddd, J1=13.5 Hz, J2=J3=4.5 Hz, 1H); 2.29-2.23 (m, 1H); 1.60-1.50 (m, 1H). 
13
C 
NMR (125 MHz, CD3OD); ppm): 158.6, 140.5, 138.7, 133.2, 130.6, 129.66, 129.54, 129.36, 
128.9, 128.6, 127.4, 74.7, 67.2, 63.8, 58.6, 38.0, 37.3. HRMS (ESI) calcd for C21H25NO4Na 
[M+Na] 378.1681, found 378.1692. 
 
NHCbz
OH
OH
Re2O7 (2.5 mol%), CH2Cl2, rt, 20 h
MeO
OMe
OMe
(2 eq)
NHCbz
O O
PMP
 
Benzyl 2-(4-methoxyphenyl)-6-vinyl-1,3-dioxan-4-yl)-2-phenylethylcarbamate. The 
typical procedure was followed: 
out into a flame-dried flask.  The flask was evacuated and backfilled with argon (x3).  To the 
flask was added dichloromethane (0.2 ml).  The substrate (35.5 mg, 0.10 mmol) in 
dichloromethane (0.8 ml total with rinses) was added to the reaction vessel followed by addition 
After 20 h of stirring at rt, saturated aqueous 
sodium bicarbonate was added and the biphasic mixture stirred vigorously for 10 min. The 
aqueous layer was extracted with dichloromethane (3x10 ml).  The combined organic layers were 
dried with sodium sulfate, concentrated, and the residue was purified by column chromatography 
(silica, dichloromethane (to remove anisaldehyde) then 5% ethyl acetate – dichloromethane) 
-1
) 3324.7, 3028.7, 2957.3, 1698.0, 
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1615.1, 1517.7; 
1
H NMR (500 MHz, CDCl3); ppm): 7.47 (m, 2H); 7.35-7.18 (m, 10H); 6.92 
(m, 2H); 5.92 (ddd, J1=16.5 Hz, J2=10.5 Hz, J3=5.5 Hz, 1H); 5.54 (s, 1H); 5.31 (d, J=17.0 Hz, 
1H); 5.17 (d, J=10.5 Hz, 1H); 5.03 (s, 2H); 4.83 (d, J=9.5 Hz, 1H); 4.32-4.26 (m, 1H); 4.08-4.01 
(m, 1H); 3.90-3.84 (m, 1H); 3.82 (s, 3H); 3.05 (dd, J1=14.0 Hz, J2=3.5 Hz, 1H); 2.93 (dd, 
J1=14.5 Hz, J2=8.5 Hz, 1H); 1.74-1.64 (m, 2H). 
13
C NMR (125 MHz, CDCl3); ppm): 160.2, 
156.1, 137.7, 136.7, 131.1, 129.7, 128.7(2C), 128.3, 128.1, 127.8, 126.7, 116.0, 113.8, 100.8, 
77.8, 77.4, 66.8, 55.5, 55.3, 35.7, 33.6. HRMS (ESI) calcd for C29H31NO5Na [M+Na] 496.2100, 
found 496.2093. 
 
NHCbz
OH
OH
Re2O7 (2.5 mol%), CH2Cl2, rt, 1.5 h
MeO
OMe
OMe
(2 eq)
NHCbz
O O
PMP
 
Benzyl 2-(4-methoxyphenyl)-6-vinyl-1,3-dioxan-4-yl)-2-phenylethylcarbamate. The 
typical procedure was followed: 
out into a flame-dried flask.  The flask was evacuated and backfilled with argon (x3).  To the 
flask was added dichloromethane (0.2 ml).  The substrate (35.5 mg, 0.10 mmol) in 
dichloromethane (0.8 ml total with rinses) was added to the reaction vessel followed by addition 
aqueous sodium bicarbonate was added and the biphasic mixture stirred vigorously for 10 min. 
The aqueous layer was extracted with dichloromethane (3x10 ml).  The combined organic layers 
were dried with sodium sulfate, concentrated, and the residue was purified by column 
chromatography (silica, dichloromethane (to remove anisaldehyde) then 5% ethyl acetate – 
-1
) 3430.7, 3331.4, 
3028.7, 1717.3, 1648.8, 1516.7, 1248.7; 
1
H NMR (500 MHz, CDCl3); ppm): 7.47-7.45 (m, 
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2H); 7.38-7.23 (m, 10H); 6.93-6.91 (m, 2H); 5.87 (ddd, J1=17.0 Hz, J2=10.5 Hz, J3=5.5 Hz, 
1H); 5.48 (s, 1H); 5.28 (d, J=17.5 Hz, 1H); 5.21 (d, J=9.5 Hz, 1H); 5.15 (d, J=11.0 Hz, 1H); 5.12 
(d, J=13.0 Hz, 1H); 5.06 (d, J=12.5 Hz, 1H); 4.30-4.25 (m, 1H); 3.93 (dd, J1=16.5 Hz, J2=8.0 
Hz, 1H); 3.83 (s, 3H); 3.83-3.81 (m, 1H); 3.00-2.92 (m, 2H); 1.76 (dd, J1=24.5 Hz, J2=12.0 Hz, 
1H); 1.46 (d, J=13.5 Hz, 1H). 
13
C NMR (125 MHz, CDCl3); ppm): 160.2, 156.5, 138.2, 137.6, 
136.7, 131.1, 129.6, 128.8, 128.7, 128.3, 128.2, 127.6, 126.7, 115.9, 113.8, 100.6, 77.1, 74.8, 
67.0, 55.8, 55.5, 38.5, 33.2. HRMS (ESI) calcd for C29H31NO5Na [M+Na] 496.2100, found 
496.2090. 
 
OHPMBO
TBDPSO
OHPMBO
TBDPSO
OHPMBO
TBDPSO
1. Swern Ox.
2. MgBr
A B
+
 
Compounds A and B. Dimethylsulfoxide (0.17 ml, 2.4 mmol) was added to a solution of 
oxalyl chloride (0.105 ml, 1.18 mmol) in dry dichloromethane (1.9 ml) at -78 °C. After 15 min, a 
solution of the alcohol
140
 (0.300 g, 0.592 mmol) in dichloromethane (4 ml total with rinses) was 
added. The mixture was stirred for 20 min, and then triethylamine (0.50 ml, 3.55 mmol) was 
added dropwise.  After 15 min the mixture was warmed to 0 °C and stirred for 10 min. The 
reaction was quenched with 1 M aqueous HCl. The mixture was extracted with ethyl acetate 
(3x10 ml), and the combined organic layers were washed with water and brine, dried with 
sodium sulfate, concentrated, and the residue was submitted to the next reaction without further 
purification. 
 Allyl magnesium bromide (1M in ether, 0.71 ml, 0.71 mmol), was added to a solution 
of the crude aldehyde in ether (5.9 ml) at -78 °C. After 30 min of stirring, the reaction was 
warmed to -15 °C where it continued to stir for an additional 30 min before being quenched with 
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saturated aqueous ammonium chloride. The mixture was extracted with ethyl acetate (3x10 ml).  
The combined organic layers were washed with water and brine, dried with sodium sulfate, 
concentrated, and the residue was purified by column chromatography (silica, 10% EtOAc – 
hexanes) to give product A (88 mg, 0.160 mmol, 27%) and product B (0.175 g, 0.320 mmol, 
54% over 2 steps). Data for Product A. []D
22 +11.9 (c 1.0, CH2Cl2). IR (cm
-1
) 3466.4, 3048.9, 
2930.3, 1613.2, 1513.9, 1247.7; 
1
H NMR (500 MHz, CDCl3); ppm): 7.67-7.64 (m, 4H); 7.43-
7.40 (m, 2H); 7.38-7.33 (m, 4H); 7.05-7.02 (m, 2H); 6.78-6.75 (m, 2H); 5.89-5.81 (m, 1H); 5.17 
(d, J=3.5 Hz, 1H); 5.15 (s, 1H); 4.52 (d, J=10.5 Hz, 1H); 4.39 (d, J=10.5 Hz, 1H); 3.83 (dd, 
J1=9.0 Hz, J2=1.0 Hz, 1H); 3.80-3.73 (m, 2H); 3.78 (s, 3H); 3.60-3.55 (m, 1H); 2.48-2.42 (m, 
1H); 2.23 (d, J=4.0 Hz, 1H); 2.14 (ddd, J1=15.5 Hz, J2=J3=8.0 Hz, 1H); 1.96-1.88 (m, 1H); 
1.74-1.68 (m, 1H); 1.09 (s, 9H); 0.96 (d, J=7.0 Hz, 3H); 0.88 (d, J=7.0 Hz, 3H). 
13
C NMR (125 
MHz, CDCl3); ppm): 159.2, 136.00, 135.9, 135.3, 134.1, 134.0, 131.2, 129.8, 129.4, 127.83, 
127.78, 118.4, 113.9, 79.7, 73.7, 72.58, 66.2, 55.5, 40.2, 39.8, 38.9, 27.2, 19.5, 14.8, 10.7. 
HRMS (ESI) calcd for C34H46O4SiNa [M+Na] 569.3063, found 569.3062. Data for Product B. 
[]D
22 +21.7
 
(c 1.0, CH2Cl2). IR (cm
-1
) 3466.4, 3048.9, 2930.3, 1613.2, 1513.9, 1247.7; 
1
H NMR 
(500 MHz, CDCl3); ppm): 7.67-7.63 (m, 4H); 7.44-7.40 (m, 2H); 7.39-7.33 (m, 4H); 7.03-7.01 
(m, 2H); 6.79-6.76 (m, 2H); 5.82 (dddd, J1=18.0 Hz, J2=11.0 Hz, J3=J4=7.5 Hz, 1H); 5.12 (dd, 
J1=17.5 Hz, J2=1.5 Hz, 1H); 5.09 (dd, J1=12.5 Hz, J2=1.5 Hz, 1H); 4.49 (d, J=10.5 Hz, 1H); 
4.43 (d, J=11.0 Hz, 1H); 3.87 (dd, J1=J2=7.0 Hz, 1H); 3.79 (dd, J1=10.0 Hz, J2=5.5 Hz, 1H); 
3.78 (s, 3H); 3.73 (dd, J1=9.5 Hz, J2=4.0 Hz, 1H); 3.65 (dd, J1=8.5 Hz, J2=3.0 Hz, 1H); 3.05 (s, 
1H); 2.31 (ddd, J1=13.5 Hz, J2=J3=7.0 Hz, 1H); 2.24-2.17 (m, 1H); 2.02-1.97 (m, 1H); 1.81-
1.75 (m, 1H); 1.09 (s, 9H); 0.97 (d, J=7.0 Hz, 3H); 0.91 (d, J=7.5 Hz, 3H). 
13
C NMR (125 MHz, 
CDCl3); ppm): 159.4, 136.0, 135.9, 135.7, 133.85, 133.79, 130.3, 129.9, 129.7, 127.9, 127.8, 
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117.3, 114.0, 85.0, 75.2, 73.8, 65.6, 55.5, 39.9, 38.7, 38.0, 27.2, 19.5, 14.4, 6.7. HRMS (ESI) 
calcd for C34H46O4SiNa [M+Na] 569.3063, found 569.3055. 
 
Determination of stereochemistry for Products A and B for the above reaction: 
OHPMBO
TBDPSO
DDQ, 4A MS
CH2Cl2
OO
TBDPSO
PMP
 
DDQ (9.3 mg, 41.1 mol) was added to the substrate (15 mg, 27.4 mol) 4A molecular 
sieves in dichloromethane (0.5 ml) at 0 °C.  After 10 min the reaction flask was warmed to rt 
where it continued to stir for 20 min before being quenched with saturated aqueous sodium 
bicarbonate. The mixture was extracted with dichloromethane (3x5 ml).  The combined organic 
layers were dried with sodium sulfate, concentrated, and the residue was purified by column 
chromatography (silica, 7% EtOAc – hexanes) to give desired product (6 mg, 11 mol, 40%). 
[]D
22 -14.2
 
(c 0.60, CH2Cl2). IR (cm
-1
) 3071.1, 2931.3, 1615.1, 1516.7, 1248.7; 
1
H NMR (500 
MHz, CDCl3); ppm): 7.67-7.62 (m, 4H); 7.42-7.30 (m, 6H); 7.24-7.20 (m, 2H); 6.88-6.85 (m, 
2H); 5.86 (dddd, J1=17.0 Hz, J2=10.0 Hz, J3=J4=7.5 Hz, 1H); 5.68 (s, 1H); 5.14 (dd, J1=17.0 
Hz, J2=2.0 Hz, 1H); 5.12 (d, J=9.5 Hz, 1H); 4.15 (dd, J1=10.5 Hz, J2=2.0 Hz, 1H); 3.99-3.94 
(m, 2H); 3.81 (s, 3H); 3.65 (dd, J1=9.5 Hz, J2=2.0 Hz, 1H); 2.88-2.82 (m, 1H); 2.57-2.51 (m, 
1H); 1.86-1.81 (m, 1H); 1.61 (dddd, J1=J2=J3=7.0 Hz, J4=1.0 Hz, 1H); 1.20 (d, J=7.0 Hz, 3H); 
1.07 (s, 9H); 1.02 (d, J=7.0 Hz, 3H). 
13
C NMR (125 MHz, CDCl3); ppm): 159.9, 135.8, 135.7, 
135.0, 134.1, 132.1, 129.72, 129.65, 127.81, 127.77, 127.57, 117.3, 113.7, 94.9, 79.7, 74.4, 64.9, 
55.6, 36.9, 35.4, 31.1, 27.1, 19.7, 13.1, 12.7. HRMS (ESI) calcd for C34H44O4SiNa [M+Na] 
567.2907, found 567.2896. 
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OHPMBO
TBDPSO
DDQ, 4A MS
CH2Cl2
OO
TBDPSO
PMP
 
DDQ (8.5 mg, 37.6 mol) was added to the substrate (13.7 mg, 25.1 mol) 4A molecular 
sieves in dichloromethane (0.5 ml) at 0 °C.  After 10 min the reaction flask was warmed to rt 
where it continued to stir for 20 min before being quenched with saturated aqueous sodium 
bicarbonate. The mixture was extracted with dichloromethane (3x5 ml).  The combined organic 
layers were dried with sodium sulfate, concentrated, and the residue was purified by column 
chromatography (silica, 7% EtOAc – hexanes) to give desired product (7 mg, 12.8 mol, 51%). 
[]D
22 +9.8
 
(c 0.70, CH2Cl2). IR (cm
-1
) 3071.1, 2930.3, 1616.1, 1517.7, 1248.7; 
1
H NMR (500 
MHz, CDCl3); ppm): 7.67-7.65 (m, 2H); 7.63-7.61 (m, 2H); 7.42-7.38 (m, 1H); 7.36-7.33 (m, 
5H); 7.22-7.19 (m, 2H); 6.88-6.85 (m, 2H); 5.91-5.83 (m, 1H); 5.47 (s, 1H); 5.16 (dd, J1=17.0 
Hz, J2=1.5 Hz, 1H); 5.10 (d, J=10.5 Hz, 1H); 3.96 (dd, J1=9.5 Hz, J2=4.0 Hz, 1H); 3.90 (ddd, 
J1=J2=7.0 Hz, J3=2.0 Hz, 1H); 3.86 (dd, J1=10.5 Hz, J2=1.5 Hz, 1H); 3.82 (s, 3H); 3.64 (dd, 
J1=9.5 Hz, J2=2.5 Hz, 1H); 2.52-2.46 (m, 1H); 2.29-2.23 (m, 1H); 1.90-1.86 (m, 1H); 1.64-1.60 
(m, 1H); 1.05 (s, 9H); 1.04 (d, J=7.0 Hz, 3H); 0.96 (d, J=7.0 Hz, 3H). 
13
C NMR (125 MHz, 
CDCl3); ppm): 159.9, 135.81, 135.76, 134.7, 134.1, 134.0, 131.9, 129.7, 129.6, 127.8, 127.75, 
127.6, 117.3, 113.7, 101.4, 81.0, 64.9, 55.6, 37.5, 36.9, 32.1, 27.1, 19.7, 12.6, 5.7. HRMS (ESI) 
calcd for C34H44O4SiNa [M+Na] 567.2907, found 567.2894. 
 
OHPMBO
TBDPSO
OHPMBO
TBDPSO OAc
AcO OAc
Hoveyda-Grubbs II catalyst (1 mol%), CH2Cl2
(10 eq)
 
(5R,6S,7S,8S,E)-9-(tert-Butyldiphenylsilyloxy)-5-hydroxy-7-(4-methoxybenzyl-oxy)-6,8-
dimethylnon-2-enyl acetate. Prepared following the typical procedure for cross-metathesis with 
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the HoveydGrubbs II catalyst (1.6 mg, 2.51 mol) and the substrate (0.137 g, 0.251 mmol). E-
selectivity >90%. Purified by column chromatography (silica, 20%  30% EtOAc – hexanes) 
delivering the product (0.138 g, 0.223 mmol, 89%).
  
[]D
22 +24.8
 
(c 1.0, CH2Cl2). 
1
H NMR (500 
MHz, CDCl3); ppm): 7.67-7.63 (m, 4H); 7.45-7.42 (m, 2H); 7.39-7.35 (m, 4H); 7.02-7.00 (m, 
2H); 6.79-6.76 (m, 2H); 5.80 (ddd, J1=15.0 Hz, J2=J3=6.5 Hz, 1H); 5.66 (ddd, J1=15.5 Hz, 
J2=J3=6.0 Hz, 1H); 4.53 (dd, J1=6.5 Hz, J2=1.5 Hz, 2H); 4.68 (d, J=10.5 Hz, 1H); 4.42 (d, 
J=10.5 Hz, 1H); 3.88 (ddd, J1=7.5 Hz, J2=5.5 Hz, J3=2.0 Hz, 1H); 3.80 (dd, J1=10.0 Hz, J2=5.0 
Hz, 1H); 3.78 (s, 3H); 3.73 (dd, J1=10.0 Hz, J2=4.0 Hz, 1H); 3.64 (dd, J1=8.0 Hz, J2=2.5 Hz, 
1H); 3.20-3.04 (bs, 1H); 2.33 (ddd, J1=14.0 Hz, J2=J3=7.0 Hz, 1H); 2.21-2.15 (m, 1H); 2.06 (s, 
3H); 2.02-1.93 (m, 1H); 1.76-1.72 (m, 1H); 1.09 (s, 9H); 0.97 (d, J=7.0 Hz, 3H); 0.90 (d, J=7.5 
Hz, 3H). 
13
C NMR (125 MHz, CDCl3); ppm): 171.0, 159.4, 136.0, 135.9, 133.8, 133.7, 133.0, 
130.2, 129.9, 129.7, 127.9, 127.8, 126.5, 114.0, 84.9, 75.2, 73.8, 65.6, 65.3, 55.4, 38.6, 38.4, 
38.2, 27.2, 21.2, 19.5, 14.4, 6.7. HRMS (ESI) calcd for C37H50O6SiNa [M+Na] 641.3274, found 
641.3255.  
 
OHPMBO
TBDPSO OAc
OHPMBO
TBDPSO OH
K2CO3 (0.4 eq), MeOH
 
(5R,6S,7S,8S,E)-9-(tert-Butyldiphenylsilyloxy)-7-(4-methoxybenzyloxy)-6,8-
dimethylnon-2-ene-1,5-diol. The typical procedure for deacetylation was followed with 0.138 g 
(0.223 mmol) of the substrate. Purified by column chromatography (silica, 50% to 60% to 80% 
EtOAc – hexanes) delivering the product (0.115 g, 0.199 mmol, 89%). []D
22 +24.1 (c 1.0, 
CH2Cl2). IR (cm
-1
) 3398.0, 3071.1, 2931.3, 1514.8, 1248.7; 
1
H NMR (500 MHz, CDCl3); 
ppm): 7.70-7.63 (m, 4H); 7.45-7.42 (m, 2H); 7.39-7.35 (m, 4H); 7.02-7.00 (m, 2H); 6.79-6.76 
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(m, 2H); 5.75 (dd, J1=15.5 Hz, J2=4.5 Hz, 1H); 5.70 (dd, J1=15.0 Hz, J2=5.0 Hz, 1H); 4.50 (d, 
J=11.0 Hz, 1H); 4.42 (d, J=10.5 Hz, 1H); 4.11 (bs, 1H); 3.86 (dd, J1=J2=6.0 Hz, 1H); 3.80 (dd, 
J1=10.5 Hz, J2=5.5 Hz, 1H); 3.78 (s, 3H); 3.73 (dd, J1=10.0 Hz, J2=4.5 Hz, 1H); 3.65 (dd, 
J1=8.5 Hz, J2=3.0 Hz, 1H); 3.14 (bs, 1H); 2.34-2.28 (m, 1H); 2.19-2.15 (m, 1H); 2.02-1.95 (m, 
1H); 1.78-1.71 (m, 1H); 1.44-1.35 (bs, 1H); 1.09 (s, 9H); 0.97 (d, J=7.0 Hz, 3H); 0.90 (d, J=7.0 
Hz, 3H). 
13
C NMR (125 MHz, CDCl3); ppm): 159.4, 135.99, 135.95, 133.82, 133.78, 131.8, 
130.3, 129.90, 129.72, 127.94, 127.86, 114.1, 85.0, 75.4, 73.8, 65.6, 63.8, 55.5, 38.6, 38.4, 38.3, 
27.2, 19.5, 14.4, 6.7. HRMS (ESI) calcd for C35H48O5SiNa [M+Na] 599.3169, found 599.3158. 
 
OHPMBO
TBDPSO OH
OOO
Ph
O
Ph
Re2O7 (2.5 mol%), PhCH(OMe)2 (2 eq)
 
(2S,4S,5S)-5-methyl-2-phenyl-4-((S)-1-((2R,4R,6S)-2-phenyl-6-vinyl-1,3-dioxan-4-
yl)ethyl)-1,3-dioxane. The typical procedure was followed: rhenium(VII) oxide (1.2 mg, 2.5 
mol) was quickly weighed out into a flame-dried flask.  The flask was evacuated and backfilled 
with argon (x3).  To the flask was added dichloromethane (0.2 ml).  The substrate (57.7 mg, 0.10 
mmol) in dichloromethane (0.8 ml total with rinses) was added to the reaction vessel followed by 
addition of benzaldehyde dimethyl acetal (30 l, 0.200 mmol). After 20 h of stirring at rt, 
saturated aqueous sodium bicarbonate was added and the biphasic mixture stirred vigorously for 
10 min. The aqueous layer was extracted with dichloromethane (3x10 ml).  The combined 
organic layers were dried with sodium sulfate, concentrated, and the residue was purified by 
column chromatography (silica, 50% to 80% dichloromethane – hexane) delivering the product 
(31.1 mg, 79 mol, 79%). []D
22 +39.0
 
(c 1.0, CH2Cl2). IR (cm
-1
) 3033.5, 2938.0, 1647.9, 
1460.8, 1214.0; 
1
H NMR (500 MHz, CDCl3); ppm): 7.55-7.53 (m, 2H); 7.49-7.47 (m, 2H); 
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7.42-7.31 (m, 6H); 5.96 (ddd, J1=17.0 Hz, J2=11.0 Hz, J3=5.5 Hz, 1H); 5.61 (s, 1H); 5.47 (s, 
1H); 5.36 (ddd, J1=17.5 Hz, J2=J3=1.5 Hz, 1H); 5.18 (d, J=11.0 Hz, 1H); 4.35-4.33 (m, 1H); 
4.14 (dd, J1=11.0 Hz, J2=4.5 Hz, 1H); 3.92 (ddd, J1=11.0 Hz, J2=8.5 Hz, J3=2.5 Hz, 1H); 3.65 
(dd, J1=10.5 Hz, J2=2.0 Hz, 1H); 3.54 (dd, J1=J2=11.0 Hz, 1H); 2.18-2.11 (m, 1H); 2.03-1.97 
(m, 1H); 1.83 (ddd, J1=12.5 Hz, J2=J3=2.0 Hz, 1H); 1.61-1.55 (m, 1H); 1.19 (d, J=7.0 Hz, 3H); 
0.76 (d, J=6.5 Hz, 3H). 
13
C NMR (125 MHz, CDCl3); ppm): 139.04, 139.02, 138.2, 128.94, 
128.75, 128.44, 128.34, 126.28, 126.25, 115.8, 101.0, 100.6, 81.8, 78.9, 77.4, 73.5, 39.5, 34.6, 
30.6, 12.2, 10.1. HRMS (ESI) calcd for C25H30O4Na [M+Na] 417.2042, found 417.2046. 
 
OHPMBO
TBDPSO
OHPMBO
TBDPSO OAc
AcO OAc
Hoveyda-Grubbs II catalyst (1 mol%), CH2Cl2
(10 eq)
 
(5S,6S,7S,8S,E)-9-(tert-Butyldiphenylsilyloxy)-5-hydroxy-7-(4-methoxybenzyl-oxy)-6,8-
dimethylnon-2-enyl acetate. The typical procedure for cross-metathesis was followed with the 
HoveydGrubbs II catalyst (1.7 mg, 2.74 mol) and the substrate (0.150 g, 0.274 mmol). E-
selectivity >90%. Purified by column chromatography (silica, 20% to 30% EtOAc – hexanes) 
delivering the product (0.140 g, 0.226 mmol, 83%). []D
22 +15.5
 
(c 1.0, CH2Cl2). 
1
H NMR (500 
MHz, CDCl3); ppm): 7.66-7.34 (m, 4H); 7.43-7.40 (m, 2H); 7.38-7.33 (m, 4H); 7.05-7.02 (m, 
2H); 6.78-6.76 (m, 2H); 5.81 (ddd, J1=14.0 Hz, J2=J3=6.5 Hz, 1H); 5.69 (ddd, J1=15.5 Hz, 
J2=J3=6.0 Hz, 1H); 4.55 (d, J=6.0 Hz, 2H); 4.51 (d, J=11.5 Hz, 1H); 4.40 (d, J=11.0 Hz, 1H); 
3.81 (dd, J1=9.0 Hz, J2=1.5 Hz, 1H); 3.78 (s, 3H); 3.78-3.74 (m, 2H); 3.60-3.56 (m, 1H); 2.44-
2.39 (m, 1H); 2.31 (d, J=4.5 Hz, 1H); 2.19-2.13 (m, 1H); 2.06 (s, 3H); 1.95-1.90 (m, 1H); 1.73-
1.68 (m, 1H); 1.09 (s, 9H); 0.96 (d, J=7.0 Hz, 3H); 0.88 (d, J=7.5 Hz, 3H). 
13
C NMR (125 MHz, 
CDCl3); ppm): 171.0, 159.2, 136.0, 135.9, 134.0, 133.9, 132.4, 131.1, 129.8, 129.4, 127.81, 
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127.76, 127.46, 113.8, 79.8, 73.5, 72.9, 66.1, 65.1, 55.4, 39.8, 38.8, 38.6, 27.2, 21.2, 19.5, 14.8, 
11.0. HRMS (ESI) calcd for C37H50O6SiNa [M+Na] 641.3274, found 641.3262. 
 
OHPMBO
TBDPSO OAc
OHPMBO
TBDPSO OH
K2CO3 (0.4 eq), MeOH
 
(5S,6S,7S,8S,E)-9-(tert-butyldiphenylsilyloxy)-7-(4-methoxybenzyloxy)-6,8-
dimethylnon-2-ene-1,5-diol. The typical procedure for deacetylation was followed with 0.140 g 
(0.226 mmol) of the substrate. Purified by column chromatography (silica, 50% to 60% to 80% 
EtOAc – hexanes) delivering the product (0.110 g, 0.191 mmol, 84%). []D
22 +18.6
 
(c 1.0, 
CH2Cl2). IR (cm
-1
) 3366.1, 3070.1, 2930.3, 1513.9, 1247.7; 
1
H NMR (500 MHz, CDCl3); 
ppm): 7.68-7.63 (m, 4H); 7.44-7.40 (m, 2H); 7.40-7.33 (m, 4H); 7.04-7.02 (m, 2H); 6.78-6.76 
(m, 2H); 5.772 (dd, J1=15.5 Hz, J2=5.0 Hz, 1H); 5.72 (dd, J1=15.0 Hz, J2=5.5 Hz, 1H); 4.50 (d, 
J=10.5 Hz, 1H); 4.40 (d, J=11.0 Hz, 1H); 4.15-4.11 (m, 2H); 3.82 (d, J=9.5 Hz, 1H); 3.78 (s, 
3H); 3.78-3.74 (m, 1H); 3.59-3.53 (m, 1H); 2.45-2.39 (m, 1H); 2.39-2.28 (m, 1H); 2.17 (s, 1H); 
2.17-2.11 (m, 1H); 1.97-1.88 (m, 1H); 1.75-1.67 (m, 1H); 1.09 (s, 9H); 0.966 (d, J=7.0 Hz, 3H); 
0.886 (d, J=7.0 Hz, 3H). 
13
C NMR (125 MHz, CDCl3); ppm): 159.9, 135.98, 135.94, 134.03, 
133.98, 132.7, 131.1, 129.76, 129.44, 129.10, 127.83, 127.78, 113.9, 79.8, 73.6, 73.0, 66.1, 63.6, 
55.4, 39.9, 38.8, 38.5, 27.2, 19.5, 14.8, 11.0. HRMS (ESI) calcd for C35H48O5SiNa [M+Na] 
599.3169, found 599.3147.  
 
OHPMBO
TBDPSO OH
OOO
Ph
O
Ph
Re2O7 (2.5 mol%), PhCH(OMe)2 (2 eq)
 
  399 
(2S,4S,5S)-5-Methyl-2-phenyl-4-((S)-1-((2R,4S,6R)-2-phenyl-6-vinyl-1,3-dioxan-4-
yl)ethyl)-1,3-dioxane. The typical procedure was followed: rhenium(VII) oxide (1.2 mg, 2.5 
mol) was quickly weighed out into a flame-dried flask.  The flask was evacuated and backfilled 
with argon (x3).  To the flask was added dichloromethane (0.2 ml).  The substrate (57.7 mg, 0.10 
mmol) in dichloromethane (0.8 ml total with rinses) was added to the reaction vessel followed by 
addition of benzaldehyde dimethyl acetal (30 l, 0.200 mmol). After 20 h of stirring at rt, 
saturated aqueous sodium bicarbonate was added and the biphasic mixture stirred vigorously for 
10 min. The aqueous layer was extracted with dichloromethane (3x10 ml).  The combined 
organic layers were dried with sodium sulfate, concentrated, and the residue was purified by 
column chromatography (silica, 50% to 80% dichloromethane – hexane) delivering the product 
]D
22 +76.8
 
(c 1.0, CH2Cl2). IR (cm
-1
) 3034.4, 2928.4, 1647.9, 
1585.2, 1274.7; 
1
H NMR (500 MHz, CDCl3); ppm): 7.54-7.50 (m, 2H); 7.50-7.47 (m, 2H); 
7.43-7.33 (m, 6H); 5.96 (ddd, J1=17.0 Hz, J2=10.5 Hz, J3=5.5 Hz, 1H); 5.60 (s, 1H); 5.52 (s, 
1H); 5.35 (ddd, J1=17.5 Hz, J2=J3=1.5 Hz, 1H); 5.17 (ddd, J1=10.5 Hz, J2=J3=1.5 Hz, 1H); 
4.38-4.35 (m, 1H); 4.14 (dd, J1=11.0 Hz, J2=4.5 Hz, 1H); 4.00-3.96 (m, 2H); 3.56 (dd, 
J1=J2=11.0 Hz, 1H); 2.13-2.06 (m, 1H); 2.01-1.95 (m, 1H); 1.84 (ddd, J1=13.0 Hz, J2=J3=2.0 
Hz, 1H); 1.53-1.46 (m, 1H); 1.00 (d, J=7.5 Hz, 3H); 0.75 (d, J=6.5 Hz, 3H). 
13
C NMR (125 
MHz, CDCl3); ppm):  139.3, 139.0, 138.2, 128.83, 128.75, 128.38, 128.35, 126.28, 126.25, 
115.7, 101.2, 100.4, 81.0, 77.6, 76.9, 73.5, 39.2, 35.4, 30.4, 12.2, 8.7. HRMS (ESI) calcd for 
C25H30O4Na [M+Na] 417.2042, found 417.2050. 
 
OHPMBO
TBDPSO OAc
OHMBzO
TBDPSO OH
1. DDQ, H2O-CH2Cl2
2. K2CO3, MeOH
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(2S,3S,4S,5R,E)-1-(tert-Butyldiphenylsilyloxy)-5,9-dihydroxy-2,4-dimethylnon-7-en-3-yl 
benzoate. DDQ (0.180 g, 0.795 mmol) was added to a solution of the substrate (0.164 g, 0.265 
mmol) in dichloromethane (5.3 ml) and water (4.8 l) at rt.  After stirring for 4 h the reaction 
mixture was quenched with saturated aqueous sodium bicarbonate. The mixture was extracted 
with dichloromethane (3x5 ml).  The combined organic layers were dried with sodium sulfate, 
concentrated, and the residue was submitted to the next reaction without further purification. 
Potassium carbonate (14.7 mg, 0.106 mmol) was added to a solution of the crude substrate in 
methanol (2.7 ml) at 0 C.  After 10 min the reaction was warmed to rt and continued to stir for 1 
h.  Dilute with water and ethyl acetate. The mixture was extracted with ethyl acetate (4x30 ml), 
and the organic layers were washed with brine, dried with sodium sulfate, concentrated, and the 
residue was purified by column chromatography (silica, 20%  40%  60% EtOAc – hexanes) 
delivering the product (83.4 mg, 0.141 mmol, 53% over 2 steps). []D
22 -4.9
 
(c 1.0, CH2Cl2). IR 
(cm
-1
) 3388.3, 3048.9, 2931.3, 1709.6, 1605.5, 1510.0, 1257.4; 
1
H NMR (500 MHz, CDCl3); 
ppm): 7.91-7.89 (m, 2H); 7.64-7.62 (m, 2H); 7.57-7.55 (m, 2H); 7.41-7.31 (m, 4H); 7.26-7.23 
(m, 2H); 6.09-6.87 (m, 2H); 5.73 (ddd, J1=15.0 Hz, J2=J3=10.0 Hz, 1H); 5.68 (ddd, J1=16.0 Hz, 
J2=J3=9.5 Hz, 1H); 5.23 (dd, J1=8.0 Hz, J2=4.0 Hz, 1H); 4.08 (d, J=4.5 Hz, 2H); 3.87 (s, 3H); 
3.73-3.68 (s, 1H); 3.64 (dd, J1=10.0 Hz, J2=4.5 Hz, 1H); 3.57 (dd, J1=10.0 Hz, J2=6.0 Hz, 1H); 
2.33 (ddd, J1=14.5 Hz, J2=J3=5.5 Hz, 1H); 2.27-2.21 (m, 2H); 2.19-2.12 (m, 1H); 2.01-1.95 (m, 
1H); 1.46-1.32 (m, 1H); 1.04 (d, J=7.0 Hz, 3H); 1.02 (s, 9H); 0.98 (d, J=7.0 Hz, 3H). 
13
C NMR 
(125 MHz, CDCl3); ppm): 166.6, 163.6, 135.80, 135.76, 133.8, 133.6, 132.5, 131.9, 129.76, 
129.69, 129.3, 127.8, 127.7, 122.8, 113.8, 76.9, 73.2, 65.3, 63.7, 55.7, 39.6, 38.5, 38.0, 27.0, 
19.4, 14.6, 8.6. HRMS (ESI) calcd for C35H46O6SiNa [M+Na] 613.2961, found 613.2939. 
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OHPMBO
TBDPSO OAc
OHMBzO
TBDPSO OH
1. DDQ, H2O-CH2Cl2
2. K2CO3, MeOH
 
(2S,3S,4S,5S,E)-1-(tert-Butyldiphenylsilyloxy)-5,9-dihydroxy-2,4-dimethylnon-7-en-3-yl 
benzoate. DDQ (86.5 mg, 0.381 mmol) was added to a solution of the substrate (78.5 mg, 0.127 
mmol) in dichloromethane (2.5 ml) and water (4.8 l) at rt.  After stirring for 5 h the reaction 
mixture was quenched with saturated aqueous sodium bicarbonate. The mixture was extracted 
with dichloromethane (3x5 ml).  The combined organic layers were dried with sodium sulfate, 
concentrated, and the residue was submitted to the next reaction without further purification. 
Potassium carbonate (7.1 mg, 51 mol) was added to a solution of the crude substrate in 
methanol (1.3 ml) at 0 C.  After 10 min the reaction was warmed to rt and continued to stir for 1 
h 20 min.  Dilute with water and ethyl acetate. The mixture was extracted with ethyl acetate 
(4x30 ml), and the organic layers were washed with brine, dried with sodium sulfate, 
concentrated, and the residue was purified by column chromatography (silica, 20%  40%  
60% EtOAc – hexanes) delivering the product (44.7 mg, 75.7 mol, 60% over 2 steps). []D
22 -
11.1
 
(c 1.0, CH2Cl2). IR (cm
-1
) 3428.8, 3048.9, 2930.3, 1687.4, 1605.5, 1511.0, 1258.3; 
1
H NMR 
(500 MHz, CDCl3); ppm): 7.92-7.89 (m, 2H); 7.61-7.59 (m, 2H); 7.47-7.46 (m, 2H); 7.39-7.36 
(m, 1H); 7.32-7.22 (m, 3H); 7.13-7.10 (m, 2H); 6.91-6.88 (m, 2H); 5.85 (ddd, J1=15.5 Hz, 
J2=J3=7.0 Hz, 1H); 5.71 (ddd, J1=15.0 Hz, J2=J3=5.5 Hz, 1H); 5.66 (d, J=10.0 Hz, 1H); 4.33 (d, 
J=3.5 Hz, 1H); 4.13-4.08 (m, 2H); 3.89 (s, 3H); 3.61 (dd, J1=9.5 Hz, J2=5.0 Hz, 1H); 3.55 (dd, 
J1=10.0 Hz, J2=2.5 Hz, 1H); 3.22-3.14 (m, 1H); 2.45-2.38 (m, 1H); 2.20-2.06 (m, 2H); 1.84-1.77 
(m, 1H); 1.83 (d, J=7.0 Hz, 3H); 1.0 (s, 9H); 0.89 (d, J=7.0 Hz, 3H). 
13
C NMR (125 MHz, 
CDCl3); ppm): 167.6, 163.8, 135.8, 135.7, 133.7, 133.5, 132.1, 131.4, 130.0, 129.7, 129.6, 
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127.7, 127.6, 122.2, 113.9, 74.7, 71.6, 65.5, 63.9, 55.7, 40.5, 37.5, 37.1, 27.0, 19.4, 14.4, 9.7. 
HRMS (ESI) calcd for C35H46O6SiNa [M+Na] 613.2961, found 613.2964. 
 
OHMBzO
TBDPSO OH
OMBzO
RO
O
Ph
A : R= TBDPS
B : R= H
Re2O7 (2.5 mol%), PhCH(OMe)2 (2 eq)
CH2Cl2, rt, 4 h
 
(2S,3S,4S)-1-Hydroxy-2-methyl-4-((2S,4S,6R)-2-phenyl-6-vinyl-1,3-dioxan-4-yl)pentan-
3-yl 4-methoxybenzoate. According to the typical procedure, rhenium(VII) oxide (0.8 mg, 1.7 
mol) was quickly weighed out into a flame-dried flask. The flask was evacuated and backfilled 
with argon (x3). To the flask was added dichloromethane (0.1 ml).  The substrate (39 mg, 66 
mol) in dichloromethane (0.6 ml total with rinses) was added to the reaction vessel followed by 
addition of benzaldehyde dimethyl acetal (20 l, 0.13 mmol). After 4 h of stirring at rt, saturated 
aqueous sodium bicarbonate was added and the biphasic mixture stirred vigorously for 10 min. 
The aqueous layer was extracted with dichloromethane (3x5 ml).  The combined organic layers 
were dried with sodium sulfate, concentrated, and the residue was purified by column 
chromatography (silica, 10% to 20% to 30% EtOAc – hexane) delivering compound A (11.0 mg, 
16.2 mol, 25%) and compound B (16.3 mg, 38.4 mol, 58%). Data for compound A: []D
22 
+48.3
 
(c 0.82, CH2Cl2). 
1
H NMR (500 MHz, CDCl3); ppm): 7.94-7.91 (m, 2H); 7.73-7.71 (m, 
1H); 7.65-7.61 (m, 4H); 7.57-7.55 (m, 2H); 7.42-7.27 (m, 6H); 7.22-7.15 (m, 2H); 6.92-6.89 (m, 
2H); 5.93 (ddd, J1=17.5 Hz, J2=10.5 Hz, J3=5.5 Hz, 1H); 5.67 (dd, J1=9.5 Hz, J2=2.0 Hz, 1H); 
5.53 (s, 1H); 5.33 (ddd, J1=17.5 Hz, J2=J3=1.0 Hz, 1H); 5.16 (ddd, J1=11.0 Hz, J2=J3=1.5 Hz, 
1H); 4.29-4.26 (m, 1H); 3.88 (s, 3H); 3.67 (ddd, J1=11.0 Hz, J2=9.0 Hz, J3=2.0 Hz, 1H); 3.63-
3.60 (m, 2H); 2.14-2.02 (m, 2H); 1.68 (ddd, J1=13.0 Hz, J2=J3=2.0 Hz, 1H); 1.51-1.44 (m, 1H); 
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1.07 (d, J=7.0 Hz, 3H); 1.02 (s, 9H); 0.972 (d, J=7.0 Hz, 3H). 
13
C NMR (125 MHz, CDCl3); 
ppm): 165.6, 163.4, 138.9, 138.2, 135.9, 135.8, 133.9, 133.8, 131.8, 129.64, 129.58, 128.5, 
128.2, 127.73, 127.67, 126.4, 123.2, 115.5, 113.8, 100.2, 77.6, 73.6, 65.6, 55.7, 39.9, 38.2, 34.9, 
29.9, 27.0, 19.4, 14.6, 8.9. HRMS (ESI) calcd for C42H50O6SiNa [M+Na] 701.3274, found 
701.3261. Data for compound B: []D
22 +112.2
 
(c 1.00, CH2Cl2). 
1
H NMR (500 MHz, CDCl3); 
ppm): 8.03-7.98 (m, 2H); 7.52-7.51 (m, 2H); 7.37-7.28 (m, 3H); 6.95-6.91 (m, 2H); 5.93 (ddd, 
J1=17.0 Hz, J2=10.5 Hz, J3=5.5 Hz, 1H); 5.58 (dd, J1=10.0 Hz, J2=1.5 Hz, 1H); 5.35 (s, 1H); 
5.33 (ddd, J1=17.0 Hz, J2=J3=1.5 Hz, 1H) 5.17 (ddd, J1=10.5 Hz, J2=J3=1.5 Hz, 1H); 4.28-4.25 
(m, 1H); 3.87 (s, 3H); 3.67 (ddd, J1=11.0 Hz, J2=9.0, J3=2.0 Hz, 1H); 3.60-3.56 (m, 1H); 3.49-
3.44 (m, 1H); 2.90-2.82 (bs, 1H); 2.10-2.04 (m, 1H); 1.98-1.91 (m, 1H); 1.79 (ddd, J1=13.0 Hz, 
J2=J3=2.5 Hz, 1H); 1.53-1.46 (m, 1H); 1.09 (d, J=7.0 Hz, 3H); 1.06 (d, J=7.0 Hz, 3H). 
13
C NMR 
(125 MHz, CDCl3); ppm): 167.3, 163.9, 138.5, 138.0, 132.0, 128.7, 128.3, 126.2, 122.4, 115.7, 
114.0, 100.2, 77.9, 77.3, 73.3, 64.2, 55.7, 39.4, 37.3, 35.3, 14.0, 9.0. HRMS (ESI) calcd for 
C26H32O6SiNa [M+Na] 463.2097, found 463.2090. 
 
OHMBzO
TBDPSO OH
OMBzO
RO
O
Ph
A : R= TBDPS
B : R= H
Re2O7 (2.5 mol%), PhCH(OMe)2 (2 eq)
CH2Cl2, rt, 4 h
 
(2S,3S,4S)-1-Hydroxy-2-methyl-4-((2R,4R,6S)-2-phenyl-6-vinyl-1,3-dioxan-4-yl)pentan-
3-yl 4-methoxybenzoate. In accord with the typical procedure, rhenium(VII) oxide (0.9 mg, 1.9 
mol) was quickly weighed out into a flame-dried flask.  The flask was evacuated and backfilled 
with argon (x3).  To the flask was added dichloromethane (0.1 ml).  The substrate (44 mg, 75 
mol) in dichloromethane (0.7 ml total with rinses) was added to the reaction vessel followed by 
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addition of benzaldehyde dimethyl acetal (22 l, 0.15 mmol). After 4 h of stirring at rt, saturated 
aqueous sodium bicarbonate was added and the biphasic mixture stirred vigorously for 10 min. 
The aqueous layer was extracted with dichloromethane (3x5 ml).  The combined organic layers 
were dried with sodium sulfate, concentrated, and the residue was purified by column 
chromatography (silica, 10%  30%  EtOAc – hexane) delivering product A (24.2 mg, 35.6 
mol, 48%) and product B (12.5 mg, 28.4 mol, 38%). Data for compound A:  []D
22 +0.2
 
(c 
1.00, CH2Cl2). IR (cm
-1
) 3048.9, 2930.3, 1709.6, 1605.5, 1510.0, 1257.4; 
1
H NMR (500 MHz, 
CDCl3); ppm): 7.87-7.84 (m, 2H); 7.26-7.61 (m, 2H); 7.56-7.55 (m, 2H); 7.42-7.21 (m, 11H); 
6.87-6.84 (m, 2H); 5.94 (ddd, J1=17.5 Hz, J2=10.5, J3=5.5 Hz, 1H); 5.47 (s, 1H); 5.35 (d, J=17.5 
Hz, 1H); 5.31 (dd, J1=9.0 Hz, J2=3.0 Hz, 1H); 5.16 (d, J=10.5 Hz, 1H); 4.32-4.29 (m, 1H); 3.87 
(s, 3H); 3.78 (ddd, J1=11.0 Hz, J2=7.0 Hz, J3=2.0 Hz, 1H); 3.62 (dd, J1=10.5 Hz, J2-4.0 Hz, 
1H); 3.56 (dd, J1=10.5 Hz, J2=6.5 Hz, 1H); 2.17 (m, 1H); 2.05-1.99 (m, 2H); 1.57-1.50 (m, 1H); 
1.13 (d, J=6.5 Hz, 3H); 1.06, (d, J=6.5 Hz, 3H); 1.02 (s, 9H). 
13
C NMR (125 MHz, CDCl3); 
ppm): 166.0, 163.4, 138.9, 138.1, 135.8, 133.9, 133.7, 131.9, 129.71, 129.66, 128.5, 128.1, 
127.8, 127.7, 126.3, 123.0, 115.5, 113.7, 100.5, 78.6, 77.2, 74.9, 65.4, 55.7, 40.3, 38.0, 35.1, 
27.0, 19.4, 14.7, 9.3. HRMS (ESI) calcd for C42H50O6SiNa [M+Na] 701.3274, found 701.3267.  
Data for compound B: []D
22 +11.1
 
(c 1.00, CH2Cl2). IR (cm
-1
) 3493.4, 3035.4, 2925.5, 1708.6, 
1605.5, 1511.0, 1258.3; 
1
H NMR (500 MHz, CDCl3); ppm): 7.99-7.96 (m, 2H); 7.44-7.42 (m, 
2H); 7.31-7.27 (m, 3H); 6.92-6.89 (m, 2H); 5.91 (ddd, J1=17.0 Hz, J2=10.5 Hz, J3=5.0 Hz, 1H); 
5.49 (s, 1H); 5.32 (dd, J1=17.5 Hz, J2=J3=1.5 Hz, 1H); 5.22 (dd, J1=10.5 Hz, J2=2.5 Hz, 1H); 
5.16 (ddd, J1=10.5 Hz, J2=J3=1.5 Hz, 1H); 4.26-4.22 (m, 1H); 3.87 (s, 3H); 3.72 (ddd, J1=11.0 
Hz, J2=7.5 Hz, J3=2.0 Hz, 1H); 3.56 (dd, J1=11.5 Hz, J2=2.5 Hz, 1H); 3.48 (bd, J=11.5 Hz, 1H); 
2.58-2.48 (bs, 1H); 2.09-1.96 (m, 2H); 1.82 (ddd, J1=13.0 Hz, J2=J3=2.5 Hz, 1H); 1.58-1.51 (m, 
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1H); 1.25 (d, J=7.0 Hz, 3H); 1.07 (d, J=7.0 Hz, 3H). 
13
C NMR (125 MHz, CDCl3); ppm): 
167.4, 164.0, 138.8, 137.8, 132.2, 128.7, 128.2, 126.3, 122.1, 115.8, 114.0, 100.7, 79.1, 77.1, 
74.5, 64.0, 55.7, 39.9, 37.4, 35.0, 14.2, 9.4. HRMS (ESI) calcd for C26H32O6Na [M+Na] 
463.2097, found 463.2090. 
 
OHMBzO
TBDPSO OH
OMBzO
HO
O
Ph1. Re2O7 (2.5 mol%), PhCH(OMe)2 (2 eq) 
    CH2Cl2, rt, 4 h
2. TBAF, THF
 
(2S,3S,4S)-1-Hydroxy-2-methyl-4-((2R,4R,6S)-2-phenyl-6-vinyl-1,3-dioxan-4-yl)pentan-
3-yl 4-methoxybenzoate (procedure for two steps). According to the typical procedure, 
rhenium(VII) oxide (0.8 mg, 1.7 mol) was quickly weighed out into a flame-dried flask. The 
flask was evacuated and backfilled with argon (x3). Dichloromethane (0.1 ml) was added to the 
flask.  The substrate (34 mg, 58 mol) in dichloromethane (0.7 ml total with rinses) was added to 
the reaction vessel followed by addition of benzaldehyde dimethyl acetal (18 l, 0.12 mmol). 
After 4 h of stirring at rt, saturated aqueous sodium bicarbonate was added and the biphasic 
mixture stirred vigorously for 10 min. The aqueous layer was extracted with dichloromethane 
(3x5 ml).  The combined organic layers were dried with sodium sulfate, concentrated, and the 
residue was submitted to the next reaction without further purification.  
Tetrn-butylammonium fluoride (1M in THF, 0.18 ml, 0.18 mmol) was added to a solution 
of the crude residue in THF (0.8 ml).  After 1 h 30 min the reaction was quenched with saturated 
aqueous ammonium chloride. The mixture was extracted with dichloromethane (3x10 ml). The 
combined organic layers were dried with sodium sulfate, concentrated, and the residue was 
purified by column chromatography (silica, 10% to 20% to 30% EtOAc – hexane) delivering the 
product (19 mg, 44 mol, 76% over two steps). 
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OHMBzO
TBDPSO OH
OMBzO
HO
O
Ph1. Re2O7 (2.5 mol%), PhCH(OMe)2 (2 eq) 
    CH2Cl2, rt, 4 h
2. TBAF, THF
 
(2S,3S,4S)-1-Hydroxy-2-methyl-4-((2S,4S,6R)-2-phenyl-6-vinyl-1,3-dioxan-4-yl)pentan-
3-yl 4-methoxybenzoate (procedure for two steps). According to the typical procedure, 
rhenium(VII) oxide (0.4 mg, 0.9 mol) was quickly weighed out into a flame-dried flask. The 
flask was evacuated and backfilled with argon (x3). Dichloromethane (0.1 ml) was added to the 
flask. The substrate (16 mg, 27 mol) in dichloromethane (0.4 ml total with rinses) was added to 
the reaction vessel followed by addition of benzaldehyde dimethyl acetal (10 l, 54 mol). After 
4 h of stirring at rt, saturated aqueous sodium bicarbonate was added and the biphasic mixture 
stirred vigorously for 10 min. The aqueous layer was extracted with dichloromethane (3x5 ml).  
The combined organic layers were dried with sodium sulfate, concentrated, and the residue was 
submitted to the next reaction without further purification. 
Tetrn-butylammonium fluoride (1M in THF, 0.10 ml, 0.10 mmol) was added to a solution 
of the crude residue in THF (0.5 ml).  After 1 h the reaction was quenched with saturated 
aqueous ammonium chloride. The mixture was extracted with dichloromethane (3x10 ml) The 
combined organic layers were dried with sodium sulfate, concentrated, and the residue was 
purified by column chromatography (silica, 10% to 20% to 30% EtOAc – hexane) delivering the 
product (10 mg, 23 mol, 84% over two steps). 
 
O
OTBSBnO
Me H
BnO
HH
O
OEt
O
OHBnO
Me H
BnO
HH
OH
1. i-Bu2AlH
2. TBAF, THF
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(2R,3S,5R,6S)-5-(Benzyloxy)-6-(benzyloxymethyl)-2-((E)-3-hydroxyprop-1-enyl)-6-
methyltetrahydro-2H-pyran-3-ol. Diisobutylaluminum hydride (1 M in toluene, 1.7 ml, 1.7 
mmol) was added to a solution of the substrate
141
 (0.473 g, 0.788 mmol) in dichloromethane (8 
ml) at -78 °C. After stirring at the same temperature for 1 h, i-PrOH, H2O, SiO2, Celite and 
dichloromethane were added and the mixture was warmed to rt. The mixture was stirred at rt for 
1 h. MgSO4 was added. The mixture was filtered through a pad of Celite and the filtrate was 
concentrated in vacuo. The residue was passed through a short column (silica, n-hexane:EtOAc = 
3:1). 
Tetrn-butylammonium fluoride (1M in THF, 1.18 ml, 1.18 mmol) was added to a solution 
of the crude substrate at room temperature.  The solution was stirred at room temperature for 1 h. 
Water was added and the mixture was extracted with EtOAc. The organic layer was washed with 
brine, dried over magnesium sulfate, and concentrated in vacuo. The residue was purified by 
flash column chromatography (silica, n-hexane:EtOAc = 3:1 to 2:1) to give the diol (0.307 g, 
0.770 mmol, 98% over 2 steps). []D
22 –9.0 (c 1.0, CH2Cl2). IR (cm
-1
) 3367.2, 2987.2, 2940.9, 
1605.5, 1496.5, 1455, 1370.2, 1207.2, 1089.6, 904.5, 736.7, 698.1; 
1
H NMR (500 MHz, CDCl3) 
δ 7.31–7.22 (m, 10H), 6.00 (ddd, J = 16.0, 5.0, 5.0 Hz, 1H), 5.75 (dd, J = 16.0, 7.5 Hz, 1H), 4.63 
(d, J = 12.5 Hz, 1H), 4.57 (d, J = 11.5 Hz, 1H), 4.52 (d, J = 12.5 Hz, 1H), 4.41 (d, J = 11.5 Hz, 
1H), 4.19 (d, J = 4.5 Hz, 2H), 3.81 (m, 1H), 3.78 (dd, J = 12.0, 5.0 Hz, 1H), 3.55 (d, J = 10.5 Hz, 
1H), 3.45 (d, J = 10.5 Hz, 1H), 3.35 (ddd, J = 11.5, 9.5, 5.0 Hz, 1H), 2.39 (ddd, J = 12.0, 4.5, 4.5 
Hz, 1H), 1.85 (bs, 1H), 1.63 (ddd, J = 12.0, 12.0, 12.0 Hz, 1H), 1.20 (s, 3H); 
13
C NMR (125 
MHz, CDCl3) δ 138.7 (2C), 134.0, 129.7, 128.51 (2C), 128.50 (2C), 127.9 (2C), 127.73 (2C), 
127.71 (2C), 77.6, 76.1, 74.7, 73.84, 73.79, 71.5, 69.5, 63.0, 32.9, 13.8; HRMS (ESI) calcd for 
C24H30O5Na [(M + Na
+
)] 421.1991, found 421.1982.  
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O
OHBnO
Me H
BnO
HH
OH
O
OBnO
Me H
BnO
HH
O
H
PhRe2O7 (2.5 mol%), PhCH(OMe)2 (2 eq), CH2Cl2, 20 h
 
(2S,4R,4aS,6S,7R,8aS)-7-(Benzyloxy)-6-(benzyloxymethyl)-6-methyl-2-phenyl-4-
vinylhexahydropyrano[3,2-d][1,3]dioxine. Following the typical procedure, rhenium(VII) 
oxide (4.0 mg, 8.16 mol) was quickly weighed out into a flame-dried flask.  The flask was 
evacuated and backfilled with argon (x3).  To the flask was added dichloromethane (1.25 ml).  
The substrate (0.130 g, 0.326 mmol) in dichloromethane (2.0 ml total with rinses) was added to 
the reaction vessel followed by addition of benzaldehyde dimethyl acetal (0.10 ml, 0.65 mmol). 
The reaction vessel was sealed and heated at 40
 
°C.  After 20 h the reaction was allowed to cool 
to rt and saturated aqueous sodium bicarbonate was added and the biphasic mixture stirred 
vigorously for 10 min. The aqueous layer was extracted with dichloromethane (3x10 ml).  The 
combined organic layers were dried with sodium sulfate, concentrated, and the residue was 
purified by column chromatography (silica, 10% EtOAc – hexane) delivering the product (0.128 
g, 0.263 mmol, 81%). []D
22 +5.2 (c 1.0, CH2Cl2). IR (cm
-1
) 3088, 3063.4, 3030.6, 2987.2, 
2944.8, 2859, 1496.5, 1454.1, 1365.4, 1292.1, 1207.2, 1097.3, 1027.9, 926.6; 
1
H NMR (500 
MHz, CDCl3) δ 7.54–7.52 (m, 2H), 7.39–7.24 (m, 13H), 6.02 (ddd, J= 17.5, 10.5, 5.5 Hz, 1H), 
5.66 (s, 1H), 5.47 (ddd, J = 17.5, 1.5, 1.5 Hz, 1H), 5.27 (ddd, J = 10.5, 1.5, 1.5 Hz, 1H), 4.64–
4.56 (m, 3H), 4.44 (d, J = 11.5 Hz, 1H), 4.19 (dd, J = 9.0, 5.0 Hz, 1H), 3.88 (ddd, J = 11.5, 4.5 
Hz, 1H), 3.57 (m, 1H), 3.57 (d, J = 10.5 Hz, 1H), 3.48 (d, J = 10.5 Hz, 1H), 3.31 (dd, J = 9.0, 9.0 
Hz, 1H), 2.46 (ddd, J = 11.5, 4.0, 4.0 Hz, 1H), 1.78 (ddd, J = 11.5, 11.5, 11.5 Hz, 1H), 1.20 (s, 
3H); 
13
C NMR (125 MHz, CDCl3) δ 138.8, 138.5, 137.8, 134.7, 129.1, 128.5 (3C), 128.4 (2C), 
127.74 (3C), 127.67 (2C), 127.6 (2C), 126.4 (2C), 117.2, 101.2, 79.7, 79.0, 76.6, 74.4, 74.1, 
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73.7, 71.43, 71.41, 30.6, 14.2; HRMS (ESI) calcd for C31H34O5Na [M+Na] 509.2304, found 
509.2296.  
 
O
OTBSBnO
Me H
BnO
HH
OH
OAc
O
OTBSBnO
Me H
BnO
HH
OH
AcO OAc
Grubbs II catalyst (5 mol%), CH2Cl2
(10 eq)
 
(S,E)-5-((2R,3S,5R,6S)-5-(Benzyloxy)-6-(benzyloxymethyl)-3-(tert-butyldime-
thylsilyloxy)-6-methyltetrahydro-2H-pyran-2-yl)-5-hydroxypent-2-enyl acetate. Prepared 
according to the typical procedure for cross-metathesis using Grubbs II catalyst (6.8 mg, 8.1 
mol) and 85 mg (0.161 mmol) of the substrate. E-selectivity >90%. Purified by column 
chromatography (silica, 25% EtOAc - hexanes) delivering the product (92 mg, 0.154 mmol, 
96%).
 
[]D
22 +13
 
(c 1.0, CH2Cl2). 
 1
H NMR (500 MHz, CDCl3 -7.26 (m, 10H); 
5.78 (ddd, J1=14.5 Hz, J2=7.5 Hz, J3=6.5 Hz, 1H); 5.64 (ddd, J1=15.0 Hz, J2=J3=6.5 Hz, 1H); 
4.54 (d, J=12.0 Hz, 1H); 4.56-4.50 (m, 3H); 4.45 (d, J=11.5 Hz, 1H); 3.78 (bs, 1H); 3.70-3.65 
(m, 2H); 3.54 (d, J=10.5 Hz, 1H); 3.42 (d, J=10.0 Hz, 1H); 3.18 (dd, J1=9.5 Hz, J2=1.0 Hz, 1H); 
2.41-2.34 (m, 1H); 2.31-2.25 (m, 1H); 2.20-2.16 (m, 2H); 2.05 (s, 3H); 1.82 (bs, 1H); 1.57 (dd, 
J1=24.0 Hz, J2=11.5 Hz, 1H); 1.13 (s, 3H); 0.87 (s, 9H); 0.08 (s, 3H); 0.06 (s, 3H). 
13
C NMR 
(125 MHz, CDCl3) δ 171.0, 138.8, 138.6, 132.7, 128.58, 128.56, 128.14, 127.79, 127.78, 127.77, 
126.5, 77.3, 75.2, 74.8, 73.60, 73.55, 71.7, 68.5, 66.3, 65.3, 37.9, 34.6, 26.0 (3C), 21.2, 18.1, 
13.8, -4.0, -4.6. HRMS (ESI) calcd for C34H50O7SiNa [M+Na] 621.3224, found 621.3217. 
 
O
OTBSBnO
Me H
BnO
HH
OH
OAc
O
OTBSBnO
Me H
BnO
HH
OH
OH
K2CO3 (0.4 eq), MeOH
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(S,E)-5-((2R,3S,5R,6S)-5-(Benzyloxy)-6-(benzyloxymethyl)-3-(tert-butyldime-
thylsilyloxy)-6-methyltetrahydro-2H-pyran-2-yl)pent-2-ene-1,5-diol. Prepared according to 
the typical procedure for deacetylation from 92 mg (0.154 mmol) of the substrate. Purified by 
column chromatography (silica, 65% to 80% EtOAc – hexanes) delivering the product (80 mg, 
0.144 mmol, 93%). []D
22 –6.7 (c 1.0, CH2Cl2); IR (cm
-1
) 3426.9, 3064.2, 3030.6, 2926.5, 
2855.1, 1496.5, 1455, 1362.5, 1252.5, 1208.2, 1088.6, 864, 837; 
1
H NMR (500 MHz, CDCl3) δ 
7.33–7.24 (m, 10H), 5.70 (m, 2H), 4.56– 4.50 (m, 3H), 4.43 (d, J = 11.5 Hz, 1H), 4.08 (d, J = 3.0 
Hz, 2H), 3.77 (dd, J = 7.0, 7.0 Hz, 1H), 3.67 (ddd, J = 10.5, 4.5, 4.5 Hz, 1H), 3.62 (dd, J = 12.0, 
5.0 Hz, 1H), 3.51 (d, J = 11.0 Hz, 1H), 3.42 (d, J = 11.0 Hz, 1H), 3.19 (d, J = 9.0 Hz, 1H), 2.35 
(m, 1H), 2.27 (m, 1H), 2.17 (ddd, J = 12.0, 5.0, 5.0 Hz, 1H), 1.60 (bs, 1H), 1.56 (ddd, J = 11.5, 
11.5, 11.5 Hz, 1H), 1.14 (s, 3H) 0.89 (s, 9H), 0.07 (s, 3H), 0.05 (s, 3H); 
13
C NMR (125 MHz, 
CDCl3) δ 138.8 , 138.6, 131.7, 129.4, 128.6 (2C), 128.5 (2C), 127.82 (2C), 127.81 (2C), 127.79 
(2C), 77.3, 75.4, 74.9, 73.7, 73.6, 71.7, 68.6, 66.3, 63.9, 38.0, 34.6, 26.0 (3C), 18.2, 13.8, –4.0, –
4.6; HRMS (ESI) calcd for C32H48O6SiNa [M+Na] 579.3118, found 579.3103.  
 
O
ORBnO
Me H
BnO
HH
O O
Ph
O
OTBSBnO
Me H
BnO
HH
OH
OH
A : R= TBS
B : R= H
Re2O7 (2.5 mol%), PhCH(OMe)2 (2 eq), CH2Cl2, rt, 20 h
 
Compounds A and B. The typical procedure was followed: rhenium(VII) oxide (1.7 mg, 3.6 
mol) was quickly weighed out into a flame-dried flask.  The flask was evacuated and backfilled 
with argon (x3), and dichloromethane (0.4 ml) was added.  The substrate (80 mg, 0.144 mmol) in 
dichloromethane (1.0 ml total with rinses) was added to the reaction vessel followed by addition 
of benzaldehyde dimethyl acetal (45 l, 0.288 mmol). After 20 h of stirring at rt, saturated 
aqueous sodium bicarbonate was added and the biphasic mixture stirred vigorously for 10 min. 
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The aqueous layer was extracted with dichloromethane (3x5 ml).  The combined organic layers 
were dried with sodium sulfate, concentrated, and the residue was purified by column 
chromatography (silica, 10% to 20% to 50%  EtOAc – hexanes) delivering the product A (11.8 
mg, 18.3 mol, 13%) and product B (52.6 mg, 99.1 mol, 69%). Data for Product A: []D
22 –5.7 
(c 1.0, CH2Cl2); IR (cm
-1
) 3064.3, 031.6, 2927.4, 2856.1, 1496.5, 1455, 1250.6, 1177.3, 1145.5, 
1012.5, 924.7, 862, 837; 
1
H NMR (500 MHz, CDCl3) δ 7.48 (dd, J = 8.0, 2.0 Hz, 2H), 7.36 (d, J 
= 7.0 Hz, 2H), 7.31–7.23 (m, 11H), 5.97 (ddd, J= 17.5, 10.5, 5.0 Hz, 1H), 5.52 (s, 1H), 5.35 (d, J 
= 17.5 Hz, 1H), 5.18 (d, J = 10.0 Hz, 1H), 4.78 (d, J = 12.5 Hz, 1H), 4.67 (d, J = 12.5 Hz, 1H), 
4.57 (d, J = 11.5 Hz, 1H), 4.52 (d, J = 11.5 Hz, 1H), 4.39 (dd, J = 10.5, 5.0 Hz, 1H), 4.17 (d, J = 
11.5 Hz, 1H), 3.86 (ddd, J = 11.0, 9.5, 5.0 Hz, 1H), 3.77 (dd, J = 12.0, 4.5 Hz, 1H), 3.64 (d, J = 
11.0 Hz, 1H), 3.44 (d, J = 11.0 Hz, 1H), 3.24 (dd, J = 14.0, 1.0 Hz, 1H), 2.20–2.13 (m, 2H), 1.59 
(ddd, J = 12.0, 12.0, 12.0 Hz, 1H), 1.41 (ddd, J = 13.0, 2.0, 2.0 Hz, 1H), 1.12 (s, 3H) 0.89 (s, 
9H), 0.02 (s, 6H); 
13
C NMR (125 MHz, CDCl3) δ 139.3, 139.1, 139.0, 138.3, 128.8 (2C), 128.46, 
128.44, 128.2 (2C), 128.0 (2C), 127.7 (2C), 127.6, 127.3 (2C), 126.8 (2C), 115.8, 101.6, 78.3, 
78.0, 76.3, 74.0, 73.65, 73.61, 73.5, 71.9, 65.4, 35.1, 32.5, 26.0 (3C), 18.1, 13.4, –4.0, –4.6; 
HRMS (ESI) calcd for C39H52O6SiNa [M+Na] 667.3431, found 667.3409.  Data for Product B:  
D
22
 –35.6 (c 1.0, CH2Cl2); IR (cm
-1
) 3443.3, 3031.6, 2925.5, 2868.6, 1496.5, 1454.1, 
1342.2, 1309.4, 1211.1, 1143.6, 1090.6, 1027.9, 926.6, 839.8; 
1
H NMR (500 MHz, CDCl3) δ 
7.48–7.46 (m, 2H), 7.33–7.24 (m, 13H), 5.95 (ddd, J= 17.0, 10.5, 5.0 Hz, 1H), 5.59 (s, 1H), 5.35 
(ddd, J = 17.0, 1.5, 1.5 Hz, 1H), 5.20 (ddd, J = 10.5, 1.0, 1.0 Hz, 1H), 4.63 (d, J = 12.0 Hz, 1H), 
4.59 (d, J = 12.0 Hz, 1H), 4.55 (d, J = 12.5 Hz, 1H), 4.43 (d, J = 12.0 Hz, 1H), 4.40 (m, 1H), 
4.32 (ddd, J = 11.0, 3.0, 2.5 Hz, 1H), 3.85 (ddd, J = 11.0, 11.0, 5.0 Hz, 1H), 3.65 (ddd, J = 11.5, 
11.5, 4.5 Hz, 1H), 3.55 (d, J = 11.0 Hz, 1H), 3.45 (d, J = 11.0 Hz, 1H), 3.05 (bs, 1H), 2.37 (ddd, 
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J = 12.0, 4.5, 4.5 Hz, 1H), 1.86 (ddd, J = 11.5, 11.5, 11.5 Hz, 1H), 1.74 (ddd, J = 13.5, 2.5, 2.5 
Hz, 1H), 1.62 (ddd, J = 12.0, 12.0, 12.0 Hz, 1H), 1.20 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 
139.0, 138.7, 138.2, 137.7, 129.2, 128.52 (2C), 128.51 (2C), 128.49 (2C), 127.8 (2C), 127.74 
(2C), 127.71 (2C), 127.6, 126.3, 116.0, 101.6, 77.9 (2C), 77.6, 74.7, 73.6 (2C), 73.4, 71.4, 65.9, 
32.9, 31.1, 13.5; HRMS (ESI) calcd for C33H38O6Na [M+Na] 553.2566, found 553.2560.  
 
O
O
Me H
BnO
BnO
CO2Et
TBS
O
OTBS
O
Me H
BnO
BnO
CO2Et
P
OEtO
OEt
NaH (4.5 eq), THF
(5.0 eq),
 
(Z)-Ethyl 2-(((2R,3S,5R,6S)-5-(benzyloxy)-6-(benzyloxymethyl)-3-(tert-butyldi-
methylsilyloxy)-6-methyltetrahydro-2H-pyran-2-yl)methylene)-3-methylbutanoate. To a 
stirred solution of triethyl 2-phosphono-isopentyrate (0.466 g, 1.75 mmol) in THF (10 mL) was 
added NaH (63 mg, 1.58 mmol) at 0 C. After stirring for 10 min, a solution of aldehyde (0.170 
g, 0.351 mmol) in THF (25 mL) was added dropwise at 0 C under argon atmosphere. After 
stirring at rt for 14 h, saturated aqueous NH4Cl was added at 0 C, and the mixture was extracted 
with EtOAc. The organic layer was washed with brine, dried over MgSO4, and concentrated in 
vacuo. The residue was purified by flash column chromatography (n-hexane:EtOAc = 5:1→3:1) 
to give ester (0.111 g, 53% yield).  []D
22 +29.3 (c 1.0, CH2Cl2); IR (cm
-1
) 3087.5, 3063.4, 
3030.6, 2959.2, 1948.7, 1721.2, 1659.5, 1604.5, 1496.5, 1462.7, 1363.4, 1221.7, 1094.4, 939.2, 
906.4, 837; 
1
HNMR (500 MHz, CDCl3) δ 7.35–7.23 (m, 10H), 5.54 (dd, J= 8.5, 1.5 Hz, 1H), 
4.63 (d, J = 12.5 Hz, 1H), 4.53 (d, J = 11.5 Hz, 1H), 4.52 (d, J = 12.5 Hz, 1H), 4.44 (dd, J = 8.5, 
8.5 Hz, 1H), 4.42 (d, J = 12.0 Hz, 1H), 4.24–4.13 (m, 2H), 3.75 (dd, J = 12.0, 5.0 Hz, 1H), 3.53 
(d, J = 10.0 Hz, 1H), 3.43 (d, J = 10.0 Hz, 1H), 3.36 (ddd, J = 11.0, 9.5, 5.0 Hz, 1H), 2.70 
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(dquin, J = 7.0, 7.0, 7.0, 7.0, 1.5 Hz, 1H), 2.16 (ddd, J = 12.0, 4.5, 4.5 Hz, 1H), 1.59 (ddd, J = 
12.5, 12.5, 12.5 Hz, 1H), 1.28 (dd, J = 7.0, 7.0 Hz, 1H), 1.17 (s, 3H), 1.06 (dd, J = 7.0, 4.5 Hz, 
6H), 0.83 (s, 9H), 0.00 (s, 3H), -0.02 (s, 3H); 
13
C NMR (125 MHz, CDCl3) δ 168.9, 143.4, 138.9, 
138.8, 130.8, 128.7 (2C), 128.1 (2C), 127.8 (2C), 127.71 (2C), 127.67 (2C), 77.4, 74.6, 73.8, 
73.6, 72.1, 71.6, 70.7, 60.4, 35.2, 32.0, 25.9 (3C), 21.5, 21.0, 18.1, 14.4, 13.9, -4.1, -4.4; HRMS 
(ESI) calcd for C35H52O6SiNa [M+Na] 619.3424, found 619.3425.  
 
O
O
Me H
BnO
BnO
CO2Et
TBS
OH
O
Me H
BnO
BnO2. TBAF, THF OH
1. i-Bu2AlH
 
(2R,3S,5R,6S)-5-(benzyloxy)-6-(benzyloxymethyl)-2-((Z)-2-(hydroxymethyl)-3-
methylbut-1-enyl)-6-methyltetrahydro-2H-pyran-3-ol. To a solution of ,-unsaturated ester 
(46.0 mg, 77 µmol) in CH2Cl2 (0.8 mL) was added DIBALH (1.0 M in toluene, 0.23 mL, 0.23 
mmol) at 78 C under argon atmosphere. After stirring at the same temperature for 1 h, i-PrOH, 
H2O, SiO2, Celite and CH2Cl2 were added, and the mixture was warmed to rt. The mixture was 
stirred at rt for 1 h and magnesium sulfate was added. The mixture was filtered through Celite 
pad and the filtrate was concentrated in vacuo, and the residue was submitted to the next reaction 
without further purification.  
To a solution of the crude was added TBAF (1.0 M in THF, 0.16 mL, 0.16 mmol) at room 
temperture. After stirring for 1 h, water was added and the mixture was extracted with EtOAc. 
The organic layer was washed with brine, dried over magnesium sulfate, and concentrated in 
vacuo. The residue was purified by flash column chromatography (silica, hexane:EtOAc = 2:1) to 
give diol (30.0 mg, 88% yield, 2 steps). []D
22  +7.6 (c 1.0, CH2Cl2); IR (cm
-1
) 3348.8, 3063.4, 
3029.6, 3958.3, 2870.5, 1496.5, 1454.1, 1365.4, 1234.2, 1207.2, 1104.1, 1027.9, 903.5; 
1
HNMR 
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(500 MHz, CDCl3) δ 7.33–7.22 (m, 10H), 5.38 (d, J= 7.5 Hz, 1H), 4.61 (d, J = 12.5 Hz, 1H), 
4.57 (d, J = 12.0 Hz, 1H), 4.52 (d, J = 12.5 Hz, 1H), 4.41 (d, J = 12.0 Hz, 1H), 4.18 (dd, J = 9.5, 
8.0 Hz, 1H), 4.02 (d, J = 12.0 Hz, 1H), 3.74 (dd, J = 11.5, 4.5 Hz, 1H), 3.51 (d, J = 10.0 Hz, 1H), 
3.45 (d, J = 10.0 Hz, 1H), 3.38 (ddd, J = 11.0, 9.5, 4.5 Hz, 1H), 2.41 (dquin, J = 7.0, 7.0, 7.0, 7.0, 
1.0 Hz, 1H), 2.38 (ddd, J = 12.0, 4.5, 4.5 Hz, 1H), 1.66 (ddd, J = 12.0, 12.0, 12.0 Hz, 1H), 1.24 
(s, 3H), 1.08 (dd, J = 7.0, 1.5 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) δ 151.2, 138.64, 138.58, 
128.5 (2C), 128.0 (2C), 127.8 (2C), 127.7 (2C), 125.3, 77.6, 74.7, 73.9, 73.7, 71.7, 71.5, 69.3, 
59.8, 35.0, 33.7, 21.7, 13.7; HRMS (ESI) calcd for C27H36O5Na [M+Na] 463.2460, found 
463.2448.  
 
OH
O
Me H
BnO
BnO
O
O
O
Me H
BnO
BnO PhRe2O7 (5 mol%), PhCH(OMe)2 (2 eq), CH2Cl2, rt, 20 hOH
H H
 
(2S,4R,4aS,6S,7R,8aS)-7-(benzyloxy)-6-(benzyloxymethyl)-6-methyl-4-(3-methyl-but-1-
en-2-yl)-2-phenylhexahydropyrano[3,2-d][1,3]dioxine. Following the typical procedure, to a 
solution of diol (15.0 mg, 0.034 mmol) and benzaldehyde dimethyl acetal (10 µL, 0.068 mmol) 
in CH2Cl2 (0.35 mL) was added rhenium(VII) oxide (0.8 mg, 1.7 µmol) under argon atmosphere. 
After stirring at the same temperature for 20 h, saturated aqueous NaHCO3 was added at 0 C, 
and the mixture was extracted with EtOAc. The organic layer was washed with brine, dried over 
MgSO4, and concentrated in vacuo. The residue was purified by flash column chromatography 
(silica, hexane:EtOAc = 10:1→5:1) to give the product (17.4 mg, 97% yield). []D
22 -1.9 (c 1.0, 
CH2Cl2); IR (cm
-1
) 2923.6, 1496.5, 1457.9, 1369.2, 1284.4, 1207.2, 1095.4, 1025.9, 910.2, 
806.1; 
1
H NMR (500 MHz, CDCl3) δ 7.52–7.50 (m, 2H), 7.36–7.27 (m, 13H), 5.64 (s, 1H), 5.23 
(s, 1H), 5.08 (s, 1H), 4.61 (d, J = 11.5 Hz, 1H), 4.58 (s, 1H), 4.46 (d, J = 11.5 Hz, 1H), 4.14 (d, J 
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= 9.0 Hz, 1H), 3.86 (dd, J = 12.0, 5.0 Hz, 1H), 3.58 (ddd, J = 12.0, 9.5, 4.5 Hz, 1H), 3.54 (d, J = 
10.5 Hz, 1H), 3.46 (dd, J = 9.0, 9.0 Hz, 1H), 3.45 (d, J = 11.0 Hz, 1H), 2.52 (quin, J = 7.0 Hz, 
1H), 2.45 (ddd, J = 11.0, 4.0, 4.0 Hz, 1H), 1.79 (ddd, J = 11.5, 11.5, 11.5 Hz, 1H), 1.19 (s, 3H), 
1.10 (d, J = 7.0 Hz, 6H); 
13
C NMR (125 MHz, CDCl3) δ 153.2, 139.0, 138.6, 138.0, 129.1, 
128.53 (2C), 128.49 (2C), 128.45 (2C), 127.81 (2C), 127.77 (2C), 127.7 (2C), 127.6, 126.5, 
111.1, 101.5, 82.2, 79.0, 76.9, 74.6, 74.1, 73.7, 71.5, 71.2, 30.80, 30.78, 23.0, 22.8, 14.0; HRMS 
(ESI) calcd for C34H40O5Na [M+Na] 551.2768, found 551.2775.  
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